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ABSTRACT 
Angiogenesis is fundamental to many physiological processes, and associated with various 
pathologies, including atherosclerosis and malignant disease.  
Increasing evidence suggests a role for the cytoprotective enzyme heme oxygenase-1 (HO-1) 
and its products in angiogenesis. However, the mechanisms through which HO-1 exerts its effects 
remain elusive. This study aims to identify signalling pathways and novel HO-1 downstream 
targets regulating angiogenesis. 
I show that inhibition of HO-1 with synthetic antagonist (ZnPP) or specific siRNA alters the 
angiogenic process at various levels. HO-1 inhibition significantly reduced vascular endothelial 
growth factor A (VEGF)-mediated human endothelial cell (EC) proliferation and inhibited capillary-
like formation on 2D-Matrigel. Further, I demonstrate that VEGF-induced EC cell cycle 
progression is inhibited by HO-1 siRNA; an observation associated with decreased expression of 
cell cycle regulators cyclin A1 and cyclin E1. In contrast, HO-1-deficient cells were still protected 
from apoptosis by VEGF, most likely through induction of anti-apoptotic genes Bcl-2 and A1. 
Interestingly, HO-1 depletion negatively affected directional migration of EC towards a VEGF 
gradient; a phenotype reversed by HO-1 over-expression using an adenoviral vector. Moreover, 
migrating HO-1-deficient cells showed decreased cyclin A1 protein accompanied by decreased 
cyclin-dependent kinase 2 activity. Importantly, a combined proteomics and microarray approach 
has identified downstream targets of HO-1 and their potential roles in HO-1-driven angiogenesis 
have been investigated. For instance, HO-1 depletion results in impaired assembly of the 
intermediate filament vimentin. HO-1-deficient cells show reduced activity of the calcium-
dependent protease calpain in response to VEGF; this observation was accompanied by a 
decrease in vimentin cleavage. The differences in vimentin cleavage and filament assembly may 
in turn account for the impaired angiogenic phenotype of HO-1-deficient cells.  
Identification of HO-1 downstream target genes may reveal potential therapeutic approaches for 
enhancing angiogenesis at sites of ischaemia or wound healing, or alternatively inhibiting 
angiogenesis associated with atherosclerosis or tumourogenesis. 
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CHAPTER 1 - INTRODUCTION 
1.1. THE VASCULAR ENDOTHELIUM IN HEALTH AND DISEASE 
The vascular endothelium is a continuous cellular monolayer lining the interior surface of all 
vessels of the vascular tree, starting from the origin at the exit of the heart to its final branches, 
the capillaries. The endothelium is a highly dynamic and heterogeneous organ that acts in an 
autocrine and paracrine manner and principally serves as a physiological and physical barrier 
between the vascular and extra-vascular compartments. It actively regulates the passage of 
solutes, macromolecules and blood cells across the vascular wall, generates and integrates 
biological signals and plays an essential role in haemostasis, leukocyte traffic and vascular tone, 
maintaining an anti-thrombotic, fibrinolytic and anti-inflammatory surface (Cines et al., 1998). 
 
1.1.1. Development of the vascular endothelium 
The cardiovascular system is the first organ system to form in the gastrulating embryo. Vascular 
development requires two organised processes to occur: vasculogenesis and angiogenesis. 
Vasculogenesis is the de novo organisation of endothelial cells (EC) into vessels in the absence 
of any pre-existing vascular system, and angiogenesis is the continued expansion of the vascular 
tree as a result of EC sprouting from existing vessels (Risau and Flamme, 1995; Risau 1997). EC 
derive from the embryonic mesoderm via the differentiation of mesodermal cells into 
hemangioblasts leading to the formation of the primitive blood islands in the yolk sac. 
Hemangioblasts are common progenitors of EC and hematopoietic cells. Hemangioblasts from 
the centre of the islands give rise to hematopoietic stem cells from which the first embryonic blood 
cells develop and hemangioblasts of the periphery of the islands differentiate into angioblasts, the 
precursors of mature EC (Risau and Flamme, 1995; Cines et al., 1998; Robb and Elefanty, 1998; 
Carmeliet, 2000). Following activation by chemotactic and haptotactic chemoattractants such as 
soluble growth factors and immobilized extracellular matrix (ECM) proteins respectively, migration 
of angioblasts is initiated which in turn allows the fusion of the blood islands and their 
rearrangement into luminised, tubular structures known as the first primitive vascular plexus 
(Risau and Flamme, 1995; Rossant and Howard, 2002). Remodelling of the vascular plexus into 
larger vessels also occurs via the process of angiogenesis (Risau and Flamme, 1995). Tissues 
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that are vascularised by this process are generally of endodermal origin and include the lung, 
pancreas, and spleen as well as the heart tube and dorsal aorta, whereas tissues of ectodermal 
and mesodermal derivation such as kidney and brain are vascularised primarily by angiogenesis 
(Pardanaud et al., 1989). Common to both vasculogenesis and angiogenesis is the process of 
vascular remodelling, involving changes in lumen diameter and vessel wall thickness to suit the 
functional and metabolic requirements of the local tissue (Beck and D’Amore, 1997). 
Vascular development is driven by specific polypeptide growth factors and interaction with their 
transmembrane receptor tyrosine kinases (RTK), extracellular matrix proteins, tissue remodelling 
by proteinases/enzymes and specific cell-matrix and cell-cell interactions. Among the most 
important growth factors are basic fibroblast growth factor (bFGF) and vascular endothelial growth 
factor (VEGF), both playing a pivotal role in the early development of the vascular endothelium 
(Beck and D’Amore, 1997). This is demonstrated by the fact that mutations affecting the VEGF 
gene cause abnormal vascular development and ultimately embryonic lethality (Carmeliet et al., 
1996; Ferrara et al., 1996).  Interaction of bFGF and VEGF with their respective receptors results 
in autophosphorylation of the receptors, triggering downstream signalling cascades leading to EC 
proliferation and migration, and subsequent assembly into vessels (Cines et al., 1998). 
Once the primary capillary plexus is formed, mesenchyme and smooth muscle cells (SMC) 
surrounding the developing vessel synthesise and secrete angiopoietin (Ang) glycoproteins 
(Davis et al., 1996; Maisonpierre et al., 1997). Four angiopoietins, Ang-1 to -4, have been 
identified to date, with Ang-1 and Ang-2 promoting vascular development (Tallquist et al., 1999). 
Ang-1 and Ang-2 drive the expansion of the vascular tree, endocardial and ventricular 
development, and formation of the vascular wall via binding to Tie receptor family members 
(Davies et al., 1996; Maisonpierre et al., 1997; Valenzuela et al., 1999). The two Tie receptors, 
Tie-1 and Tie-2/TEK comprise a separate class of endothelial-specific receptor tyrosine kinases. 
Their intracellular structure is similar to that of VEGF receptors, while the extracellular domain is 
unique having epidermal growth factor (EGF)-like, immunoglobin (Ig)-like, and fibronectin type 
three motifs (Partanen et al., 1992; Ziegler et al., 1993). Both receptors Tie-1 and Tie-2 are 
expressed throughout the vasculature from early stages and remain predominantly endothelial-
specific throughout development, while in adult life Tie-2 may also be found on monocytes 
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(Dumont et al., 1995). All four angiopoietins (Ang-1 to-4) exclusively bind Tie-2, while ligands for 
Tie-1 remain unknown (Davies et al., 1996; Maisonpierre et al., 1997; Valenzuela et al., 1999). 
Ang-1 is an activating ligand, promoting tyrosine phosphorylation of the receptor while Ang-2 is an 
inhibitory ligand, antagonising the action of Ang-1 (Maisonpierre et al., 1997). Recruitment of 
supporting cells, i.e. pericytes and SMC, which stabilise the maturing vessels, is critical to the 
integrity of the developing vasculature. Ang-1 in particular recruits accessory cells and creates 
stable vessels (Rossant and Howard, 2002; Suburo and D’Amore, 2006).  
Extracellular matrix components such as collagen type IV, fibronectin, vitronectin, and 
proteoglycans interact with EC via cell-matrix adhesion receptors and regulate capillary tube 
formation. The predominant receptors that mediate cell-matrix interactions are members of the 
integrin family, although other ECM receptors are also known, including dystroglycan and 
discoidin domain receptors (DDR; Hynes, 2007). Integrin-ligand binding anchors the cell to the 
ECM in turn triggering intracellular signals that regulate cytoskeletal organisation at specific sites 
on the surface membrane to facilitate cell movement or maintain tissue stability, and to regulate 
proliferation and cell survival (Hynes, 2007). Among the integrins, many have been implicated in 
the development of the vascular system, including collagen receptors (α1β1, α2β1), laminin 
receptors (α3β1, α6β1, α6β4), fibronectin receptors (α4β1, α5β1), and the αv receptors, αvβ3 and αvβ5 
(Hynes et al., 1999; Serini et al., 2006; Hynes, 2007). EC express more than one integrin and the 
combination is constantly changing, suggesting that specific combinations are required as 
development proceeds (Cines et al., 1998). 
Vessel sprouting and lengthening requires angioblasts and EC to be in contact with like cells. 
Such cell-cell contacts are mediated by a distinct series of cell surface receptors that include 
platelet EC adhesion molecule (PECAM-1/CD31), a member of the Ig superfamily, and vascular 
endothelial (VE)-cadherin, also known as cadherin-5 (Risau and Flamme, 1995; Albelda et al., 
1991; Cines et al., 1998). These rather weak adhesion complexes are thought to assist cell-cell 
recognition and facilitate the assembly of more classic junctional complexes in maturing vessels, 
such as tight junctions and gap junctions, depending on the underlying vascular bed (Cines et al., 
1998). Vascular extension and remodelling requires co-ordinated synthesis and degradation of 
various tissues, such as the basement membrane and ECM, by specific enzymes including matrix 
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metalloproteinases (MMP) and plasminogen activators, allowing EC movement and subsequent 
expansion of the vascular tree (Bretscher, 1996; Carmeliet and Collen, 1995). 
Vascular development is a complex multi-step process, involving multiple cell types interacting 
with one another, surrounding cells and the ECM. Many of these molecular processes required for 
vasculogenesis and angiogenesis are also involved in maintaining vascular homeostasis within 
the adult, and are recapitulated after injury or as part of inflammatory responses (Cines et al., 
1998). 
 
1.1.2. Functions of the vascular endothelium 
The vascular endothelium is composed of a single layer of cells that lines the inner lumen of all 
blood vessels. In adults, it is estimated to comprise around 10
13
 cells, representing a weight of 1.5 
kg and covering 4,000-7,000 m
2
 (Wolinsky et al., 1980; Augustin et al., 1994; Ait-Oufella et al., 
2010). Endothelial cells (EC) lie at the interface of the circulating blood and the vessel wall. They 
are flattened cells, 50-100 µm long, 10-15 µm wide, and about 0.5 µm in thickness. Their 
elongated shapes are juxtaposed in a mosaic such that their long axis is orientated in the 
direction of blood flow. Individual EC are interconnected by cell-to-cell adherent junctions formed 
by junctional adhesion molecules including PECAM-1/CD31 and VE-cadherin. They are anchored 
to an underlying basal membrane rich in collagen and glycoproteins, forming a complex interface 
between the circulation and the platelet-activating, pro-coagulant vascular matrix (Dejana et al., 
1995; Dejana et al., 2009; Ait-Oufella et al., 2010). 
Nowadays, the endothelium is no longer viewed as an inert tissue. EC structure and functional 
integrity are important in the maintenance of the vessel wall and circulatory function. Cells 
respond to physical and chemical signals by production and secretion of a large variety of 
mediators that regulate vascular homeostasis and blood flow, vascular tone, cellular adhesion 
and permeability, thrombosis and thrombolysis, endothelial proliferation and angiogenesis, and 
vessel wall inflammation (Fig. 1.1.; Galley and Webster). 
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Figure 1. 1.: Metabolic and synthetic functions of the endothelium. Endothelial cells (EC) 
influence cellular functioning of the body through the secretion of a wide range of mediators. LDL 
– low density lipoprotein, MHC II – major histocompatibility complex class II (modified after Galley 
and Webster, 2004). 
 
Endothelium transport and barrier functions 
The endothelium functions as an important barrier to the free passage of plasma, molecules and 
cells from the blood to the underlying tissues and cells. Specific transport mechanisms, including 
trans- and paracellular permeability, and extracellular barriers such as focal adhesions, allow the 
transport of essential circulating blood macromolecules across EC to the subendothelial space to 
meet the metabolic demands of the surrounding tissue (Mann et al., 2003). The endothelial barrier 
is maintained by two main types of intracellular junctions; tight junctions and adherens junctions. 
The latter are ubiquitous throughout the vasculature and provide barrier functions in most 
vascular beds principally via the intracellular junction protein VE-cadherin (Mehta and Malik, 
2006; Rudini and Dejana, 2008; Komarova and Malik, 2010). Tight junctions are found in most 
vascular beds but contribute to microvascular barrier function only in a few specialised tissues, 
including the brain, retina and testes. The intracellular junction proteins mainly responsible for 
tight junction barrier function are occludin and claudin-5 (Hawkins and Davies, 2005; Mehta and 
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Malik, 2006; Abbott et al., 2010). Small molecules and fluids tend to pass through the endothelial 
barrier using paracellular pathways via cell junctions, whereas larger molecules, such as albumin 
and low density lipoproteins (LDL), use an active transcellular route employing receptor-
dependent and independent mechanisms, caveolae, vesico-vacuolar organelles (VVO) and 
transcellular channels (Feng et al., 2002; Aird, 2007; Frank et al., 2009). Endothelial transcellular 
permeability is mainly mediated by caveolae involving vesicle-mediated endocytosis of 
macromolecules at the luminal membrane, followed by transcytosis across the cell, and 
exocytosis at the basolateral membrane (Fig. 1.2.) (Predescu et al., 2007) 
 
Figure 1. 2.: Vascular permeability in different vascular beds. In continuous non-fenestrated 
endothelium as present in skin, lung or heart, smaller molecules such as water (H2O) and small 
solutes pass freely between EC, whereas larger molecules (tracer) pass through EC either via 
transendothelial channels (TEC) or transcytosis meditated by caveolae. Diaphragms of the 
fenestrae present in the continuous fenestrated endothelium as found in endorine glands, the 
gastrointestinal tract (GI) and the glomerulus, act as molecular filters, allowing greater 
permeability for H2O and small molecules but refecting the passage of larger macromolecules. A 
discountinious endothelium as found in the liver is characterised by a sinusoidal fenestrae lacking 
diaphragms, and a poorly organised basement membrane allowing the free passage of fluids, 
small solutes and larger macromolecules. Clathrin-coated pits assist in receptor-mediated 
endocytosis (modified after Aird, 2007). 
 
Caveolae are ‘cave-like’ invaginations in the plasma membrane containing caveolin-1, a 
scaffolding protein that is recruited to the membrane and regulates caveolar internalisation 
(Minshall et al., 2003). By forming vesicles, caveolae are capable of moving considerable 
amounts of fluid and solutes across the cell. Focal adhesions are attachments between the 
endothelial basolateral membrane and surrounding ECM of the microvascular wall, principally 
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composed of the transmembrane receptor family of integrins. Integrins are heterodimeric 
glycoproteins containing an α and β subunit (Petit and Thiery, 2000; Hodivala-Dilke et al., 2003; 
Wu, 2005). Their intracellular domains interact with the cytoskeleton either directly, or indirectly 
via the linker proteins paxillin, talin, vinculin, or α-actinin, and their large extracellular domains 
bind respective proteins present in the ECM, such as fibronectin, vitronectin, collagen, fibrinogen, 
and laminin (Petit and Thiery, 2000; Hodivala-Dilke et al., 2003). The precise mechanisms by 
which focal adhesions contribute to endothelial barrier function are not completely understood, but 
integrin-matrix binding is essential for the establishment and stabilisation of endothelial barriers 
(Wu, 2005). Alterations in integrin-binding properties decrease focal adhesion strength, cause cell 
detachment from the ECM and EC apoptosis, or affect transendothelial flux of fluids and large 
solutes (Dejana and Lauri, 1990; Cheng et al., 1991; Trache et al., 2005; del Zoppo and Milner, 
2006).   
 
Vascular tone 
The endothelium produces a variety of vasodilator and vasoconstrictor substances which regulate 
vasomotor tone, blood flow and pressure, and vascular haemodynamics (Fig. 1.1.). Among the 
most important vasodilatory substances produced by the endothelium are nitric oxide (NO) and 
prostacyclin (PGI2), which are co-released from every vessel, thereby forming a particular 
partnership in the regulation of vascular function (Moncada et al., 1976; Palmer et al., 1987; de 
Nucci et al., 1988). Important vasoconstrictors include endothelin-1 (ET-1), platelet-activating 
factor (PAF), thromboxane A2, angiotensin II (Ang II), and reactive oxygen species (ROS) 
(Yanagisawa et al., 1988; Schiffrin, 2001; Anderson et al., 2000). The production of NO by the 
endothelium is constitutive and modulated by different stimuli, whereas the synthesis of other 
meditators, PGl2, ET-1, and PAF, is inducible. The delicate balance between these mediators 
provides minute-by-minute control of tone and blood pressure. 
NO is a highly soluble, gaseous molecule which is synthesised during oxidation of the semi-
essential amino acid L-arginine and oxygen to L-citrulline by the enzyme nitric oxide synthase 
(NOS). NOS shares homology with the cytochrome p450 family of enzymes and requires 
tetrahydrobiopterin (BH4), nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) and 
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calcium/calmodulin for NO production (Knowles and Moncada, 1994; Scott-Burden, 1995). There 
are three recognised NOS isoforms which differ in their regulation and tissue expression; 
neuronal NOS (nNOS or NOS I), inducible NOS (iNOS or NOS II) mainly expressed in 
inflammatory cells and sites of inflammation, and endothelial NOS (eNOS or NOS III) the 
predominant isoform present in EC (Palmer et al., 1988; Pollack et al., 1991; Ghosh and Salerno, 
2003). eNOS is constitutively expressed in the vascular endothelium and activated by increased 
intracellular calcium and phosphorylation in response to changes in shear forces or via receptor-
mediated processes, thereby constantly generating NO (Stamler et al., 1992). Laminar shear 
stress is the main stimulus for NO production, enhancing enzyme activity and synthesis (Féletou 
and Vanhoutte, 2009). Other receptor agonists stimulating eNOS include acetylcholine, 
bradykinin, histamine, serotonin, adenosine triphosphate (ATP) and adenosine diphosphate 
(ADP) (Moncada and Higgs, 2006). Released NO rapidly diffuses into neighbouring vascular 
smooth muscle cells (VSMC) where it binds and activates soluble guanylate cyclase (GC), 
leading to the generation of cyclic guanosine monophosphate (cGMP) and activation of protein 
kinase G (PKG) (Moncada et al., 1991). PKG activation causes reduced calcium influx into 
VSMC, and decreased calcium/calmodulin stimulation of myosin light chain kinase. This in turn 
decreases the phosphorylation of myosin light chains, decreasing smooth muscle contraction and 
causing vasodilation (Moncada et al., 1991; Moncada and Higgs, 2006; Vanhoutte et al., 2009). 
The liberation of NO into the circulation also inhibits platelet aggregation and activation 
contributing to an anti-thrombotic vasculature (Riddell and Owen, 1999; Broos et al., 2011).  
In contrast to NO, endothelin is a potent vasoconstrictor also produced by endothelial cells, with 
marked effects on vascular tone. Three endothelin isoforms have been characterised, but only 
endothelin-1 (ET-1) is uniquely synthesised and released by the endothelium in response to 
stimuli including hypoxia, ischaemia and shear stress (Inoue et al., 1989; Levin, 1995). Liberated 
ET-1 diffuses to neighbouring VSMC and binds to the abundant G-protein coupled receptor 
endothelin receptor type A (ETA) present on the cell surface. Receptor binding promotes the 
release of intracellular calcium from the endoplasmic reticulum (ER) triggering VSMC proliferation 
and inducing vasoconstriction (Inoue et al., 1989; Levin, 1995; Abraham and Dashwood, 2008). 
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Prostacyclin (PGl2) and platelet-activating factor (PAF) are both intercellular signalling molecules 
synthesized by stimulated EC and derived from the metabolism of arachidonic acid. PGl2 is an 
eicosanoid produced by the vascular enzymes cyclo-oxygenase (COX)-1 and COX-2, stimulating 
vasodilation and inhibiting platelet aggregation via paracrine signalling cascades that involve G-
protein coupled receptors on nearby EC and platelets (Mitchell and Warner, 1999; Simmons et 
al., 2004). In contrast, PAF, a phospholipid signalling via juxtacrine mechanisms, causes 
vasoconstriction and stimulates the adhesion of leukocytes to the endothelium (Imaizumi et al., 
1995; Lorant et al., 1995). 
 
Regulation of leukocyte traffic 
The endothelium is of vital importance in the functioning of the immune system and regulation of 
immune responses. Both innate and adaptive immunity depend on the exit of leukocytes from the 
bloodstream and their migration across the endothelium to underlying target tissues, a process 
referred to as extravasation (Johnson-Léger et al., 2000). Leukocyte extravasation occurs both as 
part of a constitutive physiological process, e.g. during lymphocyte re-circulation, and at sites of 
inflammation. In lymphoid organs, specialised vascular sites within postcapillary venules known 
as high endothelial venules (HEV) represent the major constitutive extravasation route in vivo 
(Anderson and Anderson, 1976; Anderson et al., 1976; Lasky, 1992). In response to vascular 
injury or inflammatory stimuli the endothelium adopts an activated phenotype and rapidly 
upregulates its expression of cell surface leukocyte-adhesion molecules: E-selectin, P-selectin, 
vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1). This 
enhances the recruitment of neutrophils and stimulates secretion of soluble mediators such as 
cytokines (interleukin [IL]-1, IL-6) and chemoattractants (RANTES, monocyte chemotactic protein-
1 [MCP-1]), which perpetuate inflammation and leukocyte recruitment (Bratt and Palmblad, 1997). 
Consequently, leukocytes are captured by EC initiating the leukocyte-adhesion cascade, a 
multistep process of successive interactions of adhesion receptors between leukocytes and EC.  
Over the past decade, new insights into mechanisms underlying the adhesion process led to the 
expansion of the classical cascade consisting of selectin-mediated leukocyte rolling, chemokine-
triggered activation, and integrin-dependent arrest, to a more detailed version now including slow 
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rolling, adhesion strengthening and spreading, intraluminal crawling, paracellular and transcellular 
migration, and migration through the basement membrane (Fig. 1.3.; Butcher, 1991; Springer, 
1995; Muller, 2003; Imhof and Aurrand-Lions, 2004; Ley et al., 2007). E- and P-selectin interact 
with their corresponding ligands P-selectin glycoprotein ligand 1 (PSGL-1) and E-selectin ligand 1 
(ESL-1) on leukocytes, slowing down their velocity in the bloodstream and leading to a rolling 
movement on the vascular wall. Leukocyte activation enhances integrin affinity and avidity to 
ICAM-1 and VCAM-1 expressed on EC, resulting in the firm cell adhesion to the apical endothelial 
plasma membrane. Finally, leukocytes transmigrate to sites of injury via a gradient of chemotactic 
molecules which include MCP-1, complement components (C3a and C5a), cytokines and 
prostaglandins through paracellular pathways using interactions with junctional adhesion 
molecules (JAM), CD99 and PECAM-1, or alternatively through the transcellular route via ICAM-1 
and PECAM-1 (Fabbri et al., 1999; Muller, 2003; Vestweber, 2003). 
 
Figure 1. 3.: The leukocyte adhesion cascade. The originally described steps selectin-
mediated leukocyte rolling, chemokine-triggered activation and integrin-dependent arrest are 
shown in bold. Additionally identified steps include capture, adhesion strengthening and 
spreading, intravascular crawling, and paracellular and transcellular transmigration. ESAM – 
endothelial cell-selective adhesion molecule, ICAM-1 – intercellular adhesion molecule 1, JAM – 
junctional adhesion molecule, LFA-1 – lymphocyte function-associated antigen 1, MAC-1 – 
macrophage antigen 1, MADCAM-1 – mucosal vascular addressin cell-adhesin molecule 1, 
PSGL-1 – P-selectin glycoprotein ligand 1, PECAM-1 - platelet endothelial cell adhesion molecule 
1, Pl3K – phosphoinositide 3-kinase, VCAM-1 – vascular cell adhesion molecule, VLA4 – very 
late antigen 4 (adapted from Ley et al., 2007). 
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Regulation of haemostasis and coagulation 
A crucial physiological function of the endothelium is to facilitate blood flow by providing an anti-
thrombotic surface that inhibits platelet adhesion and clotting. However, when the continuity of the 
vascular endothelium is disrupted, EC undergo biochemical changes that culminate in their 
transformation to a pro-thrombotic surface promoting platelet aggregation and activation, 
coagulation and fibrinolysis (Cines et al., 1998). Haemostasis is a defence mechanism to regulate 
bleeding in response to vascular wall injury and comprises a series of events classified as primary 
haemostasis (platelet aggregation), secondary haemostasis (blood coagulation), and tertiary 
haemostasis (fibrinolysis) (Arnout et al., 2006). Haemostatic processes are tightly controlled by 
the delicate balance between anti-thrombotic and pro-thrombotic factors secreted or expressed by 
the endothelium and surrounding tissues (Tab. 1.1.; Ait-Oufella et al., 2010). When a vascular 
lesion occurs, the immediate response of the endothelium is vascular constriction to reduce blood 
flow locally followed by platelet recruitment initiating repair mechanisms (Roth, 1992). The pivotal 
ligand in the initiating event in haemostatic plug formation is von Willebrand factor (vWF). vWF is 
a high-molecular weight multimeric glycoprotein present in the subendothelium and in plasma, 
where it is conformationally activated by shear forces linking platelets through the glycoprotein 
(GP) Ib component of the GPIb/IX/V receptor to the subendothelium (Savage et al., 1996; 
Siedlecki et al., 1996; Ruggeri, 1999). Adhering activated platelets express P-selectin and 
integrins on their surface to facilitate the further recruitment of circulating platelets, which are in 
turn activated and form a platelet aggregate (Ait-Oufella et al., 2010). Aggregation requires 
fibrinogen, energy and calcium (Troy, 1988). By secreting the granular contents ADP and 
serotonin, and producing prostaglandins, platelets provide a catalytic surface for the assembly of 
coagulation complexes necessary for α-thrombin production and subsequent conversion of 
soluble fibrinogen into insoluble fibrin (Ait-Oufella et al., 2010).  
Thrombin is produced from factor Xa via the extrinsic coagulation pathway and is among the most 
potent stimulators of platelets through proteolytic cleavage and activation of platelet protease-
activated receptors (PAR), especially PAR1 and PAR4 (Coughlin, 1999). Receptor activation 
leads to formation of fibrin and expression of pro-thrombotic factors including tissue factor (TF), 
plasminogen activator inhibitor-1 (PAI-1), PAF and ET-1 thereby amplifying the coagulation 
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cascade (Woolkalis et al., 1995). Excessive thrombin generation is prevented by antithrombin and 
activation of the protein C pathway (Esmon, 1992; Arnout et al., 2006). Activation of the fibrinolytic 
system results from conversion of the pro-enzyme plasminogen into the active serine proteinase 
plasmin, controlled by proteases secreted by EC including tissue plasminogen activator (tPA) and 
urokinase-type plasminogen activator (uPA). Plasmin digests fibrin components of a blood clot 
and releases degradation products into the circulation. Two inhibitors control the fibrinolytic 
system; the plasmin inhibitor α2 antiplasmin and plasminogen activator inhibitor (PAI) (Stassen et 
al., 2004; Aid-Oufella et al., 2010). Together, these physiological processes act to maintain 
normal functioning blood vessels and a non-thrombotic state. 
Table 1. 1.: Regulation of haemostasis through secretion and expression of molecules with 
anti- and pro-thrombotic properties. (adapted from Ait-Oufella et al., 2010). 
Haemostasis   
Primary haemostasis Activation von Willebrand Factor (vWF) 
 Inhibition nitric oxide (NO) 
Secondary 
haemostasis 
Activation tissue factor (TF) 
 Inhibition tissue factor pathway inhibitor 
endothelial protein C receptor 
thrombomodulin  
heparan/dermatan sulphate 
Tertiary haemostasis Activation tissue plasminogen activator (tPA) 
urinary plasminogen activator (uPA) 
 Inhibition plasminogen activator inhibitor (PAI) 
 
 
1.1.3. Intrinsic cytoprotective mechanisms of the endothelium 
The endothelium is constantly exposed to a variety of factors capable of inducing an inflammatory 
response, including endotoxins, cytokines, complement components, activated leukocytes and 
oxidatively-modified lipoproteins. Thus, the endothelium has evolved various intrinsic 
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cytoprotective mechanisms to minimize inflammatory reactions and protect itself against injury 
(Bach et al., 1997; Tedgui and Mallat, 2001). These mechanisms include the synthesis of anti-
inflammatory cytokines, such as interleukin (IL)-10, IL-13, and IL-1RA, extracellular signalling 
molecules such as transforming growth factor-beta (TGFβ), and vascular endothelial growth 
factor (VEGF). Furthermore, activation of constitutive and inducible cytoprotective genes including 
endothelial eNOS, NO, PGI2, and the anti-oxidant enzyme heme oxygenase-1 (HO-1), 
complement regulatory proteins, as well as anti-inflammatory and anti-apoptotic genes including 
A1, A20, and Bcl-2. In addition, more recent studies suggest that endothelial cells at sites in the 
vasculature, exposed to pulsatile, unidirectional blood flow are more protected from inflammatory 
insults than those areas where a bidirectional, oscillatory blood flow occurs, at least in part 
through induction of the cytoprotective genes mentioned above (Chatzizisis et al., 2007). 
 
Interleukin-10 
Interleukin (IL)-10 is an immunomodulatory cytokine produced by endothelial cells, smooth 
muscle cells, Th2 lymphocytes, B-lymphocytes and monocytes/macrophages. The cytokine 
inhibits antigen driven proliferation and attenuates Th1 cellular responses (Tedgui and Mallat, 
2006). 
IL-10 exerts its biological effects on cells via interaction with a specific cell-surface receptor 
belonging to the class II cytokine receptor family (Liu et al., 1994). The functionally active receptor 
is composed of two distinct subunits; the IL-10 receptor α-chain mediates high-affinity ligand 
binding and signal transduction, while the β-chain serves as an accessory chain and is essential 
for the active receptor complex (Liu et al., 1994; Spencer et al., 1998). Anti-inflammatory actions 
of IL-10 are predominantly mediated through initiation of the Janus kinase/signal transducer and 
activators of transcription (JAK-STAT) pathway eventually affecting nuclear factor kappa B 
(NFκB) activation (Riley et al., 1999). Other intracellular signalling pathways regulated by IL-10 
include the mitogen-activated protein (MAP) kinases extracellular signal-regulated kinase (ERK) 1 
and ERK2 (Suttles et al., 1999).  
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Protective and anti-inflammatory properties of IL-10 are demonstrated by in vitro studies showing 
that IL-10 down-regulates ICAM-1 and VCAM-1 expression on IL-1-activated human umbilical 
vein endothelial cells (HUVEC), inhibits tumour necrosis factor (TNF)-induced or fibroblast growth 
factor (FGF)-2-induced human aortic SMC proliferation, and attenuates low density lipoprotein 
(LDL)-induced monocyte binding (Van der Meeren et al., 1999; Selzman et al., 1998; Pinderski 
Oslund et al., 1999). The cytoprotective importance of IL-10 is further supported by in vivo 
studies; mice fed a high-fat diet demonstrate a significant reduction in NFκB activation and ICAM-
1 and VCAM-1 expression in response to IL-10 overexpression, while IL-10 deficient mice show a 
marked increase in lipopolysaccharide (LPS)-mediated expression of ICAM-1 and VCAM-1 
(Potteaux et al., 2006, Morise et al., 1999). These animals also demonstrate increased leukocyte 
infiltration into the vascular wall when fed an atherogenic diet (Mallat et al., 1999). Additional 
mechanisms of vascular protection attributable to IL-10 include reduced superoxide anion 
production in blood vessels in response to LPS, protection against myocardial ischaemia-
reperfusion injury, and attenuation of neo-initimal hyperplasmia in mice subjected to balloon 
angioplasty (Gunnett et al., 2000; Hayward et al., 1997; Feldman et al., 2000). 
 
Transforming growth factor-beta  
Transforming growth factor-beta (TGF-β) is a potent anti-inflammatory and pro-fibrotic cytokine, 
playing important regulatory functions within the cardiovascular system, including proliferation, 
cellular differentiation and immunity. To date, three mammalian isoforms have been identified, i.e. 
TGF-β1, TGF-β2, and TGF-β3, which are ubiquitously found in vascular cells, including EC, 
arterial and venous SMC, macrophages, neutrophils and platelets (Lefer, 1991).  
TGF-β superfamily members are secreted in an inactive complex with latent TGF-β binding 
protein (LTPB) and latency-associated peptide (LAP), proteins derived from the N-terminal region 
of the TGF-β gene. Extracellular activation of latent TGF-β is regulated by the 
plasminogen/plasmin system and is an essential step in the regulation of TGF-β function in vivo 
(Grainger et al., 1994). Active TGF-β elicits its biological functions through the distinct cell-surface 
receptors TGF-β type 1 (TGF-βRI) and type II (TGF-βRII) receptor, upregulating the kinase 
activity of these receptors and their downstream effectors, the transcription factors Smad proteins 
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(Derynck and Zhang, 2003; Shi and Massagué, 2003). Smad-mediated signalling activates 
CREB, in turn blocking the association of CPB with p65/NFkB and inhibiting NFkB activity (Dabek 
et al., 2006). 
Numerous in vitro studies demonstrate the potent anti-inflammatory effects of TGF-β on vascular 
cells. TGF-β attenuates cytokine-induced expression of E-selectin on EC as well as VCAM-1 on 
EC and SMC, reduces MCP-1 expression in TNF-α or IL-1β-stimulated HUVEC, and inhibits IL-8-
dependent transmigration of neutrophils through the TNF-α-activated endothelium (DiChiara et 
al., 2000; Park et al., 2000; Gamble et al., 1995; Honda et al., 1999; Smith et al., 1996). In 
addition, TGF-β restores TNF-α-mediated endothelial vasodilation (Lefer et al., 1990). The 
vasoprotective properties of TGF-β1 are confirmed by TGF-β1 deficient mice, which die in utero 
due to widespread uncontrolled inflammation most severely affecting the heart and lungs (Shull et 
al., 1992). Moreover, TGF-β1 heterozygous mice (TGF-β1
+/-
), when fed a cholate-enriched 
atherogenic diet, demonstrate increased endothelial activation with elevated levels of ICAM-1 and 
VCAM-1, and enhanced macrophage infiltration into the vascular wall compared to wild-type 
controls, further supporting the cytoprotective role of endogenous TGF-β1 in the vascular system 
(Grainger et al., 2000). 
 
Angiogenic mediators and growth factors 
Vascular endothelial growth factor (VEGF), initially known as vascular permeability factor (VPF), 
was first discovered as a tumour-secreted factor that increases vascular permeability (Senger et 
al., 1983). Subsequently, VEGF has been identified as an important regulator of angiogenesis 
and EC homeostasis, which stimulates receptor tyrosine kinases and acts as a potent mitogen for 
vascular endothelial cells (Greenaway et al., 2004; Siemeister et al., 1998). VEGF is a high 
affinity ligand for the tyrosine kinase receptors VEGF-R1/Flt-1 and VEGF-R2/KDR/Flk, and exerts 
its cellular effects through interactions with these receptors (De Vries et al., 1992). Along with the 
proliferative effects on endothelial cells, VEGF has been recognised as a cytoprotective 
modulator, by protecting EC from apoptosis by increased induction of the anti-apoptotic genes A1 
and Bcl-2 (Gerber et al., 1998), enhanced induction of decay-accelerating factor (DAF), thereby 
protecting EC against complement-mediated injury (Mason et al., 2001), upregulation of 
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endothelial NOS (Bussolati et al., 2001), and stimulating synthesis of NO and PGI2 (Kroll and 
Waltenberger, 1999; Laitinen et al., 1997; Murohara et al., 1998; He et al., 1999), and induction of 
the cytoprotective enzyme heme oxygenase-1 (HO-1) (Bussolati et al., 2004; Siner et al., 2007).  
Recent studies have shown that the angiogenic mediator angiopoietin-1 (Ang-1) also exhibit 
potent protective effects in the adult vasculature including promotion of vessel survival, inhibition 
of vascular leakage, and suppression of inflammatory gene expression (Brindle et al., 2006). In 
fact, Ang-1 treated EC demonstrate increased PECAM-1 localisation to EC junctions thereby 
inhibiting TNF-α-induced leukocyte transmigration (Gamble et al., 2000). In addition, Ang-1 
abrogates leukocyte adhesion by suppressing VEGF-induced expression of adhesive and 
inflammatory molecules, including E-selectin, ICAM-1 and VCAM-1, and blocks TNF-α- and 
VEGF-mediated tissue factor (TF) expression on cultured EC (Kim et al., 2001a; Gamble et al., 
2000; Kim et al., 2002). Moreover, Ang-1 has been shown to protect against endothelial apoptosis 
in response to a variety of stimuli, including serum-deprivation, oxidised LDL, and TNF-α (Kwak et 
al., 1999; Papapetropoulos et al., 1999; Kim et al., 2001b). Anti-inflammatory and anti-apoptotic 
properties of Ang-1 are mediated through binding to its endothelium specific tyrosine kinase 
receptor Tie-2 and activation of the PI3K/Akt signalling pathway (Kim et al., 2000; 
Papapetropoulos et al., 2000; Gamble et al., 2000).  
 
Nitric oxide 
Besides its well-described role as a vasodilatory molecule, endothelial-derived nitric oxide (NO) 
has been recognised to exhibit potent anti-inflammatory properties, which are mainly mediated via 
inhibition of NFκB activation through enhanced induction and nuclear translocation of inhibitor of 
kappa B alpha (IκBα) (De Caterina et al., 1995; Spiecker et al., 1997). For instance, endogenous 
NO synthesis attenuates cytokine-induced endothelial activation, decreases the expression of the 
adhesion molecules ICAM-1 and VCAM-1, and inhibits leukocyte trafficking (Kubes et al., 1991; 
De Caterina et al., 1995). In contrast, inhibition of NO results in increased expression of MCP-1 in 
cultured human EC (Zeiher et al., 1995). The vascular protective effects of NO are confirmed by 
in vivo studies utilising the NO synthesis inhibitor N
ω
-nitro-L-arginine methyl ester (L-NAME) and 
eNOS-deficient mice. Chronic in vivo blockade of NO synthesis results in increased leukocyte 
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infiltration with increased expression of ICAM-1 and VCAM-1, enhanced expression of the pro-
inflammatory mediators MCP-1, IL-6, macrophage colony-stimulating factor (M-CSF), and NFκB 
activation (Luvara et al., 1998; Kitamoto et al., 2000; Koyanagi et al., 2000; Gonzalez et al., 
2000). In line with these findings, eNOS-deficient mice display enhanced leukocyte adhesion and 
increased atherosclerotic lesion size (Knowles et al., 2000; Kuhlencordt et al., 2001). Moreover, 
NO synthesis inhibition is associated with increased oxidative stress and ROS production, an 
effect abrogated by the anti-oxidant N-acetyl cysteine (NAC) and blockage of angiotensin II type 1 
receptor (Luvara et al., 1998; Gonzalez et al., 2000; Usui et al., 2000). 
 
Anti-apoptotic proteins 
In addition to protecting EC from apoptosis, several anti-apoptotic proteins including members of 
the Bcl-2 gene family (Bcl-2, Bcl-XL, and A1), A20 and heme oxygenases (HO) have been shown 
to possess potent anti-inflammatory properties. A1 and A20 are induced in response to 
inflammatory stimuli and protect EC from uncontrolled activation and cell death through an NFkB-
dependent mechanism (Cooper et al., 1996). Overexpression of Bcl-2, Bcl-XL, A1, or A20 inhibits 
VCAM-1, E-selectin, and IL-8 expression in EC by inhibiting NFκB activation (Ferran et al., 1998; 
Stroka et al., 1999). In vivo experiments underscore the importance of these protective genes; 
A20-deficient mice fail to regulate TNF-α-dependent NFκB activation and inflammation, develop 
severe inflammation and cachexia, are hypersensitive to LPS and TNF, and die prematurely (Lee 
et al., 2000). Double-mutated mice, deficient in apolipoprotein E (ApoE) and haplo-insufficient for 
A20, demonstrate an increase in atherosclerotic aortic root lesion area correlating with increased 
expression of the NFκB target genes ICAM-1, VCAM-1, and M-CSF, while overexpression of A20 
results in reduced lesion area (Wolfrum et al., 2007). Furthermore, specific human A20 
polymorphisms resulting in decreased A20 expression confer increased cardiovascular risk in 
diabetic patients through modulation of NFκB activation (Boonyasrisawat et al., 2007).  
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Vasoprotective effects of laminar shear stress 
The endothelium has not only evolved intrinsic cytoprotective mechanisms capable of responding 
to hormonal stimuli in the circulation, but may also respond to biochemical forces created by 
blood flow and the cardiac cycle (Davies, 1995). As a result of their unique anatomical location, 
EC are constantly exposed to a variety of mechanical forces. These local haemodynamic forces 
include pressure, created by the hydrostatic forces of blood within the blood vessel; blood 
pressure-derived tensile stress, created as a result of defined intracellular connections between 
EC that exert longitudinal forces on the cell during vasomotion; and flow-generated shear stress, 
which is the frictional force of the flowing blood on the endothelial surface (Davies, 1995). Shear-
induced mechanotransduction transforms mechanical forces to biochemical responses, inducing 
endothelial structural changes, and activating signal transduction and endothelium-dependent 
gene and protein expression that determines endothelial cell phenotype (Davies, 1995; Pan, 
2009). For instance, numerous mechanoreceptors expressed on the luminal surface of EC, 
including ion channels, G-proteins, VEGF-R2, VE-cadherin, PECAM-1, proteoglycans, caveolae, 
tyrosine kinase receptors and NADPH oxidase, have been shown to play important roles in the 
shear stress sensing mechanisms (Traub and Berk, 1998; Li et al., 2005; Lehoux et al., 2006; 
Chatzizsis et al., 2007; Ando and Yamamoto, 2011). Receptor engagement in turn leads to the 
simultaneous activation of several intracellular signalling pathways, including mitogen-activated 
protein kinases (MAPK), protein kinase C (PKC), Rho family small GTPases, the PI3K/Akt 
cascade (Traub and Berk, 1998; Li et al., 2005; Lehoux et al., 2006; Chatzizsis et al., 2007; Ando 
and Yamamoto, 2011), and downstream transcription factors such as Krüppel-like factor 2 (KLF-
2) and nuclear factor erythroid 2-related factor-2 (Nrf-2; Dekker et al., 2002; Wang et al., 2006; 
Chen et al., 2003). These transcription factors recognise specific shear stress response elements 
(SSRE) within the promoter of mechanosensitve genes thereby regulating their expression 
(Chatzizisis et al., 2007). 
In the arterial circulation, localised haemodynamic shear stress determines site-specific 
susceptibility to atherosclerosis and its progression (Fig. 1.4.; Caro et al., 1969; Pan, 2009). 
Regions within the vasculature that are exposed to disturbed, bidirectional flow with low and 
oscillatory shear forces (0 to 10 dynes/cm
2
) such as those in the vicinity of branch points, the 
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outer wall of bifurcations, and the inner wall of curvatures, are associated with an enhanced risk 
of endothelial dysfunction and cardiovascular diseases such as atherosclerosis and subsequent 
occlusive thrombosis triggering acute myocardial infarction or stroke (Cheng et al., 2005; Cheng 
et al., 2006; Suo et al., 2008; VanderLaan et al., 2004; Chatzizisis et al., 2007; Malek et al., 
1999a). In contrast, at straight parts of the arterial tree, where streamlined unidirectional blood 
flow occurs with high laminar shear stress (10 to 70 dynes/cm
2
), the endothelium adopts an anti-
inflammatory and anti-coagulant surface with reduced EC turnover characterised by both 
decreased proliferation and apoptosis (Davies et al., 1986; Kaiser et al., 1997; Davies, 2000). In 
addition, atherosclerotic lesion size is reduced in these areas (Cheng et al., 2006). Molecular 
mechanisms underpinning the anti-inflammatory actions of shear stress include protection against 
oxidative stress and inhibition of NFκB and jun-N-terminal kinase (JNK)-AP-1 pathways and their 
downstream targets. In vitro experiments demonstrate that the prolonged exposure of EC to 
laminar flow diminishes ICAM-1 and VCAM-1 surface expression in the unstimulated but also 
activated endothelium (Sampath et al., 1995; Chappell et al., 1998), whereas prolonged low and 
oscillatory shear stress enhances E-selectin, VCAM-1 expression and monocyte adhesion 
(Mohan et al., 1999; Chappell et al., 1998). The cytoprotective effects of shear stress are further 
demonstrated by increased secretion of the vasodilators PGI2 and eNOS and subsequent 
increased bioavailability of NO (Hanada et al., 2000; Topper et al., 1996; Malek et al., 1999b; 
Mashour and Boock, 1999). In addition, expression of vasoconstrictors including ET-1 (Malek and 
Izumo, 1992), are supressed, thereby contributing to a quiescent atheroprotective phenotype. 
Gene expression profiling further revealed that cultured vascular EC respond to fluid mechanical 
forces by modulating the messenger ribonucleic acid (mRNA) level of a large number of genes. 
Sustained exposure of EC to high shear laminar flow up-regulates the expression of 
atheroprotective, anti-oxidant transcription factors including KLF-2 and Nrf-2 and their 
downstream target genes such as the cytoprotective enzyme HO-1 (De Keulenaer et al., 1998), 
manganese superoxide dismutase (MnSOD; Topper et al., 1996), and cupper/zinc superoxide 
dismutase (Cu/ZnSOD; Inoue et al., 1996), thereby reducing the production of reactive oxygen 
species (ROS). In contrast, disturbed flow, with associated reciprocating low shear stress, 
generally induces genes that promote atherogenesis (Mohan et al., 1999; De Keulenaer et al., 
1998). The protective effects of high shear stress are further supported by in vivo studies 
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demonstrating constitutive NFκB activation and VCAM-1 expression in EC located in regions 
highly susceptible to atherosclerotic lesion formation, where low or oscillatory shear forces occur 
(Hajra et al., 2000; Potteaux et al., 2006).  
Figure 1. 4.: Cytoprotective mechanisms of laminar shear stress in the vasculature. 
Laminar shear stress promotes an anti-thrombotic and anti-inflammatory endothelial phenotype. It 
inhibits leukocyte migration and smooth muscle proliferation, while simultaneously promoting 
endothelial survival (printed with permission from Prof Justin C. Mason). 
 
1.1.4. Vascular injury and its role in disease 
The normal healthy endothelium serves as an autocrine and paracrine organ that controls vessel 
wall integrity and function by maintaining an anti-thrombotic, anti-inflammatory, and 
vasoregulatory phenotype. Moreover, the endothelium acts as an important regulator of vessel 
wall inflammation, thrombosis, and normal host defence mechanisms by adopting an ‘activated’ 
phenotype, expressing pro-inflammatory chemokines, cytokines, and surface adhesion molecules 
that leukocytes to the site of inflammation, to clear microorganisms and initiate wound healing and 
repair. However, an imbalance in these highly regulated processes may lead to a dysfunctional 
endothelium and subsequent perpetuation of inflammatory diseases (Cines et al., 1998).  
Its anatomical location constantly exposes the endothelium to potentially harmful stimuli including 
oxidised lipoproteins, C-reactive protein, pro-inflammatory cytokines, bacterial endotoxins such as 
LPS, anti-phospholipid antibodies, complement activation products, proteolytic enzymes, and 
haemodynamic forces. These factors may injure and activate the endothelium, promoting a shift 
from the constitutive, anti-inflammatory, anti-coagulant, and anti-proliferative phenotype to an 
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‘activated’ phenotype, which facilitates inflammation, thrombosis and mitogenesis (Tesfamariam 
and DeFelice, 2007). If persistent, the pro-inflammatory and pro-coagulant state of the activated 
endothelium may eventually lead to endothelial dysfunction. Endothelial dysfunction is a systemic 
pathological condition characterised by a shift of the endothelium towards impaired vasodilation, 
and a pro-inflammatory and pro-thrombotic milieu (Fig. 1.5.). Endothelial dysfunction is primarily 
the consequence of a reduction in NO bioavailability caused by impaired NO production by the 
endothelium and/or increased inactivation of NO by ROS (Kaneto et al., 2010; Witting et al., 
2007). Endothelial dysfunction is one of the earliest events in the initiation and progression of 
atherosclerosis (Vanhoutte, 1997) and has been detected in patients suffering from 
hypercholesterolemia, hypertension, coronary and peripheral artery disease, chronic heart failure, 
as well as autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid 
arthritis (RA), and diabetes mellitus (Ross, 1999; Schachinger et al., 2000; Heitzer et al., 2001; 
Bijl, 2003; Endemann and Schiffrin 2004; Higashi et al., 2009). 
Figure 1. 5.: Endothelial dysfunction in the pathogenesis of cardiovascular diseases. The 
endothelium is constantly exposed to numerous cardiovascular risk factors that facilitate 
endothelial activation and may lead to endothelial dysfunction, the earliest step in the 
pathogenesis of atherosclerosis and other cardiovascular diseases (adapted from Widlansky et 
al., 2003). 
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Atherosclerosis is the most prevalent disease in developed countries (Cines et al., 1998). It is a 
multifactorial, progressive disease of large and medium-sized muscular arteries characterised by 
endothelial dysfunction, vascular inflammation and the accumulation of lipids, fibrous materials, 
calcium and cellular debris within in intima of the vessel wall. Atherosclerosis results from 
excessive inflammatory and fibroproliferative responses to vascular insults such as dyslipidaemia, 
free radicals resulting from cigarette smoke, hypertension, and diabetes mellitus, and/or genetic 
predisposition which culminates in the formation of oxidatively-modified LDL contributing to EC 
injury and activation (Ross, 1999).  EC activation subsequently up-regulates the expression of 
leukocyte adhesion molecules such as VCAM-1 and platelet receptors, as well as pro-
inflammatory chemokines (e.g. MCP-1) and cytokines such as IL-1 which facilitate the infiltration 
of platelets, monocytes/macrophages and T-lymphocytes into the subendothelial intima. Uptake 
of oxidised LDL by activated initimal macrophages, through scavenger receptors, then results in 
the formation of foam cells and fatty streaks and secondary secretion of free radicals, proteases 
and pro-inflammatory cytokines, including TNF-α and IL-1, that further contribute to vascular 
injury. Next, progressive lipid accumulation, extracellular matrix deposition, and SMC proliferation 
and migration contribute to the formation of a fibrous cap, resulting in vascular remodelling, 
luminal narrowing, alterations in blood flow patterns, and diminished oxygen supply to target 
organs.  
Pathological neovascularisation has been described in the evolving plaque. Vessels of the 
neovascular vasa vasorum are leaky and associated with intraplaque haemorrhage and the 
subsequent rupture of the protective fibrous cap. In addition, elaboration of interferon gamma 
(INF-γ) by Th1 cells, the predominant lymphocytes within the evolving plaque, and synthesis and 
release of matrix metalloproteinases (MMP) by activated macrophages result in inhibition of SMC 
proliferation and collagen degradation contributing to thinning and rupture of the vulnerable 
plaque. Plaque rapture exposes thrombogenic contents, e.g. lipid-laden foam cells, extracellular 
lipid and necrotic cell debris, to the circulating blood further facilitating progression of the 
atherosclerotic lesion (Kolodgie et al., 2003; Milei et al., 1998) and predisposes to thrombus 
formation, partial or complete obstruction of the blood vessel, and myocardial infarction (Ross, 
1999; Cines et al., 1998; Galley and Webster, 2004; Hansson, 2005; Rocha and Libby, 2009).  
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Diabetes mellitus is a major accelerator of cardiovascular disease and is associated with an 
increased risk of atherosclerosis. Fundamental pathogenic mechanisms in diabetes-associated 
vascular disease include endothelial dysfunction, vascular inflammation, and increased oxidative 
stress (Onat et al., 2011). Hyperglycaemia alters endothelial function and contributes to vascular 
injury through the extensive formation of advanced glycation end products (AGEs) (Barlovic et al., 
2011). AGEs represent a heterogeneous group of proteins, lipids and nucleic acids, irreversibly 
cross-linked with reducing sugars (Barlovic et al., 2011). AGEs are implicated in the pathogenesis 
of atherosclerosis, either directly or via receptor-mediated mechanisms. Ligand-dependent 
activation of receptor for AGE (RAGE) leads to increased ROS formation, and triggers activation 
of NFκB and other pro-inflammatory signalling pathways leading to increased synthesis of growth 
factors and pro-inflammatory cytokines, thereby promoting vascular dysfunction (Barlovic et al., 
2011). 
Autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE), have also been associated with accelerated atherosclerosis, which is preceded by 
endothelial dysfunction (López-Pedrera et al., 2012). RA is a chronic systemic inflammatory 
disease predominately affecting the synovial joints and eventually leading to physical disability 
and linked to higher morbidity and mortality rates. Mortality risk factors include amyloidosis, 
infections, and underlying cardiovascular diseases (CVD), with coronary atherosclerosis 
representing the main cause of cardiovascular-related deaths in RA patients (Maradit-Kremers et 
al., 2005; Szekanecz et al., 2007). Among the traditional CVD risks factors, such as smoking, 
hypercholesterolemia, and dyslipidaemia, inflammatory and atherogenic mediators have been 
identified as distinct CV risks factors in RA and include acute phase proteins, autoantibodies, 
autoreactive lymphocytes and pro-atherogenic cytokines (Szekanecz et al., 2007; López-Pedrera 
et al., 2012).  Cardiovascular events and underlying endothelial dysfunction are a leading cause 
of death in SLE patients. The increased frequency of atherosclerosis and thromboembolic events 
in patients with SLE is likely due to a combination of traditional CVD risk factors, and disease-
related factors including vasculititis and steroid therapy, as well as systemic inflammatory 
responses that contribute to accelerated atherosclerosis in SLE including complement activation, 
antibodies against heat-shock proteins (HSP) and an abnormal lipid profile (Agarwal et al., 2009; 
Sherer et al., 2010). 
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1.2. ANGIOGENESIS IN HEALTH AND DISEASE 
The vascular system ensures the efficient and simultaneous transport of gases, liquids, nutrients, 
signalling molecules and circulating cells between organs and tissues, a requirement for the 
functioning of the complex body of vertebrates. Blood vessels are responsible for systemic 
circulation, proceeding from the heart through the aorta, arteries, into smaller arterioles and finally 
into capillary beds. Capillaries form extensive networks that facilitate the exchange of gases and 
metabolic products before blood is returned through venules and veins to the heart and then into 
the lungs to be replenished by oxygen (Adams and Alitalo, 2007).  
In the healthy organism the vascular system is essential for homeostasis and hence vascular 
malformations or dysfunction contribute to the pathogenesis of numerous diseases (Carmeliet, 
2005; Adams and Alitalo, 2007). Insufficient blood supply causes tissue ischaemia, whereas in 
cancer stimulation of angiogenesis allows tumours access to nutrients and oxygen, stimulating 
their growth and metastasis. Therefore the ability to control the growth of blood vessels has 
considerable therapeutic potential. 
  
1.2.1. The angiogenic process 
Angiogenesis is a highly complex, multistep process, requiring the tight coordination of cell 
proliferation, differentiation, migration, matrix adhesion and cell-cell signalling. The destabilisation 
phase entails the enzymatic breakdown of the basement membrane and the loosening of 
junctional connections with surrounding cells. During the proliferation and migration phase, 
activated EC migrate towards an angiogenic stimulus, invading and proliferating into the 
underlying extracellular matrix. Eventually during the maturation phase, EC align to form a luminal 
vessel, a new basement membrane is secreted, intracellular adhesions and EC-basement 
membrane connections mature and pericytes are recruited to the new vessel wall (Patan, 2000; 
Bouïs et al., 2006; Sun and Schiller, 2007). The formation of new blood vessels is strictly 
regulated and depends on the concerted activities of various growth factors and their receptors 
expressed on the surface of endothelial and accessory cells, including macrophages, mast cells, 
and stromal components. The delicate balance between the release of pro- and anti-angiogenic 
factors from these cells is essential for the regulation of angiogenesis (Tab. 1.2.). 
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Table 1. 2.: Endogenous pro- and anti-angiogenic factors. (adapted from Sun and Schiller, 
2007). 
Pro-angiogenic factors Anti-angiogenic factors 
 
VEGF 
 
angiostatin 
epidermal growth factor (EGF) endostatin 
platelet-derived growth factor (PDGF) canstatin 
fibroblast growth factor (FGF) tumstatin 
stromal cell-derived growth factor 1 alpha (SDF-1α) interferon α and β  
transforming growth factor beta(TGF-β) tissue inhibitors of metalloproteinases 
tumour necrosis factor alpha (TNF-α) thrombospondin 
hepatocyte growth factor (HFG) pigment epithelium-derived factor 
granulocyte colony-stimulating factor vascular endothelial growth inhibitor 
interleukin-1, -6, -8 (IL-1, IL-6, IL-8) vasoinhibin 
matrix metalloproteinases  
angiogenin  
proliferin  
pleiotropin  
ephrin  
 
 
Selection of sprouting EC 
The recent recognition that specialised EC contribute to the formation of vessel branches has 
been an exciting breakthrough (Tab. 1.3.). During angiogenic growth, some EC within the 
capillary vessel wall are selected for sprouting. These cells which are known as tip cells lead the 
growing sprout. Tip cells extend long and motile filopodia, thin (0.1-0.3 µm), finger-like structures 
filled with tight parallel bundles of filamentous (F)-actin, towards the source of pro-angiogenic 
growth factors to enable directional and prevent disorganised vessel growth (Gerhardt et al., 
2003; Matilla and Lappalainen, 2008). “Stalk” cells trail behind, elongating the stalk of the sprout 
and forming a lumenised tube. So called “phalanx” cells, which resemble the “phalanx formation” 
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of ancient Greek soldiers, are the most quiescent EC, and line vessels once the new vessel 
branches have been consolidated (Carmeliet et at., 2009; De Smet et al., 2009). 
Table 1. 3.: Molecular signature and properties of specialised EC involved in angiogenesis. 
(modified after Carmeliet et al., 2009; De Smet et al., 2009) 
Cell type Molecular signature Function 
 
Tip cell 
 
- VEGF-R2 
- VEGF-R3-1 
- PDGF-BB 
- Unc5B 
- Neuropilin-1 (NRP1) 
↑ Delta-like ligand-4 (Dll4) 
↓ Notch 
 
 located at the forefront of vessel branches 
 highly polarised nature 
 numerous filopodia probing the 
environment while migrating toward an 
angiogenic stimulus 
 do not form a lumen 
 proliferate minimally 
 detect gradients of navigator cues and 
integrate combinatorial molecular codes 
into directional migration 
Stalk cell ↑ Notch 
↑ Jagged1 
↓ Dll4 
↓ VEGF-R2 
↓ VEGF-R3 
↓ NRP1 
↓ CXC-R4 
- Notch-related ankyrin- 
  repeat protein (Nrarp) 
 trail behind the tip cell 
 elongate the stalk of the sprout 
 do not extend filopodia 
 they proliferate 
 form junctions 
 lay down extracellular matrix 
 form a lumen 
Phalanx cell   most quiescent EC 
 line vessels once the vessel branches 
have been consolidated 
 form a smooth cobblestone monolayer 
 are covered by pericytes 
 stick to each other via adherens junctions 
 are embedded in a thick basement 
membrane 
 
The fate and differentiation of EC into specialised cells involved in angiogenesis is strongly 
controlled by the Notch pathway. The family of Notch receptors comprises four members, Notch-
1, -2, -3, and -4, which are recognised and their activation controlled by their transmembrane 
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ligands Delta-like ligand 1 (Dll1), Dll3, and Dll4 and Jagged1 and Jagged2 (Rocha and Adams, 
2007; Carmeliet et al., 2009). Activation of Notch results in a proteolytic generation of the Notch 
intracellular domain (NICD), which induces transcription of target genes (Roca and Adams, 2007; 
Carmeliet et al., 2009).  
Tip cells contain relatively high levels of Dll4, whereas stalk cells preferentially express a different 
Notch ligand, Jagged1. In quiescent EC, Dll4 and Notch signalling are thought to be balanced but 
upon exposure to pro-angiogenic stimuli, such as VEGF, Dll4 expression is upregulated in tip 
cells inducing the expression of Notch in adjacent stalk cells (Hofmann and Iruela-Arispe, 2007; 
Hellström et al., 2007). VEGF-R2 signalling in the tip cell allows cells to extend filopodia and 
move ahead, while Dll4/Notch signalling leads to downregulation of VEGF-R2 and VEGF-R3 in 
stalk cells, thereby dampening the VEGF-induced migratory response in these cells (Tammela et 
al., 2008; Hellström et al., 2007; Suchting et al., 2007). The ligand Jagged1 is a pro-angiogenic 
regulator that antagonises Dll4/Notch signalling suppressing the motile, invasive and sprouting 
phenotype of tip cells and thereby positively controls the number of sprouts and tips (Benedito et 
al., 2009). 
 
Endothelial proliferation and cell cycle regulation 
The endothelial sprout extends via proliferation of endothelial stalk cells. The rate of proliferation 
depends on three different aspects. Firstly, the rate of cell division representing the time it takes to 
complete a cell division cycle, secondly the fraction of cells within the population undergoing cell 
division, and thirdly the rate of cell loss from the population due to terminal differentiation or cell 
death. The mammalian cell cycle can be divided into two functional phases, the DNA synthesising 
(S)-phase and the mitosis (M)-phase, and two preparatory gap (G)-phases, G1 and G2. Non-
dividing cells persist in a resting state, called the G0-phase (Lukas et al., 2004; Satyanarayana 
and Kaldis, 2009).  
The proliferative state of mammalian cells is determined by the availability of growth factors and 
mitogens such as VEGF in their immediate environment. The presence of extrinsic growth factors 
triggers numerous cytoplasmic signalling cascades, including the ERK 1/2 MAPK pathway (see 
section 1.2.3.), which eventually result in the sequential activation of distinct cyclin-dependent 
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kinase (Cdk) activities. Cdks are serine/threonine kinases that drive the ordered transition through 
the phases of the cell cycle. Kinase activity of all Cdks requires the binding of a positive regulatory 
subunit known as a cyclin (Morgan, 1997; Solomon et al., 1990). Each of the phases of the cell 
cycle is characterised by the expression of a distinct type of cyclin (Fig 1.6.), and binding of 
cyclins to Cdks results in the partial activation of the Cdk enzyme. Full activation of the cyclin/Cdk 
complex requires further phosphorylation of the Cdk by a separate kinase, the Cdk activation 
kinase. Active cyclin/Cdk complexes then initiate phosphorylation of downstream targets, thereby 
inducing specific cell cycle events (Obaya and Sedivy, 2002; Satyanarayana and Kaldis, 2009). 
 
 
 
 
 
 
Figure 1. 6.: Cell cycle phase-specific expression patters of cyclins and Cdk activities. 
(adapted from Obaya and Sedivy, 2002). 
 
In mammalian cells approximately 20 Cdk-related proteins have been identified and can be 
grouped in specialised G1, G1/S, S and G2/M phase specific Cdks and cyclins (Obaya and Sedivy, 
2002). Among the most studied cyclins are type D-cyclins that assemble with Cdk4 and Cdk6 
driving progression through the G1-phase (Inaba et al., 1992). In early G1-phase, active cyclin 
D/Cdk4/6 complexes initiate phosphorylation of retinoblastoma protein (pRb), which in turn leads 
to the release of the cell cycle transcription factor E2F. Release of E2F from pRb results in its 
activation and the transcription of target genes required for cell cycle progression (Weinberg, 
1995; Dyson, 1998; Sherr and Roberts, 1999). Early E2F responsive genes include E- and A-type 
cyclins (Lundberg and Weinberg, 1998; Sherr and Roberts, 1999). Cyclin E forms a complex with 
Cdk2 in late G1-phase. This leads to Cdk2 activation and further phosphorylation of pRb by the 
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active cyclin E/Cdk2 complex. Hyperphosphorylation of pRb in turn results in further E2F-
mediated transcription and passage through the restriction point at the boundary of the G1/S-
phase, and to S-phase initiation (Fig.1.7.) (Dulic et al., 1992; Koff et al., 1992). In S-phase, Cdk2 
is bound and activated by A-type cyclins and. cyclin A/Cdk2 activity is required for S-phase 
transition and control of DNA replication (Elledge et al., 1992; Cardoso et al., 1993). Later in G2-
phase, cyclin A also binds to and activates Cdk1 (Cdc2) and regulating G2/M-phase transition and 
initation of prophase (Furuno et al., 1999). Finally, cyclin B is expressed in late S-phase and G2-
phase and assembles with Cdk1 participating in the entry and completion of mitosis (Pines and 
Hunter, 1989; Nurse, 1990; Maller, 1991). 
 Figure 1. 7.: S-phase initiation. In its active form, retinoblastoma protein (pRb) persists in a 
hypophosphorylated state in G1-phase and binds the cell cycle transcription factor E2F, thereby 
rendering it inactive. Upon phosphorylation of pRb by active cyclin D/Cdk4/6 complexes, E2F is 
released and activated, which in turn results in transcription of cell cycle regulatory genes 
including cyclin E (cycE) and cyclin A (cycA). Cyclin E complex with and activates Cdk2 resulting 
in further phosphorylation of pRb, E2F-mediated transcription, and progression to the S-phase. 
Active cyclin A/Cdk2 complexes mediate the transition through the S-phase. 
 
The cell cycle is negatively regulated by cyclin-dependent kinase inhibitor (CKI) proteins. Seven 
CKIs have been described in mammalian cells and can be divided into two families. Family 
members of the inhibitor of Cdk4 (INK4) family include p16
INK4a
, p15
INK4b
, p18
INK4c
, and p19
INK4d
, 
and bind exclusively to and inhibit the D-type cyclin-dependent kinases Cdk4 and Cdk6. The three 
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members of the CIP/KIP CKI family p21
CIP1/WAF1
, p27
KIP1
 and p57
KIP2
 are able to inhibit kinase 
activity of all Cdks. Binding of CKIs to active cyclin/Cdk complexes causes a conformational 
change in the active site of Cdks thereby decreasing their activity (Sherr and Roberts, 1995; 
Roussel, 1999; Obaya and Sedivy, 2002). 
 
Endothelial cell migration 
Endothelial migration is essential to angiogenesis. To migrate, cells must have an asymmetric 
morphology with defined leading and trailing edges. Cell motility is a multistep process and 
requires the activation of polarised intracellular signalling pathways that initiate cytoskeletal 
remodelling and protrusion formation at the leading edge, regulate integrin-mediated adhesion to 
the underlying substrate, as well as contraction and detachment at distinct regions of the cell (Fig. 
1.8.) (Lauffenburger and Horitz, 1996; Ridley et al., 2003).  
Actin is a major cytoskeletal component of endothelial cells and cell migration is dependent on 
different actin filament structures. Monomeric globular actin subunits (G-actin) polymerise into 
elongated helical filaments (F-actin) at the barbed/positive end (oriented towards the plasma 
membrane) of the actin string, a process mediated by the actin regulatory proteins profilin, 
Ena/VASP and formin family members (Pollard and Borisy, 2003; Matilla and Lappalainen, 2008). 
Elongation of actin filaments is required for the formation of cell protrusions and pushes the 
leading edge forward and thus promotes cell migration (Pollard and Borisy, 2003; Chhabra and 
Higgs, 2007). The protrusive structures at the leading edge of a cell are called lamellipodia and 
filopodia. Lamellipodia are thin, sheet-like cytoplasmic protrusions composed of branched actin-
networks, Lamellipodia formation is regulated by the small GTPase Rac1, as well as the actin-
related protein complex-2/3 (Arp2/3) and members of the Wiscott-Aldrich Syndrome protein 
(WASP) family, which regulate F-actin filament branching (Ridley, 2001; Lamalice et al., 2007; 
Matilla and Lappalainen, 2008). Filopodia are thin, finger-like membrane projections filled with 
tight bundles of F-actin. Formation of these structures is mainly regulated by the small GTPase 
Cdc42 that associates with WASP members (Ridley, 2001; Lamalice et al., 2007; Matilla and 
Lappalainen, 2008). Filopodia act as sensors of pro-migratory stimuli, they contain integrins and 
cadherins in their tips or along their shafts, probing the matrix for migratory cues and promoting 
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cell adhesion and migration (Galbraith et al., 2007). Stress fibres are contractile structures, which 
are also present in non-muscle cells and are composed of actin and myosin filaments grouped 
into bundles by myosin II. Stress fibres provide contractile forces for cell migration (Hotulainen 
and Lappalainen, 2006; Pellegrin and Mellor, 2007; Matilla and Lappalainen, 2008). Retraction of 
the cell at the trailing end is mediated by cofilin. Cofilin depolymerises and shortens the actin 
string at the pointed/negative end (pointing towards the inside of the cell), resulting in the release 
of the rear of the cell from the substrate and the promotion of forward movement (Pollard and 
Borisy, 2003; Huber et al., 2003). 
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Figure 1. 8.: Sequential events during endothelial cell migration. (A) Cell motility is initiated 
by Cdc42-dependent sensing of migratory cues by filopodia and Rac1-dependent formation of 
lamellipodia. Both cell protrusions contain actin-filaments, with elongating barbed ends oriented 
towards the plasma membrane. (B) Protrusions attach to the substratum at the leading front via 
focal adhesions and integrins. (C) Stress fibre-mediated contraction forces translocate the 
nucleus and cell body, allowing forward movement. (D) Retraction fibres pull the rear of the cell 
forward, adhesions at the rear disassemble and the trailing end retracts. (adapted from Mattila 
and Lappalainen, 2008). 
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Endothelial migration involves 3 major mechanisms that determine the velocity and directionality 
of the growing sprout in the tissue environment, namely chemotaxis, haptotaxis and 
mechanotaxis (Lamalice et al., 2007). The coordinated interplay of all three mechanisms is 
required for the angiogenic response of EC and further involves the activation of intracellular 
signalling cascades that converge on cytoskeletal remodelling, including activation of small 
GTPases, PI3K and eNOS, MAPK p38 and phosphorylation of focal adhesion kinase (FAK).  
Chemotaxis is the directional migration of cells towards a gradient of soluble chemoattractants. 
Among the numerous cytokines, VEGF, bFGF and angipoietins are three major growth factors 
contributing to this type of actin-based motility. VEGF-R2-mediated activation of small GTPases 
of the Rho family is centrally involved in the regulation of chemotaxis. In particular, Cdc42 induces 
the formation of dynamic filopodia to sense guidance cues and migrate coordinately, and is also 
involved in the formation of stress fibres via activation of the MAPK p38 pathway (Kater et al., 
1995; Lamalice et al., 2004). Moreover, VEGF-induced activation of Rac1 leads to the formation 
of lamellipodia assuring the crawling movement of cells (Lamalice et al., 2004). The small 
GTPase RhoA is also an important regulator of EC migration and mediates VEGF-R2 
phosphorylation and downstream activation of phosphatidylinositol 3-kinase (PI3K), thereby 
regulating the function of actin-regulatory proteins such as profiling, cofilin and FAK (van Nieuw 
Amerongen et al., 2003; Gingras et al., 2000; Rousseau et al., 2000; Qi and Claesson-Welsh, 
2001). 
Haptotaxis is defined as the directional movement of cells towards a gradient of immobilised 
extracellular matrix ligands (Davis and Senger, 2005). Under physiological conditions the ECM 
contributes to maintain EC in a quiescent state. However, during early angiogenesis the ECM is 
broken down by metalloproteinases resulting in the release of mitogenic signals either generated 
by the proteolytic fragments or the release of embedded angiogenic stimuli such as VEGF, in turn 
promoting EC migration (Wang et al., 2005; Lamalice et al., 2007). The adhesive interaction that 
triggers haptotaxis of EC are mainly directed by ECM components such as collagen and 
fibronection and integrins expressed on EC (Davis and Senger, 2005). Focal adhesions are sites 
of tight adhesion where integrins connect the ECM with the cellular cytoskeleton and recruit a 
complex network of signalling and scaffolding proteins (Geiger et al., 2001). In migrating cells, 
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focal adhesions and stress fibres are aligned in the direction of migration and focal adhesions are 
characterised by a rapid turnover, thereby allowing the forward movement of the cell. Activation of 
integrins initiates and regulates angiogenic signalling. Activation of integrins at focal adhesion 
initiates and regulates several angiogenic signalling pathways that converge on actin 
polymerisation, cellular contractility and cell migration (Guo and Giancotti, 2004). Active integrins 
trigger the activation of the small GTPases Rac and Cdc42, inducing actin polymerisation and 
filament assembly, presumably through activation of the Arp2/3 complex and WASP. Moreover, 
Rac and Cdc42 activation may result in further recruitment of integrins to the tips of filopodia 
thereby forming a positive feedback loop to amplify the haptotatic signal (Hsu et al., 2005, 
Lamalice et al., 2007). Concomitantly, the activation of integrins at focal adhesion sites leads to 
the activation of RhoA and ERK pathways, resulting in increased contractility (Guo and Giancotti, 
2004; Klemke et al., 1997). Together, integrin-mediated actin polymer elongation and contractility 
trigger haptotatic EC migration. 
Mechanotaxis is the directional migration generated by mechanical forces (Li et al., 2005). Due to 
their anatomical location, EC are constantly exposed to fluid shear stress. Shear stress is sensed 
by the luminal membrane of EC and its associated receptors and transmitted throughout the cell 
activating intracellular signalling pathways that regulate EC migration. In particular, shear stress 
may induces the small GTPases Rac1 and RhoA to promote lamellipodia formation in the 
direction of flow and to increase the contractility of stress fibres at the trailing end of the cell, 
respectively (Sander et al., 1999; Li et al., 2005).  
  
Sprout fusion and lumen formation 
To form new vascular connections, tip cells need to suppress their motile, explorative behaviour. 
Strong adhesive interactions that occur when tip cells encounter each other regulate fusion of 
adjacent sprouts and vessels. VE-cadherin, a junctional transmembrane protein that mediates 
adhesive interactions between adjacent EC, is a critical regulator of vascular integrity and 
permeability and inhibits angiogenic growth (Dejana et al., 2009; Vestweber et al., 2008; 
Lampugnani et al., 2006; Abraham et al., 2009). VE-cadherin has been found to be expressed in 
filopodia and thus VE-cadherin interactions between adjacent tip cells may stabilise the contact 
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and simultaneously downregulate pro-angiogenic signalling and tip cell behaviour (Almagro et al., 
2010; Eilken and Adams, 2010).  Fantin and colleagues show that specialised macrophages 
polarised to the M2 type, which promote angiogenesis by releasing pro-angiogenic factors such 
as VEGF (Sica et al., 2008; Tammela et al., 2008), are located in the vicinity of vessel branches 
and that these tissue-resident macrophages can act as bridges between adjacent tip cells (Fantin 
et al., 2010).  
The establishment of blood flow requires the formation of a vascular lumen, which may occur in 
vascular endothelial sprouts before or after they have joined with other vessels, and involves cell 
shrinking, and vacuole formation. Intracellular and intercellular vacuoles fuse to establish a lumen 
in EC, which further requires integrin-matrix adhesions and activation of the small GTPases 
Cdc42 and Rac1 (Bayless and Davis, 2002; Davis and Bayless, 2003). 
 
Perfusion and maturation of blood vessels 
The generation of a lumen triggers the onset of blood flow. This in turn improves oxygen delivery 
to the growing vessel sprout and reduces local hypoxia-induced expression of pro-angiogenic 
factors such as VEGF (Adams and Alitalo, 2007). Perfusion also promotes maturation processes. 
Maturation describes the stepwise transition from an actively growing vascular bed to a quiescent, 
fully formed and functional network, and involves the inhibition of cell proliferation and sprouting, 
stabilisation of vessels and establishment of tight intracellular junctions, deposition of ECM 
proteins into the subendothelial basement membrane and the recruitment and incorporation of 
mural cells such as pericytes and vascular SMC (Jain et al., 2003; Cleaver and Melton, 2003). 
Pericytes establish direct cell-cell contacts with EC and cover capillaries and immature vessels, 
whereas vascular SMC cover mature arteries and veins, and are separated from the endothelium 
by a basement membrane layer (Adams and Alitalo, 2007). 
 
1.2.2. The role of vascular endothelial growth factor in angiogenesis 
The most important molecule controlling blood vessel morphogenesis is vascular endothelial 
growth factor A (VEGF-A), which is part of a large family of potent angiogenic regulators including 
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placental growth factor (PlGF), VEGF-B, VEGF-C, VEGF-D, and the Orf-virus encoded VEGF-E 
(Ferrara et al., 2003; Shibuya, 2006). Its biological importance is evidenced by the fact that the 
lack of only one VEGF allele results in embryonic lethality (Carmeliet et al., 1996; Ferrara et al., 
1996). 
In normal tissues, the highest levels of VEGF-A are found in the lung, kidney, heart, and adrenal 
gland and lower levels in liver, spleen and the gastrointestinal tract. Human VEGF-A is a 32 to 42 
kDa, homodimeric, disulphide-bound glycoprotein, whose gene is organised as eight exons 
separated by seven introns (Houck et al., 1991; Tischer et al., 1991). In humans, alternative 
splicing results in at least seven VEGF-A isoforms, having respectively 121, 145, 148, 165, 183, 
189, or 206 amino acids after cleavage (Houck et al., 1991; Tischer et al., 1991). VEGF-A121 is a 
freely diffusible polypetide with no heparin-binding properties, whereas VEGF-A189 and VEGF-A206 
bind to heparin with high affinity and are tightly bound to ECM proteoglycans (Houck et al., 1992). 
VEGF-A165 (here referred to as VEGF) is the most predominant isoform and has intermediary 
properties. VEGF contains only one of two possible heparin-binding domains and exists in part as 
a secreted, moderately diffusible protein, but a significant fraction remains bound to the cell 
surface and ECM (Park et al., 1993). The latter may be released in a diffusible form by plasmin 
cleavage (Houck et al., 1992).   
VEGF is a high affinity ligand for the tyrosine kinase receptors (RTK) VEGF-R1/Flt1 and VEGF-
R2/KDR/Flk (Terman et al., 1994). Both receptors consist of seven immunoglobulin-like domains 
in the extracellular domain, a single transmembrane region and a consensus tyrosine kinase 
sequence that is interrupted by a kinase-insert domain (Shibuya et al., 1990; Terman et al., 1991). 
VEGF-R1 is also recognised by PlGF and VEGF-B, and VEGF-E as well as VEGF-C and VEGF-
D bind and activate VEGF-R2 (Gale and Yancopoulous, 1999). In addition, VEGF-C and VEGF-D 
have high binding affinities for VEGF-R3/Flt4 (Joukov et al., 1996; Achen et al., 1998). Soluble 
VEGF-R1 (sVEGF-R1), which is physiologically released and acts as a VEGF antagonist, may be 
overproduced in some pathologies. sVEGF-R1 is bound and activated by PlGF and VEGF-B 
(Hornig and Weich, 1999). VEGF family members also interact with a family of co-receptors, 
namely the neuropilins NRP1 and NRP2 (Fig. 1.9.) (Soker et al., 1998).  
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Figure 1. 9.: The VEGF family and its receptors. The VEGF family consists of the four VEGF 
genes VEGF-A, VEGF-B, VEGF-C, VEGF-D, the Orf-virus encoded VEGF-E, and the related 
growth factor PlGF. VEGF-A binds and activates the tyrosine kinase receptors (RTKs) VEGF-R1 
and VEGF-R2. VEGF-R1 is also activated by PlGF and VEGF-B. VEGF-C and VEGF-B bind to 
and activate VEGF-R2 and VEGF-R3, whereas VEGF-E has only high binding affinity for VEGF-
R2. In addition to RTKs, VEGF family members interact with neutropilin co-receptors (NRP1, 
NRP2) (adapted from Shibuya, 2009). 
 
In endothelial cells, VEGF stimulates differentiation, survival, migration, proliferation, 
tubulogenesis and vascular permeability. This multifunctionality of VEGF results from its ability to 
activate diverse, complex and integrated signalling pathways (Carmeliet, 2000; Ferrara, 2000; 
Zachary and Gliki, 2001). VEGF-R2 is the major mediator of the mitogenic, angiogenic and 
permeability-enhancing effects of VEGF and its key role in angiogenesis is revealed by the lack of 
vascuologenesis and failure to develop blood islands and organised blood vessels in VEGF-R2 
knockout mice, resulting in embryonic lethality between gestation days 8.5 and 9.5 (Shalaby et 
al., 1995). VEGF-R2 signalling is initiated through ligand-induced receptor dimerization and 
autophosphorylation of tyrosine residues in the cytoplasmic domain (Fig. 1.10.).  
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VEGF-mediated survival is mainly regulated via PI3K signalling. PI3K-dependent activation of the 
anti-apoptotic kinase Akt/protein B in turn results in the phosphorylation and inactivation of the 
pro-apoptotic mediators Bad and caspase-9. Moreover, VEGF induces anti-apoptotic proteins, 
including Bcl-2 and A1, inhibitors of apoptosis proteins (IAPs), survivin and X-chromosome-linked 
IAP (XIAP) (Gerber et al., 1998; Tran et al., 1999). Akt survival signalling further mediates VEGF-
induced NO production via eNOS phosphorylation (Dimmeler et al., 1999; Fulton et al., 1999). 
Moreover, VEGF-induced PI3K/Akt signalling is dependent on VE-cadherin, as indicated by 
reduced Akt signalling and Bcl-2 expression in response to VE-cadherin deficiency (Carmeliet et 
al., 1999). 
The proliferative effects of VEGF during the angiogenic process are mainly regulated by the 
MAPKs ERK1 and ERK2. VEGF-R2-dependent activation of ERK1/ERK2 is initiated by 
phosphorylation of growth factor receptor-bound protein 2 (Grb2) and subsequent stimulation of 
the guanine nucleotide exchange factor SOS (son of sevenless) and Ras activation, leading to 
activation of the Raf-1/MEK/ERK cascade (Ilan et al., 1998). Mitogenic signalling of VEGF can be 
also regulated via a Ras-independent pathway involving phospholipase C-γ (PLC-γ) (Takahashi 
et al., 1999; Gliki et al., 2001). VEGF induces PLC-γ phosphorylation leading to the activation of 
PKC. PKC mediates activation of ERK1/2 via Raf-1 and MEK. PKC inhibition blocks VEGF 
signalling and subsequent angiogenic capacities of EC (Xia et al., 1996; Wellner et al., 1999; 
Higaki et al., 1999; Gliki et al., 2002). Studies also point towards a cross-talk between the ERK 
and JNK MAPK pathways in the regulation of EC proliferation. VEGF activates JNK and 
expression of a dominant-negative JNK-1 mutant inhibited VEGF-induced thymidine 
incorporation, while a dominant-negative ERK2 mutant blocked JNK activation (Pedram et al., 
1998). 
VEGF-mediated EC migration involves activation of p38 MAPK downstream of the small GTPase 
Cdc42, resulting in actin remodelling and EC migration, effects inhibited by a p38 inhibitor 
(Rousseau et al., 2000). VEGF-R2 signalling has also been shown to activate other small 
GTPases including RhoA and Rac1, in turn promoting cell migration (Zeng et al., 2002). The 
vasodilator NO may also regulate VEGF-induced migration dependent on eNOS phosphorylation 
(Dimmeler et al., 2000). Another key signalling pathway in VEGF-mediated EC migration involves 
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phosphorylation of FAK and focal adhesion-associated protein paxillin to recruit FAK to focal 
adhesion in EC (Abedi and Zachary, 1997; Abu-Ghazaleh, 2001). 
Although signalling pathways regulating VEGF-induced cell permeability still remain poorly 
understood, they may involve PI3K/Akt-dependent phosphorylation of eNOS and subsequent NO 
production (Zachary, 2003). Moreover, VEGF-induced phosphorylation of components of 
adherens and tight junctions may be a mechanism through which endothelial cell-cell adhesions 
are disrupted, leading to increased permeability (Esser et al., 1998; Zachary and Gliki, 2001). 
Indeed, VEGF stimulation promotes rapid endocytosis of VE-cadherin, thereby disrupting the 
endothelial barrier function. This process is initiated by VEGF-R2-dependent activation of Rac, in 
turn promoting p21-activated kinase (PAK)-mediated phosphorylation of VE-cadherin (Gavard 
and Gutkind, 2008). 
VEGF-R2-dependent VEGF signalling further determines the fate of individual cells by enabling 
one EC to take the lead and become a tip cell, while instructing adjacent cells to become stalk 
cells. Such lateral inhibition relies on tip-to-stalk communication by Dll4/Notch signalling 
(Hellström et al., 2007; Eilken and Adams, 2010). (please see section 1.1.1. Selection of 
sprouting EC). 
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Figure 1. 10.: VEGF signalling pathways in the regulation of angiogenesis. VEGF is a high 
affinity ligand for the tyrosine kinase receptor VEGF-R2, which is the main signal transducing 
VEGF receptor for angiogenesis and mitogenesis of EC. Ligand binding results in receptor 
dimerization and autophosphorylation, which in turn activates PI3K/Akt, MAPK p38, ERK1/2, and 
JNK MAPK signalling pathways. VEGF plays important roles during angiogenic remodelling, 
regulating EC survival, proliferation and migration, as well as cell organisation. 
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1.2.3. Angiogenesis in disease 
Angiogenesis occurs primarily during embryogenesis and development and only to a limited 
extent in postnatal life contributing to organ growth. Physiological angiogenesis in adults is mainly 
downregulated, with blood vessels exhibiting a quiescent phenotype, but is reactivated during the 
female reproductive cycle, is necessary for maturation of oocytes, and plays a profound role 
during pregnancy, establishing a link between the maternal and foetal circulation in the placenta. 
Besides those internally regulated processes, angiogenesis is an inherent feature of wound 
healing and repair. Moreover, dysregulated angiogenesis is involved in numerous diseases 
ranging from cancer to chronic inflammatory syndromes such as atherosclerosis, rheumatoid 
arthritis, diabetes mellitus, and ischaemic heart disease (Carmeliet, 2005; Bouïs et al., 2006; Sun 
and Schiller, 2007). 
 
Angiogenesis in atherosclerosis 
Human arteries possess a microvasculature in their advential layers called the vaso vasorum. 
Normal vaso vasorum originate from coronary artery branch points at regular intervals and run 
longitudinally along the vessel wall. These vessels then separate to form circumferential arches 
around the main coronary lumen. Because diffusion of blood nutrients from the lumen is limited to 
a distance of ~100 µm, a primary function of these vessels is thought to be the transport of 
nutrients to the vessel wall (Heistadt and Marcus, 1979; Khurana et al., 2005). 
Angiogenesis is a recognised feature of the atherogenic process in both coronary and carotid 
disease. Numerous studies further confirm the presence of an increased microvessel density in 
vulnerable and ruptured plaques compared with stable lesions, arising from repeated activation 
and proliferation of the dense network of vessels in the adventitia adjacent to a plaque (Fleiner et 
al., 2004, Jerziorska and Wooley, 1999, and Morena et al., 2004). In developing lesions, new 
vaso vasorum invade the intima at specific sites of medial disruption, whilst the intima and media 
of complicated plaques in coronary atherosclerotic vessels are infiltrated with a tumour-like mass 
of microvessels which are prone to leak, and are associated with a high degree of macrophage 
infiltration and thin-cap lesions (Herrmann et al., 2006; Moreno et al., 2004). These angiogenic 
blood vessels have been identified in complex regions of human aortic lesions following CD105 
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(endoglin) and TGFβ-1 immunostaining (Piao and Tokunaga, 2006), and are thought to be 
important regulators of plaque growth and lesion instability. In addition to an association between 
microvessels and vulnerable plaques, the expression of several pro-angiogenic cytokines in 
human lesions, including VEGF and its receptors, bFGF, PDGF, HGF, and TGFβ-1, further 
supports a role for angiogenesis in atherosclerosis (Hughes et al., 1993; Lappalainen et al., 2004; 
Ignatescu et al., 1999; Lupia et al., 2003; Barrett and Benditt, 1988; Ma et al., 2002). The 
strongest experimental evidence that angiogenesis plays a causative role in the atherogenic 
process has come from studies in the hypercholesterolemic ApoE
-/-
 mouse model, demonstrating 
that the endothelium-specific anti-angiogenic agents endostatin, TNP-40 and angiostatin 
significantly reduce plaque formation when compared to control mice (Moulton et al., 1999; 
Moulton et al., 2003). Moreover, intraperitoneal administration of human VEGF protein into 
ApoE/ApoB100 double knockout mice promotes atherosclerotic plaque formation in these animals 
as indicated by increased EPC and macrophage/monocytes counts, plaque EC density, and 
macrophage infiltration (Celletti et al., 2001). 
 
Angiogenesis in rheumatoid arthritis 
Rheumatoid arthritis (RA) is chronic systemic inflammatory and destructive disease predominately 
affecting the peripheral synovial joints (Paleolog, 2002). Disease progression involves an 
inflammatory response in the synovium, which significantly increases in mass due to hyperplasia 
of synovial cells and an increase in the volume of synovial fluid, resulting in joint swelling and 
pain. Blood-derived cells, including T cells, B cells, macrophages and plasma cells infiltrate the 
sublining of the synovium, resulting in the development of a fibrous tissue, the ‘pannus’, at the 
synovial interface with cartilage and bone. The pathology of the disease leads to the destruction 
of articular cartilage, subchondral bone, and periarticular soft tissues, producing deformities of the 
affected joints (Paleolog, 2002). 
Angiogenesis plays a central role in the initiation and progression of RA. Indeed, the synovium of 
RA patients is characterised by a dense vascular network, and an increase in the number of 
synovial blood vessels is essential for the expansion of synovial tissue. Moreover, the number of 
synovial blood vessels has been found to correlate with hyperplasia of synovial cells, infiltration of 
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mononuclear cells, and joint stiffness (Rooney et al., 1988). Further support for a role for 
angiogenesis in RA is the finding that EC lining the synovial blood vessel express high levels of 
PCNA and Ki67, both markers for active EC proliferation (Ceponis et al., 1998; Walsh et al., 
1998). A consequence of synovial hyperplasia is the demand for oxygen and nutrients by the 
growing tissue resulting in local hypoxia, which in turn is a potent signal for angiogenic growth. 
The augmented proliferation of synovial EC further promotes hypoxia and angiogenesis, and 
hence synovial infiltration of inflammatory cytokines and growth factors and eventually 
hyperplasia (Paleolog, 2002). In fact, VEGF levels are significantly increased in serum and 
synovial fluid from RA patients when compared to normal controls and serum VEGF 
concentration correlates with C-reactive protein expression, a marker for inflammation and 
disease activity (Koch et al., 1994; Paleolog et al., 1998; Lee et al., 2001). Moreover, EC lining 
small blood vessels in the pannus stain positive for VEGF (Koch et al., 1994, Fava et al., 1994; 
Pufe et al., 2001). Other angiogenic growth factors have been reported to be expressed in 
synovial fluid and tissue from RA patients and may contribute to disease initiation and progress, 
including acidic and basic FGF, PDGF and HGF (Koch, 2000; Paleolog, 2002). 
 
Diabetes mellitus 
Diabetes mellitus is a chronic metabolic disease characterised by hyperglycaemia due to lack of 
(type I) or resitance to insulin (type 2) (Kolluru et al., 2012). Diabetic patients are frequently 
afflicted with cardiovascular complications such as accelerated atherosclerosis, endothelial 
dysfunction, impaired neovascularisation and wound healing, demonstrate vascular abnormalities 
of the retina, the kidneys, and have an increased risk of organ transplant rejection (Martin et al., 
2003; Kolluru et al., 2012). In each of these complications, abnormal angiogenesis can be 
implicated in the pathogenesis. Indeed, diabetic retinopathy arises from excessive angiogenesis. 
Hyperglycemia-induced intramural pericyte apoptosis leads to an impaired blood-retina-barrier 
and chronic hypoxia, followed by aberrant neovascularisation. The resulting vessels are 
malformed and show increased permeability and are prone to haemorrhage (Lip et al., 2000; 
Geraldes et al., 2009). In contrast, impaired diabetic wound healing is the consequence of a 
deficiency in angiogenesis (Martin et al., 2003). Wound healing is a multistep process involving 
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haemostasis, inflammation and debridement, proliferation, epithelialisation, and remodelling 
(Loots et al., 1999). The non-healing nature of diabetic wounds has been attributed to 
disturbances in both the inflammation/debridement phase and the proliferation phase, which 
prevent the wound from progressing to a later step of the healing process (Loots et al., 1999).  
 
Aberrant angiogenesis is also intimately associated with solid tumour growth. The study of tumour 
angiogenesis is a rapidly developing field and is beyond the scope of this thesis. Angiogenesis 
promotes tumour growth and persistence of primary solid tumours and their metastases. An 
increase in vascular density allows easier access of tumour cells in the circulation and correlates 
with the invasive properties of tumours and thus the malignant tumour phenotype (Cavallaro and 
Christofori, 2000). A variety of anti-angiogenic drugs are being studied in clinical trials in various 
malignant diseases. For example the anti-VEGF drug avastin has been approved in the treatment 
of colonic carcinoma. 
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1.3. THE HEME OXYGENASE SYSTEM 
Heme oxygenases (HO) are the rate-limiting enzymes in the degradation of heme into equimolar 
amounts of carbon monoxide, biliverdin/bilirubin, and free iron. In humans, two distinct isoforms 
have been identified, namely the inducible HO-1 and the constitutive HO-2. HO enzymes and 
their products play a critical role in the vasculature by exhibiting important physiological actions 
that are ultimately linked to endothelial cell protection, including anti-inflammatory, anti-oxidant, 
and anti-apoptotic effects. Induction of HO-1 is an important cellular adaptive response, 
minimising tissue injury and facilitating repair. In addition, a role for HO-1 in the regulation of 
angiogenesis has been proposed (Kim et al., 2011). 
 
1.3.1. Heme oxygenases: An introduction 
Heme oxygenases catalyse the rate-limiting step in heme metabolism. Both HO isoforms oxidise 
heme (ferriprotoporphyrin IX) to the bile pigment biliverdin-IXα. Biliverdin-IXα is further 
metabolised to bilirubin-IXα by NAD(P)H:biliverdin reductase (BVR). HO-catalysed heme 
cleavage releases iron in its ferrous form Fe II (Fe
2+
) and eliminates the α-methene-bridge carbon 
of heme as carbon monoxide (CO) (Tenhunen et al., 1969). The enzymatic activity of HO requires 
three moles of molecular oxygen (O2) per heme molecule oxidised and reducing equivalents from 
NAPDH:cytochrome P450 (cytochrome C) reductase (Fig. 1.11.). The generation and release of 
intracellular Fe
2+
 during heme metabolism induces expression of the iron-binding protein ferritin 
heavy chain (FHC). FHC associates with ferritin light chain to form a multimeric complex (Harrison 
and Arosio, 1996) and catalyses the oxidation of iron from the ferrous (Fe
2+
) to the ferric form 
(Fe
3+
) (Balla et al.,1992; Berberat et al., 2003). HO-mediated cleavage of the α-methene-bridge 
carbon is inhibited by various metalloporphyrins, including the synthetic HO antagonists zinc 
protoporphyrin (ZnPP) and tin protoporphyrin (SnPP) (Ryter et al., 2006). 
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Figure 1. 11.: Oxidative degradation of heme by HO enzymes. HO isoforms (HO-1, HO-2) 
catalyse the degradation of heme into its products carbon monoxide (CO), ferrous iron (Fe
2+
), 
thereby inducing the expression of ferritin, and biliverdin-IXα, which is converted into bilirubin-IX 
by the NAPDH-dependent biliverdin reductase (BVR). Enzymatic activity of HO requires 3 moles 
of molecular oxygen (O2) and NAPDH:cytochrome P450 as an electron source. Each product 
activates several cytoprotective pathways in the vascular endothelium. 
 
Two genetically distinct HO isoforms have been identified in mammals, the inducible isoform HO-
1 and the constitutively expressed HO-2. Both proteins are products of distinct genes, but share 
43% amino acid sequence homology (Fig. 1.12). HO-1 is the product of only one transcript, but 
HO-2 is encoded by two transcripts from one gene arising from differences in polyadenylation 
(McCoubry and Maines, 1994). The two HO isoforms share a heme catalytic site that allows them 
to have similar functions in heme degradation, but vary in terms of tissue distribution, regulation 
and kinetics (Maines et al., 1986). Analysis of the crystal structure of mammalian HO-1 reveals 
that it is composed of 7 α-helicals with heme fitting into the heme pocket between the proximal 
and distal helix (Dennery, 2005). The crytal structure of HO-2 has not been identified yet, but 
differences in the structure of the two isoforms may account for their different kinetic properties. 
Indeed, comparison the amino acid sequence of the two isoforms, show that HO-1 and HO-2 
differ at their amino and carboxy terminus. The amino terminus of HO-2 has additional residues 
which help to account for the differences in size of the isoforms (McCoubrey and Maines, 1993; 
Dennery, 2005). In addition, numerous serine phosphorylation sites have been identified for HO-
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2. Although the precise mechanisms remain elusive, phosphorylation of serine residues has been 
shown to alter HO-2 activity (Dore et al., 1996). It is therefore plausible to suggest that HO activity 
could be modified by posttranslational events such as phosphorylation or mutations of the amino 
acid sequence, which may alter the heme catalytic site. The heme pocket of HO enzymes is 
flexible and can open and close which allows for increased distance between heme and the 
catalytic site in turn affecting HO activity. Furthermore, the multi-step process of HO reaction has 
differing reaction rates. The biliverdin formation step is rate limiting whereas the oxygen binding 
followed by a second electron transfer to give biliverdin products is more rapid (Trakshel and 
Maines, 1989; Colas and Ortiz de Montellan, 2003). These variations in rates of synthesis of 
biliverdin suggest that there could be many conditions where the rate of heme degradation is 
altered thereby affecting the HO activity level. 
 
Figure 1. 12: Crystal structure of HO-1 and amino acid sequence alignment of HO-1 and 
HO-2. (A) Crystal structure of HO-1 (adapted from Dennery, 2005). (B) HO-1 and HO-2 share 
43% amino acid homology. Conserved amino acids are marked in green (modified after 
Linnenbaum et al., 2012). 
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HO-1 is a 32 kDa protein, also denoted as heat shock protein 32 (HSP32) (Keyse and Tyrrell, 
1989). Apart from high expression levels in the spleen and specialised reticuloendothelial cells, 
HO-1 is typically expressed at low to undetectable levels under basal conditions, but rapidly 
responds to transcriptional activation by numerous physiological and pathological stimuli, 
including heme, hypoxia, heavy metals, NO and reactive oxygen species (ROS), as well as pro-
inflammatory cytokines and haemodynamic forces exerted by the flowing blood (Wagner et al., 
1997; Ryter and Choi, 2002; Ali et al., 2009). Thus, HO-1 is a stress-induced protein which aims 
to maintain cellular integrity (Ryter et al., 2006). In regard of compartmentalisation, HO-1 is 
predominantly localised to the endoplasmic reticulum (ER), but can be found in other subcellular 
domains, including the plasma membrane and the nucleus (Ishikawa et al., 1991; Shibahara et 
al., 1985; Kim et al., 2004; Ryter et al., 2006). 
HO-2, a 36 kDa protein, is constitutively expressed and present at high levels in the brain and 
testes, and is also abundantly and ubiquitously expressed in the endothelium, liver, kidney and 
gut (Maines, 1997; Maines et al., 1986; Trakshel et al., 1986; Zachary et al., 1996). Unlike HO-1, 
HO-2 does not respond to transcriptional activation by environmental stress but may be 
transcriptionally modulated by corticosteroids and its activity may be dynamically regulated by 
post-translational modifications, as indicated by the three cysteine phosphorylation sites present 
in the HO-2 protein (Maines et al., 1997; Raju et al., 1997; Boehning et al., 2003). Moreover, the 
function of HO-2 is poorly understood but may include a regulatory role in heme homeostasis, by 
sequestering heme to maintain the intracellular heme level. HO-2 may also function as an oxygen 
sensor and HO-2 deletion causes EC activation marked by oxidative stress, inflammation and 
angiogenesis, underscoring important functions of this enzyme in endothelial homeostasis (Kemp, 
2005; Bellner et al., 2009). In addition, HO-2 deficiency is associated with impaired reparative and 
inflammatory responses after injury, implicating a role for HO-2 in the regulation of these 
responses (Seta et al., 2006).  Moreover, it has been postulated that HO-2 is critical for HO-1 
expression, which may explain why HO-2 null mice cannot compensate for the loss of HO-2 by 
increasing HO-1 expression (Sodhi et al., 2009). 
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1.3.2. Regulation of HO-1 expression  
The human HO-1 gene (HMOX1) is organised into five exons and four introns and is located on 
chromosome position 22q12 and its expression is mainly regulated at the transcriptional level 
(Shibahara et al., 1989; Gozzelino et al., 2010). HMOX1 transcription can be induced by a variety 
of signal transduction pathways in an inducer-, cell-type- and species-specific manner. A 
significant role in the activation of HO-1 has been implicated for mitogen-activated protein kinases 
(MAPK). MAPKs belong to the signal transduction superfamily of serine/threonine kinases that 
regulate cellular growth, apoptosis, motility, differentiation, and responses to environmental 
stimuli. The MAPK superfamily is comprised of the extracellular signal regulated kinases 
(ERK1/2), the c-Jun NH2-terminal kinase (JNK), and the p38 MAPK signalling cascade. Each 
kinase sequentially phosphorylates and activates its downstream target kinases, that ultimately 
converge on multiple target proteins, including transcription factors (Kyriakis and Avruch, 2001; 
Cowan and Storey, 2003).  
p38 MAPK signalling has been described as the major MAPK pathway responsible for HO-1 gene 
activation (Kacimi et al., 2000), whereas a number of in vitro and in vivo models now suggest that 
simultaneous activation of more than one MAPK pathway is required for optimal gene induction 
(Chen and Maines, 2000; Zhang et al., 2002; Ryter et al., 2006). Phosphorylation-dependent 
activation of these signalling cascades ultimately activates transcription factors that regulate 
HMOX1 transcription including KLF-2, Nrf-2, CREB, NFκB, AP-1, and ETS factors that recognise 
specific response element-rich regions within the proximal (-0.3 kb) and distal (-4 kb and -10 kb) 
HMOX1 promoter  (Fig. 1.13.) (Ryter et al., 2006; H. Mylroie, unpublished data). The distal -10 kb 
HMOX1 promoter region has been implicated in the upregulation of HO-1 in response to organic 
hydroperoxides (Hill-Kapturczak et al., 2003a), and the -4 kb region mediates in part the induction 
response to heme and cadmium (Hill-Kaptuczek et al., 2003b; Takeda et al., 1994), as well as 
shear stress, NO donor compounds, cigarette smoke, and oxidised phospholipids (Chen et al., 
2003; Hara et al., 1999; Favatier and Polla, 2001; Kronke et al., 2003). An additional response-
rich region, the -0.3 kb region, has been identified in the proximal promoter adjacent to the 
transcriptional start site, containing binding sites for ETS transcription factors, NFκB, and activator 
protein 2 (AP-2) (Deramaudt et al., 1999; Lavrovsky et al., 1994). The dominant sequence 
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element in these transcription enhancer regions is the stress-responsive element (StRE), a 10 bp 
motif with the consensus sequence of (T/C)GCTGAGTCA. The StrRE, which is structurally and 
functionally similar to the Maf response element (MARE) and the anti-oxidant response element 
(ARE), mediates transcription to almost all HO-1 inducers via c-Jun, CREB, ATF, Maf and Nrf-2 
transcription factors (Ryter et al., 2006). A distinct StRE-binding factor, Bach 1, is critical for the 
negative regulation of HMOX1 transcription. Bach-1 dimerises with Maf proteins and competes 
against Nrf-2/Maf dimers for binding at the StRE. Unlike Nrf-2, Bach 1 lacks a transactivation 
domain and therefore functions as a transcriptional repressor (Sun et al., 2002). Although there 
are multiple positive regulatory elements, only two negative regulatory regions located at -981 bp 
and -412 bp have been identified (Takahashi et al., 1999). In addition, another potential negative 
regulatory element specific to the human HMOX1 promoter corresponds to a variable GT-rich 
region ((GT)n). Both inducible and basal expression of HO-1 is variable in the human population, 
reflecting the presence of highly polymorphic fragments in the human HMOX1 locus, including a 
(GT)n microsatellite polymorphism, ranging from 11 to 42 repeats, in the proximal HMOX1 
promoter region (Exner et at., 2004). In recent years, research has shown that these (GT)n 
repeats affect transcription, modulate basal and induced HO-1 expression and are of clinical 
relevance.  
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Figure 1. 13.: Signalling and transcriptional mechanisms leading to HMOX1 activation. 
Numerous inducers of HO-1 activate protein phosphorylation-dependent signalling cascades that 
ultimately converge on the transcription factors that regulate the HMOX1 gene by binding to 
specific response elements in the proximal (-0.3 kb) and/or distal (-4 kb and -10 kb) regions of the 
HMOX1 promoter. AP-1 – activator protein 1, ATF-2 – activating transcription factor 2, BVR – 
biliverdin reductase, CREB – cAMP response element-binding protein, KLF-2 – Krüppel-like factor 
2, MAPK – mitogen-activated protein kinase, NFκB – nuclear factor kappa B, Nrf-2 – NF-E2 
related factor 2; PI3K- phosphoinositide 3-kinase; PKA – protein kinase A, PKC – protein kinase 
C, Sp-1 – specificity protein 1 (modified after Ryter et al., 2006; Kim et al., 2011). 
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1.3.3. Cytoprotective mechanisms of HO-1 and its products 
Heme consists of a tetrapyrrole ring with a central iron ion and is the most abundant source of 
redox active iron in the human body. Heme exhibits contradictory biological functions. On the one 
hand heme is responsible for oxygen and mitochondrial electron support as an essential 
prosthetic group of haemoglobin, myoglobin and cytochromes (Wijayanti et al., 2004; Mense and 
Zhang, 2006). On the other hand, non-protein bound free heme is inherently dangerous and 
greatly amplifies cellular damage arising from activated oxygen, with the vasculature being at 
particular risk (Balla et al., 2007). Heme degradation and removal of the highly reactive heme 
moiety from cells and tissues by HO-1 was the initial explanation for the protective effects 
afforded by HO-1 (Maines et al., 1993; Otterbein et al., 2003; Kirkby and Adin, 2006).  
The importance of HO-1 in heme and iron metabolism was first demonstrated by Tonegawa and 
Poss who characterised the HO-1-deficient mouse (HO-1
-/-
). HO-1
-/-
 mice demonstrate a state of 
iron overload, excess tissue iron deposition, splenomegaly, hepatitis with hepatic fibrosis and 
premature mortality. In addition, they suffer from chronic inflammation and exaggerated sensitivity 
to stress, and have been shown to develop more extensive and complex atherosclerotic lesions 
when bred on an ApoE
-/-
 background (Poss and Tonegawa, 1997; Yet et al., 2003). In man, HO-1 
deficiency is a rare phenomenon and the first reported case was of a child that died at the age of 
six and suffered a chronic inflammatory illness characterised by intravascular haemolysis and 
heme-induced endothelial cell damage. The inability to handle free iron results in iron 
accumulation within, and enhanced oxidative modification of LDL, leading to endothelial damage, 
fatty streak  and fibrous plaque formation within the vascular wall (Yachie et al., 1999; Kawashima 
et al., 2002). Furthermore, endothelial cells obtained from this patient were more susceptible to 
oxidative stress in vitro (Jeney et al., 2002). These observations suggested that HO-1 is a critical 
vascular anti-oxidant and anti-inflammatory system in man. 
Atherosclerosis, a multifactorial, progressive disease of large and medium-sized arteries 
characterised by EC dysfunction, vascular inflammation and the accumulation of lipids, fibrous 
materials, calcium and cellular debris within the vessel wall, is the most prevalent disease in 
developed countries (Cines et al., 1998; Ross et al., 1999). Numerous studies suggest that HO-1 
is a readily inducible cytoprotective protein during atherogenesis exhibiting anti-inflammatory, 
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anti-oxidant and vasodilatory actions, as well as inhibitory effects on SMC proliferation. 
Atherosclerotic risk factors such as raised oxidised LDL, cigarette smoke and hypertension induce 
HO-1 (Ishizaka et al., 1997; Ishikawa et al., 1997; Favatier and Polla, 2001). Indeed, HO-1 
expression is greatly upregulated in atherosclerotic plaques in all cell types and the degree of 
expression correlates with the severity of the lesion (Wang et al., 1998; Morsi et al., 2006). The 
multiple anti-inflammatory, anti-oxidant and cytoprotective properties of HO-1 are evident in 
several cell types involved in atherosclerosis. In endothelial cells, HO-1 overexpression inhibits 
ROS-mediated cell growth and apoptosis and attenuates macrophage-derived superoxide 
formation by inhibiting NADPH oxidase assembly and activity (Abraham et al., 2003; Taille et al., 
2004). In addition, HO-1 inhibits TNF-α-mediated E-selectin and VCAM-1 upregulation thereby 
preventing leukocyte adhesion to the vascular endothelium, and attenuates oxidised LDL-induced 
transmigration of monocytes into the vascular wall (Kawamura et al., 2005; Hayashi et al., 1999; 
Soares et al., 2004). HO-1 has an inhibitory effect on vascular SMC proliferation and migration, 
an important step in the process of atheroma formation, by decreasing the expression of 
endothelin-1 (ET-1) and placenta-derived growth factor (PDGF) (Morita and Kourembanas, 1995). 
Of note, these actions of HO-1 may be reproduced by its products biliverdin/bilirubin and CO.  
The vascular protective effects of HO-1 have been demonstrated in several disease models 
involving HO-1 modulation and HO-1-deficient mice. Adenoviral-mediated induction of HO-1 
attenuates vascular remodelling and neointima formation following balloon injury in rat carotid 
arteries, while concomitant administration of the HO-1 inhibitor SnPP abolishes this effect (Tulis et 
al., 2001a; Tulis et al., 2001b). Moreover, the HO-1 inducer probucol inhibits vascular SMC 
proliferation and decreases the intima-media ratio in balloon-injured rat aortas (Lau et al., 2003; 
Deng et al., 2004). LDL-deficient mice fed a high-cholesterol diet abundantly express HO-1 in 
atherosclerotic lesions (Alam, 1994). Moreover, HO-1 overexpression reduces atherosclerotic 
plaque formation in this disease model, whilst inhibition of HO activity increases plasma and 
tissue lipid peroxide levels and plaque formation (Ishikawa et al., 2001). Yet and colleagues 
reported that mice deficient in both HO-1 and ApoE develop larger and more advanced 
atherosclerotic plaques, and more aggressive vein graft stenosis when compared to animals 
deficient in ApoE alone (Yet et al., 2003). In contrast, selective overexpression of HO-1 using 
adenovirus-mediated gene transfer inhibits the development of atherosclerosis in ApoE
-/-
 mice 
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(Juan et al., 2001). Furthermore, adenoviral-mediated expression of HO-1 in the porcine vascular 
wall improves vascular function and inhibits SMC proliferation by activating a guanylate cyclase 
and cGMP-dependent pathway (Duckers et al., 2001). 
More recent studies have shown that the products of heme degradation carbon monoxide, 
biliverdin/bilirubin and an increase in intracellular ferritin are more likely to be responsible for the 
biological activity of HO-1 and its cytoprotective and anti-inflammatory functions (Brouard et al., 
2000; Soares et al., 2004). 
 
Carbon monoxide 
Carbon monoxide (CO), although initially thought of as a toxic molecule, has profound influence 
on intracellular signalling processes, culminating in anti-inflammatory, anti-oxidant, and anti-
apoptotic effects (Tenhunen et al., 1969; Gozzelino et al., 2010). CO is the best studied HO 
product and is most likely to be primarily responsible for many of the cytoprotective actions.  
CO is a gaseous transcellular messenger mediating cytoprotection through activation of several 
signalling pathways. Like NO, CO interacts with soluble guanylate cyclase (sGC) resulting in 
elevation of cGMP levels that induce protective vascular relaxation (Pae et al., 2008). In fact, 
endogenous HO-1-derived CO has been reported to elevate cGMP in vascular SMC, whilst 
inhibition of sGC completely abolishes vasodilation induced by CO in rabbit aortic rings (Morita et 
al., 1995; Hussain et al., 1997). Consistent with this, HO-1 inhibition attenuates hemin-induced 
vasodilation, suggesting a role for endogenous CO from vascular tissues in vasodilation (Wang et 
al., 1997). Moreover, CO has been shown to inhibit platelet activation and aggregation via a 
guanylate cyclase/cGMP-dependent pathway (Brune and Ullrich, 1987). CO also suppresses the 
induction of plasminogen-activator inhibitor-1 (PAI-1) in macrophages, an important mediator of 
pulmonary microvascular thrombosis (Fujita et al., 2001). 
CO additionally exerts numerous anti-inflammatory, anti-apoptotic and anti-proliferative effects 
through MAPK-dependent signalling, but these may be dependent on cell type and stimuli (Morse 
and Sethi, 2002; Ryter et al., 2006). CO suppresses the expression of pro-inflammatory cytokines 
such as TNF-α and  IL-1β through modulation of p38 MAPK or JNK signalling pathways, and the 
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transcription factor AP-1, whilst enhancing the expression of anti-inflammatory mediators, 
including IL-10 (Otterbein et al., 2000; Morse et al., 2003; Ryter et al., 2006).  
The anti-proliferative effects of HO-1 on SMC and T-cells may also be attributed to CO. CO 
inhibits IL-2-dependent T-cell proliferation which may involve ERK and caspase-dependent 
pathways (Pae et al., 2004; Song et al., 2004). Similarly CO is shown to inhibit SMC proliferation 
and migration involving a guanylate cyclase and cGMP-dependent pathway, and this effect is 
associated with downregulation of endothelial-derived mitogens ET-1 and PDGF (Morita et al., 
1995; Morita and Kourembanas, 1995). CO also activates p38 MAPK signalling in SMC in turn 
inducing the expression of cell cycle inhibitor p21 and subsequent cell cycle arrest. Consistent 
with this, the anti-proliferative effect of CO is abolished in SMC from p21-deficient mice (Otterbein 
et al., 2003). 
Anti-apoptotic actions of CO were first demonstrated by in vitro studies showing enhanced 
protection against TNF-α-induced apoptosis in fibroblast and endothelial cultures exposed to 
exogenous CO (Petrache et al., 2000; Brouard et al., 2000). These effects mimic the anti-
apoptotic effects observed with HO-1 overexpression and are exerted via the p38 MAPK 
signalling pathway in human EC (Brouard et al., 2000). Furthermore, CO and HO-1 may inhibit 
TNF-α-mediated EC apoptosis through induction of anti-inflammatory genes Bcl-2, Bcl-XL, A1 
and A20 via an NFκB-dependent pathway (Brouard et al., 2002). Other signalling molecules 
which may regulate the cytoprotective effects of CO include STAT3 and HIF-1α (Otterbein et al., 
2003; Zhang et al., 2006; Chin et al., 2007). Moreover, CO exposure induces the expression of 
heat shock protein 70 in EC, which plays a critical role in protection against cytokine-induced 
apoptosis (Kim et al., 2005). The anti-apoptotic effects of CO are reinforced by several animal 
models of disease. CO protects against liver ischaemia-reperfusion injury via activation of p38 
MAPK (Amersi et al., 2002), and improved survival rates of HO-1-deficient mice in an ischaemic 
lung injury model (Fujita et al., 2001). Thus, CO mediates many of the cytoprotective effects of 
HO-1, which contribute to the maintenance of vascular homeostasis during inflammation and 
vascular injury. 
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Biliverdin and bilirubin 
There is increasing evidence that the bile pigments biliverdin and bilirubin mediate some of the 
vascular protective functions of HO-1, in turn preserving EC integrity and survival, enhancing EC 
reactivity, and inhibiting restenosis (Ryter et al., 2006).  
The protective effects of biliverdin/bilirubin have been demonstrated in multiple in vitro and in vivo 
studies. In fact, hyperbilirubinemic rats displayed reduced expression of oxidative stress markers 
in response to hyperoxia, and protection against ischaemic/reperfusion injury when compared to 
wild type animals (Dennery et al., 1995; Kitamura et al., 2003). In addition, the protective effects 
of biliverdin/bilirubin have been demonstrated in other models of vascular inflammation including 
cardiac allograft rejection and post-angioplasty restenosis (Yamashita et al., 2004; Ollinger et al., 
2005; Ollinger et al., 2007), and bilirubin plasma and serum concentration levels have been 
shown to inversely correlate with the risk of coronary artery disease and severity of 
atherosclerosis in man (Schwertner et al.,1994; Novotny and Vitek, 2003; Schwertner and Vitek, 
2008). The bile pigments biliverdin and bilirubin have been demonstrated to exhibit potent anti-
oxidant properties which may account for their anti-atherogenic effects. In fact, biliverdin and 
bilirubin can directly scavenge ROS, inhibit the oxidation of LDL and other lipids, interact with the 
free radical NO and the oxidant peroxinitrite and counteract oxidative stress overall (Neuzil and 
Stocker, 1994; Stocker et al., 1987; Schwertner et al., 1998; Mancuso et al., 2006). Bilirubin also 
exerts anti-inflammatory and anti-proliferative actions, including inhibition of the inflammatory 
adhesion proteins VCAM-1, P- and E-selectin and abrogation of leukocyte trafficking (Hayashi et 
al., 1999; Keshavan et al., 2005). HO-1-derived bilirubin also attenuates EC activation and 
dysfunction (Kawamura et al., 2005). Moreover, biliverdin treatment inhibits NFκB activation in 
response to TNF-α and LPS (Gibbs and Maines, 2007; Wegiel et al., 2009).  
The anti-proliferative effects of biliverdin/bilirubin were demonstrated in vascular SMC. 
Administration of exogenous biliverdin/bilirubin resulted in G1-phase cell cycle arrest, an effect 
associated with diminished expression of positive cell cycle regulators, including A-, D-, and E-
type cyclins as well as Cdk2, resulting in hypophosphorylation and activation of pRb (Ollinger et 
al., 2005). In addition, recent work from our laboratory demonstrated that HO-1-derived bilirubin 
protects EC from complement-dependent injury through induction of decay-accelerating factor 
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(DAF) (Kinderlerer et al., 2009). The notion that oxidation of bilirubin by ROS results in the 
formation of biliverdin, which in turn is reduced to bilirubin by BVR, led to the postulation that this 
increase in bilirubin augments the protective properties of biliverdin/bilirubin, forming a 
cytoprotective amplification loop (Baranano et al., 2002). This might relate to the ability of 
biliverdin reductase to exhibit serine/threonine and tyrosine activity. Indeed, BVR has been 
identified as a signalling molecule in various cytoprotective pathways (Salim et al., 2001; Lerner-
Marmarosh et al., 2005). Thus, phosphorylation of cell surface-associated BVR leads to 
phosphorylation and activation of Akt/PKB via PI3K signalling, thereby enhancing the production 
of IL-10 in various cell types including macrophages and EC (Wegiel et al., 2009). Furthermore, 
BVR also activates signalling pathways involving MAPKs and protein kinase C by direct 
interaction and phosphorylation (Amit and Boneh, 1993; Hansen et al., 1996). Thus, the bile 
pigments biliverdin and bilirubin as well as biliverdin reductase represent a distinct pathway with 
various anti-oxidant and anti-inflammatory effects which ultimately confer vascular protection. 
 
Ferrous iron and ferritin 
Ferrous iron (Fe
2+
), is an extremely pro-oxidative molecule and is released during the breakdown 
of free heme by HO-1, but is rapidly removed by ferritin. Ferritin is a ubiquitously existing 
intracellular multimeric protein complex consisting of a heavy chain and a light chain subunit 
(Harrison and Arosio, 1996). Ferritin is able to effectively sequester intracellular iron and, hence, 
limits the pro-oxidant capacity of Fe
2+
 by catalysing the oxidation to the ferric form Fe
3+
 (Balla et 
al., 1992; Berberat et al., 2003). It is likely that increased ferritin expression in conjunction with 
HO-1 expression may contribute to additional protection afforded by HO-1 (Balla et al., 1992; 
Ryter et al., 2006). Indeed, ferritin co-localises with HO-1 in atherosclerotic lesions and its 
expression is significantly upregulated in various cell types present in atherosclerotic plaques 
including macrophages, fibroblasts and EC, and this may confer protection against oxidised LDL 
(Juckett et al., 1995). Ferritin also demonstrates EC anti-apoptotic effects, inhibits complement 
activation by enhancing endothelial DAF expression and may inhibit cytokine-induced leukocyte 
adhesion molecule upregulation (Pham et al., 2004; Soares et al., 2004; Kinderlerer et al., 2009). 
In vivo, the salutary effects of ferritin appear to be dependent on the disease model and cell type. 
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In a rat model of endotoxic shock, ferritin and iron dosing was insufficient to offer protection 
(Otterbein et al., 1997). However, overexpression of FHC attenuated ischaemia-reperfusion-
induced liver injury and protected EC and hepatocytes from apoptosis (Berberat et al., 2003). 
The recognition of the highly inducible properties of HO-1 in conjunction with its multiple anti-
inflammatory, anti-oxidant, and anti-apoptotic properties have aroused interest in HO-1 and its 
products as a therapeutic target for several varied inflammatory diseases including 
atherosclerosis, transplant rejection and ischaemia-reperfusion injury.  
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1.3.4. HO-1 and angiogenesis 
Reparative and pathological angiogenesis is driven by various inflammatory mediators that 
influence the synthesis of growth factors. Indeed, reactive oxygen species and nitric oxide have 
been shown to regulate the synthesis and activity of VEGF, the most important molecule 
controlling blood vessel morphogenesis (Chua et al., 1998; Murohara and Asahara, 2002; Ushio-
Fukai, 2006). Moreover, expression of the cytoprotective enzyme HO-1, which is also induced by 
ROS and NO in the vascular endothelium, has been shown to be upregulated in response to 
VEGF, indicating a potential role for HO-1 in the regulation of VEGF-mediated angiogenesis. Data 
to date suggest that HO-1 may influence angiogenesis at various levels, affecting the proliferative 
and migratory capacities of endothelial cells as well as their subsequent formation into lumenised 
vessels. 
The first evidence came from Deramaudt and colleagues in 1998, demonstrating that gene 
transfer of human HO-1 into coronary EC enhances their proliferation and formation of capillary-
like structures (Deramaudt et al., 1998). HO-1 overexpression promotes cell cycle progression of 
EC, but has contrary effects on that of vascular SMC (Li Volti et al., 2002). Moreover, in vascular 
SMC, HO-1-derived CO has been shown to activate p38 MAPK signalling and upregulate 
caveolin-1, which in turn inhibits cell proliferation (Kim et al., 2005). Supportive of the proliferative 
effects of HO-1 in the endothelium, studies from our laboratory show that overexpression of HO-1 
utilising a recombinant adenovirus expressing the human HO-1 gene increases proliferation of EC 
isolated from human umbilical veins (Bussolati and Mason, 2006). In contrast, inhibition of HO-1 
decreases EC proliferation, capillary formation, and cell cycle progression (Bussolati et al., 2004; 
Li Volti et al., 2005). Moreover, this effect is associated with an increased expression of the cell 
cycle inhibitors p21 and p27, and is restored by CO but not bilirubin (Li Volti et al., 2005). The 
proliferative effects of HO-1 are reinforced by studies utilising aortic EC isolated from HO-1-
deficient mice. When compared to HO-1
+/+
 littermate controls, HO-1
-/-
 MAEC demonstrate 
reduced proliferation (Chen et al., 2004).  
HO-1 may indirectly affect angiogenesis through its ability to increase VEGF synthesis. In fact, 
augmentation of HO-1 by inducers such as heme, cobalt protoporphyrin (CoPP), prostaglandin J2 
(PGJ2), hydrogen peroxide (H2O2), or hypoxia leads to stimulation of VEGF synthesis in a HO-1-
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dependent manner (Dulak et al., 2002; Jozkowicz et al., 2002; Marinissen et al., 2006; Dulak et 
al., 2008). Consistent with these findings, overexpression of HO-1 in vascular SMC and EC 
increases the production of VEGF, whilst the pharmacological antagonists SnPP and ZnPP inhibit 
hypoxia- and PGJ2-induced VEGF biosynthesis (Dulak et al., 2002; Jozkowicz et al., 2002; 
Jozkowicz et al., 2003). Furthermore, MAEC deficient in HO-1
-/-
 show decreased VEGF synthesis 
in response to H2O2 (Ciscowski et al., 2005). In a rat model of hindlimb ischaemia, overexpression 
of HO-1 enhances VEGF synthesis and augments the formation of vascular capillaries, and in 
turn improves blood flow in ischaemic tissues, an effect abolished by a pharmacologic antagonist 
of HO-1, ZnPP (Suzuki et al., 2003). HO-1 overexpression promotes VEGF synthesis and 
modulates foetal growth in the rat (Kreiser et al., 2002). Besides acting as an inducer of VEGF, 
HO-1 appears to be involved downstream of the VEGF-mediated activation of EC, further 
supporting the role for HO-1 in angiogenesis.  Indeed, the pro-angiogenic factor VEGF and more 
recently stromal cell-derived factor-1 alpha (SDF-1α) have been shown to activate HO-1 
expression and activity in the vascular endothelium (Bussolati et al., 2004; Deshane et al., 2007).  
Studies from our laboratory demonstrated increased HO-1 expression in response to VEGF in 
primary human EC and EC of the dermal microvasculature, in turn modulating their angiogenic 
capacities. Induction of HO-1 with CoPP alone results in EC proliferation comparable to that seen 
with VEGF, whilst inhibition of HO-1 using the synthetic antagonist SnPP or ZnPP attenuates 
VEGF-induced EC proliferation in vitro (Bussolati et al., 2004). Moreover, HO-1 inhibition prevents 
development of VEGF-induced neovessels in vitro and also in vivo and ex vivo (Bussolati et al., 
2004). In concordance with these findings, VEGF increases HO-1 protein expression in the chick 
embryo chorioallantoic membrane, an effect inhibited by staurosporine, indicating a potential role 
for protein kinase C (PKC) (Fernandez and Bonkovsky, 2003). Furthermore, the chemokine SDF-
1α, an important regulator of endothelial progenitor cell migration and recruitment to sites of 
ischaemic injury, has been linked to HO-1-driven angiogenesis. Deshane and colleagues 
demonstrated that exposure to SDF-1α results in a marked upregulation of HO-1 mRNA and 
protein in human aortic EC (HAEC). Moreover, pharmacological and genetic inhibition of HO-1 
impaired SDF-1α mediated endothelial tube formation, an effect reversed by a CO donor, CO-
releasing molecule (CORM-2), but not bilirubin. This study further confirms the functional 
significance of HO-1 in angiogenesis by using the Matrigel plug and wound healing models in the 
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HO-1
-/-
 mouse, demonstrating a close association of HO-1 deficiency with impaired 
neovascularisation and wound healing in injured tissue (Deshane et al., 2007). 
A role for HO-1 in endothelial migration is emerging but so far poorly understood. Exposure to the 
HO-1 antagonist SnPP inhibits VEGF-induced migration of primary human EC as assessed using 
a modified Boyden chamber (Jozkowicz et al., 2003). Genetic inhibition of HO-1 in HAEC 
abrogates their migratory capacity in response to SDF-1α, an effect also seen in aortic EC and 
EPC isolated from HO-1 knockout mice (Deshane et al., 2007). Moreover, the migratory 
properties of HO-1 overexpressing coronary microvascular EC are enhanced, as demonstrated by 
increased propensity to form vascular tubes in Matrigel (Deramaudt et al., 1998). 
The importance of HO-1 in angiogenesis is confirmed in vivo. Even though, HO-1-deficient mice 
show no obvious phenotype suggestive of defective vascular morphogenesis, the infertility of 
female HO-1 null mice and the high mortality rate of embryos lacking the functional HO-1 gene 
suggests an effect of HO-1 on developmental angiogenesis (Bainbridge and Smith, 2005; 
Zenclussen et al., 2007; Gozzelino et al., 2010). HO-1 overexpression enhances VEGF levels in 
the rat placenta and this is associated with increased pup size (Kreiser et al., 2002). In addition, 
VEGF treatment increases angiogenesis simultaneously with HO-1 expression during chick 
embryo development, an effect attenuated by HO-1 inhibition (Fernandez and Bonkovsky, 2003). 
Consistent with this, HO-1 deficiency has been associated with pregnancy-related disorders such 
as recurrent miscarriages, intrauterine growth restriction and preeclampsia (Yachie et al., 1999; 
Bainbridge and Smith, 2005; Lyall and Myatt, 2002). Preeclampsia is a medical condition 
occurring during pregnancy and the postpartum period and is characterised by hypertension and 
proteinuria. Moreover, preeclampsia is associated with endothelial dysfunction and elevated 
plasma levels of anti-angiogenic mediators soluble Flt1 (sFlt1) and soluble endoglin (sEng). 
Interestingly, when compared with matched wild-type controls, plasma of HO-1
-/-
 mice contains 
higher levels of sFlt1 and sEng (Cudmore et al., 2007). Accordingly, HO-1 inhibition potentiates 
VEGF-mediated sFLt1 release and IFNγ and TNF-α-induced sEng release from placental villous 
explants and EC, while adenoviral-mediated HO-1 overexpression inhibits this effect (Cudmore et 
al., 2007). Supportive of a role for HO-1 in postnatal in vivo angiogenesis are the observations 
that pharmacological or genetic inhibition of HO-1 diminishes neovascularisation in wounded 
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tissues and impairs cutaneous wound healing in mice (Grochot-Przeczek et al., 2009). Moreover, 
human HO-1 deficiency revealed both prominent intravascular haemolysis and EC dysfunction 
(Yachie et al., 1999; Kawashima et al., 2002). 
Beside its role in vascular remodelling and reparative angiogenesis a link between HO-1 and 
pathological angiogenesis has been proposed. Indeed, several human tumours express high 
levels of HO-1, including renal and prostate cancer (Goodman et al., 1997; Maines and 
Abrahamsson, 1996; Was et al., 2006; Fang et al., 2003). Numerous in vitro and in vivo studies 
support the influence of HO-1 on carcinogenesis and tumour growth. However, a pro- or anti-
proliferative effect of HO-1 on cancer cells appears to be highly tissue-specific (Was et al., 2010; 
Degese et al., 2012). On one hand, HO-1 accelerates pancreatic cancer growth by promoting 
tumour angiogenesis in mice, whilst HO-1 inhibition increases their responsiveness to anti-cancer 
therapy (Sunamura et al., 2003; Berberat et al., 2005). Consistent with this, HO-1 deficiency 
causes enhanced tumour regression in severe combined immune deficient (SCID) mice and 
reduces tumour growth in a mouse model of lung cancer (Fang et al., 2003; Hirai et al., 2007). On 
the other hand, protective, anti-tumour effects of HO-1 have been demonstrated in hepatoma and 
breast cancer. HO-1 inhibits the proliferation of breast carcinoma cells and induces apoptosis in 
these cells. Moreover, the chemopreventive agent sulforaphane contributes to tumour growth 
suppression through induction of HO-1 in hepatoma and breast cancer cells (Hill et al., 2005; 
Keum et al., 2006; Cornblatt et al., 2007; Lin et al., 2008). 
The constitutive HO isoform, HO-2, may also play a role in inflammation and angiogenesis. 
Animals lacking HO-2 demonstrate impaired corneal wound healing, enhanced 
neovascularisation, and exaggerated inflammation (Seta et al., 2006). Murine aortic EC from HO-
2 null mice show an activated phenotype marked by oxidative stress, inflammation and 
angiogenesis (Bellner et al., 2009). Interestingly, while HO-1 expression is downregulated in 
corneal tissue from HO-2
-/-
 mice, MAEC from these animals show increased HO-1 levels. 
However, enzymatic activity of HO is significantly diminished in both and may account for the 
aggregated inflammation-dependent angiogenesis. These findings support a dual role for HO-1 in 
angiogenesis as postulated previously by our laboratory. Here, VEGF-mediated activation of HO-
1 favours endothelial proliferation and prevents EC apoptosis, while anti-inflammatory actions of 
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HO-1 inhibit leukocyte migration, thus resulting in non-inflammatory angiogenesis. In contrast, 
inhibition of HO-1 activity increases leukocyte migration and subsequent local release of pro-
angiogenic growth factors, so inducing inflammatory angiogenesis. Indeed, pharmacological 
inhibition of HO-1 by SnPP or ZnPP significantly increased vascularisation in an in vivo 
angiogenesis model, an effect associated with increased leukocyte infiltration. CoPP treatment 
however, significantly decreased LPS-induced angiogenesis and pro-inflammatory leukocytic 
infiltration into a Matrigel plug (Bussolati et al., 2004; Bussolati and Mason, 2006). 
A role in angiogenesis for the products of heme catabolism by HO enzymes, namely CO, 
biliverdin/bilirubin and ferrous iron has also been proposed but remains poorly understood (Fig. 
1.12.). Exogenous CO induces proliferation of rat aortic EC and enhances their migratory capacity 
(Wegiel et al., 2010). Low concentrations of CO are protective in EC and inhibit apoptosis through 
a p38 MAPK-dependent pathway. Thus, a reduced rate of apoptosis may also contribute to CO-
mediated proliferation. Moreover, CO induces the production of angiogenic mediators. Indeed, 
CO supplementation increases HO-1 expression but also augments the synthesis of VEGF and 
SDF-1α and potentiates their synergistic effects on EC (Jozkowicz et al., 2003; Lin et al., 2009). 
Consistent with this, CO has been shown to significantly enhance VEGF synthesis in various 
organs in an animal model (Martin and Risau, 1998). In addition, CO exposure results in 
increased expression of the pro-angiogenic factor IL-8, but decreases the expression of anti-
angiogenic factor sFlt1 and sEng. CO-mediated increase in pro-angiogenic mediators in turn 
results in enhanced endothelial proliferation and migration, and augmentation of vessel formation 
(Cudmore et al., 2007; Dulak et al., 2008; Kim et al., 2011). Moreover, CO restores the impaired 
angiogenic responses of HO-1-deficient EC and EPC and enhances re-endothelisation after 
vascular injury by increasing circulating SDF-1α in a mouse model (Li Volti et al., 2005; Deshane 
et al., 2007).  
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Figure 1. 14.: Pro-angiogenic effects of HO products. CO synthesised by the catalytic reaction 
of HO-1 induces the production of angiogenic mediators such as VEGF, IL-8 and SDF-1α, 
decreases the anti-angiogenic mediators soluble VEGF-R1 (sFlt1) and soluble endoglin (sEng) 
and increases soluble guanylate cyclase activity (cGMP). Biliverdin stimulates the induction of 
pro-angiogenic factors, such as VEGF and IL-8 in human keratinocytes. Ferritin binds cleaved 
high molecular weight kininogen (HKa) and antagonises its anti-angiogenic effects. 
 
Iron can influence angiogenesis by acting as a co-factor for enzymes involved in the regulation of 
VEGF synthesis, or by enhancing oxidative stress through the Fenton reaction and formation of 
noxious hydroxyl radicals. On the other hand, ferrous iron induces the expression of ferritin, which 
acts as an anti-oxidant by catalysing the oxidation of toxic ferrous iron to its non-toxic form, ferric 
iron (Ponka, 1999; Watts, 2003). Potential pro-angiogenic effects of ferritin have been 
demonstrated by Coffman and colleagues. High molecular weight kininogen (HKa) acts as a 
potent inhibitor of angiogenesis by inducing the apoptosis of proliferating EC. Supplementation 
with serum ferritin significantly inhibited the anti-angiogenic effects of HKa, improving EC 
proliferation, migration and subsequent organisation into luminal vessel-like structures on Matrigel 
in vitro (Coffman et al., 2009). Moreover, treatment of vascular SMC with the iron chelator 
deferoxamine mesylate (DFO) results in increased VEGF synthesis, and this may in turn indirectly 
promote angiogenesis (Dulak et al., 2002). 
The effects of biliverdin and bilirubin on angiogenesis are largely unknown and may be cell type-
specific. Biliverdin has been shown to stimulate the production of pro-angiogenic factors such as 
VEGF and IL-1 in human keratinocytes in an ERK-dependent manner, but no biliverdin-mediated 
effect on VEGF expression was observed either in rat vascular SMC or in a human endothelial 
cell line (Dulak et al., 2002; Jawza et al., 2006; Lobada et al., 2008). 
HO-1 
CO 
Biliverdin 
Fe
2+
  Ferritin 
↑Pro-angiogenic factors (VEGF, IL-8, SDF-1α) 
↓Anti-angiogenic factors (sFlt1, sENG) 
↑cGMP activity 
↑Pro-angiogenic factors (VEGF, IL-8) 
↓anti-angiogenic effects of HKa 
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1.4. HYPOTHESIS AND AIMS 
Increasing evidence clearly demonstrates the functional importance of the cytoprotective enzyme 
HO-1 in the regulation of physiological and reparative but also pathological angiogenesis and data 
to date suggest that HO-1 may influence the angiogenic process at various levels. Based on 
these observations we hypothesised that the cytoprotective enzyme HO-1 and its products play 
an important role in VEGF-driven angiogenesis, whereby VEGF increases HO-1 expression and 
activity which in turn results in enhanced endothelial proliferation and migration and subsequent 
organisation into lumenised vessels. However, the precise transcriptional and signalling 
mechanisms through which HO-1 exerts its effects during angiogenesis and the role of the HO 
products CO, biliverdin/bilirubin, and iron remain elusive. A better understanding of the angiogenic 
effects of HO-1 may in turn reveal novel therapeutic targets for the manipulation of angiogenesis 
at sites of ischaemia and wound healing, or conversely to inhibit angiogenesis associated with 
atherosclerosis or tumourogenesis. Therefore, the aim of my work is to further elucidate the 
specific role of HO-1 and its products in the regulation of VEGF-induced angiogenesis, using a 
variety of in vitro and in vivo angiogenesis assays. In particular, this includes the following aims: 
 To identify the transcriptional and signalling mechanisms regulating the induction of the 
cytoprotective enzyme HO-1 by the pro-angiogenic mediator VEGF 
 To establish the functional importance of HO-1 during different stages of angiogenesis in 
vitro. 
 To identify novel HO-1 downstream targets and to investigate their role in the regulation 
of VEGF-induced angiogenesis 
 To elucidate the functional importance of HO-1 and its target proteins in in vivo 
angiogenesis. 
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CHAPTER 2 - MATERIALS AND METHODS 
2.1. MATERIALS 
2.1.1. Antibodies 
The following primary and monoclonal antibodies (mAb) were used: Bcl-2 (C-2) mAb, cyclin A (B-
8) mAb, and retinoblastoma protein (Rb; C-2) mAb were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, California, USA). HO-1 mAb and anti-vimentin [RV202] mAb 
were from Stressgen (Exeter, UK) and Abcam plc (Cambridge, UK) respectively. Anti-VASP (9A2) 
was from Cell Signaling Technology, Inc. (Danvers, MA, USA). The anti-α-tubulin mAb was from 
Sigma-Aldrich Ltd. (Poole, Dorset, UK) and GAPDH mAb and anti-integrin αvβ3, clone LM609 
were both purchased from Millipore (Billerica, MA, USA).  
The polyclonal antibodies against HO-1 (H-105), Bcl-xl (H-62) and anti-PKCε were from Santa 
Cruz Biotechnology, Inc., and anti-phospho-PKCε (Ser
729
) was from Millipore. HO-2 and anti-
retinoblastoma (Rb) [pT
821
] phosphospecific antibodies were purchased from Stressgen and 
Invitrogen (Paisley, UK), respectively. Anti-Phospho-VASP (Ser
239
) was from Cell Signaling 
Technology, Inc. 
The anti-VCAM-1 mAb 1.4C3 was generated in house. RMAC8 (anti-endoglin) was a kind gift 
from Dr A. d’Apice (St Vincent’s Hospital, Victoria, Australia) and the anti-ICAM-2 mAB CBR-IC/2 
was kindly provided by D. T. Springer (Harvard University, Cambridge, MA, USA). P2B1α (anti-
CD31) was purchased from the Developmental Studies Hybridoma Bank (University of Iowa, 
Iowa, USA) and PCNA (PC-10) was from Santa Cruz Biotechnology, Inc. 
The following secondary Abs were used: Fluorescein isothiocyanate (FITC)-labelled polyclonal 
rabbit anti-mouse immunoglobulin, swine anti-rabbit immunoglobulin/horseradish peroxidase 
(HRP), goat anti-mouse immunoglobulins/HRP were all purchased from DAKO (Glostrup, 
Denmark). Goat anti-mouse IgG1 Alexa Fluor 568, goat anti-mouse IgG1 Alexa Fluor 488 and 
goat anti-rabbit IgG1 Alexa Fluor 568 were from Invitrogen. A list of all antibody working dilutions 
used in this study is provided in the Appendix (Tab A.1. to Tab. A.6.). 
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2.1.2. Animals 
Eight to ten-week old female C57BL/6 mice were purchased from Harlan Laboratories, Inc. 
(Bicester, Oxford, UK) and housed under controlled climatic conditions in microisolator cages with 
autoclaved bedding. Irradiated food and drinking water were readily available. All of the animals 
were housed and studied according to UK Home Office guidelines. Sentinel mice were housed 
alongside test animals and regularly screened for a standard panel of murine pathogens. 
 
2.1.3. Compounds 
Recombinant human VEGF165 and recombinant human SDF-1α (CXCL12) were purchased from 
PeproTech EC Ltd., London, UK and reconstituted in 3% bovine serum albumin (BSA; Sigma-
Aldrich Ltd.) in ultrapure water (H2O; Millipore) to stock solutions of 1 mg/ml. Hemin and zinc (II) 
protoporphyrin IX chloride (ZnPP) were both obtained from Frontier Scientific (Logan, UT, USA) 
and dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich Ltd.) to a stock concentration of 100 
mM and 25 mM, respectively. Tricarbonyldichlorouthenium(II) dimer (CORM-2) and deferoxamine 
mesylate (DFO) were both from Sigma-Aldrich Ltd.. CORM-2 was dissolved in DMSO to a stock 
concentration of 50 mM and DFO was dissolved in ultrapure H2O to a stock concentration of 10 
mM. The enzyme-triggered CORMs (ET-CORMs) Stro074, SROM158, and Stro258 were all kind 
gifts from Prof H. G. Schmalz (Universität zu Köln, Köln, Germany) and dissolved in DMSO to 
stock concentrations of 100 mM. Actinomycin D was from Sigma-Aldrich Ltd. and dissolved in 
DMSO to stock concentration of 1 mg/ml.  
 
2.1.4. Adenoviruses 
The recombinant adenovirus expressing the HO-1 gene (AdHO-1) was a kind gift from Dr M. 
Soares (Instituto Gulbenkian de Ciencia, Oeiras, Portugal). Adenoviruses with an empty vector 
(Ad0) were provided by Dr E. Paleolog (Oxford University, Oxford, UK) and used as a control. 
Adenoviruses were amplified in human embryonic kidney (HEK) 293A cells in Dulbecco’s 
Modified Eagle Medium (DMEM; Invitrogen) with 10% fetal calf serum (FCS; Biosera, Ringmer, 
UK) and grown at 37°C in 5% CO2. When the cell monolayer reached 60-80% confluence, cells 
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were infected with the appropriate adenovirus. The infected cells were cultured at 37°C in 5% 
CO2 for 3-5 days until HEK cells showed cytopathic effects, characterised by a round cell 
morphology and detachment from the culture flask. HEK293A cells were then harvested by 
pipetting, transferred into 50 ml tubes, and pelleted by centrifugation. The cell pellet was 
resuspended in 10 ml of the supernatant and the remaining supernatant was decanted into a 
sterile container and kept at 4°C. The cell suspension was freeze/thawed three times to disrupt 
the cells, and cell debris was pelleted by centrifugation at 3,500 x g for 15 min. The supernatant 
was removed and the previously reserved supernatant added. Adenoviruses were then purified 
using the AdEasyTM Virus Purification Kit (Stratagen, La Jolla, CA, USA) following the 
manufacturer’s instructions. Purified adenoviruses were then titred using the Adeno-XTM Rapid 
Titer Kit (Clontech Laboratories Inc., Mountain View, CA, USA). The infectious units per ml (ifu/ml) 
for each virus was calculated as follows: 
Ifu/ml = (mean infected cell/field) x (fields/well) 
            volume virus (ml) x (dilution factor). 
 
 
2.1.5. Cell Culture Reagents 
Collagenase type II: Roche Diagnostics Ltd., West Sussex, UK. 2% gelatin and phosphate-
buffered saline (PBS) with calcium (Ca
2+
) and magnesium (Mg
2+
): purchased from Gibco BRL Life 
Technologies, Paisley, UK. Heparin (1,000 U/ml): Leo Laboratories, Princes Risborough, UK. 
Fetal calf serum: Biosera, Ringmer, UK. EC culture medium 199 (M199), EC growth supplement 
(ECGS; 30 µg/ml), penicillin (100 IU/ml), streptomycin (0.1 mg/ml), and L-glutamine (2 mmol/L): 
all purchased from Sigma-Aldrich Ltd. EC culture medium MCDB-131 and Optimen: both Gibco 
BRL Life Technologies. Hank’s balanced salt solution with Ca
2+
 and Mg
2+
 (HBSS) or without Ca
2+
 
and Mg
2+
 (HBSS w/o), trypsin/ethylenediaminetetraacetic acid (EDTA): Sigma-Aldrich Ltd. 
Endothelial basal medium (EBM)-2 and endothelial growth medium (EGM)-2 supplemented with 
2% fetal bovine serum (FBS), hydrocortisone, human fibroblast growth factor beta (h-FGF-β), 
VEGF, insulin-like growth factor analogue (R
3
-IGF-1), ascorbic acid, human endothelial growth 
factor (hEGF), gentamicin, amphotericin-B (GA), and heparin: all purchased from Lonza, Basel, 
Switzerland. The 25 cm
2
 and 75 cm
2
 tissue culture flasks (T25 and T75) were from: Costar, 
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Cambridge, MA, USA. 6-well, 12-well, and 24-well tissue culture plates: Nunc, Thermo Fisher 
Scientific, Rochester, NY, USA. Flat bottom 96-well plates: Corning B. V. Life Sciences, 
Amsterdam, Netherlands. 
 
2.1.6. Reagents and Apparatus for Western Blotting 
Protein lysis: RIPA buffer was purchased from Thermo Fisher Scientific. Complete protease 
inhibitor cocktail and PhosSTOP phosphatase inhibitor cocktail: both Roche Diagnostics Ltd 
(Burgess Hill, West Sussex, UK). 
Protein quantification: Bio-Rad Dc protein assay kit (Bio-Rad Laboratories, Hemel Hempstead, 
Herfordshire, UK) containing 250 ml alkaline copper tartrate solution (solution A), 2 ml dilute Folin 
reagent (solution B), 5 ml surfactant solution (solution S). Bovine gamma-globulin standard: Bio-
Rad Laboratories. 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-Page): The XCell SureLock
c
 
Mini-Cell was purchased from Invitrogen. NuPAGE
®
 Novex System reagents and apparatus 
included: NuPAGE
®
 Novex 10% or 4-12% Bis-Tris Gel 1.0 mm, 10 well or 10% Bis-Tris Gel, 1.5 
mm, 15 well; NuPAGE
®
 MOPS SDS Running Buffer (20X); NuPAGE
®
 LDS Sample Buffer (4X); 
Protein size marker: SeaBlue Plus2 Pre-Stained Standard: all purchased from Invitrogen. DL-
Dithiothreitol (DTT) was from Sigma-Aldrich Ltd. The Phos-tag
TM
 SDS-Page System included: 
Phos-tag
TM
 Acrylamide AAL-107: Wako Chemicals GmbH, Neuss, Germany. Acrylamide/Bis-
acrylamide, 30% solution (29:1); manganese(II) chloride (MnCl2), SDS, hydrochloric acid (HCl), 
Trizma
c
 base (Tris); N,N,N’,N’-Tetramethylethylenediamine (TEMED); diammonium 
peroxydisulfate ((NH4)2S2O8): all Sigma-Aldrich Ltd. Novex
® 
Sharp Unstained Protein Standard, 
Novex
®
 Gel Cassettes, 1 mm, and Novex
®
 combs, 1 mm, 10-well were all purchased from 
Invitrogen. 
Transfer System: Trans-Blot SD Semi-Dry Transfer cell and 10X Tris/Glycine transfer buffer were 
from Bio-Rad. Immobilon
TM
-P transfer membrane: Millipore. 
Signal detection: Blocking buffer and Ab dilution buffer: 1X Tris buffered saline and Tween 20 
(TBS-T) containing 5% BSA: all Sigma-Aldrich Ltd. Western Blotting Detection Reagents: 
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Amersham
 
ECL
TM
 (enhanced chemiluminescence) or Amersham ECL Plus
TM
 Western Blotting 
Detection Reagents (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Developing films: 
Kodak XOMat film (Sigma-Aldrich Ltd.). Developing machine: Compact X4 X-ray film processor 
(Xograph Healthcare Ltd., Tetbury, Gloucestershire, UK). Densitometry: ImageJ analysis software 
(National Institutes of Health, Bethesda, Maryland, USA). 
 
2.1.7. HO-1 promoter constructs and luciferase reporter vectors 
The HO-1 promoter construct pHOGL3/9.4 was kindly provided by Prof A. Agarwal (University of 
Alabama at Birmingham, Birmingham, Alabama, USA) and the plasmids pGL3-hHO4.9luc, pGL3-
hHO2.2luc, and pGL3-hHO0.3luc were kind gifts from Prof N. Leitinger (Department of Vascular 
Biology and Thrombosis Research, University of Vienna, Vienna, Austria). pGL3-Basic luciferase 
reporter vector without the promoter insert (Promega, Madison, WI, USA) was used as a 
procedure control. pGL4.74[hRluc/TK] reporter vector (Promega) containing an herpes simplex 
virus thymidine kinase (HSV-TK) promoter and synthetic Renilla luciferase gene was used as the 
control vector for the dual luciferase reporter assay. 
All plasmids were transformed in Escherichia coli (E. coli) DH5α competent cells (Invitrogen) and 
plasmid DNA was purified using the QIAGEN Plasmid Maxiprep Kit (Qiagen Ltd., Crawley, West 
Sussex, UK) in accordance with the manufacturer’s instructions. 
 
2.1.8. Reagents for Dual-Luciferase® Reporter Assay 
The Dual-Luciferase
®
 Reporter Assay System (DLR
TM
 assay), containing Luciferase Assay Buffer 
II, Luciferase Assay Substrate, Stop&Glo
®
 Buffer, Stop&Glo
® 
Substrate, and 5X Passive Lysis 
Buffer (PLB) was purchased from Promega. The luminescence generated by the DLR
TM
 assay 
was measured by a Biotek Synergy
TM
 4 Multi-Mode Microplate Reader (BioTek Instruments, Inc., 
Vermont, USA). 
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2.2. METHODS 
2.2.1. Isolation and culture of endothelial cells 
Human umbilical cords were donated by the Department of Obstetrics, Queen Charlotte’s 
Hospital. The use of human umbilical vein endothelial cells (HUVEC) was approved by 
Hammersmith Hospital Research Ethics Committee (ref. no. 06/Q0406/21). 
Fresh umbilical cords obtained at normal deliveries were stored in HBSS containing 0.1 mg/ml 
gentamicin and 1 mmol/l sodium pyruvate at 4°C. HUVEC were isolated from umbilical cords by 
digestion with collagenase type II based on a modified method from Jaffe et al. (1973). In brief, 
the umbilical vein was identified and washed with 50 ml HBSS w/o to remove blood in the lumen. 
The vein was then filled with 25 ml 0.5 mg/ml collagenase dissolved in HBSS w/o and incubated 
for 8 min at 37°C in 5% CO2. After incubation, the cord was gently massaged to encourage cell 
detachment from extracellular matrix and the collagenase solution containing the EC was 
collected from the cord. The cord was then flushed with 25 ml HBSS w/o, which was added to the 
collagenase solution. To recover cells, the pooled solution was centrifuged at 335 x g for 10 min 
(Allegra X–15R Centrifuge, Beckman Coulter Ltd., High Wycombe, UK) and transferred to a 25 
cm
2
 1% gelatin-coated tissue culture flask containing complete M199 medium supplemented with 
20% FCS, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, 2 mmol/L L-glutamine, 10 U/ml heparin, 
and 30 µg/ml ECGS. The day after isolation, the cells were washed with HBSS twice and medium 
replaced. Upon confluency, EC were harvested by trypsin/EDTA and passaged into 75 cm
2
 1% 
gelatin-coated tissue culture flasks. The morphological and molecular characteristics of isolated 
EC used in this study are detailed in Chapter 3. 
 
2.2.2. Culture of human dermal microvascular endothelial cells 
The human dermal microvascular endothelial cell line (HMEC-1) was a kind gift from Dr E. Ades 
(CDC Atlanta, USA). HMEC-1 were originally isolated from human dermal microvessels and 
immortalized by infection with an adenovirus carrying a SV40 promoter (Ades et al., 1992). 
HMEC-1 were cultured on 1% gelatin-coated tissue culture flasks in MCDB-1 medium 
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supplemented with 10% FCS, 100 IU/ml penicillin, 0.1 mg/ml streptomycin. 2 mmol/L L-glutamine, 
and 10 ng/ml epidermal growth factor. 
 
2.2.3. Culture of murine aortic endothelial cells  
Murine aortic EC (MAEC) from HO-1
-/-
 and HO-1
+/+
 littermate controls (backcrossed 10 
generations into the C57BL/6 background) were a kind gift from Dr M. Soares (Instituto 
Gulbenkian de Ciencia, Oeiras, Portugal). Cells were isolated as previously described and the 
MAEC phenotype was confirmed by characteristic cobblestone morphology and by uniform 
expression of endoglin (CD105) in more than 95% of cells, demonstrated by flow cytometry 
(Marelli-Berg et al., 2000; Seldon et al., 2007; Kinderlerer et al., 2009). MAEC were cultured on 
1% gelatin-coated tissue culture flasks in MCDB-131 medium supplemented with 20% FCS, 100 
IU/ml penicillin, 0.1 mg/ml streptomycin, 2 mmol/l L-glutamine, and 30 µg/ml ECGS. 
 
2.2.4. EC stimulation/treatment 
All experiments with primary cells were conducted at passage 2 to 4. For each experiment, 
HUVEC were harvested by trypsin/EDTA and cultured in 1% gelatin-coated 6-, 12-, 24- or 96-well 
plates in EC plating M199 medium, supplemented with 10% FCS, 100 IU/ml penicillin, 0.1 mg/ml 
streptomycin, 2 mmol/L L-glutamine, 10 U/ml heparin, and 7.5 µg/ml ECGS. EC were allowed to 
settle overnight before stimulation/treatment.  
EC were stimulated with 25 ng/ml VEGF or 100 ng/ml SDF-1α in growth factor free medium. 
ZnPP, CORM-2, ET-CORM and DFO were added directly to the culture medium. In all 
experiments, EC monolayers were treated with the appropriate vehicle controls (DMSO). The final 
concentration of DMSO was <0.1% in all samples. Stimulated cells were incubated for 2 to 72 h at 
37°C in 5% CO2 before further proceeding. 
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2.2.5. In vitro transfection of EC with siRNA by lipid-mediated transfection 
Small interfering ribonucleic acid (siRNA) was introduced into EC by lipid-mediated transfection 
using the proprietary lipid complex geneFECTOR (VennNova, Pompano Beach, Florida, USA). A 
schematic of this process is shown in Fig. 2.1. Single sequence siRNAs against human HO-1 and 
PKCε were purchased from Qiagen Ltd. An siRNA pool of 4 sequences against human HO-1 was 
from Dharmacon, Inc. (Lafayette, Colorada, USA). Murine siRNA against HO-1 and cyclin A1 
were both from Dharmacon, Inc. The non-targeting siRNA Silencer
®
 Negative Control #1 was 
purchased from Ambion (Austin, Texas, USA). 3’-end Alexa Fluor 488-labelled siRNA against 
HO-1 and the AllStars Negative Control siRNA Alexa Fluor 488 were both from Qiagen Ltd (Tab. 
2.1.). 
HUVEC and MAEC were plated at 3 x 10
5
 cells in 6-well plates in M199 or MCBD-131 plating 
medium, respectively to obtain 50% confluency. siRNA complexes were formed by mixing 100 µl 
geneFECTOR solution composed of 6 µl geneFECTOR in 100 µl Optimem and 100 µl siRNA 
solution containing 20 or 40 nM siRNA and 100 µl Optimem, followed by incubation at room 
temperature (RT) for 5 minutes (min). Culture medium was replaced with Optimem and siRNA 
complexes were added dropwise and incubated for 6 h. After incubation, culture medium was 
replaced with EBM-2 supplemented with 2% FCS, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, 2 
mmol/l L-glutamine, and 1.875 µg/ml ECGS. Transfected cells were incubated at 37°C in 5% CO2 
for up to 48 h before harvesting or further proceeding. Knockdown efficiency of siRNA sequences 
was assessed by quantitative real-time PCR (qRT-PCR) and western blotting (Chapter 5). 
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Figure 2. 1.: RNA interference by long double-stranded RNAs. Upon introduction, the long 
double-stranded RNAs (dsRNAs; typically >200 nt) enter a cellular pathway known as RNA 
interference (RNAi) pathway. During the initiation step, dsRNAs are cleaved into 20-25 nucleotide 
(nt) small interfering RNAs (siRNAs) by the RNase III-like enzyme Dicer. siRNAs then assemble 
into endoribonuclease-containing complexes known as RNA-induced silencing complexes (RISC), 
unwinding in the process and activating RISC (effector step). The siRNA strands subsequently 
guide the activated RISC to complementary RNA molecules, where they cleave and destroy the 
cognate RNA, thereby preventing protein translation (Meister and Tuschl, 2004). In this study, 
siRNA was introduced into cells by lipofection, which is not cleaved by dicer but directly 
recognised by RISC. 
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Table 2. 1.: Human and murine siRNA sequences. 
Species Target Gene  siRNA Name mRNA target sequence 5’3’ 
Human HO-1 siHO-1 seq2 AAC AUU GCC AGU GCC ACC AAG 
Human  HO-1  siHO-1 seq2 AF488 AAC AUU GCC AGU GCC ACC AAG 
Human HO-1 siHO-1 pool GGC AGA GGG UGA UAG AAG A 
ACA CUC AGC UUU CUG GUG G 
AGA GAA UGC UGA GUU CAU G 
GAG GAG AUU GAG CGC AAC A 
Human HO-2 siHO-2 seq3 UGG GAG GUG AGU GGC CUG UAA 
Human HO-2 siHO-2 seq4 AAA GUG GGC UUU GCA AGC UAA 
Human HO-2 siHO-2 seq5 CAC GGC ACU UUA CUU CAC AUA 
Human HO-2 siHO-2 seq6 CAA GGA CUU CUU GAA AGG CAA 
Human PKCε siPKCε seq5 CCC GAC CAU GGT AGU AGU GUU CAA 
Mouse HO-1 murine siHO-1 pool GGA UUU GUC UGA GGC CUU G 
GGA GAU AGA GCG CAA CAA G 
CGA GAA UGC UGA GUU CAU G 
GGG AAU UUA UGC CAU GUA A 
Mouse cyclin A1 murine siCycA1 pool UGA UUA ACG UAA CGG AGU A 
GGU CAA UGA ACC AGC CAA A 
AGU ACA AGG CUU CGA AGU A 
AUA CGU ACA CAA AGC GAC A 
Human/Mouse/
Rat 
N/A siCTL N/A 
Human/Mouse/
Rat 
N/A siCTL AF488 N/A 
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2.2.6. Adenoviral infection of EC 
EC were infected by incubation with the relevant adenovirus in serum-free M199 for 2 h at 37°C in 
5% CO2. Culture medium was then changed to M199 plating medium and cells were incubated 
overnight prior to harvesting and/or further proceeding. Infection of HUVEC with βgal or AdGFP 
control viruses previously demonstrated a transfection efficiency of 95% (Steinberg et al., 2007). 
The multiplicity of infection (MOI) for adenoviruses used in this study was 100 virus particles per 
cell, which was determined by western blotting experiments (Chapter 5). 
 
2.2.7. CellTiter 96® Aqueous One Solution cell proliferation assay 
EC were plated at 5 x 10
3
 cell/well in 1% gelatin-coated 96-well plates in growth factor-free 
medium supplemented with 5% FCS and incubated at 37°C in 5% CO2 overnight. Cells were then 
treated with the compound of interest or the appropriate control for 24 to 72 h. Each treatment 
was performed in triplicate. After incubation, medium was replaced with 20% 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) in 
growth factor-free medium and plates were incubated for another 3 h. The number of viable cells 
was determined with a Synergy HT plate reader (BioTek Instruments, Inc.) by measuring the 
absorbance at 490 nm.  
 
2.2.8. In vitro cell proliferation assay 
Cell proliferation was assessed using the Cell Proliferation ELISA, BrdU (colorimetric) from Roche 
Diagnostics Ltd. in accordance with the manufacturer’s instructions. In brief, EC were plated at 5 x 
10
3
 cells/well in 1% gelatin-coated 96-well plates in growth factor-free medium supplemented with 
5% FCS and incubated at 37°C in 5% CO2 overnight. Cells were then treated with the compound 
of interest or the appropriate control for 24 to 72 h. Each treatment was performed in triplicate. 
After incubation, cells were labelled with 10 µM BrdU and re-incubated for 3 h. The labelling 
solution was removed and cells were fixed and denatured with FixDenat solution and incubation 
at RT for 30 min. The FixDenat solution was then replaced with anti-BrdU-POD working solution 
(mAb conjugated with peroxidase; POD) and the plate was incubated at RT for 90 min. Cell were 
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washed three times with 1x PBS and the immune complexes were detected by the addition of 
substrate solution (tetramethyl-benzidine) and incubated at RT up to 30 min until colour 
development was sufficient for photometric detection. The reaction product was quantified by 
measuring the absorbance at 370 nm on a Synergy HT plate reader. A reference wavelength was 
measured at 492 nm. The reaction product-specific absorbance at 370 nm was then normalised 
to the non-specific absorbance measured at 492 nm. 
 
2.2.9. In vitro scratch assay 
The in vitro scratch assay was used to study EC migration. EC were plated at 3 x 10
5 
cell/well in 
1% gelatin-coated 6-well plates in EBM-2 supplemented with 2% FCS and incubated at 37°C in 
5% CO2 overnight. The confluent monolayers were scratched using a Gilson pipette tip (200 µl) 
and migration was assessed by live cell imaging. The migration path of individual cells in the 
leading edge of the scratch was tracked with the aid of time-lapse microscopy (LSM 510 Meta; 
Zeiss, Oberkochen, Germany) and image analysis software (ImageJ plugin Manual Tracking; 
National Institutes of Health; and Ibidi Chemotaxis and Migration tool; Ibidi GmbH, München, 
Germany). Cell motility was quantified in terms of the accumulated distance [µm], the Euclidean 
distance [µm], and velocity [µm/min]. 
 
2.2.10. Ibidi µ-slide chemotaxis assay 
The Ibidi µ-slide chemotaxis assay was used to assess the directional migration of EC towards a 
growth factor gradient. EC suspended at a concentration of 3 x 10
6
 cells/ml in complete EGM-2 
supplemented with 10% FSC were prepared and 7 µl of the cell suspension was carefully pipetted 
into the observation area of collagen IV-coated chemotaxis µ-slides (Ibidi). Slides were placed 
into 15 mm Petri dishes and incubated at 37°C in 5% CO2 for 3 h to allow EC to adhere. Floating 
cells were gently washed off and the medium within the observation area was replaced with 
growth factor-free EBM-2 supplemented with 2% FCS. One of the reservoirs was then filled with 
growth factor-free medium and the second reservoir with growth factor-supplemented medium. 
The directional migration of EC was assessed by live cell imaging. The migration path of 
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individual cells was tracked with the aid of time-lapse microscopy (LSM Meta 510) and image 
analysis software (ImageJ plugin Manual Tracking; and Ibidi Chemotaxis and Migration tool). 
 
2.2.11. In vitro Matrigel tube formation assay 
The Matrigel tube assay was used to investigate the effect of HO-1 inhibition on the ability of EC 
to form capillary-like structures in vitro. Pre-chilled 12-well plates were coated with growth factor-
reduced Matrigel (BD Biosciences, San Jose, California, USA) and incubated at 37°C in 5% CO2 
for 30 min to allow gels to form. EC were plated onto the Matrigel at 1.2 x 10
5
 cells/well in growth 
factor-free EBM-2 supplemented with 2% FCS. In vitro tube formation was assessed after 16 h. 
Five random pictures were captured for each well and tube length was quantified using the 
ImageJ plugin NeuronJ (National Institutes of Health). 
 
2.2.12. In vitro adhesion assay 
96-well plates were coated with 1% gelatin or 50 µg/ml collagen type I (BD Biosciences) for 1 h at 
37°C, washed twice with PBS, and blocked with 1% BSA for 1 h. Control or HO-1 specific siRNA-
treated HUVEC were labelled with 6.25 µM 5-chloromethylfluorescein diacetate in serum-free 
medium (Cell Tracker
TM
 Green CMFDA; Invitrogen) following the manufacturer’s protocol. In brief, 
culture medium was removed and replaced with pre-warmed Cell Tracker
TM
 dye solution and 
incubated for 30 min at 37°C in 5% CO2. After incubation, the dye working solution was replaced 
with fresh, pre-warmed medium and cells were incubated for another 30 min at 37°C. CMFDA-
labelled cells were then reseeded at 20,000 cells per well onto the coated 96-well plates in EBM-2 
supplemented with 2% FCS, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, 2 mmol/l L-glutamine in 
the presence or absence of 25 ng/ml VEGF. After 40 min, the total cellular fluorescence was 
measured with a Synergy HT plate reader with absorption and emission settings at 492 and 517 
nm respectively. Wells were then washed three times with PBS containing Ca
2+
 and Mg
2+
 at 37°C 
to remove non-adherent cells. The fluorescence of bound cells was then measured with the 
Synergy HT plate reader using the same settings. The percentage of bound cells relative to the 
total number seeded was then calculated. 
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2.2.13. In vitro immunofluorescent staining and confocal analysis 
EC cultured on 1% gelatin-coated coverslips (VWR International Ltd., Lutterworth, UK) were fixed 
in methanol for 15 min at -20°C and permeabilized with 0.5% Triton X-100 (Sigma-Aldrich Ltd.) in 
PBS for 5 min. Non-specific Ab-binding was blocked by incubation with 10% normal goat serum 
(Sigma-Aldrich Ltd.) for 1 h at RT. EC were incubated with primary Ab (1:200) at 4°C overnight, 
washed with PBS and incubated with the appropriate AlexaFluor-conjugated secondary Ab 
(1:1,000; Invitrogen) for 1 h at RT. Cells were washed with PBS, stained with nuclear dye Draq5 
(1:1,000: Cell Signaling Technology, Inc.) for 15 min and mounted onto microscope slides (VWR 
International Ltd.) with Fluoromount G (Cambridge Bioscience Ltd., Cambridge, UK). 
Immunofluorescent staining was analysed by z-stack confocal microscopy (LSM 510 Meta) using 
images at 63X magnification from 3 fields of view per experiment. 
 
2.2.14. Apoptosis and cell cycle parameter analysis 
Propidium iodide (PI) staining followed by flow cytometry was used to assess apoptosis and 
simultaneous analysis of cell cycle parameters of surviving cells. EC were harvested by exposure 
to trypsin/EDTA and fixed with 70% ethanol for 30 min at 4°C. After washing, cells were stained 
with propidium iodide staining solution composed of 50 µg/ml propidium iodide, 20 U/ml RNase 
(both Sigma-Aldrich Ltd.), 18 mg/ml EDTA, and 0.1% Triton X-100 for 45 min at 37°C prior to 
analysis by flow cytometry counting 20,000 cells per sample. Results are plotted as cell number 
versus DNA fluorescence and representative graphs are shown in Fig. 2.2. Apoptotic cells were 
identified by their hypodiploid nuclei resulting in a broad peak, clearly distinguishable from the 
sharp diploid DNA peak of normal cells. 
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Figure 2. 2.: Apoptosis and cell cycle parameter analysis of human umbilical vein 
endothelial cells by propidium iodide staining and flow cytometry. A representative FACs 
blot of HUVEC stained with PI is shown. Cells were gated according to their DNA content into the 
different phases of the cell cycle. SS - side scatter, FS - forward scatter, PE-Texas Red – R-
phycoerythrin Texas Red. 
 
2.2.15. Senescence-associated beta-galactosidase (SA-β-gal) staining 
EC cultured in 1% gelatin-coated 6-well plates were washed twice with PBS and fixed in 0.5% 
glutaraldehyde (Sigma-Aldrich Ltd.) in PBS for 15 min at RT. Cells were then washed twice with 
PBS supplemented with 1 mM magnesium chloride (MgCl2; Sigma-Aldrich Ltd.) and incubated 
with X-gal staining solution composed of 20 mg/ml 5-bromo-4-chloro-3-indolyl β-D-galactosidase 
(X-gal) in N,N-dimethylformamide (both Sigma-Aldrich Ltd.), and 100 mM potassium hexacyano-
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ferrate (III) (K3[Fe(CN)6]) and 100 mM potassium hexacyano-ferrate (II) trihydrate 
(K3[Fe(CN)6]*3H2O; Sigma-Aldrich Ltd.) in PBS for 24 h at 37°C. After incubation, wells were 
washed with ultrapure H2O and allowed to air dry. Blue-stained senescent cells were identified by 
phase-contrast microscopy (Leitz Labovert, Leica UK Ltd., Milton Keynes, UK) from 3 fields of 
view per experiment. Late passage cells (older/higher than P12) were used as a positive control 
for senescence. 
 
2.2.16. Calpain activity assay 
Calpain activity was measured using the calpain substrate 7-amino-4-chloromethlycoumarin 
(tBoc-LM-CMAC; Invitrogen). The substrate has an excitation/emission maxima of ~330/403. 
After cleavage by peptidases, the product produces blue-fluorescence with excitation/emission 
maxima ~351/430. 
Control or HO-1 specific siRNA-treated HUVEC were loaded with 30 µM of the tBoc-LM-CMAC 
for 30 min at 37°C in 5% CO2 in serum-free medium. EC were then treated with or without 25 
ng/ml VEGF for the indicated time points. Fluorescence was measured by flow cytometry using 
the Violet-1 filter (FL6). 
 
2.2.17. Exposure of EC to high shear unidirectional laminar flow in vitro 
HUVEC were cultured on 10 µg/ml fibronectin-coated glass slides (Sigma-Aldrich Ltd.; glass 
slides: Thermo Fisher Scientific) in M199 plating medium and incubated at 37°C at 5% CO2 
overnight. Confluent monolayers were exposed to control static conditions or high shear 
unidirectional laminar flow (12 dynes/cm
2
) for 24 h using the CytoDyne Streamer System 
(CytoDyne, La Jolla, CA, USA), consisting of the CytoShear Parallel Plate Flow Chamber and the 
CytoDyne Recirculating Flow Loop (Fig. 2.3.). The recirculating flow loop consists of two 
reservoirs, an upper and lower reservoir, with a parallel plate flow chamber positioned between 
them. Flow is governed by the hydrostatic pressure created by the vertical height distance 
between the upper and the lower reservoir. A constant pressure is maintained by continuous 
recirculation of culture medium from the lower to the upper reservoir at rates in excess of that 
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flowing through the chamber. The excess drains down the glass overflow manifold, which also 
serves to facilitate gas exchange with the medium. The flow chamber consists of machine-milled 
polycarbonate, a rectangular silastic gasket, and the glass slide with the attached endothelial 
monolayer, which are all held together by a vacuum maintained at the periphery of the slide, 
forming a channel of parallel-plate geometry (Frangos et al., 1988). The system was assembled in 
a sterile class II laminar flow hood. Once the assembly was complete, the entire setup was moved 
into an enclosed chamber kept at 37°C and the system was gassed with a 95% air and 5% CO2 
mixture (BOC Industrial, London, UK). Morphologic and molecular characteristics of HUVEC 
exposed to high shear unidirectional laminar flow are described in Chapter 3. 
 
 
 
 
 
 
 
 
Figure 2. 3.: Schematic of the CytoDyne Streamer System. (a) upper reservoir, (b) lower 
reservoir, (c) overflow manifold, (d) filtered humidified 95% air + 5% CO2 input, (e) gas outlet, (f) 
flow chamber, (g) gasket, (h) slide with cell monolayer, (i) microscope (if required), (j) vacuum (k) 
sampling port, (l) roller pump, (m) PFA Teflon tubing, (n) height between upper and lower 
reservoir/constant pressure head (modified after Frangos et al., 1988). 
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2.2.18. Flow cytometry 
EC were harvested by exposure to trypsin/EDTA and cell suspensions were collected into FACs 
tubes (Marathon Laboratory Supplies, London, UK) and pelleted by centrifugation. EC were 
stained with the appropriate primary mAb or isotype-matched control for 30 min at 4°C. After 
washing, cells were pelleted and stained with FITC-labelled rabbit anti-mouse Ig for 30 min at 4°C 
followed by washing and fixation in 1% paraformaldehyde. Samples were analysed on a CyAn
TM
 
ADP analyzer (Beckman Coulter Ltd., High Wycombe, UK) by counting 20,000 cells per sample. 
Representative histograms and plots are shown in Fig. 2.4. Results are expressed as a 
percentage of the relative fluorescent intensity (RFI) of non-stimulated cells. The RFI is calculated 
from the mean fluorescent intensity (MFI) of the test antibody divided by the MFI obtained with an 
isotype-matched irrelevant antibody. 
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Figure 2. 4.: Flow cytometric analysis of human umbilical vein endothelial cells. A 
representative HUVEC FACs blot is shown. Gated cells were analysed for protein of interest. 
Molecular characterization of these cells is described in Chapter 3.2.2.. SS - side scatter, FS - 
forward scatter, FITC - fluorescein isothiocyanate. 
 
2.2.19. Quantitative real-time polymerase chain reaction 
Quantitative real-time PCR was performed using a CFX Connect real-time PCR detection system 
(Bio-Rad). β-actin was the housekeeping gene, with data calculated in relation to β-actin and 
verified using glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
In brief, EC were washed with ice-cold PBS and lysed with Buffer RLT (Qiagen Ltd.) 
supplemented with 10 µl/ml β-mercaptoethanol (Sigma-Aldrich Ltd.) and total RNA was isolated 
using the RNeasy Mini Kit (Qiagen Ltd.) in accordance with the manufacturer’s instructions. 
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Isolated RNA was quantified by spectrophotometry (Ultrospec 3000, Amersham Pharmacia 
Biotech Ltd.). DNase-1-digested total RNA (1 µg) was then reverse transcribed using 1 µM 
oligo(dT) (Invitrogen), 10 µM dNTP (Roche), and SuperScript II RNase Reverse Transcriptase 
(Invitrogen). cDNA was amplified in a 25 µl reaction containing 5 µl of cDNA template, 12.5 µl of 
iSYBR supermix, 0.5 pM sense and antisense gene-specific primers, and ultrapure water. Cycling 
parameters were 3 min at 95°C, and 40 cycles of 95°C for 10 sec and 60°C for 45 sec. Primers 
were previously designed, optimized and verified by other investigators within the laboratory 
(Kinderlerer et al., 2006; Ali et al., 2007; Partridge et al., 2007; Hamdulay et al., 2010). Human 
and mouse primer sequences are detailed in Tab. 2.2. and Tab. 2.3., respectively, and 
representative PCR curves are shown in Fig. 2.5. Gene expression was quantified using the 
comparative cycle threshold method (∆∆Ct). The Ct values of both the reference and the sample 
of interest were normalised to the housekeeping gene. 
 
 
 
 
 
 
 
Figure 2. 5.: Representative quantitative PCR curves from cDNA prepared from EC. cDNA 
samples from HUVEC either transfected with 40 nM control siRNA (siCTL) or HO-1 specific 
siRNA (siHO-1 pool) and either left untreated or treated with 25 ng/ml VEGF for 24 h were 
analysed by qRT-PCR for mRNA expression of actin (A), GAPDH (G), and HO-1 (H). Three 
technical replicates for each condition are shown. RFU – relative fluorescence units. 
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Table 2. 2.: Human qRT-PCR primer sequences. 
Gene Name Target sequence 5’  3’ 
A1 forward CAC AGG AGA ATG GAT AAG GCA AA 
 reverse AGT CAT CCA GCC AGA TTT AGG TCC 
Actin forward GAG CTA CGA GCT GCC TGA CG 
 reverse GTA GTT TCG TGG ATG CCA CAG GAC T 
Cdk1 forward GAT TCT ATC CCT CCT GGT C 
 reverse AAT ATG GTG CCT ATA CTC C 
Cdk2 forward ATG GAG AAC TTC CAA AAG GTG GA 
 reverse CAG GCG GAT TTT CTT AAG CG 
Cyclin A1 forward TCA GGA CTG AGA ACC TGG CTA AGT ACG 
reverse CCT AAT TGC TTG CTG AGG TCG ATG GG 
Cyclin B1 forward AAG AGC TTT AAA CTT TGG TCT GGG 
 reverse CTT TGT AAG TCC TTG ATT TAC CAT G 
Cyclin D1 forward CCG TCC ATG CGG AAG ATC 
 reverse GAA GAC CTC CTC CTC GCA CTT 
Cyclin E1 forward TCC AGG AAG AGG AAG GCA AAC 
 reverse CCT GTC GAT TTT GGC CAT TT 
GAPDH forward CAA CAG CCT CAA GAT CAT C 
 reverse GAG TCC TTC CAC GAT ACC 
HO-1 forward CTT CTT CAC CTT CCC CAA CA 
 reverse TTC TAT CAC CCT CTG CCT GA 
HO-2 forward ATG TCA GCG GAA GTG GAA AC 
 reverse CGA GAG GTC AGC CAT TCT CA 
p21 forward GCA GAC CAG CAT GAC AGA TTT 
 reverse GGA TTA GGG CTT CCT CTT GGA 
p27 forward GCA ACC GAC GAT TCT TCT A 
 reverse GTC CAT TCC ATG AAG TCA GC 
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Table 2. 3.: Murine qRT-PCR primer sequences. 
Gene Name Target sequence 5’  3’ 
Actin forward GGC TGT ATT CCC CTC CAT CG 
 reverse CCA GTT GGT AAC AAT GCC ATG T 
Cyclin A1 forward TGC TCA AGT CAG ATC TCC ACT TCC 
 reverse TTA TAT TCT TCC CCA ACC TCC ACC 
Cyclin A2 forward GAG GGC GAT CCT TGT GGA T 
 reverse CAC AGC CAA ATG CAG GGT CT 
HO-1 forward AAG CCG AGA ATG CTG AGT TCA 
 reverse GCC GTG TAG ATA TGG TAC AAG GA 
GAPDH forward AGG TCG GTG TGA ACG GAT TTG 
 reverse TGT AGA CCA TGT AGT TGA GGT CA 
 
 
2.2.20. SABiosciences Human Cytoskeleton Regulators RT
2
 Profiler
TM
 PCR Array 
The SABiosciences Human Cytoskeleton Regulators RT
2
 Profiler
TM
 PCR Array (Qiagen Ltd.) was 
used to compare the mRNA expression profile of HUVEC depleted of HO-1 by siRNA and control 
cells in response to VEGF. The array profiles the expression of 84 genes controlling the 
intracellular biogenesis, organisation, polymerisation, and depolymerisation of cytoskeleton 
components. In addition, the PCR array includes five housekeeping genes and controls for 
genomic DNA contamination, RNA quality, and general PCR performance. 
In brief, HUVEC cultured on 1% gelatin-coated 6-well culture plates were washed with ice-cold 
PBS and lysed with Buffer RLT (Qiagen Ltd.) supplemented with 10 µl/ml β-mercaptoethanol 
(Sigma-Aldrich Ltd.). RNA lysates from three donor cords were pooled at time of collection and 
total RNA was isolated using the RNeasy Mini Kit (Qiagen Ltd.) in accordance with the 
manufacturer’s instructions. Isolated RNA was quantified by Nanodrop analysis measuring the 
absorbance ratios A260nm:A280nm and A260nm:A230nm and ribosomal RNA band integrity was analysed 
on the Agilent
®
 2100 BioAnalyzer using an RNA 6000 Nano LabChip
®
 (both Agilent Technologies, 
Inc., Santa Clara, CA, USA; Fig. 2.6.).  
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High-quality total RNA was then reversed transcribed using the RT
2
 First Strand Kit (Qiagen Ltd.) 
in accordance with the manufacturer’s instructions. In brief, the genomic DNA elimination mix was 
prepared by combining 1 µg of total RNA, 2 µl Buffer GE and RNase-free water to a final volume 
of 10 µl. The mix was incubated at 42°C for 5 min and then immediately placed on ice. The 
reverse-transcription mix was made up of 5X Buffer BC, Control P2, RE3 Reverse Transcriptase 
Mix, and RNase-free water to a final volume of 10 µl and combined with 10 µl genomic DNA 
elimination mix. The resulting mixture was incubated at 42°C for 15 min, followed by incubation at 
95°C for 5 min. 91 µl RNase-free water was added to each cDNA synthesis reaction and kept on 
ice until further proceeding. 
Real-time PCR was performed using the Bio-Rad iCycler (Bio-Rad). A 2.7 ml PCR components 
mix was prepared for each 96-well plate format composed of 2X RT
2
 SYBR Green Mastermix, 
cDNA synthesis reaction, and RNase-free water, and 25 µl PCR components mix was dispensed 
into each well of the RT
2
 Profiler
TM
 PCR array using an 8-channel pipettor. PCR plates were 
sealed with Optical Thin-wall 8-Cap Strips and centrifuged for 1 min at 1000 x g at RT and 
analysed by real-time PCR. Cycling parameters were 10 min at 95°C, and 40 cycles of 95°C for 
15 sec and 60°C for 1 min. A melting curve program was run for 1 min at 95°C followed by 1 min 
at 60°C, and 70 cycles starting at 60°C for 10 sec with a temperature increase of 0.5°C after the 
second cycle. Gene expression was quantified using the RT
2
 Profiler
TM
 PCR Array Data Analysis 
tool (Qiagen Ltd.). The Ct values of both the reference and the sample of interest were 
normalised to the housekeeping genes included on the PCR array. 
 
 
 
 
 
Chapter 2 
109 
 
Figure 2. 6.: Ribosomal RNA band integrity. Agilent
®
 2100 BioAnalyzer electropherogram and 
gel-like image of high-quality total RNA showing sharp peaks and bands, respectively, for the 18S 
(left peak/lower band) and 28S (right peak/upper band) ribosomal RNA. 
 
2.2.21. Western blotting 
EC were washed with ice-cold PBS and lysed with RIPA buffer supplemented with complete 
protease inhibitor cocktail and PhosSTOP phosphatase inhibitor cocktail for 10 min at 4°C. The 
lysates were collected into Eppendorf tubes, sonicated for 1 min, and centrifuged at 17,968 x g for 
20 min at 4°C (Sigma 1-15PK, Sigma-Aldrich Ltd.). The protein concentration of each sample was 
quantified using the Bio-Rad Dc protein assay kit according to the manufacturer’s instructions 
using a gamma globulin standard. Proteins contained in cell lysates were separated by SDS 
PAGE. The samples were prepared by combining 15 µg of protein, 7.5 µl of 4xNuPAGE
®
 LDS 
sample buffer and 2 µl DTT for 10% or 4-12%, 1 or 1.5 mm, 10 or 15 well Bis-Tris NuPAGE
®
 gels. 
The final volume of each sample was diluted with ultrapure water to 30 µl and 20 µl for 10 and 15 
well gels, respectively. Samples were denatured by boiling for 5 min, centrifuged for 1 min at 4°C 
and loaded onto the gels. Gels were run at 150 volts for 90 min. The separated proteins were 
transferred from gels to Immobilon
TM
-P transfer membranes by semi-dry transfer for 1h with a 
current of 1 milliamp per membrane. The membrane was activated by methanol for 20 seconds 
and then washed with ultrapure water for 5 min followed by transfer buffer for 5 min. After 
transfer, the membranes were blocked in 5% BSA blocking buffer for 1 h at RT. Membranes were 
then probed with primary Ab, in 5% BSA dilution buffer at the working concentration, by 
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incubation on a rotator overnight at 4°C. On the second day, the membranes were rinsed and 
washed three times with TBS-T prior to incubation with the appropriate secondary HRP-
conjugated Ab in 5% BSA dilution buffer at the working concentration. After incubation on a 
rotator at RT for 1 h, the membranes were washed three times with TBS-T and the signals were 
detected using an ECL detection kit. The blots were developed by exposing the membranes to 
Kodak XOMat films at varied time points to obtain the optimal results. Each film was developed by 
a Compact X4 X-ray processor. Membranes were stripped and/or reprobed for other proteins 
including a housekeeping gene as a loading control. Band intensity was quantified using ImageJ 
software. 
 
2.2.22. Phos-tag
TM
 SDS-PAGE 
Protein lysates were collected and the protein concentration quantified as described in 2.2.21. 
Phosphorylated proteins were separated from non-phosphorylated proteins using Phos-tag
TM
 
SDS-PAGE (Fig. 2.7.). An 8% acrylamide resolving gel containing 50 µM Phos-tag
TM
 acrylamide 
AAL-170 and 50 µM manganese chloride (MnCL2) in 30% (w/v) acrylamide, 1.5 mol/L Tris/HCL 
buffered solution (pH=8.8), 0.5 % TEMED and 10% (w/v) diammonium peroxydisulfate solution 
was prepared and allowed to polymerize for 30 min at RT. 5.5% stacking gel composed of 30% 
(w/v) acrylamide and 0.5 mol/L Tris/HCL buffered solution (pH=6.8) was mixed with 0.5% TEMED 
and 10% (w/v) diammonium peroxydisulfate solution poured onto the polymerized resolving gel 
and allowed to settle for 60 min at RT. Protein samples were prepared by combining 20 µg 
protein with 3X bromphenol blue (BPB) sample buffer (Appendix), denatured by boiling for 5 min, 
centrifuged for 1 min at 4°C and loaded onto the gels. For lambda protein phosphatase treatment 
(λ PP; New England Biolabs, Inc., Ipswich, MA, USA), 20 µg protein was first mixed with 200 units 
λ PP, 1X NEBuffer, and 1 mM MnCl2, and incubated for 30 min at 30°C prior to combining with 
BPB sample buffer. Gels were run at 150V for 120 min. After electrophoresis, gels were first 
soaked in general transfer buffer containing 1 mmol/L EDTA for 10 min, followed by soaking in 
general transfer buffer without EDTA for further 10 min, with gentle agitation to eliminate 
manganese ions from the gel and improve transfer of proteins onto PVDF membranes. Transfer 
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of proteins, probing of membranes with primary and appropriate secondary Abs, and signal 
detection was performed as described in 2.2.21.  
 
Figure 2. 7.: Phos-tag
TM
 SDS-PAGE. Phos-tag
TM
 acrylamide specifically binds to phosphorylated 
forms of Serine/Threonine/Tyrosine thereby separating phosphorylated proteins from non-
phosphorylated proteins in the same sample. During electrophoresis, Phos-tag
TM
 is directly added 
to the polyacrylamide gel and binds to phosphorylated proteins present in the cell lysate. Binding 
of Phos-tag
TM
 alters the molecular weight (MW) of these proteins thereby decreasing migration 
speed and separating them from non-phosphorylated proteins. Membranes are then probed with 
total antibodies against the protein of interest and multiple bands become visible after 
chemiluminescent detection, with the lowest band representing non-phosphorylated proteins and 
upper bands representing phosphorylated forms of the protein of interest (Wako Chemicals 
GmbH; http://www.wako-chem.co.jp/english/labchem/product/life/phos-
tag_aal_guidebook/index.htm). 
 
2.2.23. Difference in-gel electrophoresis and Mass Spectroscopy 
HUVEC cultured in 1% gelatin-coated T75 culture flasks were washed three times with DIGE 
washing buffer containing 5 mM magnesium acetate (Mg(CH3COO)2) and 10 mM Tris (pH=8). 
After the final wash, the buffer was replaced with 2 ml fresh DIGE washing buffer and cells were 
collected by scraping. Cells were then pelleted by centrifugation at 17,968 x g for 1 min at 4°C, 
lysed in DIGE lysis buffer containing 8 M urea, 4% CHAPS, and 30 mM Tris (pH=8.5) and 
sonicated for 2 min. DIGE washing and DIGE lysis buffer were both supplied by our collaborator 
Prof M. Mayr (King’s College London, London, UK). Cell lysates were incubated on ice for 15 min 
with vigorous vortexing every 5 min. After centrifugation at 17,968 x g for 15 min at 4°C, 
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supernatant was harvested and protein concentration was quantified using the Bio-Rad Dc protein 
assay kit according to the manufacturer’s instructions using a gamma globulin standard. Protein 
samples were then shipped to King’s College London on dry ice and analysed by difference in-gel 
electrophoresis (DIGE) coupled to mass spectroscopy by our collaborators. Detailed protocols are 
available on: http://www.vascular-proteomics.com/. A list of differential expressed proteins was 
returned to our laboratory and then analysed by myself using DAVID Bioinformatics Resources 
6.7 (National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health) and 
grouped according to gene ontology (GO). 
 
2.2.24. In vitro transfection of EC with promoter constructs by lipofection 
EC were co-transfected with the relevant promoter construct and pGL4.74[hRluc/TK] by 
lipofection using the proprietary lipid complex GeneJuice (Merck Chemicals Ltd., Nottingham, 
UK). 
HUVEC were plated at 3 x 10
4
 cells per well in 1% gelatin-coated 24-well plates in M199 plating 
medium and incubated at 37°C in 5% CO2 overnight. GeneJuice solution was prepared by mixing 
1.5 µl GeneJuice with 50 µl Optimen and incubated at RT for 5 min before addition of 250 ng of 
the relevant plasmid and 250 ng pGL4.74[hRluc]/TK]. The transfection mixture was incubated at 
RT for 15 min. Culture medium was replaced with Optimem and transfection mixture was added 
dropwise and incubated for 6 h. After incubation, culture medium was replaced with EBM-2 
supplemented with 2% FCS, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, 2 mmol/l L-glutamine, 
and 1.875 µg/ml ECGS. Transfected cells were incubated at 37°C in 5% CO2 overnight and then 
treated with the appropriate compound for the indicated time points. Analysis of promoter activity 
was performed using the dual luciferase reporter assay. 
 
2.2.25. Dual-Luciferase® Reporter Assay 
The Dual-Luciferase
®
 Reporter Assay System (DLR
TM
 assay; Promega) was used as per 
instructions. The DLR
TM
 assay enables the sequential measurement of the activities of both the 
firefly (Photinus pyralis) and Renilla (Renilla reniformis, also known as sea pansy) luciferases 
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from a single sample. The firefly luciferase reporter is measured first by adding Luciferase Assay 
Reagent II (LAR II) to generate a stabilized luminescent signal. After quantifying the firefly 
luminescence, this reaction is quenched, and the Renilla luciferase reaction is subsequently 
initiated by adding Stop&Glo
®
 Reagent to the same tube. The Stop&Glo
®
 Reagent also produces 
a stabilized signal from the Renilla luciferase, which decays slowly over the course of the 
measurement. 
Cell lysis buffer was prepared by adding 1 volume of 5X Passive Lysis Buffer (PLB) to 4 volumes 
of ultrapure H2O. LAR II was prepared by adding 10 ml Luciferase Assay Buffer II to Luciferase 
Assay Substrate. Stop&Glo
®
 Reagent was prepared by adding 20 µl Stop&Glo
®
 Substrate to 1 ml 
Stop&Glo
®
 Buffer. Culture medium was aspirated and cell monolayers were washed with PBS 
twice. To each 24-well plate, 100 µl 1X PLB was added per well and plates were incubated at RT 
for 15 min on a rocking platform. Cell lysates were collected and transferred into Eppendorf tubes. 
For each reaction, 20 µl of cell lysate was transferred into one well of a white 96-well plate 
(Appleton Woods Ltd., Birmingham, UK). Each sample was prepared in triplicates. Plates were 
read on the Biotek SynergyTM 4 Multi-Mode Microplate Reader which dispensed LAR II and 
Stop&Glo
®
 Reagent sequentially generating firefly and Renilla luminescence, respectively. Data 
was expressed as the ratio of firefly over Renilla luminescence. 
 
2.2.26. In vivo Matrigel plug assay 
The formation of new vessels in vivo was evaluated by the Matrigel plug assay as previously 
described (Bussolati et al., 2004; Birdsey et al., 2008). In brief, female C57BL/6 mice (10 weeks 
old) were anesthetized with an isoflurane gas (IsoFlo
®
, Abbott Laboratories Ltd., Queensborough, 
UK) and injected subcutaneously with Matrigel Basement Membrane Matrix mixture (BD 
Biosciences) near the abdominal midline, to induce the formation of a single solid gel plug. In 
gene silencing studies, Matrigel preparation included 350 µl Matrigel, 64 U/ml heparin, 40 ng/ml 
VEGF or vehicle, 2 µM siRNA (murine siHO-1 pool, murine siCycA1 pool, or siCTL), and PBS to a 
final volume of 500 µl. In gene over-expression studies, the recombinant adenovirus expressing 
the HO-1 gene (AdHO-1) and the control adenovirus containing an empty vector (Ad0) were used 
at 1 x 10
9
 ifu/ml and combined with Matrigel preparations as described above. Plugs were 
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harvested after 7 days from CO2-euthanised mice, fixed in 4% (w/v) paraformaldehyde for 2 h at 
RT, washed in PBS with Ca
2+
 and Mg
2+
 for 30 min, and stored in 70% ethanol/ultrapure H2O at 
4°C. Fixed plugs were then embedded in paraffin, and processed for hematoxylin and eosin 
staining by L. Lawrence (National Heart and Lung Institute, Imperial College London, London, 
UK). In vivo experiments were performed according to the Animals Scientific Procedures Act of 
1986.  
For quantification, vessels contained in the Matrigel plug were identified by the presence of 
nucleated cells surrounding a lumen containing red blood cells. Vessels were counted in 5 fields 
of view using a 20X objective lens (OLYMPUS BX50, OLYMPUS KEYMED, Southend on Sea, 
UK). Plugs from 3 mice were analysed for each treatment.  
 
2.2.27. Statistical analysis 
If not stated otherwise, data are expressed as the mean of individual experiments ± standard 
error of the mean (SEM). Data were grouped according to treatment and analysed using 
GraphPad PRISM Software (San Diego, CA, USA). Differences of the results between treatments 
were evaluated by analysis of variance (ANOVA) with Bonferroni correction, an unpaired 
Student’s t-test, or column statistics using a one-sample t-test. Differences were considered 
significant at p-values <0.05. 
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CHAPTER 3 - MOLECULAR AND MORPHOLOGICAL CHARACTERISATION OF 
ENDOTHELIAL CELLS 
3.1. INTRODUCTION 
The vascular endothelium is a continuous cell monolayer lining the inner lumen of all blood 
vessels, thereby forming an interface between the circulating blood and the extravascular tissue. 
It is a highly dynamic tissue regulating the passage of materials from intravascular to 
extravascular sites. The endothelium uses its strategic location to maintain homeostasis through 
maintenance of a non-thrombotic environment facilitating laminar blood flow, by regulating 
vascular tone, haemostasis, vascular wall permeability, endothelial cell (EC) proliferation and 
angiogenesis, and innate and adaptive immunity. Due to its anatomical location and its extensive 
distribution throughout several organ systems, the endothelium is involved in many diseases; 
either having a primary role in pathogenesis or facilitating disease following EC bystander injury. 
The endothelium is derived from the embryonic mesoderm via the differentiation of mesodermal 
cells into hemangioblasts leading to the formation of primitive blood islands. Hemangioblasts from 
the centre of the islands give rise to hematopoitic stem cells, and hemangioblasts at the periphery 
of the islands differentiate into angioblasts, the precursors of mature EC (Risau and Flamme, 
1995; Cines et al., 1998). EC are highly responsive to their micro-environment and exhibit marked 
plasticity with the ability to trans-differentiate into other cell lineages, whilst other cell types may 
also differentiate into EC (Aird, 2008). Although the endothelium was once viewed as an inert 
tissue consisting of a rather homogeneous population of cells, there is considerable evidence to 
suggest that although EC display many common features, they also exhibit remarkable 
heterogeneity (Garlanda and Dejana, 1997). Endothelial diversity is reflected by vessel size-
specific, organ-specific and age-specific differences and is most evident at the morphological 
level, with a capillary phenotype classified as continuous, fenestrated or discontinuous. Other 
distinguishing criteria include cell size and shape, orientation with respect to the direction of blood 
flow, complexity of inter-endothelial adhesions, and composition of the recruited vessel wall 
(Thorin and Shreeve, 1998). Functional heterogeneity of EC is reflected by organ-specific roles in 
the control of vasoconstriction and dilation, blood coagulation and anti-coagulation, leukocyte 
homing and acute inflammation, wound healing and atherogenesis (Gerritsen, 1987). The 
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diversity of morphological and functional properties makes the endothelium uniquely adapted to 
communicate regionally with specific underlying tissue. For instance, liver cells lining the hepatic 
sinusoids are highly fenestrated and discontinuous, and mediate the exchange of metabolites and 
the processing of toxins between the portal blood, Kupffer cells and hepatocytes (Kmiec, 2001). 
Brain EC, in contrast, interact with astrocytes to produce the blood-brain barrier by forming a 
continuous endothelium with complex tight junctions and highly regulated polarised endocytosis 
and transcytosis (Abbott, 2002). Although all EC share common progenitors, there are very few 
defining structural and molecular markers which can be used to identify EC and distinguish one 
type of EC from another in a different vascular bed. Some structural, molecular and functional 
markers used to characterise EC are listed in Tab. 3.1 and Tab. 3.2.  
As a result of their unique anatomical location EC are exposed to a variety of local haemodynamic 
mechanical forces. These include pressure, created by the hydrostatic forces of blood within the 
vessel; blood pressure-derived tensile stress, created as a result of defined intracellular 
connections between EC that exert longitudinal forces on the cell during vasomotion, and flow-
generated shear stress, which is the frictional force exerted by the flowing blood on the 
endothelial surface, affecting cell morphology, cell metabolism and gene expression (Davies, 
1995). For instance, within straight sections of the vasculature where high shear unidirectional 
laminar blood flow occurs, EC are transformed from their characteristic ‘cobblestone’-shaped 
morphology into cells orientated parallel in the direction of flow. EC in these areas exhibit reduced 
endothelial turnover defined by both decreased proliferation and apoptosis, and enhanced anti-
inflammatory and anti-thrombotic properties (Dewey et al., 1981; Malek and Izumo, 1994; Kaiser 
et al., 1997). Gene expression profiling demonstrated that cultured vascular EC respond to fluid 
mechanical forces by modulating the mRNA level of a large number of genes. Sustained laminar 
flow with high shear up-regulates expression of EC genes that are protective against 
atherosclerosis, including the transcription factors KLF-2 (Dekker et al., 2002; Wang et al., 2006), 
Nrf-2 (Chen et al., 2003) and their downstream targets, such as the cytoprotective enzymes HO-1 
(De Keulenaer et al., 1998), MnSOD (Topper et al., 1996) and Cu/ZnSOD (Inoue et al., 1996). 
Laminar shear further facilitates secretion of the vasodilators PGI2 and NO (Hanada et al., 2000; 
Topper et al., 1996; Malek et al., 1999; Mashour and Boock, 1999), while suppressing the 
production of vasoconstrictors, such as ET-1 (Malek and Izumo, 1992), as well as inflammatory 
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mediators and adhesion molecules, including NFκB and VCAM-1, thereby contributing to a 
quiescent atheroprotective endothelial phenotype (Ando et al., 1994). In contrast, disturbed flow, 
with associated reciprocating low shear stress, occurring at branch points and curvatures of the 
arterial tree, typically up-regulates genes that promote atherogenesis (Mohan et al., 1999; De 
Keulenaer et al., 1998). 
The anatomical location of the endothelium makes it a difficult tissue to assess, thus impeding 
direct diagnostic and experimental studies. However, advances in microscopy, cell and molecular 
biology have improved our understanding of EC biology and function considerately. Of particular 
importance was the development of techniques to culture and characterise EC in vitro, which was 
initially attempted by Maruyama in the 1960’s and later developed independently by Jaffe and 
Gimbrone in the 1970’s (Maruyama, 1963; Jaffe et al., 1973; Gimbrone et al., 1974). The studies 
in this thesis employed EC isolated from human umbilical veins adopting the technique developed 
by Jaffe and colleagues which is detailed in Chapter 2. However, as already outlined in their 
original study, isolated EC populations may be contaminated with smooth muscle cells and 
fibroblasts, while EC may also differentiate into other cell types with different molecular and 
functional properties (Jaffe et al., 1973). Therefore this initial results chapter details the 
morphological and molecular characterisation of EC isolated from umbilical veins for use in my 
studies in the forthcoming chapters. 
 
 
 
 
 
 
 
 
Chapter 3 
118 
 
Table 3. 1.: Constitutive markers of endothelial cells. Modified after Garlanda and Dejana, 
1997. EC – endothelial cell. 
 
Constitutive Endothelial Markers 
Antigen Cell Type Reference 
 
  
Angiotensin-converting enzyme EC, epithelial cells, monocyte-macrophages, 
T lymphocytes 
Belloni and 
Tressler, 1990 
CD31/PECAM-1 EC, platelets, megakaryocytes, B and T 
lymphocyte subsets, monocytes, neutrophils 
DeLisser et al., 
1994; Vecchi 
et al., 1994 
CD51/61 vitronectin receptor EC, platelets, megakaryocytes, oesteoclasts, 
mast cells, B lymphocytes 
Brooks et al., 
1996 
CD102/ICAM-2 EC, lymphocytes, monocytes, platelets Springer, 1990 
CD105/endoglin EC, monocyte-macrophages, erythroid cells, 
platelets, megakaryocytes 
Gougos and 
Letarte, 1988 
Griffonia simplicifolia aggulutinin 
binding 
EC (rodent) Sahagun et al., 
1989 
Thrombomodulin EC, smooth muscle cells Esmon, 1995 
Vascular endothelial cadherin EC, trophoblasts, peripheral lymph node 
sinus macrophages 
Lampugnani et 
al., 1992 
von Willebrand Factor EC, platelets Jaffe et al., 
1973, Wagner 
et al., 1982 
Weibel-Palade bodies EC Weibel and 
Palade, 1964 
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Table 3. 2.: Inducible markers of endothelial cells. Modified after Garlanda and Dejana, 1997. 
EC – endothelial cell. 
 
Inducible Endothelial Markers 
Antigen Cell Type Stimulus Reference 
 
   
CD54/ICAM-1 EC, leukocytes, epithelium, 
fibroblasts 
Upregulated in EC by 
inflammatory cytokines 
Springer, 1990 
CD62E/E-selectin EC, post-capillary venules, 
restricted in vivo 
inflammation, cytokines, 
neoangiogenesis 
Kansas, 1996 
CD62/P-selectin EC, platelets cytokines Kansas, 1996 
CD106/VCAM-1 EC, macrophages, 
synoviocytes, dendritic 
cells, mesothelium 
Upregulated in EC by 
inflammatory cytokines 
Springer, 1990 
Tie 1 EC neoangiogenesis Mustonen and 
Alitalo, 1995 
Tie 2/TEK EC, monocytes neoangiogenesis Mustonen and 
Alitalo, 1995 
VEGF receptor-1 
(Flt-1) 
EC neoangiogenesis, 
Kaposi’s sacroma 
Peters et al., 
1993 
VEGF receptor-2 
(KDR/Flk-1) 
EC neoangiogenesis, 
Kaposi’s sarcoma, 
vascular tumours 
Quinn et al., 
1993 
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3.2. RESULTS 
3.2.1. Morphological characterisation of endothelial cells 
Cells were isolated from umbilical veins following collagenase treatment and grown to confluence 
on gelatin-coated culture flasks. Phase-contrast microscopy showed cellular monolayers with a 
characteristic ‘cobblestone’ morphology, composed of homogenous, closely opposed, polygonal 
shaped cells with distinct borders and centrally located nuclei (Fig. 3.1.A and B). These 
appearances were maintained beyond 5 passages and were also found with human 
microvascular endothelial cells (HMEC-1), representing EC of the human dermal 
microvasculature (Fig. 3.1.C and D). In contrast, human aortic smooth muscle cells exhibited a 
distinctly different appearance; they grew as long, slender overlapping cells in parallel arrays (Fig. 
3.1.E and F). 
 
3.2.2. Expression of constitutive and inducible surface markers of endothelial cells 
Flow cytometric analysis was used to evaluate the purity of newly isolated primary cells from 
umbilical cords by assessing the constitutive expression of cell surface markers. Analysis of 
HUVEC showed a significant basal expression of EC markers CD31 (PECAM-1), endoglin 
(CD105), and ICAM-2 (Fig. 3.2.), but no basal expression of the leukocyte adhesion molecule 
VCAM-1 (Fig. 3.3.). Following TNF-α treatment for 16 h, there was a marked induction of VCAM-1 
protein on the surface of EC. Both 1 ng/ml and 10 ng/ml TNF-α treatment, significantly enhanced 
VCAM-1 expression to a similar extent when compared to untreated control cells, with a relative 
fluorescent intensity (RFI) of 30 to 35 for TNF-α treated HUVEC compared to an RFI of 1.5 for 
untreated cells (Fig. 3.3.). 
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Figure 3. 1.: Morphological characterisation of human endothelial cells. Human endothelial 
cells were cultured on gelatin-coated culture flasks and visualised using phase-contrast 
microscopy. (A, B) Images of human umbilical vein endothelial cell (HUVEC) monolayers. (A) 10X 
and (B) 20X magnification. (C, D) Images of the human dermal microvascular endothelial cell 
(HMEC-1) monolayers (C) 10X and (D) 20X magnification. (E, F) Images of human aortic smooth 
muscle cell (HAoSMC) monolayers (E) 10X and (F) 20X magnification. Bars equal 50 µm. 
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Figure 3. 2.: Expression of constitutive surface markers of endothelial cells. The expression 
of EC surface markers was assessed using flow cytometry. HUVEC monolayers were analysed 
for the expression of (A) CD31 (PECAM-1) using P2B1 mAb, (B) endoglin (CD105) using RMAC8 
mAb, and (C) ICAM-2 using CBR-IC2/2 mAB. Black histograms represent the isotype control 
population, grey histograms present the antigen of interest with percent positivity in brackets. Bar 
charts display the relative fluorescence intensity (RFI). Data is presented as mean ± SEM (n=3 
experiments), *** p<0.001. +ve – positive. 
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Figure 3. 3.: TNFα-induced surface expression of VCAM-1 on endothelial cells. HUVEC 
monolayers were left untreated (UT) or treated with 1 ng/ml TNFα or 10 ng/ml TNFα for 16 h prior 
to analysis of VCAM-1 surface expression by flow cytometry. (A) Black lines represent the isotype 
control population, grey shading represents VCAM-1 expression using 1.4C3 mAb with light grey 
untreated EC, medium grey 1 ng/ml TNFα, and dark grey 10 ng/ml TNFα treated HUVEC. (B) Bar 
charts display the relative fluorescence intensity (RFI) normalised to the isotype control. Data is 
presented as mean ± SEM (n=3 experiments), *** p<0.001 vs UT. 
 
3.2.3. Morphological and molecular characterisation of EC exposed to high shear 
unidirectional laminar flow 
Exposure to high shear unidirectional laminar flow in vitro alters morphological and molecular 
characteristics of EC. Phase-contrast microscopy showed that HUVEC maintained a confluent 
monolayer, and formation of intracellular gaps, denudation, and damage were not observed in 
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any of the experimental conditions. Cells cultured under static conditions maintained the 
characteristic ‘cobblestone’ morphology of EC with a polygonal cell shape and centrally located 
nuclei (Fig. 3.4.A). After exposure to high shear unidirectional flow (12 dynes/cm
2
) for 24 h, EC 
exhibited an elongated cell shape and were orientated parallel in the direction of flow (Fig. 3.4.B). 
These morphological responses of EC to laminar flow are consistent with previous reports 
(Dewey et al., 1981; Kataoka et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 4.: Morphological and molecular characterisation of endothelial cells exposed to 
high shear unidirectional laminar flow. HUVEC were cultured under (A) static conditions or (B) 
exposed to high shear unidirectional laminar flow (LSS; 12 dynes/cm
2
) for 24 h prior to 
assessment of cell morphology by phase-contrast microscopy. Pictures are representative images 
from three experiments for (A) static and (B) LSS conditions, the arrow indicates the direction of 
flow. Bars equal 50 µm, 10X magnification; (C) mRNA quantification by qRT-PCR of known flow 
inducible genes. Data is presented as mean ± SEM and expressed relative to cells cultured under 
static conditions (n=3 experiments), * p<0.05, ** p<0.01. 
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Molecular analysis by quantitative RT-PCR revealed an increased induction of flow-responsive 
genes. HO-1 mRNA levels of cells exposed to high shear unidirectional flow for 24 h were 
significantly enhanced by >20-fold compared to cells cultured under static conditions (Fig. 3.4.C). 
Similarly, mRNA levels of the known flow inducible markers VEGF, KLF-2, and eNOS were 
increased by >5-fold by high shear stress compared to static cells, and again these results are in 
concordance with previous findings (De Keulenaer et al., 1998; Chen et al., 2003; Wang et al., 
2005; Malek et al., 1999; Wang et al., 2006). 
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3.3. DISCUSSION 
Over the past decades, tremendous technological and methodological advances in cell and 
molecular biology have greatly improved our current understanding of the endothelium and its role 
in health and disease. The ability to isolate and characterise human EC in vitro created new 
possibilities to study the biology of EC, that are otherwise difficult to assess due to their 
anatomical location. The most common approach for EC harvesting is to enzymatically remove 
the cells by collagenase digestion from the internal lining of large blood vessels such as the 
human umbilical vein. Although a good yield of EC is generally achieved using this technique, it 
has been acknowledged by Jaffe and colleagues in 1973 that isolated EC populations may be 
contaminated with non-endothelial cells of the tissue surrounding the vessel, such as smooth 
muscle cells and fibroblasts. In addition, EC may differentiate into other cell types with different 
molecular and functional properties. The primary purpose of the studies described in this chapter 
were first to demonstrate the successful isolation and culture of EC from human umbilical veins, 
second to determine the purity of the isolated populations, and thirdly, to confirm the identity of 
these cells using well described morphological and molecular markers. 
Cultured endothelial cells display certain characteristic features that can be used to confirm their 
identity after harvesting and plating the isolates, regardless of the method of isolation. They form 
confluent monolayers that restrict the movement of macromolecules and display a ‘cobblestone’ 
appearance, composed of homogenous, closely opposed, polygonal shaped cells with distinct 
borders and centrally located nuclei (Maruyama, 1963; Jaffe et al., 1973,; Gimbrone et al., 1974). 
Cells isolated from human umbilical veins in this study displayed the described morphological 
characteristics (Fig. 3.1.A and B) and similar appearances were seen with cultured cells of the 
dermal microvasculature (HMEC-1; Fig. 3.1.C and D). These appearances however differed 
markedly from those of smooth muscle cells (HAoSMC; obtained from Promocell), which were 
spindle shaped and grew in overlapping parallel arrays (Fig. 3.1.E and F). 
Different cellular markers are localised in the cytoplasm or on the surface membrane of EC and 
are used for identification of EC in culture. Some of these markers are universal, such as CD31, 
others are specific for the vascular bed or the specific tissue, however the latter are relatively 
scarce. Some of the EC markers are constitutive and present in essentially all types of the 
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endothelium, while others are expressed after activation by inflammatory cytokines or growth 
factors (Tab. 3.1. and Tab. 3.2.). EC isolated from umbilical veins showed a marked expression of 
the surface molecules CD31, endoglin (CD105), and ICAM-2 (Fig. 3.2.). CD31 is a glycoprotein 
expressed at endothelial intercellular junctions, belongs to the immunoglobulin (Ig) superfamily 
and is important for the transendothelial migration of leukocytes, during angiogenesis and for 
integrin activation (Albelda et al., 1991; DeLisser et al., 1994; Newman and Newman, 2003). 
Endoglin is a homodimeric transmembrane protein which is a major glycoprotein of the vascular 
endothelium. The protein is part of the transforming growth factor-beta (TGF-β) receptor complex 
and is important in TGF signalling, cytoskeletal organisation and cell migration, and 
cardiovascular development and remodelling. Endoglin deficiency is embryonically lethal in mice 
due to cardiovascular defects (Gougos and Letarte, 1988; Barbara et al., 1999; Sanz-Rodrigues 
et al., 2004). ICAM-2 is a member of the intercellular adhesion molecule (ICAM) family and is 
expressed at high levels in EC.  It is a type I transmembrane glycoprotein and binds the leukocyte 
integrin LFA-1, mediating leukocyte-endothelial cell interactions important for antigen-specific 
immune responses (Springer, 1990; Simmons, 1995; Hayflick et al., 1998). VCAM-1 is a 
sialoglycoprotein and member of the Ig superfamily, mediating leukocyte-endothelial adhesion 
and signal transduction. VCAM-1 is not expressed in resting EC but strongly induced by pro-
inflammatory cytokines including TNF-α, interferon-γ (IFN-γ), and interleukin-1 (IL-1) and 
expressed on the cell surface of EC (Springer, 1990; Cybulsky et al., 1991; Preiss and Sattar, 
2007). Isolated HUVEC demonstrated a similar VCAM-1 expression profile with no expression in 
the resting state, but following treatment with TNF-α there was a marked induction of VCAM-1 
protein (Fig. 3.3.). In regard of future studies, it would be useful to further determine the purity of 
the isolated cell cultures by excluding a contamination with other cell types, such as fibroblasts 
and smooth muscle cells. Commonly used cellular markers for the characterisation of fibroblasts 
are ER-TR7 antigen and fibroblast-specific protein 1 (FSP1), and alpha smooth muscle actin (α-
SMA) for smooth muscle cells. 
A well-defined characteristic of EC is their morphological appearance when exposed to dynamic 
flow. Shear stress, which is the frictional force on the flowing blood on the endothelial surface, 
induces an elongation of the cell shape in the direction of the flow. This condition more closely 
resembles that of the blood vessel in vivo and is more physiologic than static culture for studying 
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dynamic-associated events (Dewey et al., 1981; Kataoka et al., 1998). The typical ‘cobblestone’ 
appearance of isolated primary cells used in this study was observed for cells cultured under 
static conditions, but was modified after exposure to high shear unidirectional laminar flow for 24 
h. Cells became elongated in shape and aligned parallel in the direction of flow (Fig. 3.4.A and B). 
Gene expression analysis further revealed a marked increase in mRNA expression of the flow-
responsive genes KLF-2, HO-1, eNOS and VEGF (Fig. 3.4.C) in response to high shear 
unidirectional laminar flow compared to static EC. Fluid shear stress maintains vascular 
homeostasis by influencing endothelial gene expression. One mechanism by which shear stress 
achieves this is through induction of transcription factors including KLF-2. The KLF-2 promoter 
contains a 62 bp shear stress-response element (SSRE) which is responsible for its shear stress-
induced expression (Dekker et al., 2002; Huddleson et al., 2005). KLF-2 itself activates 
downstream targets through binding to the SSRE in the promoter of these flow-responsive genes, 
including HO-1 and eNOS (Topper et al., 1996; SenBanerjee et al., 2004; Huddleson et al., 2005; 
Fledderus et al., 2008). The expression of the pro-angiogenic factor VEGF is also induced by 
shear stress in a KLF-2-depedent manner (de la Paz et al., 2012). 
Another characteristic of EC is their ability to organise into tubules or capillary-like microtubes 
when plated onto two-dimensional Matrigel, fibrin or collagen matrixes in response to stimulants 
including growth factors and serum. The ability to form vessel-like structures on Matrigel of 
isolated HUVEC is described in detail in Chapter 5. 
Morphological, structural and molecular characteristics that are restricted to the endothelium and 
can be used to define the identity of EC are limited. Many of these characteristics are shared with 
haemopoietic cells or mature blood cells, emphasising the idea of a common embryonic precursor 
(Risau, 1995). Instead the identity of EC is confirmed by the combination of a variety of 
morphological, structural, molecular and functional markers. Cell isolates from umbilical cords in 
this study demonstrated several morphological and functional characteristics of EC confirming the 
endothelial identity of these cells. The collection technique described in detail in Chapter 2 was 
therefore adopted for studies in the forthcoming chapters. Of note, there are limitations to an in 
vitro approach, as it is difficult to reproduce the in vivo endothelial micro-environment including 
aspects such as flow, interaction with other cells, connective tissues and signalling molecules. 
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This is evident from studies which demonstrated that culture disturbs EC from their quiescent in 
vivo phenotype (0.1% replications per day) to an activated state (1-10% replications per day), with 
associated loss of vessel type and organ-specific functions (Cines et al., 1998). Nevertheless, 
provided all results are interpreted appropriately and with caution, the development of techniques 
to harvest and culture EC in vitro has immensely advanced our current understanding of the 
vascular endothelium and its role in physiology and disease.  
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CHAPTER 4 - THE PRO-ANGIOGENIC FACTORS VEGF AND SDF-1 ALPHA REGULATE THE 
EXPRESSION OF THE CYTOPROTECTIVE ENZYME HO-1 IN ENDOTHELIAL CELLS 
4.1. INTRODUCTION 
HO-1 is encoded by the gene HMOX1, located on chromosome 22, and its expression is mainly 
regulated at the transcriptional level (Gozzelino et al., 2010). HMOX1 transcription can be induced 
by a variety of signal transduction pathways in an inducer-, cell-type- and species-specific 
manner.  A major role for mitogen-activated protein kinases (MAPK) has been implicated in the 
activation of HO-1 ultimately activating transcription factors that regulate HMOX1 transcription by 
recognising specific response element-rich regions within the proximal (-0.3 kb) and distal (-4 kb 
and -10 kb) HMOX1 promoter (Ryter et al., 2006; H. Mylroie, unpublished data) (please see 
section 1.3.2.). 
Biologic activities of the end-products of heme degradation, alone or in combination, and the HO-
1 protein itself have been proven to possess important cytoprotective properties in the 
cardiovascular system, including anti-inflammatory, anti-apoptotic and anti-oxidant effects (Ali et 
al., 2007; Kinderlerer et al., 2008; Grochot-Przeczek et al., 2012). Induction of HO-1 is an 
important cellular adaptive response, minimising tissue injury and facilitating repair, as revealed 
by the severe endothelial damage in human HO-1 deficiency (Yachie et al., 1999). Of note, the 
recognised roles of HO-1 are far beyond cytoprotection. HO-1 has been implicated in the 
regulation of cell proliferation, differentiation and apoptosis. Moreover, the pro-angiogenic 
mediators vascular endothelial growth factor (VEGF), and more recently stromal cell-derived 
factor-1 alpha (SDF-1α), have been shown to activate HO-1 expression in EC implying a role for 
HO-1 in angiogenesis (Fernandez Bonkovsky, 2003; Bussolati et al., 2004; Deshane et al., 2007). 
Treatment of human umbilical vein endothelial cells (HUVEC) and human microvascular EC with 
VEGF increases HO-1 protein expression and enzymatic activity. Importantly, inhibition of HO-1 
with pharmacologic antagonists, SnPP or ZnPP, significantly inhibits VEGF-induced proliferation 
in a dose-dependent manner in vitro and completely inhibits the development of capillary 
sprouting and neovessels in response to VEGF as shown using a murine muscle neovessel 
outgrowth model in Matrigel (Bussolati et al., 2004). In concordance with these findings, VEGF 
increases HO-1 protein expression in the chick embryo chorioallantoic membrane, an effect 
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inhibited by staurosporine, indicating a potential role for protein kinase C (PKC; Fernandez and 
Bonkovsky, 2003). Furthermore, the chemokine SDF-1α, an important regulator of endothelial 
progenitor cell (EPC) migration and recruitment to sites of ischaemic injury, has been linked to 
HO-1-driven angiogenesis. Deshane et al. demonstrate increased HO-1 gene transcription and 
protein translation in human aortic EC in response to SDF-1α, and this is associated with 
increased enzymatic activity. Moreover, HO-1 depletion inhibits SDF-1α-induced endothelial tube 
formation and migration in HAEC, and aortic rings from HO-1-deficient mice, grown on Matrigel, 
fail to form capillary sprouts in response to SDF-1α (Deshane et al., 2007). 
Even though growing evidence suggests an important role for HO-1 in angiogenesis, the 
transcriptional and signalling mechanisms underlying growth factor-induced HMOX1 activation 
remain elusive. The aim of this Chapter is therefore to determine the optimal time-point of HO-1 
induction in response to the pro-angiogenic mediators VEGF and SDF-1α in proliferating human 
EC, and to use these findings to identify transcriptional and signalling mechanisms involved in 
growth factor-regulated HO-1 expression. 
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4.2. RESULTS 
4.2.1. Heme oxygenase-1 is induced by the pro-angiogenic factors VEGF and SDF-1α 
To assess changes in HO-1 expression in proliferating cells, primary HUVEC were cultured to 
sub-confluency (50-70%) on gelatin-coated culture dishes prior to treatment with the pro-
angiogenic mediators VEGF-A or SDF-1α for up to 72 h. Expression levels of HO-1 in EC was 
assessed by qRT-PCR and western blotting. A significant increase in HO-1 mRNA levels 
following exposure to 25 ng/ml VEGF was seen after 8 h and peaked at 24 h (Fig. 4.1.A). HO-1 
protein expression was significantly increased after 16 h VEGF treatment with maximal 
expression at 24 h in proliferating HUVEC (Fig. 4.1.B). Exposure to 100 ng/ml SDF-1α resulted in 
HO-1 induction at earlier time points compared to VEGF, with a significant increase in HO-1 
mRNA after 2 h and maximal induction after 4 h (Fig. 4.2.A), resulting in enhanced protein 
expression after 4 h and 8 h treatment (Fig. 4.2.B). These findings are in concordance with 
previous studies reporting a significant induction of HO-1 protein after 24 h and 48 h in HUVEC 
and EC of the microvasculature (HMEC) in response to VEGF, and subsequent increase in HO-1 
activity (Bussolati et al., 2004). Likewise, SDF-1α has been reported to induce HO-1 mRNA and 
protein in human aortic EC (HAEC) with a maximum response after 4 h and 16 h exposure to 
SDF-1α, respectively (Deshane et al., 2007). Of note, in this study utilising HUVEC, a significant 
variability in HO-1 induction was observed between cell isolates from different donors in response 
to both, VEGF and SDF-1α. Although I have not investigated this, this variability in 
responsiveness might result from the effect of HO-1 promoter polymorphisms (Taha et al., 2010).  
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Figure 4. 1.: Heme oxygenase-1 is induced by the pro-angiogenic factor VEGF. HUVEC 
were cultured to sub-confluency (50-70%) prior to treatment with 25 ng/ml VEGF for the indicated 
time points. (A) mRNA levels were quantified by qRT-PCR and (B) protein expression was 
assessed by western blotting and quantified by densitometry. Tubulin was used as the loading 
control. In (A) untreated samples (UT) represent matched controls for each time point. (B) shows 
a representative blot and corresponding densitometry. Data is presented as mean ± SEM (n=8 
experiments for mRNA levels; n=6 experiments for protein levels), * p<0.05 vs UT matched 
control.
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Figure 4. 2.: Heme oxygenase-1 is induced by the pro-angiogenic factor SDF-1α. HUVEC 
were cultured to sub-confluency (50-70%) prior to treatment with 100 ng/ml SDF-1α for the 
indicated time points. (A) mRNA levels were quantified by qRT-PCR and (B) protein expression 
was assessed by western blotting and quantified by densitometry. Tubulin was used as the 
loading control. In (A) untreated samples (UT) represent matched controls for each time point. (B) 
shows a representative blot and corresponding densitometry. Data is presented as mean ± SEM 
(n=5 experiments and n=1 for 48 h time point for mRNA levels; n=5 experiments for protein 
levels), * p<0.05, ** p<0.01 vs UT matched control. 
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4.2.2. Effect of VEGF and SDF-1α on HMOX1 promoter activity 
To identify transcription factors involved in HO-1 regulation by the pro-angiogenic factors VEGF 
and SDF-1α, the Dual-Luciferase
®
 Reporter Assay System (DLR
TM
 assay) was used. The DLR
TM
 
assay enables the sequential measurement of the activities of both the firefly and Renilla (Renilla 
reniformis) luciferases from a single sample. 
HUVEC cultured on gelatin-coated 24-well culture plates were co-transfected with HO-1 promoter 
constructs ligated into the pGL3-Basic luciferase reporter vector (Fig. 4.3.) and the Renilla 
construct pGL4.74[hRluc/TK] prior to treatment with 25 ng/ml VEGF, 100 ng/ml SDF-1α, or the 
known HO-1 inducer hemin (0.2 µM) in a time course experiment for up to 48 h. The empty pGL3-
Basic luciferase reporter vector was used as a procedure control in all experiments. 
 
Figure 4. 3.: The human HMOX1 promoter. The schematic depicts some of the known 
regulatory elements within the human HMOX1 gene and HMOX1 promoter constructs ligated into 
the pGL3-Basic luciferase reporter vector. AP – activator protein, CdRE – cadmium responsive 
element, CRE – cAMP responsive element, ETS – ETS binding site, Luc – luciferase, MARE – 
Maf response element, NFκB – nuclear factor kappa B, STAT – signal transducer and activator of 
transcription, StRE – stress response element (modified after Kronke et al., 2003; Ryter et al., 
2006). 
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Hemin treatment resulted in a modest 3-fold increase in HMOX1 promoter activity after 8 h 
compared to the untreated control and was used as a positive control for promoter activity (Fig. 
4.4. and Fig. 4.5.). VEGF treatment had no effect on HMOX1 activity after 4 h to 8 h. Of note, 
basal HMOX1 promoter activity was significantly increased after 16 h to 48 h culture compared to 
earlier time points (4 h and 8 h), an effect attenuated by VEGF (Fig. 4.4.). 
 
 
 
 
 
 
 
 
 
 
Figure 4. 4.: Effect of VEGF on HMOX1 promoter activity. HUVEC were co-transfected with 
pGL3-hHO4.9luc or pGL3-basic control vector and pGL4.74[hRluc/TK] prior to treatment with 
hemin (0.2 µM) or VEGF (25 ng/ml) for the indicated time periods and HMOX1 promoter activity 
was assessed using the DLRTM-assay. Data is presented as mean ± SEM (n=3 experiments), * 
p<0.05, *** p<0.01. 
 
Likewise, exposure to the pro-angiogenic factor SDF-1α had no effect on HMOX1 promoter 
activity after 2 h to 8 h compared to time-matched controls. But as seen in experiments utilising 
VEGF, basal HMOX1 activity was notably enhanced at later time points (16 h to 24 h) and again 
SDF-1α treatment markedly decreased this response (Fig. 4.5.). 
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Figure 4. 5.: Effect of SDF-1α on HMOX1 promoter activity. HUVEC were co-transfected with 
pGL3-hHO4.9luc or pGL3-basic control vector and pGL4.74[hRluc/TK] prior to treatment with 
hemin (0.2 µM) or SDF-1α (100 ng/ml) for the indicated time periods and HMOX1 promoter 
activity was assessed using the DLRTM-assay. Data is presented as mean ± SEM (n=4 
experiments), *** p<0.001 vs matched untreated control. 
 
Recent studies demonstrated increased HMOX1 promoter activity in response to the pro-
angiogenic mediators VEGF and SDF-1α in human aortic EC (Deshane et al., 2007). These 
experiments were conducted using a promoter construct containing an additional response 
element-rich region in the distal HMOX1 promoter spanning the DNA sequence between -9.1 kb 
and -11.6 kb. To assess whether transcription factor binding sites within this region regulate 
HMOX1 activity in HUVEC, time course experiments were repeated using the pHOGL3/9.4 
promoter construct, containing 9.4 kb of the human HO-1 promoter. Here, exposure to the HO-1 
inducer hemin (0.2 µM) for 8 h resulted in a minimal promoter response in pHOGL3/9.4 
transfected cells, whereas cells transfected with pGL3-hHO4.9luc showed a 3-fold induction in 
HMOX1 activity, a similar hemin-induced response as seen in previous experiments (Fig. 4.6.). 
Again, HMOX1 activity was not altered by VEGF or SDF-1α after 2 h to 8 h compared to time-
matched untreated controls and basal promoter activity was markedly enhanced after 16 h and 24 
h culture. This effect was completely inhibited by VEGF and partially diminished by SDF-1α (Fig. 
4.7.). 
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Figure 4. 6.: Investigating HMOX1 promoter activity of HUVEC cultured in 6-well plates. 
HUVEC were co-transfected with pHOGL3/9.4 (9.4) or pGL3-hHO4.9luc (4.9) or pGL3-Basic 
control vector and pGL4.74[hRluc/TK] and left untreated (UT) or treated with hemin (0.2 µM) for 8 
hrs. HMOX1 promoter activity was assessed using the DLRTM-assay. Data is presented as mean 
± SEM (n=1 experiment). 
 
Numerous stress-responsive elements (StRE) have been identified within the distal HMOX1 
promoter that mediate transcriptional activation in response to a variety of inducers (Ryter et al., 
2006). The presence of these motifs might explain the differences in basal promoter activity 
between the pHOGL3/9.4 and pGL3-hHO4.9luc promoter plasmids. Further, the high basal 
HMOX1 activity observed in cells transfected with the 9.4 kb promoter construct might counteract 
the effect of the HO-1 inducer hemin, which itself might regulate transcriptional motifs in the more 
proximal region of the HMOX1 promoter.  
Chapter 4 
139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 7.: Effect of VEGF or SDF-1α on HMOX1 promoter activity using the pHOGL3/9.4 
promoter construct. HUVEC were co-transfected with pHOGL3/9.4 or pGL3-basic control vector 
and pGL4.74[hRluc/TK] prior to treatment with (A) VEGF (25 ng/ml), or (B) SDF-1α (100 ng/ml) 
for the indicated time periods and HMOX1 promoter activity was assessed using the DLRTM-
assay. Data is presented as mean ± SEM (n=1 experiment). 
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4.3. DISCUSSION 
The heme oxygenase system has been proven to influence numerous molecular processes within 
the vasculature. The end-products of the degradation of the higly toxic heme moiety and the HO-1 
enzyme itself regulate cell homeostasis and metabolism, and play a role in pathological 
processes. Moreover, HO-1 and its products, alone or in concert, perform important physiological 
functions in the vasculature that are linked to endothelial cytoprotection, including anti-
inflammatory, anti-apoptotic, and anti-oxidant effects (please see section 1.3.3).  
However, the recognised roles of HO-1 extend far beyond cytoprotection and growing evidence 
now suggests a role for HO-1 in angiogenesis. In recent years, research has implicated HO-1 in 
EC survival, proliferation, and tubule formation (Deramaudt et al., 1998; Jozkowicz et al., 2003; 
Bussolati et al., 2004). This is supported by the findings that VEGF treatment results in HO-1 
induction in the chick embryo chorioallantoic membrane, as well as increased expression in 
human EC, which is associated with increased enzymatic activity (Fernandez and Bonkovsky, 
2003; Bussolati et al., 2004). VEGF activates PI3K/Akt, p38, ERK1/2, and JNK MAPK signalling 
pathways, which also influence HO-1 expression in an inducer-, cell type-, and species-specific 
manner (Zachary, 2001; Ryter et al., 2006). However, the identification of the acting pathway, 
alone or in combination, to regulate VEGF-mediated induction of HO-1 still remains elusive. The 
purpose of the studies in this chapter was to demonstrate induction of HO-1 in response to pro-
angiogenic factors VEGF and SDF-1α in proliferating cultured human EC, and to identify 
transcriptional mechanisms that might regulate HO-1 driven angiogenesis in response to these 
factors. 
Previous studies from our laboratory have reported an induction of HO-1 protein in response to 
VEGF after 24 h and 48 h in human EC isolated from umbilical veins (HUVEC) and EC of the 
microvasculature (HMEC-1) (Bussolati et al., 2004). Likewise, time course experiments in this 
study resulted in a significant increase in HO-1 mRNA expression after 8 h VEGF treatment, with 
maximal expression after 24 h in proliferating HUVEC cultures (Fig. 4.1.A). Protein expression 
was significantly up-regulated after 16 h and peaked at 24 h in response to VEGF (Fig. 4.1.B). 
Deshane et al. (2007) recently proposed a relationship between the pro-angiogenic factor SDF-1α 
and HO-1. SDF-1α is the predominant chemokine for the mobilisation of hematopoietic stem cells 
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and endothelial progenitors to sites of injury and facilitates repair (Askari et al., 2003; Kucia et al., 
2004; Walter et al., 2005; Yamaguchi et al., 2003). They found significantly increased HO-1 
mRNA expression after 4 h, resulting in enhanced protein levels after 16 h exposure to SDF-1α in 
human aortic EC (HAEC). These findings are in concordance with the results from this study, 
showing SDF-1α-induced HO-1 mRNA after 2 h to 4 h and elevated HO-1 protein after 4 h and 8 
h in proliferating HUVEC (Fig. 4.2.). Of note, high variability in basal HO-1 expression was 
observed between all experiments and induction of HO-1 by both VEGF and SDF-1α varied 
notably between cell isolates from different donors.  
The proximal region of the human HO-1 promoter (~-243/-198 bp) contains a variable GT-rich 
region ((GT)n), ranging from 11 to 42 repeats (Exner et al., 2004). In recent years, research has 
shown that these (GT)n polymorphism affect transcription, modulate basal and induced HO-1 
expression, and are of clinical relevance. For instance, type II diabetes patients with longer (GT)n 
repeats display reduced HO-1 expression and are at higher risk for the development of coronary 
artery disease (Chen et al., 2002; Song et al., 2009). In contrast, short (GT)n microsatellite 
polymorphisms are associated with reduced expression of pro-inflammatory markers (Li et al., 
2005). Moreover, transfection of aortic smooth muscle cells with reporter plasmids harbouring 
HMOX1 promoter constructs with variable (GT)n repeats, demonstrated diminished HO-1 activity 
in cells transfected with constructs with longer (GT)n repeats (≥ 29) than those with short repeats 
(11, 16 or 20) (Chen et al., 2002). Importantly, promoter polymorphism-dependent variability in 
HO-1 expression has also been reported in the human EC, affecting cytoprotective, anti-
inflammatory, and pro-angiogenic properties of HO-1 (Taha et al., 2010). Cell isolates from 
umbilical veins harbouring short (GT)n repeats in the HO-1 promoter show higher basal HO-1 
expression and an increased HO-1 induction in response to a variety of inducers, are protected 
from oxidative stress, and show better responsiveness to VEGF resulting in enhanced EC 
proliferation (Taha et al., 2010).  
The presence of these DNA microsatellite polymorphisms within the HMOX1 gene promoter might 
account for the high variability in basal and VEGF- and SDF-1α-induced HO-1 expression 
observed in this study. Genotyping the HO-1 promoter of human primary cell isolates and 
selection of cells possessing shorter HO-1 promoter alleles would be one approach to diminish 
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the high variability observed in HO-1 expression, and would assist studies to identify the signalling 
mechanisms involved in the regulation of HO-1 by pro-angiogenic factors with the aid of well-
described synthetic MAPK inhibitors and/or dominant-negative adenovirus targeting MAPK. 
However, pre-selection of more active alleles does not represent the situation of the whole human 
population and therefore might result in contradictive outcomes. The use of cell lines or primary 
isolates from species that do not exhibit (GT)n polymorphisms could further assist in the 
identification of signalling mechanisms. It would be therefore of interest to screen promoter 
regions of endothelial cells from different species, including murine, porcine, and bovine EC, for 
the presence of microsatellite polymorphisms. Although clear species-specific differences exist in 
the regulation of HO-1, conserved regulatory regions within the promoter of the mouse and 
human gene have been identified, possibly allowing a more species-comprehensive conclusion 
from these studies (Alam et al., 1994; Ryter et al., 2006). 
Numerous transcription factors regulating HMOX1 gene activation have been identified in an 
inducer-, cell type-, and species-specific manner, including KLF-2, Nrf-2, and CREB among many 
others (Ryter et al., 2006). The human HO-1 promoter possesses several regulatory element-rich 
domains; the distal -10 kb region has been implicated in the induction of HO-1 in response to the 
organic hydroperoxides (Hill-Kapturczak et al., 2003a), and the -4 kb region mediates, in part, the 
induction response to heme and cadmium (Hill-Kapturczak et al., 2003b; Takeda et al., 1994), as 
well as shear stress, NO donor compounds, cigarette smoke, and oxidised phospholipids (Chen 
et al., 2003; Hara et al., 1999; Favatier and Polla, 2001; Kronke et al., 2003). An additional 
response element-rich region, the -0.3 kb region, has been identified in the proximal promoter 
adjacent to the transcriptional start site, containing binding sites for ETS transcription factors, 
NFκB, and activator protein 2 (AP-2) (Deramaudt et al., 1999; Lavrovsky et al., 1993; Lavrovsky 
et al., 1994). Currently, it remains unknown which of these regulatory element-rich regions and 
transcription factors mediate HMOX1 gene activation in response the pro-angiogenic factors 
VEGF and SDF-1α, ultimately regulating the angiogenic properties of HO-1. Therefore, an 
additional purpose of this chapter was to elucidate transcriptional mechanisms of growth factor-
mediated activation of HMOX1 with the aid of HO-1 promoter constructs of various lengths (Fig. 
4.3.). HUVEC transfected with the promoter construct pGL3-hHO4.9luc, spanning the -4 kb 
regulatory element-rich region and containing transcriptional binding sites for Nrf-2, CREB, and 
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ETS family members, exhibited a modest increase in promoter activity in response to the HO-1 
inducer hemin after 8 h (Fig. 4.4. and Fig. 4.5.). However, in time course experiments utilising this 
promoter construct no change in HMOX1 promoter activity was observed after 2 h to 8 h 
treatment with either VEGF or SDF-1α (Fig. 4.4. and Fig. 4.5.). Deshane et al. recently 
demonstrated significantly increased HO-1 promoter activity in response to SDF-1α and also 
VEGF in human aortic EC. Of note, these experiments were conducted using a promoter 
construct (pHOGL3/9.4) containing an additional response element-rich region in the distal 
HMOX1 promoter spanning the DNA sequence between -9.1 kb and -11.6 kb (Deshane et al., 
2007). However as seen before, in our hands 2 h to 8 h VEGF and SDF-1α treatment did not alter 
HMOX1 activity compared to time-matched controls in HUVEC transfected with the promoter 
construct pHOGL3/9.4 (Fig. 4.7.A and B).  
Interestingly, in both experiments, either using the pGL3-hHO4.9luc or pHOGL3/9.4 plasmid, 
basal HMOX1 promoter activity was significantly enhanced after 16 h to 24 h of culture compared 
to basal activity at earlier time points (2 h to 8 h), and this effect was completely inhibited by 
VEGF and in part diminished by SDF-1α (Fig. 4.4., Fig. 4.5., and Fig. 4.7.). This response might 
be explained by a stress-response of HUVEC during the course of the assay, resulting in 
transcriptional activation of HO-1, subsequently suppressed by the cytoprotective actions of 
VEGF. Indeed, along with the proliferating effects on EC, VEGF has been recognised as a 
cytoprotective modulator, by protecting EC from apoptosis through induction of the anti-apoptotic 
genes A1 and Bcl-2 (Gerber et al., 1998), enhanced induction of DAF, thereby protecting EC 
against complement-mediated injury (Mason et al., 2001), upregulation of eNOS (Bussolati et al., 
2001), and stimulating synthesis of NO and PGI2 (Kroll and Waltenberger, 1999; Laitinen et al., 
1997; Murohara et al., 1998; He et al., 1999). Of note, pHOGL3/9.4-transfected HUVEC showed a 
more pronounced basal induction of HO-1 compared to cells transfected with pGL3-hHO4.9luc. 
Moreover, the HMOX1 promoter response to hemin was minimal in cells transfected with the 
longer promoter construct compared to pGL3-hHO4.9luc-transfected HUVEC showing a 3-fold 
induction (Fig. 4.6.). Numerous stress-responsive elements (StRE) have been identified in the – 
10 kb regulatory region of the HMOX1 gene promoter. StRE,10 bp long motifs of the consensus 
sequence of (T/C)GCTGAGTCA, are structurally conserved among the mouse, rat, and human 
HO-1 gene, and mediate transcriptional activation in response to a large variety of HO-1 inducers 
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(Ryter et al., 2006). The presence of these motifs might explain the differences in basal promoter 
activity between the pHOGL3/9.4 and pGL3-hHO4.9luc promoter plasmids. Further, the high 
basal HMOX1 activity observed in cells transfected with the 9.4 kb promoter construct might 
counteract the effect of the HO-1 inducer hemin, which itself might regulate transcriptional motifs 
in the more proximal region of the HMOX1 promoter.  
To date, it has not been proven possible to identify potential transcriptional pathways involved in 
the regulation of HO-1-driven angiogenesis utilising primary human EC isolated from umbilical 
cords. This results from high variability in basal and induced HO-1 expression, and high basal 
HMOX1 gene promoter activity. Variability in basal and induced HO-1 expression possibly results 
from (GT)n polymorphisms within the gene promoter that have been shown to modulate HO-1 
activity, and high basal promoter activity observed is maybe caused by a stress response of cells 
in culture. The use of cell lines or primary cells from species that do not possess DNA 
microsatellite repeats within their promoter might not only reduce the variability in HO-1 
expression observed between cell isolates from different donors, but might also improve 
transfection efficiency and in turn assist in HO-1 promoter studies. 
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CHAPTER 5 - HO-1 INFLUENCES THE ANGIOGENIC PHENOTYPE OF ENDOTHELIAL 
CELLS 
5.1. INTRODUCTION 
The formation of new blood vessels is highly complex process and occurs in a series of steps 
(section 1.2.1). The angiogenic process is strictly regulated and depends on the concerted 
activities of various growth factors and their receptors expressed on the surface of endothelial and 
accessory cells. The most important molecule controlling blood vessel morphogenesis is vascular 
endothelial growth factor A (VEGF) (section 1.2.2.). 
Recent research now demonstrates a link between the pro-angiogenic factor VEGF and the 
cytoprotective enzyme HO-1, indicating a potential role for HO-1 in the regulation of VEGF-
mediated angiogenesis (please see section 1.3.4.). The first evidence came from Deramaudt and 
colleagues, demonstrating that gene transfer of human HO-1 into coronary EC enhances 
proliferation and formation of capillary-like structures (Deramaudt et al., 1998). HO-1 
overexpression promotes EC cycle progression, while inhibiting that of vascular SMC (Li Volti et 
al., 2002). Supportive of these findings, studies from our laboratory show that overexpression of 
HO-1 utilising a recombinant adenovirus expressing the human HO-1 gene increases proliferation 
of EC isolated from human umbilical veins (HUVEC) (Bussolati and Mason, 2006). In contrast, 
inhibition of HO-1 decreases EC proliferation, capillary formation, and cell cycle progression. This 
effect is associated with an increased expression of the cell cycle inhibitors p21 and p27, and is 
significantly reversed by CO but not bilirubin (Li Volti et al., 2002). Moreover, aortic EC isolated 
from HO-1 knockout (HO-1
-/-
) mice, demonstrate reduced proliferation when compared with EC 
from matched HO-1
+/+
 littermate controls (Chen et al., 2004). 
HO-1 may indirectly affect angiogenesis through its ability to increase VEGF synthesis (Dulak et 
al., 2002; Jozkowicz et al., 2002; Jozkowicz et al., 2003). In vivo experiments using a rat model of 
hindlimb ischaemia, demonstrate that overexpression of HO-1 enhances VEGF synthesis and 
augments formation of vascular capillaries, improving the blood flow in ischaemic tissues, an 
effect abolished by the synthetic HO inhibitor ZnPP (Suzuki et al., 2003). The role for HO-1 in 
angiogenesis is further supported by the finding that pro-angiogenic factors, including VEGF and 
more recently SDF-1α, activate HO-1 expression and activity (Bussolati et al., 2004, Deshane et 
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al., 2007). Studies from our laboratory demonstrate that inhibition of HO-1 using the synthetic HO 
antagonists SnPP or ZnPP attenuates VEGF-induced EC proliferation in vitro, while induction of 
HO-1 with cobalt protoporphyrin (CoPP) alone results in EC proliferation comparable to that seen 
with VEGF (Bussolati et al., 2004). HO-1 inhibition prevents development of VEGF-induced 
neovessels in vitro as well as in vivo and ex vivo (Bussolati et al., 2004). Deshane et al. 
demonstrated that exposure of human aortic EC (HAEC) to SDF-1α results in marked 
upregulation of HO-1 mRNA and protein. Pharmacological and genetic inhibition of HO-1 impaired 
SDF-1α-mediated endothelial tube formation, an effect reversed by a CO donor, CO-releasing 
molecule (CORM-2), but not bilirubin. This study further confirms the functional significance of 
HO-1 in angiogenesis using HO-1
-/-
 mouse models of Matrigel plug and wound healing. HO-1 
inhibition is closely associated with impaired neovascularisation and wound healing in injured 
tissue (Deshane et al., 2007).  
The constitutive HO isoform, HO-2, may also play a role in inflammation and angiogenesis. 
Animals lacking HO-2 demonstrate impaired corneal wound closure, enhanced 
neovascularisation, and exaggerated inflammation (Seta et al., 2006). Murine aortic EC (MAEC) 
isolated from HO-2 null mice show an activated phenotype marked by oxidative stress, 
inflammation and angiogenesis (Bellner et al., 2009).  
The role for HO-1 in angiogenesis is complex, intriguing, and remains to be fully understood. Data 
to date suggest that HO-1 may influence the angiogenic process at various levels. However, the 
precise mechanism through with HO-1 exerts its effects during angiogenesis and the role of the 
HO products CO, biliverdin/bilirubin, and iron remain elusive. The aim of this chapter is firstly to 
optimise various well-described in vitro angiogenesis assays for the use with primary EC. These 
assays will then be adopted for studies to elucidate the precise role of HO-1 during the different 
steps of angiogenesis with the aid of both, loss-of-function and gain-of-function approaches. A 
better understanding of the angiogenic effects of HO-1 may in turn not only reveal new insights 
into the role of its products but may also allow for the identification of novel downstream targets of 
HO-1 in the regulation of angiogenesis. This will be discussed in forthcoming chapters.  
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5.2. RESULTS 
5.2.1. Validation of human siRNA sequences against the human HO-1 and HO-2 genes 
Small interfering RNA (siRNA) was used for in vitro inhibition studies. Different siRNA sequences 
targeting the human HO genes were validated for their knockdown efficiency in human EC 
(HUVEC) by qRT-PCR, western blotting and/or immunofluorescence.  
The basal expression level of the inducible HO isoform, HO-1, is low in the majority of mammalian 
cells, and therefore the HO-1 inducer hemin was utilised to determine the knockdown efficiency of 
siRNA sequences targeting HO-1. Hemin treatment (0.2 µM for 6 h) resulted in a marked 
upregulation in HO-1 mRNA and protein in untransfected control cells and to the same extent in 
cells transfected with a non-targeting control siRNA (siCTL; Fig. 5.1.). Knockdown of HO-1 using 
either a single sequence siRNA (siHO-1 seq2) or a pool of 4 siRNA sequences targeting HO-1 
(siHO-1 pool), both used at 40 nM, significantly inhibited the hemin-induced response in HO-1 
mRNA and protein. mRNA expression was inhibited by 70-80% and protein expression was 
decreased by 80-85% with either siRNA compared to siCTL-transfected cells (Fig. 5.1.). 
Moreover, the immunofluorescent signal detected by antibody-staining of HUVEC transfected with 
siHO-1 pool was notably reduced compared to cells treated with the siRNA delivery agent 
geneFECTOR (GF) or non-targeting control siRNA (Fig. 5.2.). Later in this chapter, 3’-
AlexaFluor488-labelled siRNA was used in migration studies to assist quantification by single cell 
tracking. Western blotting analysis revealed a sufficient knockdown of HO-1 protein by 85% in 
HUVEC compared to GF-treated or siCTL-transfected cells. siHO-1 seq2AF488 had no effect on 
HO-2 expression levels  (Fig. 5.3.). In studies throughout this thesis, the validated siRNA 
sequences targeting HO-1 will be used in in vitro inhibition studies to specifically silence HO-1. 
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Figure 5. 1.: Knockdown efficiency of siRNA against HO-1 in HUVEC. HUVEC were either 
treated with geneFECTOR (GF) or transfected with 40 nM control siRNA (CTL) or HO-1 specific 
siRNA (seq2, pool) for 48 h in the presence of hemin (0.2 µM) for the last 6 h, prior to (A) mRNA 
quantification by qRT-PCR or (B, C) protein quantification by western blotting. (B) shows a 
representative blot, (C) shows the corresponding densitometry. Tubulin was used as a loading 
control. Data is presented as mean ± SEM (n=3 experiments), ** p<0.01, *** p<0.001. 
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Figure 5. 2.: Validation of knockdown efficiency of siRNA against HO-1 in HUVEC by 
immunofluorescent staining. HUVEC were either treated with (A) geneFECTOR (GF) alone or 
transfected with 40 nM (B) control siRNA (CTL) or (C) HO-1 specific siRNA (pool) and seeded 
onto gelatin-coated coverslips for 48 h prior to methanol fixation and HO-1 staining using an anti-
HO-1 mAb. Nuclei were stained with Draq5. Immunofluorescent staining was analysed by z-stack 
confocal microscopy. Pictures are representative images from n=3 experiments, 63X 
magnification. Bars equal 50 µm. 
 
 
 
 
Figure 5. 3.: Knockdown efficiency of 3’-AlexaFluor488-labelled siRNA against HO-1 in 
HUVEC. HUVEC were either treated with geneFECTOR (GF) alone or transfected with 40 nM 3’-
AlexaFluor488-labelled control siRNA (CTLAF488) or HO-1 specific siRNA (seq2AF488) for 48 h prior 
to protein level quantification by western blotting. Tubulin was used as a loading control. A 
representative blot from n=3 experiments is shown. 
 
The constitutive isoform HO-2 is abundantly expressed in mammalian tissues. Different HO-2 
targeting siRNA sequences (siHO-2 seq3, -4, -5, -6) were tested for their knockdown efficiency in 
HUVEC by western blotting. Transfection of HUVEC with siCTL had no effect on HO-2 protein 
compared to GF-treated cells. siHO-2 seq 3 and siHO-2 seq4 reduced protein levels to a minor 
extent, whereas siHO-2 seq5 and siHO-2 seq6 significantly decreased HO-2 protein by 75-80% 
(Fig. 5.4.). The latter two siRNA sequences targeting HO-2 will therefore be utilised for HO-2 gene 
silencing in forthcoming studies. 
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Figure 5. 4.: Knockdown efficiency of siRNA against HO-2 in HUVEC. HUVEC were either 
treated with geneFECTOR (GF) alone or transfected with 40 nM control siRNA (CTL) or different 
sequences of HO-2 specific siRNA (seq3, seq4, seq5, seq6) for 48 h prior to protein level 
quantification by western blotting. Tubulin was used as a loading control. A representative blot 
from n=3 experiments is shown. 
 
5.2.2. Validation of the recombinant adenovirus expressing the human HO-1 gene 
A recombinant adenovirus expressing the human HO-1 gene (AdHO-1) was used in gain-of-
function studies in the course of this thesis. The optimal multiplicity of infection (MOI) in human 
EC was assessed by western blotting. As seen in Fig. 5.5., infection of HUVEC with the control 
adenovirus containing an empty vector (Ad0) had no effect on HO-1 protein levels when used at 
an MOI of 50 or 100 virus particles per cell when compared to non-infected control cells. AdHO-1 
at an MOI of 50 markedly increased HO-1 protein and this effect was even more enhanced at an 
MOI of 100. Based on these findings, an adenoviral MOI of 100 virus particles per cell was used 
in this study. 
 
 
 
Figure 5. 5.: Validation of the recombinant adenovirus expressing the human HO-1 gene. 
HUVEC were either left uninfected of infected with a control adenovirus containing an empty 
vector (Ad0) or the recombinant adenovirus expressing the HO-1 gene (AdHO-1) at different 
multiplicities of infection (MOI) for 2 h in plain M199 medium prior to subsequent culture for 48 h. 
HO-1 protein expression was assessed by western blotting. Tubulin was used as a loading 
control. Representative blots from n=3 experiments are shown. 
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5.2.3. Inhibition of HO-1 impairs VEGF-mediated endothelial cell proliferation in vitro 
The non-radioactive pyrimidine analogue 5-bromo-2’-deoxyuridine (BrdU) becomes incorporated 
into the genomic DNA of dividing cells in place of thymidine, allowing the detection and 
quantification of cell proliferation in culture.  
To determine the optimal time point of vascular endothelial growth factor (VEGF)-induced 
proliferation of human EC in vitro, HUVEC were sparsely seeded onto gelatin-coated culture 
dishes in growth-factor-free medium in the absence or presence of 25 ng/ml VEGF for various 
time periods (Fig. 5.6.).  Endothelial cell growth supplement (ECGS) was used as a positive 
control for proliferation and significantly increased EC proliferation after 72 h of culture. Likewise, 
treatment with the mitogen VEGF notably increased EC proliferation by 200% after 24 h 
compared to untreated control cells, and this effect was further enhanced after 48 h and 72 h of 
culture in the presence of VEGF, resulting in an increase in proliferation by 400% and up to 
600%, respectively (Fig. 5.6.). The 48 h time point was chosen for forthcoming studies 
investigating the role of HO-1 in VEGF-mediated EC proliferation in vitro. 
 
 
 
 
 
 
 
Figure 5. 6.: VEGF-induced human endothelial cell proliferation in vitro. HUVEC were left 
untreated (UT) or treated with 30 µg/ml ECGS for 72 h, or 25 ng/ml VEGF for the indicated time 
periods. EC proliferation was quantified by BrdU incorporation. Data is presented as mean ± SEM 
(n=5 experiment), * p<0.05, ** p<0.01, *** p<0.001 vs UT control, δδ p<0.01. 
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In initial studies, utilising the synthetic HO inhibitor zinc protoporphyrin (ZnPP), sparsely seeded 
HUVEC cultured in growth factor-free medium were treated with 25 ng/ml VEGF, ZnPP alone at 5 
µM, 10 µM, or 20 µM, or VEGF and ZnPP in combination for 48 h (Fig. 5.7). ZnPP alone, at either 
concentration used, had no effect on EC proliferation. But as seen before, VEGF significantly 
enhanced proliferation after 48 h of culture. This effect was inhibited by ZnPP in a dose-
dependent manner, resulting in complete inhibition of proliferation with ZnPP used at 20 µM. 
 
 
 
 
 
 
 
Figure 5. 7.: ZnPP inhibits VEGF-mediated proliferation in a dose-dependent manner. 
HUVEC were left untreated or treated with VEGF (25 ng/ml), ZnPP (5, 10, 20 µM), or VEGF and 
ZnPP in combination for 48 h. EC proliferation was quantified by BrdU incorporation. Data is 
presented as mean ± SEM (n=5 experiments), * p<0.05, *** p<0.001 vs UT control, δδ p<0.01. 
 
Small interfering RNA (siRNA) is a more specific approach for silencing HO-1 in mammalian cells, 
as the synthetic inhibitor ZnPP not only inhibits the inducible isoform HO-1, but also HO-2 (Ryter 
et al., 2006). HUVEC were treated with the siRNA delivery agent geneFECTOR (GF) or 
transfected with 40 nM control siRNA or HO-1 specific siRNA for 24 h, and re-seeded onto 
gelatin-coated 96-well plates in growth factor-free medium for the assessment of proliferation in 
response to VEGF by BrdU incorporation. However, HO-1-deficient cells appeared stressed after 
trypsin digestion and did not survive subsequent culture for 48 h either in the absence or 
presence of VEGF, emphasing the important protective role of HO-1. 
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Proliferating cell nuclear antigen (PCNA) is highly expressed in nuclei of cells in the G1- and S-
phase of the cell cycle, acting as a cofactor for DNA poymerase delta and increasing the 
processing of leading strand synthesis during DNA replication (Paunesku et al., 2001). PCNA is a 
commonly used marker for cell proliferation.  Of note, PCNA antibody staining coupled to FACs 
analysis does not require the transfer of cells to 96-well culture plates and therefore this assay 
was adopted to study the role of HO-1 in VEGF-induced proliferation. Exposure to VEGF for 48 h 
significantly increased the number of PCNA positive cells in GF-treated as well as in siCTL-
transfected cultures. This effect was completely abrogated by siRNA-mediated HO-1 inhibition 
(Fig. 5.8.), confirming the findings obtained from inhibition studies utilising the HO inhibitor ZnPP. 
 
 
 
 
 
 
 
 
Figure 5. 8.: siRNA-mediated HO-1 depletion abrogates VEGF-induced HUVEC 
proliferation. HUVEC were treated with geneFECTOR (GF) or transfected with 40 nM control 
siRNA (CTL) or HO-1 specific siRNA (HO-1; represents pooled data from siHO-1 seq2 and siHO-
1 pool) for 24 h. Cells were cultured in growth factor-free medium in the absence or presence of 
VEGF (25 ng/ml) for additional 48 h prior to PCNA staining and FACs analysis. Data is presented 
as mean ± SEM (n=5 experiments), * p<0.05. 
 
In contrast, overexpression of the human HO-1 gene in HUVEC enhanced basal as well as 
VEGF-mediated proliferation in vitro (Fig. 5.9.). HUVEC responded to VEGF exposure with a 
significant increase in cell proliferation by 600%, measured as BrdU incorporation. Infection of 
cells with the control adenovirus containing an empty vector (Ad0) had no effect on either basal or 
VEGF-induced proliferation when compared to non-infected control cells, with a 6-fold increase in 
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proliferation in response to VEGF observed. Interestingly, basal EC proliferation was significantly 
enhanced in cells infected with the recombinant adenovirus expressing the HO-1 gene (AdHO-1) 
compared to Ad0-infected cells. Moreover, HO-1 overexpression had an effect on VEGF-
mediated EC proliferation further amplifying the response by 1.5-fold compared to cells infected 
with the control adenovirus (Fig. 5.9). 
 
 
 
 
 
 
 
 
Figure 5. 9.: Recombinant adenovirus-induced expression of HO-1 enhances VEGF-
mediated proliferation in HUVEC. HUVEC were left uninfected or infected with a control 
adenovirus containing an empty vector (Ad0) or the recombinant adenovirus expressing the 
human HO-1 gene (AdHO-1) for 2 h in plain M199 medium at a multiplicity of infection (MOI) of 
100. Cells were cultured in the absence or the presence of VEGF (25 ng/ml) for additional 48 h. 
EC proliferation was quantified by BrdU incorporation. Data is presented as mean ± SEM (n=3 
experiments), * p<0.05, *** p<0.001. 
 
5.2.4. HO-1 inhibition has no effect on VEGF-mediated protection against cell death 
Along with its proliferative effects, VEGF has been shown to act as a cytoprotective agent, 
protecting EC from apoptosis through increased induction of the anti-apoptotic genes A1 and Bcl-
2 (Gerber et al., 1998). HO-1 may also protect EC against apoptosis, indeed aortic EC isolated 
from HO-1 knockout mice are more susceptible to apoptotic stimuli and have increased caspase-
3 activity compared with EC from HO-1
+/+
 animals (Brouard et al., 2000; Chen et al., 2004). Thus, 
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the reduced proliferative properties of HO-1-deficient cells in response to VEGF may result from 
increased apoptosis of those cultures.  
The CellTiter 96
®
 Aqueous One Solution cell proliferation assay is a colorimetric method for 
determining the number of viable cells with the aid of a tetrazolium compound (MTS). MTS is 
bioreduced by cells into a formazan product that is soluble in tissue culture medium allowing 
measurement of absorbance (at 490 nm) directly from the culture-well plate (Cory et al., 1991). 
The MTS assay was used to investigate a role for HO-1 in VEGF-mediated cell protection under 
serum-deprived conditions. 
Initial optimising experiments were performed to determine the time point at which serum 
starvation results in a significant decrease in the number of viable cells in culture. HUVEC were 
cultured on gelatin-coated culture dishes in growth factor-free EC culture medium M199 
supplemented with 10% FCS or serum-starved in M199 medium supplemented with 0.1% BSA in 
the absence or presence of VEGF (25 ng/ml) for 24 h to 48 h. Serum-deprivation for 24 h resulted 
in a modest but significant decrease in cell number (25-30%) compared to cells grown in the 
presence of 10% FCS. This effect was rescued by VEGF. The serum starvation-induced cell loss 
was more pronounced after 48 h of culture, resulting in a decrease in cell viability of 70-75% 
compared to the control. Again, this effect was significantly attenuated in the presence of VEGF 
(Fig. 5.10.). Based on these observations, the 48 h time point will be used in forthcoming HO-1 
inhibition studies. 
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Figure 5. 10.: Serum starvation significantly decreases endothelial cell number after 48 h of 
culture, an effect attenuated by VEGF. HUVEC were cultured in M199 culture medium 
supplemented with 10% FCS or serum starved in M199 medium supplemented with 0.1% BSA in 
the absence (UT) or presence of VEGF (25 ng/ml) for 24 h (white bars) or 48 h (grey bars). The 
number of live cells was assessed using the MTS-assay. Data is presented as mean ± SEM (n=3 
experiments), * p<0.05, ** p<0.01. 
 
In HO-1 inhibition studies, enzyme activity was inhibited with the synthetic HO antagonist ZnPP or 
specific siRNA targeting the human HO-1 gene. ZnPP used at a concentration of 20 µM, which 
resulted in a significant inhibition of VEGF-mediated EC proliferation (Fig. 5.7.), had no significant 
effect on the cell viability of cells grown in 10% FCS after 48 h of culture. Moreover, the VEGF-
induced increase in cell number was not affected by ZnPP at different concentrations (Fig. 
5.11.A). Serum starvation resulted in 75% cell loss, an effect attenuated by VEGF. In the 
presence of ZnPP (20 µM), serum deprivation caused a decrease in cell viability to a similar 
extent (75%). Interestingly, HO-1 inhibition by ZnPP at either concentration had no significant 
effect on VEGF-mediated protection against serum starvation (Fig. 5.11.A). To confirm these 
observations, HO-1 was silenced using specific siRNA and the MTS-assay was repeated (Fig. 
5.11.B). siCTL had no effect on cell number of cells grown in 10% compared to GF-treated cells, 
while VEGF significantly increased cell viability in these cultures. Inhibition of HO-1 using siHO-1 
seq2 and siHO-1 pool decreased the number of viable cells by 50% and 40% respectively, but 
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this effect did not reach significance. Moreover, VEGF treatment was protective. Serum starvation 
decreased cell viability by 75% in siCTL-transfected cells and again this was rescued by VEGF. 
siRNA-mediated silencing of HO-1 resulted in a 90% and 75% reduction in EC viability for siHO-1 
seq2 and siHO-1 pool, respectively, under serum-deprived conditions, an effect attenuated by 
VEGF (Fig. 5.11.B). These observations strengthen the findings observed with the ZnPP study, 
and suggest that HO-1 does not play an exclusive role in VEGF-mediated cell protection against 
serum starvation.  
To further exclude apoptosis as an contributor to the impaired proliferative phenotype of HO-1-
deficient EC, propidium iodide (PI) staining in combination with FACs analysis was utilised to 
identify apoptotic cells in culture. PI is a fluorogenic compound that binds stoichiometrically to 
nucleic acids so that fluorescence emission is proportional to the DNA content of a cell. When 
apoptotic cells are stained with PI and analysed by flow cytometry, they display a broad 
hypodiploid sub-G1-peak, which can be easily discriminated from the narrow peak of cells with 
diploid DNA content (Riccardi and Nicoletti, 2006). 
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Figure 5. 11.: HO-1 inhibition has no effect on VEGF-mediated protection against serum 
starvation. (A) HUVEC were either grown in M199 culture medium supplemented with 10% FCS 
(white bars) or serum starved in M199 medium supplemented with 0.1% BSA (grey bars) in the 
absence or presence of VEGF (25 ng/ml), ZnPP (5, 10, 20 µM), or VEGF and ZnPP in 
combination for 48 h. (B) HUVEC were treated with geneFECTOR (dotted line) or transfected with 
40 nM control siRNA (CTL) or HO-1 specific siRNA (seq2, pool) for 24 h. Cells were then either 
grown in M199 medium supplemented with 10% FCS (white bars) or serum starved in M199 
medium supplemented with 0.1% BSA in the absence or presence of VEGF (25 ng/ml) for 
additional 48 h. The number of live cells was assessed using the MTS-assay. Data is presented 
as mean ± SEM (n=5 experiments for ZnPP study, n=3 experiments for siRNA study), ** p<0.01, 
*** p<0.001, ns – not significant. 
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As seen in Fig. 5.12., VEGF exposure for 48 h significantly decreased the number of apoptotic 
cells by 50% in cultures transfected with non-targeting control siRNA. Importantly, while HO-1 
inhibition by siRNA increased apoptosis by 1.5-fold, VEGF-mediated protection was not affected 
in these cells, decreasing the number of apoptotic cells to a similar extent as seen in siCTL-
transfected cultures (Fig. 5.12.). Moreover, as determined by qRT-PCR and western blotting, HO-
1-deficient cells were still able to up-regulate the anti-apoptotic genes A1 and Bcl-2, respectively, 
in response to VEGF (Fig. 5.13.). Altogether these findings strongly suggest that HO-1 has no 
major effect on VEGF-mediated protection in endothelial cells in vitro and that the impaired 
angiogenic phenotype of HO-1-deficient cells is not caused by an increased rate of apoptosis. 
 
 
 
 
 
 
 
Figure 5. 12.: HO-1 inhibition has no effect on VEGF-mediated protection against cell 
death. HUVEC were transfected with 40 nM control siRNA (CTL) or HO-1 specific siRNA (HO-1; 
data represents pooled data from siHO-1 seq2 and siHO-1 pool) for 24 h prior to subsequent 
culture in the absence or presence of VEGF (25 ng/ml) for 48 h. Apoptotic cells were identified by 
propidium iodide staining prior to FACs analysis. Data is presented as mean ± SEM (n=4 
experiments), * p<0.05. 
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Figure 5. 13.: HO-1 inhibition has no effect on VEGF-induced expression of the anti-
apoptotic genes A1 and Bcl-2. HUVEC were treated with geneFECTOR (GF) or transfected 
with 40 nM control siRNA (CTL) or HO-1 specific siRNA (HO-1; data represents pooled data from 
siHO-1 seq2 and siHO-1 pool) for 24 h prior to culture in the absence or presence of VEGF (25 
ng/ml) for 48 h. (A) Bcl-2 protein levels were assessed by western blotting and quantified by 
densitometry. Tubulin was used as a loading control, (B) A1 mRNA expression was assessed by 
qRT-PCR. Data is presented as mean ± SEM (n=4 experiments), * p<0.05, ns – not significant. 
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5.2.5. HO-1 inhibition negatively affects the directional migration of endothelial cell in vitro 
The in vitro scratch assay was used to study the role of HO-1 in EC migration in vitro. This assay 
is based on the observation that, upon creation of a new gap in a confluent monolayer, the so-
called scratch, the cells on the edge of the newly created gap will migrate to close the scratch 
until new cell-cell contacts are established again. The basic steps involve creation of a scratch on 
monolayer cells, capture of images at the beginning and at regular intervals during cell migration 
to close the scratch, and comparison and quantification of the images to determine the rate of 
migration (Liang et al., 2007). In this study, migratory properties of EC in the leading edge of the 
scratch were quantified by single cell tracking in terms of migration speed, and the accumulated 
and Euclidean distance travelled. Fluorescently-labelled siRNA was used in inhibition studies to 
specifically identify siRNA transfected cells for analysis. Non-transfected cells and dividing cells 
were excluded from the analysis. 
Human EC (HUVEC) were seeded onto gelatin-coated culture dishes, transfected with either a 3’-
AlexaFluor488-labelled non-targeting control siRNA (CTLAF488) or an siRNA specifically targeting 
the HO-1 gene (seq2AF488), and grown to confluency prior to creation of the monolayer scratch 
and subsequent culture for 16 h in the absence or presence of the pro-angiogenic mediator VEGF 
(25 ng/ml). Images of migrating cells were captured at regular 15 min intervals with the aid of 
time-lapse confocal microscopy and siRNA knockdown efficiency was validated by western 
blotting at the end of the assay. As seen in Fig. 5.14., siHO-1 seq2AF488 sufficiently inhibited HO-1 
expression in migrating EC in the absence and presence of VEGF, whereas both siRNAs, 
siCTLAF488 and siHO-1 seq2AF488, had no effect on the expression of the constitutive HO isoform 
HO-2. Single cell tracking revealed a modest increase in the accumulated distance and velocity of 
cells transfected with siCTLAF488 in response to VEGF, however this effect was not significant. 
siRNA-mediated inhibition of HO-1 did not alter the accumulated distance migrated, neither in the 
absence nor the presence of VEGF, but had a minor effect on cell migration speed (Fig. 5.15.A 
and B). Interestingly, the Euclidean distance, which is the linear distance between the starting 
point and the end point of the migration path and thereby a measure of directionality, was 
significantly increased in the presence of VEGF in control siRNA transfected cells and this effect 
was completely inhibited by HO-1 (Fig. 5.15.C). Similar results were obtained from HO-1 inhibition 
studies in human EC of the microvasculature (HMEC-1). Exposure to VEGF significantly 
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increased the Euclidean distance travelled of cells transfected with the non-targeting control 
siRNA, an effect inhibited by HO-1 depletion (Fig. 5.15.D).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 14.: Validation of siRNA-mediated knockdown of HO-1 in migrating endothelial 
cells. HUVEC were transfected with 40 nM 3’-AlexaFluor488-labelled control siRNA (CTLAF488) or 
HO-1 specific siRNA (seq2AF488) for 24 h. Confluent cell monolayers were scratched and migration 
was assessed by live cell imaging in the absence or presence of VEGF (25 ng/ml) for 16 h. (A) 
HO-1 and (B) HO-2 protein levels were quantified by western blotting. Tubulin was used as a 
loading control. Representative blots of n=3 experiments are shown. 
 
To further explore this observation the individual paths travelled by each cell were plotted in terms 
of their directionality, with the starting point of each path set to zero (Fig. 5.16). Exposure to 
VEGF resulted in a more linear directional movement of cells towards the scratch and the cells on 
the opposing side in the siCTLAF488-transfected cultures, whereas HO-1-deficient cells migrated in 
a more random, circular pattern alongside the scratch edge.  
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Figure 5. 15.: HO-1 inhibition impairs EC migration in vitro. (A, B, C) HUVEC or (D) HMEC 
were transfected with 40 nM 3’-AlexaFluor488-labelled control siRNA (CTLAF488) or HO-1 specific 
siRNA (seq2AF488) for 24 h. Confluent cell monolayers were scratched and migration was 
assessed by live cell imaging in the absence or presence of VEGF (25 ng/ml) for 16 h and 
quantified using ImageJ analysis software (Manual Tracking and Chemotaxis and Migration tool). 
(A) represents the accumulated distance, (B) the velocity, (C, D) the Euclidean distance. Data is 
presented as mean ± SD (n=3 experiments), * p<0.05, ** p<0.01, *** p<0.001. 
 
 
 
 
 
 
 
Chapter 5 
164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 16.: HO-1 inhibition alters the directional migration of EC in response to VEGF in 
vitro. The directional migration of HUVEC either transfected with  40 nM 3’-AlexaFluor488-
labelled (A) control siRNA (CTLAF488) or (B) HO-1 specific siRNA (seq2AF488) in response to VEGF 
was quantified using ImageJ analysis software (Manual Tracking and Chemotaxis and Migration 
tool). Pictures are representative images from n=3 experiments and plots show the directional 
migration paths of individual cells. Bar equals 50 µm. 
 
Moreover, overexpression of the human HO-1 gene in EC resulted in a modest but significant 
increase in Euclidean distance (Fig. 5.17.). Infection of migrating HUVEC with the recombinant 
adenovirus expressing the human HO-1 gene (AdHO-1) significantly increased HO-1 protein in 
the absence and also presence of VEGF (25 ng/ml) compared to cells infected with the control 
adenovirus (Ad0; Fig. 5.17.A). Quantification of the migration paths of individual cells 
demonstrated a significant increase in Euclidean distance in response to VEGF in control cells. 
Moreover, HO-1 overexpression alone or in combination with VEGF increased the Euclidean 
distance migrated by HUVEC, but with no synergistic effect (Fig. 5.17.B). Altogether, these 
findings are indicative of a role for HO-1 in the regulation of chemokinesis.  
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Figure 5. 17.: HO-1 overexpression favours EC migration in vitro. HUVEC were infected with 
control adenovirus containing an empty vector (Ad0) or the recombinant adenovirus expressing 
the HO-1 gene (AdHO-1) at an MOI of 100 for 2 h in plain M199 medium prior to subsequent 
culture for 16 h. Confluent cell monolayers were scratched and migration was assessed by live 
cell imaging in the absence or presence of VEGF (25 ng/ml) for 16 h. (A) HO-1 protein levels 
were quantified by western blotting. Tubulin was used as a loading control. A representative blot 
and data from n=3 experiments is shown. (B) The Euclidean distance was quantified by ImageJ 
analysis software (Manual Tracking and Chemotaxis and Migration tool). Data is presented as 
mean ± SD (n=3 experiments), * p<0.05. 
 
The in vitro migration scratch assay is a simple and easy to perform assay that mimics to some 
extent the migration of EC in vivo. However, one of its limitations is the lack of the formation of a 
chemotactic gradient of growth factors over the course of the assay (Liang et al., 2007). 
Therefore, to further investigate the potential role of HO-1 in mediating the directional migration of 
EC towards a pro-angiogenic stimulus, a more specific chemotaxis assay was utilised. The Ibidi 
µ-slide chemotaxis assay is optimised to analyse the chemotactic response of adherent cells in 
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linear and stable concentration profiles and was used to assess the directional migration of HO-1-
deficient cells. 
HUVEC transfected with either 3’-AlexaFluor488-labelled non-targeting control siRNA (CTLAF488) 
or HO-1 specific siRNA (seq2AF488) were re-seeded onto the collagen IV-coated observation area 
of the Ibidi µ-slide. The observation area is connected to two large reservoirs, one of which was 
filled with EC culture medium supplemented with 25 ng/ml VEGF and the second with growth 
factor-free medium, thereby generating a stable VEGF gradient. The migration of cells was 
captured by time-lapse microscopy in regular intervals (15 min) over a time period of 16 h and 
quantified by single cell tracking of fluorescently-labelled, non-dividing cells. Migration paths of 
individual cells were plotted with cells migrating towards the pro-angiogenic stimulus shown in 
black and cells migrating away from the stimulus shown in red (Fig. 5.18.). The majority of cells 
transfected with siCTLAF488 migrated towards the VEGF gradient, whereas siRNA-mediated 
inhibition of HO-1 impaired the directional migration of EC, decreasing the number of cells 
migrating towards the VEGF gradient by >40%. 
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Figure 5. 18.: HO-1 inhibition impairs the directional migration of EC towards a VEGF-
gradient. HUVEC were transfected with 40 nM 3’-AlexaFluor488-labelled (A) control siRNA 
(CTLAF488) or (B) HO-1 specific siRNA (seq2AF488) for 24 h and re-seeded onto collagen IV-coated 
Ibidi chemotaxis µ-slides. The upper reservoir was filled with EBM-2 culture medium 
supplemented with 25 ng/ml VEGF and the lower reservoir was filled with plain EBM-2 culture 
medium. The directional migration over a time period of 16 h was captured by time-lapse confocal 
microscopy and quantified using ImageJ analysis software (Manual Tracking and Chemotaxis and 
Migration tool). (A, B) Plots are representative images from n=3 experiments. Migration paths of 
cell moving towards the VEGF gradient are shown in black and migrations paths of cells migrating 
away from the VEGF gradient are shown in red, (C) represents the number of cells migrating 
towards the VEGF gradient. Data is presented as mean ± SEM (n=3 experiments), *** p<0.001. 
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Of note, depletion of the constitutive isoform HO-2 using specific siRNA also negatively affect the 
migratory properties of EC in culture. As with HO-1, knockdown efficiency was assessed by 
western blotting revealing a sufficient depletion of HO-2 protein in migrating HUVEC in the 
absence and also presence of VEGF (Fig. 5.19.). Interestingly, siRNA-mediated inhibition of HO-2 
resulted in a marked upregulation of HO-1 protein, independently of VEGF.  
 
  
 
 
 
 
 
Figure 5. 19.: Validation of siRNA-mediated knockdown of HO-2 in cultures containing 
migrating endothelial cells. HUVEC were transfected with 40 nM control siRNA (CTL) or HO-2 
specific siRNA (seq5) for 24 h. Confluent cell monolayers were scratched and migration was 
assessed by live cell imaging in the absence or presence of VEGF (25 ng/ml) for 16 h. (A) HO-2 
and (B) HO-1 protein levels were quantified by western blotting. Tubulin was used as a loading 
control. Representative blots of n=3 experiments are shown. 
 
Single cell tracking further demonstrated a significant reduction in migration speed, accumulated 
distance and the Euclidean distance migrated of HO-2-deficient cells compared to siCTL-
transfected cells, both in the absence and the presence of VEGF (Fig. 5.20.), further supporting a 
role for the heme oxygenase system in the regulation of angiogenesis. 
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Figure 5. 20.: HO-2 inhibition impairs VEGF-mediated migration of EC in vitro. HUVEC were 
transfected with 40 nM control siRNA (CTL) or HO-2 specific siRNA (seq5) for 24 h. Confluent cell 
monolayers were scratched and migration was assessed by live cell imaging in the absence or 
presence of VEGF (25 ng/ml) for 16 h and quantified using ImageJ analysis software (Manual 
Tracking and Chemotaxis and Migration tool). (A) represents the accumulated distance, (B) the 
velocity, (C) the Euclidean distance. Data is presented as mean ± SD (n=3 experiments), * 
p<0.05, ** p<0.01, *** p<0.001. 
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5.2.6. HO-1 inhibition impairs endothelial cell tubule formation in vitro 
Gene transfer of human HO-1 into coronary endothelial cells enhances formation of capillary-like 
structures in a 2D-Matrigel assay, whereas HO-1 antisense inhibits capillary formation 
(Deramaudt et al., 1998; Li Volti et al., 2002). Matrigel is a solubilised basement membrane 
preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumour rich in 
extracellular matrix proteins. Its major component is laminin, followed by collagen IV, heparin 
sulphate proteoglycans, entactin/nidogen, and also contains TGF-β, epidermal growth factor, 
insulin-like growth factor, fibroblast growth factor, tissue plasminogen activator, and other growth 
factors which occur naturally in the EHS tumour. Endothelial cells seeded onto Matrigel rapidly 
attach, align, and form capillary-like tubules (6 h to 20 h for primary EC, 4 h to 8 h for cell lines), 
but do not proliferate. The vessels formed contain a lumen and tight cell-cell contacts (Arnaoutova 
et al., 2009).  
To further explore the role for HO-1 in tubule formation in vitro, HO-1 activity was inhibited using 
the synthetic HO inhibitor ZnPP or specific siRNA targeting the human HO-1 gene and tubule 
formation on 2D-Matrigel was assessed by phase-contrast microscopy. In inhibition studies 
utilising the synthetic compound ZnPP, HUVEC were seeded onto growth factor-reduced Matrigel 
in growth factor-free EC culture medium, and in the absence or presence of exogenous VEGF (25 
ng/ml), ZnPP (20 µM), or VEGF and ZnPP in combination, and tube formation was assessed after 
16 h (Fig. 5.21.). Exposure to VEGF significantly increased the average tube length compared to 
untreated control cells. Further, these cells appeared more advanced in their differentiation, 
having already formed a lumen, a response not seen in untreated cells (Fig. 5.21.A, B and E). 
Inhibition of HO by ZnPP impaired tube formation, resulting in a significant decrease in the 
average tube length, an effect not rescued by VEGF (Fig. 5.21.C, D and E). 
These observations were subsequently confirmed using siRNA (Fig. 5.22.). HUVEC were 
transfected with either a non-targeting control siRNA (CTL) or HO-1 specific siRNA (seq2, pool) 
for 24 h and re-seeded on growth factor-reduced Matrigel in the absence or presence of VEGF for 
16 h. Over the course of the assay control siRNA transfected cells formed an intact tubular 
network with lumenised vessels, and this was enhanced by VEGF, resulting in a significant 
increase in the average tube length (Fig. 5.21.A, B, and G). siRNA-mediated inhibition of HO-1 
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abrogated this response. Cells transfected either with siHO-1 seq2 or siHO-1 pool failed to form 
an intact tubular network over the time period of 16 h, resulting in short and fragile-looking 
structures, with an associated modest decrease in average tube length compared to untreated 
siCTL-transfected cells (Fig 5.22.C, E and G). Moreover, the VEGF-mediated increase in tube 
length as seen in siCTL-transfected cells was attenuated by HO-1 depletion (Fig. 5.22.D, F, and 
G). Similar observations were obtained from in vitro studies using HMEC-1. Here, VEGF 
exposure caused a significant increase in the average tube length of cells transfected with control 
siRNA and this response was completely attenuated by siRNA-mediated inhibition of HO-1 (Fig. 
5.23.) 
Murine aortic EC isolated from HO-1 knockout animals (HO-1
-/-
) or wild type littermate controls 
(WT), have been recently shown to fail to form capillary-like structures on Matrigel in vitro in 
response to the chemokine SDF-1α (Deshane et al., 2007). In this study, HO-1
-/-
 MAEC and cells 
isolated from control animals were seeded onto growth factor-reduced Matrigel in growth factor-
free EC culture medium in the absence (UT) or presence of VEGF for 16 h (Fig. 5.23.). Phase-
contrast microscopy demonstrated an intact tubular network formed by WT MAEC in the absence 
and presence of VEGF, with the latter being more differentiated resulting in lumenised vessels 
with increased tube length (Fig. 5.23.A, B and E). Interestingly, EC from HO-1
-/-
 animals also 
formed capillary-like structures on Matrigel in vitro, both in the absence and presence of VEGF. 
However, these vessels were shorter compared to vessels formed by WT cells and also appeared 
to be less differentiated. Cells were growing in clusters rather than aligned and forming luminal 
vessels (Fig. 5.23.C, D and E).  
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Figure 5. 21.: ZnPP inhibits human endothelial cell tubule formation in vitro. HUVEC were 
seeded onto growth factor-reduced Matrigel in plain EC culture medium and (A) left untreated or 
treated with (B) VEGF (25 ng/ml), (C) ZnPP (20 µM), or (D) VEGF and ZnPP in combination for 
16 h and visualised using phase-contrast microscopy. Images from five fields per view were 
captured. Pictures are representative images from n=3 experiments, 4X magnification. Bar equals 
50 µm. (E) Tube length was quantified using ImageJ analysis software (NeuronJ). Data is 
presented as mean ± SEM (n=3 experiments), * p<0.05, *** p<0.001. 
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Figure 5. 22.: HO-1 inhibition inhibits human endothelial cell tubule formation in vitro. 
HUVEC were transfected with 40 nM (A, B) non-targeting control siRNA (CTL), (C, D) HO-1 
specific siRNA (seq2) or (E, F) HO-1 specific siRNA (pool) for 24 h. Cells were seeded onto 
growth factor-reduced Matrigel in plain EC culture medium in the absence (A, C, E) or presence 
(B, D, F) of VEGF (25 ng/ml) for 16 h and visualized using phase-contrast microscopy. Images 
from five fields per view were captured. Pictures are representative images from n=3 
experiments, 4X magnification. Bar equals 50 µm. (G) Tube length was quantified using ImageJ 
analysis software (NeuronJ). Data is presented as mean ± SEM (n=3 experiments), *** p<0.001. 
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Figure 5. 23.: HO-1 inhibition impairs tubule formation of microvascular endothelial cells in 
vitro. Human microvascular EC (HMEC-1) were transfected with 40 nM non-targeting control 
siRNA (CTL), HO-1 specific siRNA (seq2, pool) for 24 h. Cells were seeded onto growth factor-
reduced Matrigel in plain EC culture medium in the absence or presence of VEGF (25 ng/ml) for 6 
h and visualised using phase-contrast microscopy. Images from five fields per view were captured 
and tube length was quantified using ImageJ analysis software (NeuronJ). Data is presented as 
mean ± SEM (n=3 experiments), *** p<0.001. 
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Figure 5. 24.: HO-1-deficient mouse aortic endothelial cells are delayed in their ability to 
form capillary-like tubules in vitro. Murine aortic EC (MAEC) isolated from (A, B) HO-1
+/+
 
littermate controls (WT), or (C, D) HO-1
-/-
 mice, were seeded onto growth factor-reduced Matrigel 
in plain EC culture medium in the absence (C) (UT), or presence (D) of VEGF for 16 h and 
visualised using phase-contrast microscopy. Images from five fields per view were captured. 
Pictures are representative images from n=3 experiments, 10X magnification. Bar equals 50 µm. 
(E) Tube length was quantified using ImageJ analysis software (NeuronJ). Data is presented as 
mean ± SEM (n=3 experiments), * p<0.05, ** p<0.01. 
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5.3. DISCUSSION 
Angiogenesis is a highly complex, multistep process and depends on the concerted activities of 
various growth factors and their receptors expressed on EC and accessory cells (Risau, 1997). 
The delicate balance between the release of pro- and anti-angiogenic mediators from these cells 
is essential for the regulation of angiogenesis. Besides the regulated process, angiogenesis is an 
inherent feature of numerous pathological conditions ranging from cancer to chronic inflammatory 
syndromes, resulting from either the overproduction of normal or aberrant forms of angiogenic 
mediators, or due to a relative deficiency in inhibitors (Sun and Schiller, 2007) (section 1.2.3.). 
Therefore, a better understanding of the mechanisms that regulate physiological but also 
pathological angiogenesis is crucial for the development of therapeutic strategies for manipulation 
of angiogenesis at sites of ischaemia or wound healing, or conversely to inhibit angiogenesis 
associated with atherosclerosis or tumourogenesis.  
The major mediator of angiogenesis is vascular endothelial cell growth factor (VEGF), which 
regulates the proliferation, migration and survival of EC. During development, the level of VEGF is 
crucial for healthy growth, and the lack of even one functional allele of VEGF results in early 
embryonic lethality (Carmeliet et al., 1996; Ferrara et al., 1996). Moreover, in adult life, the 
synthesis of VEGF is potently induced by numerous stimuli, the major ones being hypoxia, 
cytokines, other growth factors, nitric oxide (NO), and reactive oxygen species (ROS) (Dulak and 
Jozkowicz, 2003; Dulak et al., 2004).  
Recent research now demonstrates a link between the pro-angiogenic factor VEGF and the 
cytoprotective enzyme HO-1 (Dulak et al., 2004; Dulak et al., 2008). Augmentation of HO-1 
activity by inducers, such as heme, cobalt protoporphyrin (CoPP), prostaglandin J2 (PGJ2), 
hydrogen peroxide (H2O2), and hypoxia or genetic overexpression of HO-1 leads to the 
stimulation of VEGF synthesis in an HO-1-dependent manner in various cell types. (Dulak et al., 
2002; Jozkowicz et al., 2002; Marinissen et al., 2006; Dulak et al., 2008). Moreover, HO-1 
modulates the angiogenic effect of VEGF on EC. HO-1 overexpression enhances EC proliferation 
and in vitro tube formation or capillary sprouting in response to VEGF, while inhibition of HO-1 
activity attenuates cell proliferation and VEGF-mediated migration of cultured EC (Deramaudt et 
al., 1998; Jozkowicz et al., 2003). Besides acting as an inducer of VEGF, HO-1 appears to be 
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involved downstream of the VEGF-mediated activation of EC. Studies from our laboratories have 
demonstrated increased HO-1 expression in response to the pro-angiogenic mediator VEGF in 
primary human EC and EC of the dermal microvasculature (Bussolati et al., 2004). Accordingly, in 
studies performed in the chick chorioallantoic membrane model of angiogenesis, VEGF leads to 
enhanced HO-1 protein expression (Fernandez and Bonkovsky, 2003).  
Despite considerable progress made in defining the role of HO-1 in the vasculature, further 
studies are required to identify the specific role of HO-1 during the different steps of the 
angiogenic process. In this study, siRNA was used to specifically silence HO-1 and to investigate 
how the angiogenic capabilities of cultured primary EC were affected. Sufficient knockdown 
efficiency of the different siRNA sequences targeting the human HO-1 gene used was confirmed 
by qRT-PCR, western blotting and immunofluorescent staining. As basal HO-1 expression is 
rather weak in cultured cells, the HO-1 inducer hemin was used to up-regulate HO-1 expression 
and this resulted in a potent induction of HO-1 mRNA and protein expression after 6 h exposure 
in non-transfected cells and cells transfected with a non-targeting control siRNA (siCTL) (Fig. 
5.1.). However, this response was significantly attenuated in HUVEC either transfected with a 
single siRNA sequence (siHO-1 seq2) or a pool of four siRNA sequences targeting HO-1 (siHO-1 
pool). HO-1 mRNA expression was inhibited by 70-80% and protein levels were decreased by 80-
85% (Fig. 5.1.). Accordingly, fluorescein isothiocyanate (FITC)-labelled antibody staining of HO-1 
in HUVEC revealed a significant decrease in the mean fluorescent intensity (MFI) of cells 
transfected with siHO-1 pool compared to non-transfected or siCTL-transfected EC (Fig. 5.2.). 
Based on these observations, the siRNAs targeting the human HO-1 gene, siHO-1 seq2 and 
siHO-1 pool, were used to silence HO-1 the forthcoming studies.  
In response to angiogenic stimuli, EC proliferate, migrate, and coalesce to form primitive vascular 
networks that undergo maturation and remodelling, accompanied by recruitment of smooth 
muscle cells to give rise to mature blood vessels. Herein, we demonstrate a role for the 
cytoprotective enzyme HO-1 in all these highly regulated and complex steps of the angiogenic 
process using numerous well-described in vitro angiogenesis assays.  
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HO-1 and EC proliferation 
In concordance with previous studies from our laboratory and others (Bussolati et al., 2004; 
Jozkowicz et al., 2003), synthetic inhibition of HO-1 using the metallophorphyrin ZnPP 
significantly diminished VEGF-induced EC proliferation in a dose-dependent manner, resulting in 
complete inhibition of proliferation at 20 µM (Fig. 5.7). In vivo ZnPP is formed in trace amounts 
during the metabolism of heme by HO enzymes, acting as a negative regulator of their enzymatic 
activity through competitive inhibition (Labbé et al., 1999). Of note, naturally occurring as well as 
synthetic ZnPP not only inhibit the inducible isoform HO-1, but also the constitutive HO-2, and 
therefore lack specificity (Ryter et al., 2006). A more specific approach to silence HO-1 without 
affecting the expression of constitutive HO-2 is afforded by the use of small interfering RNA 
targeting the human HO-1 gene, and this was used herein to determine the specific role of HO-1 
in VEGF-mediated EC proliferation. In primary EC isolated from human umbilical veins siRNA-
mediated inhibition of HO-1 abrogated VEGF-induced EC proliferation (Fig. 5.8.), confirming the 
findings obtained from HO inhibition studies utilising ZnPP and previously published data showing 
decreased EC proliferation and subsequent in vitro tube formation of EC expressing antisense 
HO-1 (Li Volti et al., 2005). Accordingly, murine aortic EC isolated from HO-1
-/-
 mice 
demonstrated reduced proliferation when compared to with EC from matched HO-1
+/+
 littermate 
controls (Chen et al., 2004). Moreover, these results suggest that depletion of the inducible 
isoform HO-1 is sufficient to impair the proliferative capacity of EC in culture, and that HO-2 does 
not compensate for the loss of HO-1.  
Adenoviral overexpression of the human HO-1 gene, at an optimal multiplicity of infection (MOI 
100), significantly increased HO-1 protein in HUVEC (Fig. 5.5.). HO-1 overexpressing EC 
demonstrated enhanced basal proliferation and increased HO-1 protein levels had a synergistic 
effect on VEGF-mediated EC proliferation in vitro (Fig. 5.9.). These observations are in line with 
earlier studies, showing an increase in the proliferative capacity of EC in response to the HO 
inducer CoPP and reproduce previous studies from our laboratory demonstrating a significant 
increase in proliferation of HO-1 overexpressing HUVEC (Bussolati et al., 2004; Bussolati and 
Mason, 2006). Likewise, Deramaudt and colleagues reported enhanced endothelial proliferation 
of coronary microvascular EC transfected with a plasmid vector harbouring the human HO-1 gene 
(Deramaudt et al., 1998).  
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Altogether, these findings are indicative for a role of HO-1 in EC proliferation in response to the 
angiogenic mediator VEGF and are in concordance with previous studies demonstrating the 
proliferative effect of HO-1 in the vasculature. However, the proliferative effects of HO-1 vary 
depending on the cell type and disease status of the tissue. Indeed HO-1 overexpression inhibited 
proliferation of vascular SMC and induced apoptosis in these cells (Li Volti et al., 2002; Li Volti et 
al., 2005). Moreover, gain-of-function studies reported anti-proliferative effects of HO-1 in rat and 
human breast cancer cells lines (Hill et al., 2005), and HO-1 inhibition augmented  mesangial cell 
proliferation, a hallmark of many progressive renal diseases (Kumar et al., 2010). 
 
HO-1 and EC survival 
HO-1 is an important regulator of cell survival. Murine aortic EC isolated from HO-1 knockout 
mice are more susceptible to apoptotic stimuli and have increased caspase-3 activity compared 
with EC from HO-1
+/+
 littermate controls (Brouard et al., 2000; Chen et al., 2004). The paradigm 
that HO-1 is an important molecule in defence against oxidative stress is supported by the only 
human case of HO-1 deficiency who died prematurely at age six, revealing intravascular 
hemolysis, increased sensitivity to oxidant injury and EC dysfunction post-mortem (Yachie et al., 
1999). In addition, a recent report demonstrated an important role for HO-1 in the regulation of 
DNA repair by diminishing radiation-induced DNA damage and improving cell survival (Otterbein 
et al., 2011). Moreover, alongside its proliferative actions, the pro-angiogenic mediator VEGF is 
cytoprotective and anti-apoptotic, protecting EC from apoptosis through increased induction of the 
anti-apoptotic genes A1 and Bcl-2 (Gerber et al., 1998).  
Herein, we investigated whether the anti-apoptotic effects of HO-1 contribute to VEGF-mediated 
EC protection using loss-of-function studies. Exposure to VEGF protected against serum 
starvation-induced cell death in control cells and this effect was not significantly attenuated by 
HO-1 inhibition, either afforded by the synthetic antagonist ZnPP or HO-1 specific siRNA (Fig. 
5.11.). Interpretation of these results has to be carried out with caution. The MTS assay is a 
measure of viable cells in culture rather than a specific apoptosis assay, i.e. changes in cell 
number can either result from increased cell death or on the other hand from decreased 
proliferation of cells. Cell counting in combination with trypan blue staining of cells, is a useful 
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measure of cell number and allows distinguishing between the number of viable and dead cells in 
culture. Moreover, more specific apoptosis assays are required to determine the effect of HO-1 
inhibition on cell viability. Herein, PI staining was utilised to specifically distinguish between 
aopotic and viable cells. The increase in apoptotic cells resulting from HO-1 deficiency was 
significantly decreased in the presence of VEGF and this was accompanied by increased VEGF-
induced expression of the anti-apoptotic mediators A1 and Bcl-2 (Fig. 5.12. and Fig. 5.13.). These 
findings are indicative of an HO-1-independent cytoprotective action of VEGF and further suggest 
that the reduced proliferative properties observed in HO-1-deficient EC in response to VEGF (Fig. 
5.7. and Fig. 5.8.) do not reflect increased apoptosis.  
 
HO-1 and EC migration 
Endothelial motility is essential to angiogenesis. EC migration is directionally regulated by 
chemotactic, haptotactic, and mechanotactic stimuli and also requires the degradation of the ECM 
to enable the forward progression of migrating cells. This involves the activation of numerous 
signalling pathways that initiate the rearrangement of the cytoskeleton, followed by a series of 
events in which the EC extend, contract, and pull their rear to the front of the cell to enable 
forward movement (Lamalice et al., 2007). 
A role for HO-1 in endothelial migration is emerging but is so far poorly understood. Deshane and 
colleagues recently demonstrated a link between HO-1 and EC and EPC migration in response to 
the chemokine SDF-1α. HO-1 depletion abrogated SDF-1α-induced migration of human aortic EC 
(HAEC), an effect also seen in aortic EC and EPC isolated from HO-1 knockout mice (Deshane et 
al., 2007). Furthermore, the synthetic HO-1 antagonist SnPP inhibited the VEGF-induced 
migration of HUVEC as assessed using a modified Boyden chamber (Jozkowicz et al., 2003). 
Moreover, the migratory properties of HO-1 overexpressing coronary microvascular EC were 
enhanced as demonstrated by increased propensity to form vascular tubes in Matrigel 
(Deramaudt et al., 1998). Herein, we show that HO-1 plays an important role in the directional 
migration of EC towards a gradient of the pro-angiogenic mediator VEGF.  
The in vitro scratch assay is a reliable tool for analysis of the migration patterns of cells in culture. 
Confocal time lapse microscopy coupled to single cell tracking allows the quantification of 
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migration paths of individual cells in terms of their accumulated distance and velocity, as well as 
their directionality expressed as the Euclidean distance. In this study, fluorescently-labelled siRNA 
was used to silence HO-1 in primary human EC and to specifically identify cells successfully 
transfected with siRNA and with depleted HO-1 (Fig. 5.3. and Fig. 5.14). Non-fluorescent cells 
were excluded from analysis. HO-1 depletion by siRNA had no significant effect on the 
accumulated distance travelled or the velocity when compared to HUVEC transfected with a 
control siRNA (siCTLAF488), either in the absence or the presence of VEGF (Fig. 5.15.A and B). 
The Euclidean distance was significantly increased in response to VEGF in siCTLAF488-transfected 
HUVEC and this effect was completely abolished in HO-1-deficient cells (Fig. 5.15.C). Further 
analysis of the directional movement of individual cells revealed that HO-1-depleted cells 
migrated in a rather random, circular pattern alongside the scratch edge, whereas control cells 
showed a more linear, directional movement towards the scratch and the cells on the opposite 
site (Fig. 5.16.). Moreover, a similar migratory pattern was observed for HO-1-deficient human EC 
derived from the dermal microvasculature (HMEC) with a diminished Euclidean distance travelled 
in response to VEGF when compared to siCTLAF488-transfected cells (Fig. 5.15.D). In contrast, we 
show that adenoviral overexpression of the human HO-1 gene significantly improves the 
Euclidean distance of HUVEC (Fig. 5.17.).  
Taken together, these results strongly suggest a role for HO-1 in the directional migration of EC 
mediated by VEGF. One of the disadvantages and limitations of the migration scratch assay is the 
lack of the formation of a chemotactic gradient of growth factors over the course of the assay, and 
this assay does not replace other well-established methods for chemotaxis, including the Boyden 
chamber (Liang et al., 2007). The Boyden chamber consists of two fluid-containing compartments 
separated by a microporous membrane, with the upper compartment containing the cells of 
interest. For the induction of chemotactic response of cells, attractants are added to the lower 
compartment and cells begin to migrate through the pores of the membrane (Chen, 2005). 
Disadvantages of this assay include that the chemotactic gradient is unknown and variable (Chen 
2005; Hulkower and Herber, 2011) Moreover, transmigration through a membrane does not 
depict the migratory behaviour of EC in vivo. Thus, herein, the Ibidi µ-slide chemotaxis assay was 
used to further investigate a potential role for HO-1 in mediating the directional migration of EC 
towards a pro-angiogenic stimulus. The µ-slide assay is optimised to analyse the chemotactic 
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response of adherent cells in linear and stable concentration profiles over a period of 48 h. In 
principle, the µ-slide consists of two large reservoirs: one filled with attractant-free and one with 
VEGF-supplemented culture medium. The two reservoirs are connected by a narrow observation 
area and cells that are seeded within the observation area become superimposed by a linear and 
time-stable VEGF gradient. Time-lapse migration coupled to single cell tracking of cells allows 
quantification of the chemotactic responses. Quantification of the directional migration paths of 
individual, fluorescently-labelled, non-dividing cells revealed that significantly less HO-1-depleted 
cells (40%) migrated towards the VEGF gradient when compared to HUVEC transfected with a 
non-targeting control siRNA (80%) (Fig. 5.18.).  
These findings, to our knowledge for the first time, demonstrate a link between the cytoprotective 
enzyme HO-1 and the directed movement of EC in response to a VEGF gradient. The cellular and 
molecular machinery underlying EC migration is highly regulated and complex. Further studies 
are required to establish the specific role of HO-1 and its products in this process. In response to 
angiogenic stimuli, EC undergo morphological changes allowing their directed forward movement. 
Lamellipodia and filopodia are highly dynamic structures, generated within minutes at the moving 
front of the EC (Huber et al., 2003). Both structures are capable of probing the environment, 
thereby sensing the presence of attractive guidance cues and initiating migration towards these 
(Defilippi et al., 1999). It would be of great interest to assess whether changes in the 
morphological appearance of HO-1-deficient cells, i.e. changes in lamellipodia and filopodia 
extensions, are accountable for their impaired migratory capacity in response to VEGF. 
Interference Reflection microscopy (IRM) could be one approach to address this. Furthermore, 
the identification of HO-1 downstream targets and signalling pathways regulating HO-1-driven 
migration are of great importance and will be discussed in in forthcoming chapters. 
 
HO-1 and EC tubule formation 
In the final step of the angiogenic process, migrating EC rearrange into lumenised capillary 
structures that undergo maturation and remodelling to give rise to mature blood vessels. Using 
the in vitro 2D-Matrigel assay, we demonstrate a role for HO-1 in this process.  
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Synthetic inhibition afforded by the HO inhibitor ZnPP or specific silencing of HO-1 by siRNA 
abolished HUVEC tubule formation on growth factor-reduced Matrigel in response to VEGF (Fig. 
5.21. and Fig. 5.22.). Moreover, a similar response was observed with HO-1-depleted human 
dermal microvascular EC and murine aortic EC (MAEC) isolated from HO-1
-/-
 mice when 
compared to HO-1
+/+
 littermate controls (Fig 5.23. and Fig. 5. 24.). Of note, the results have to be 
interpreted with caution. While the 2D Matrigel assay is a commonly used in vitro angiogenesis 
assay and has been found to be the most potent matrix for tube formation, there is some debate 
as to whether these tubules represent capillaries. While some groups have confirmed lumen 
formation of these newly formed tubes by electron microscopy, others could not demonstrate the 
presence of a lumen (Grant et al., 1991; Connolly et al., 2002; Bikfalvi et al., 1991). In addition, it 
should be noted that other non-endothelial cell types including primary human fibroblasts, human 
prostate carcinoma cell lines and glioblastoma cells have been shown to rearrange in tubular 
structures on Matrigel (Donovan et al., 2001). Therefore, to investigate the effect on HO-1 
inhibition on tube formation, the findings should be confirmed by the use of other in vitro 
angiogenesis assays, such as a three dimensional (3D) Matrigel assay or a co-culture assay of 
EC with human fibroblasts that more closely mimic the in vivo situation in terms of tubulogenesis. 
Fibroblasts secret matrix components that act as a scaffold and enables EC to form tubules that 
contain a lumen, with a heterogenous tubes length pattern, more closely resembling the capillary 
bed in in vivo (Bishop et al., 1999; Donovan et al., 2001). 
Nontheless, the findings observed in this study demonstrate a role for HO-1 in the assembly of 
EC into blood vessels and are in concordance with previously published reports. Gene transfer of 
human HO-1 into coronary endothelial cells enhanced formation of capillary-like structures in a 
2D-Matrigel assay, whereas inhibition of HO-1 decreased capillary formation (Deramaudt et al., 
1998; Li Volti et al., 2002). Moreover, HO-1 inhibition with both SnPP and ZnPP completely 
inhibited capillary sprouting and neovessel outgrowth in response to VEGF in a murine abdominal 
muscle model (Bussolati et al., 2004). Further, Deshane et al. demonstrated that MAEC isolated 
from HO-1 knockout mice fail to form tubules on 2D-Matrigel in vitro in response to the chemokine 
SDF-1α and aortic rings isolated from these animals were unable to form SDF-1α-induced 
capillary sprouts ex vivo (Deshane et al., 2007). Moreover, HO-1 inhibition delayed cutaneous 
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wound healing in mice which was accompanied by impaired neovascularisation of tissues 
(Deshane et al., 2007; Grochot-Przeczek et al., 2009). 
Our findings and previously published data clearly demonstrate an important role for HO-1 in 
VEGF- and SDF-1α-mediated angiogenesis for vascular remodelling and repair. But despite the 
progress made in identifying the role for HO-1 in angiogenesis in vitro, further in vivo studies 
using murine specific siRNA targeting the mouse HO-1 gene in the Matrigel plug assay are now 
necessary to define the role of HO-1 in VEGF-mediated angiogenesis (see Chapter 7). 
 
HO-2 and angiogenesis 
The role of HO-2, the constitutive HO isoform, in endothelial homeostasis is poorly understood 
and may include a regulatory role in heme homeostasis, by sequestering heme to maintain the 
intracellular heme level. HO-2 may also function as an oxygen sensor and HO-2 deletion causes 
EC activation marked by oxidative stress, inflammation, and angiogenesis, underscoring 
important functions of this enzyme in endothelial homeostasis (Kemp, 2005; Bellner et al., 2009). 
Moreover, it has been postulated that HO-2 is critical for HO-1 expression and function, which 
may explain the reason why HO-2
-/-
 mice could not compensate for the loss of HO-2 by increasing 
HO-1 expression (Sodhi et al., 2009).  
In this study, we show an impaired migratory phenotype of HO-2-deficient primary human EC in 
culture. Wound closure of an artificial scratch on a confluent monolayer of HUVEC, was 
significantly impaired by HO-2 inhibition afforded by specific siRNA in terms of the accumulated 
distance, velocity and Euclidean distance both in the absence and presence of VEGF (Fig. 5.20.).  
These observations reflect those from previous studies postulating a role for HO-2 in 
angiogenesis. Animals lacking HO-2 are characterised by impaired corneal wound closure, 
enhanced neovascularisation, and exaggerated inflammation as demonstrated by NFκB activation 
and increased expression of inflammatory cytokines including MCP-1, IL-1 and IL-6 (Seta et al., 
2006; Bellner et at., 2009). Moreover, MAEC isolated from HO-2
-/-
 mice showed an activated 
phenotype marked by oxidative stress, inflammation and angiogenesis (Bellner et al., 2009). 
Interestingly, while HO-1 expression was downregulated in corneal tissue, MAEC from HO-2
-/-
 
mice showed increased HO-1 expression. However, in both cases HO activity was significantly 
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reduced, suggesting that decreased enzymatic activity of HO-2
-/-
 mice is responsible for the 
aggravated inflammation-dependent angiogenesis supporting the dual role of HO-1 in 
angiogenesis, postulated by our laboratory. This hypothesis suggests that activation of HO-1 by 
VEGF favours EC proliferation and prevents EC apoptosis, while inhibiting leukocyte migration, 
thus resulting in non-inflammatory reparative angiogenesis, whereas inhibition of HO activity 
increases leukocyte migration and subsequent local release of growth factors inducing pro-
inflammatory angiogenesis (Bussolati et al., 2004; Bussolati and Mason, 2006). 
Of note, migrating HUVEC deficient in HO-2 also showed a significant upregulation in HO-1 
protein, independent of VEGF exposure (Fig. 5.19.), which could be a response to injury resulting 
from the generation of the scratch. The HO-2-deficient cells exhibited impaired migration despite 
an increase in HO-1, suggesting that HO-1 function requires HO-2. Thus, it would be of interest to 
assess whether HO activity is also altered in these cultures, as a decrease in enzymatic activity 
may explain the impaired migratory capacity of the HO-2 depleted HUVEC. 
 
Summary 
Herein, we show that HO-1 deficiency affects the angiogenic capacity of EC in culture at various 
levels. VEGF-induced endothelial proliferation was significantly inhibited and HO-1-depleted cells 
failed to form an intact tubular network in a 2D-Matrigel assay in response to VEGF. Moreover, 
the directional migration of EC towards a VEGF gradient was negatively affected by HO-1 
inhibition, with significantly less cells migrating towards the angiogenic stimulus in HO-1-depleted 
cultures compared to control cells.  
Despite the considerable progress made in defining the angiogenic properties of HO-1, further 
studies are required to identify the signalling pathways involved and those activated by HO-1 
products. Likewise, further studies are required to define the role of HO-1 in angiogenesis in vivo. 
HO-1-deficient mice and tissue-specific or inducible knockout models, as well as murine specific 
siRNA used in combination with the Matrigel plug assay will help to establish the angiogenic 
functions of HO-1. 
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CHAPTER 6 -  HO-1 PRODUCTS AND DOWNSTREAM TARGETS IN ANGIOGENESIS 
6.1. INTRODUCTION 
The precise mechanisms through which HO-1 exerts its effects during angiogenesis and the role 
of its products CO, biliverdin/bilirubin, and iron remain poorly understood (please see section 
1.3.4.). A better understanding of the signalling pathways and downstream targets of HO-1 and its 
products in the process of angiogenesis may lead to identification of novel therapeutic targets. 
To date, only one potential downstream target of HO-1-mediated angiogenesis has been 
identified. Vasodilator-stimulated phosphoprotein (VASP) is a cytoskeletal-associated protein 
located at regions of dynamic actin remodelling, such as cell-cell contacts and filopodia 
protrusions (Krause et al., 2003; Bear and Gertler et al., 2009; Trichet et al., 2008). In cells, 
differential VASP phosphorylation controls remodelling of the actin cytoskeleton affecting anti-
capping, bundling, and anti-branching activities of F-actin (Barzik et al., 2005; Pasic et al., 2008; 
Applewhite et al., 2007; Bachmann et al., 2009; Schirenbeck et al., 2006; Bear et al., 2002; 
Skoble et al., 2001). Human VASP harbours three phosphorylation sites serine 157 (Ser157), 
Ser239, and threonine 278 (Thr278) which are substrates of serine/threonine kinases (Butt et al., 
1994; Blume et al., 2007). Ser157 and Ser239 are phosphorylated by cAMP-dependent protein 
kinase (PKA) and cGMP-dependent protein kinase (PKG) respectively (Butt et al., 1994; Zhuang 
et al., 2004). Thr278 phosphorylation is initiated by AMP-activated protein kinase (AMPK) (Blume 
et al., 2007). Recently, it was shown that phosphorylation of VASP at Ser239 in response to SDF-
1α is lost in HO-1-deficient mice, but can be restored by the CO-releasing molecule (CORM)-2 
(Deshane et al., 2007), suggesting a role for HO-1 in the regulation of VASP activity. In addition 
exposure to VEGF results in VASP phosphorylation (Ser239) in HUVEC and bovine aortic EC 
(BAEC), and this is associated with increased capillary-like formation in an in vitro Matrigel assay 
(Fiedler et al., 2009; Chen et al., 2008). Moreover, Price and Brindle demonstrate a role for VASP 
in stress-fibre and membrane ruffle formation in endothelial cells, which can influence endothelial 
migration and organisation during capillary formation, and modulate vascular permeability via 
effects on EC contractility (Price and Brindle, 2000).  
Despite the considerable progress made in establishing a role for HO-1 in angiogenesis, the 
functions of HO products CO, biliverdin/bilirubin and iron and other downstream targets in HO-1 
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driven angiogenesis still remain elusive. This chapter aims to investigate whether the HO products 
CO and iron mediate the pro-migratory effects of HO-1 and whether supplementation with a CO 
donor or DFO would restore the impaired angiogenic capacity of HO-1-deficient HUVEC. 
Moreover, we aim to determine whether VEGF-mediated phosphorylation of the potential HO-1 
downstream target VASP is affected in HO-1-deficient HUVEC, thereby contributing to their 
impaired migratory phenotype. Finally, to further elucidate downstream effectors of HO-1 in 
angiogenesis, a targeted PCR array and a proteomic screen will be performed between HO-1-
deficient EC and control cells in response to the mitogen VEGF, with the ultimate aim of 
identifying novel therapeutic targets for the manipulation of angiogenesis. 
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6.2. RESULTS 
6.2.1. DFO does not reverse the impaired migratory phenotype of HO-1-deficient EC in vitro 
The generation and release of intracellular Fe
2+
 during heme metabolism, leads to the subsequent 
up-regulation of the iron-binding protein ferritin heavy chain (FHC). FHC associates with ferritin 
light chain to form a multimeric complex (Harrison and Arosio, 1996) and catalyses the oxidation 
of iron from the ferrous (Fe
2+
) to the ferric form (Fe
3+
) thereby removing excess iron from the 
system (Balla et al., 1992; Berberat et al., 2003). In this study, the synthetic compound 
deferoxamine mesylate (DFO) was used to mimic the action of FHC. DFO acts as an iron chelator 
by binding free iron (Fe
2+
). Once bound to an iron chelator, Fe
2+
 is inert and lacks the ability to 
perform in chemical reactions as it is removed from the system.  
To investigate whether HO-1 products regulate the pro-migratory effects of HO-1, primary human 
EC (HUVEC) were cultured onto gelatin-coated culture dishes (6-well) and transfected with 40 nM 
3’-AlexaFluor488-labelled non-targeting control siRNA (siCTLAF488) or HO-1 specific siRNA (siHO-
1 seq2AF488) for 24 h. Cells were then left untreated or pre-treated with 100 µM DFO prior to 
exposure to VEGF and generation of a scratch on the confluent monolayer. Scratch closure was 
observed by live cell confocal imaging over a period of 16 h and the directional migration of 
individual cells was assessed by single cell tracking.  Exposure to the iron chelator DFO had no 
effect on the Euclidean distance travelled by HUVEC transfected with the control siRNA in 
response to VEGF (Fig. 6.1.). Moreover, HO-1 depletion significantly reduced the Euclidean 
distance travelled in response to VEGF in the absence of DFO, and this response reproduced 
previous observations made during this study (compare Fig. 5.15.C). Interestingly, the presence 
of DFO in HO-1-deficient cultures did not alter the response to VEGF and the directional migration 
paths of cells were still significantly diminished compared to siCTLAF488-transfected cells exposed 
to DFO (Fig. 6.1.). Taken together these observations suggest that DFO, at least on its own, is not 
sufficient to restore the impaired directional migration of HO-1-deficient cells. 
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Figure 6. 1.: DFO alone is not sufficient to reverse the impaired migratory phenotype of HO-
1-deficient endothelial cells in response to VEGF. HUVEC were transfected with 40 nM 3’-
AlexaFluor488-labelled control siRNA (CTLAF488) or HO-1 specific siRNA (seq2AF488) for 24 h. Cells 
were left untreated or pre-treated with DFO (100 µM) for 2 h. Confluent monolayers were then 
scratched and treated with 25 ng/ml VEGF for 16 h. Migration was assessed by live cell imaging 
and quantified using ImageJ analysis software (Manual Tracking and Chemotaxis Migration tool). 
(A) represents the Euclidean distance. Plots show the directional migration of HUVEC (B) 
transfected with CTLAF488 or (C) seq2AF488 and pre-treated with DFO. Data is presented as mean ± 
SD (n=3 experiments), ** p<0.01. 
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6.2.2. CO-releasing molecules are not sufficient to reverse the impaired migratory phenotype 
of HO-1-deficient EC in vitro 
Like NO, HO-1 derived CO has been recognised as an important signalling molecule in the 
vascular system inducing numerous beneficial effects including cytoprotection, vasodilation and 
inhibition of inflammation and is likely to be attributable for the angiogenic effects of HO-1 (Choi 
and Otterbein, 2002; Ryter et al., 2006). One approach to deliver CO directly into living cells in 
culture, in an accurate, safe and measurable manner, is the use of CO-releasing molecules 
(CORMs). The dinuclear ruthenium complex 1, known as CORM-2 ([Ru(CO)3Cl2]2), is a water 
soluble transition metal-carbonyl complex that liberates CO upon ligand exchange with DMSO, 
and is frequently used as a CO-releasing molecule in biological studies (Motterlini et al., 2002). 
To investigate whether pro-migratory effects of HO-1 are mediated by its product CO and whether 
delivery of CO reverses the impaired directional migration of HO-1-deficient cells, siCTLAF488 or 
siHO-1 seq2AF488-transfected HUVEC were pre-treated with vehicle (DMSO) or the CO donor 
CORM-2 (50 µM) for 2 h prior to the generation of a scratch on the confluent cell monolayer and 
subsequent exposure to VEGF for 16 h. Time lapse microscopy coupled to single cell tracking 
revealed no change in Euclidean distance of control cells in response to CORM-2. Moreover, the 
diminished migration of HO-1-deficient HUVEC was not improved by CORM-2 treatment (Fig. 
6.2.). Noteworthy, CO release from CORM-2 is very fast (t1/2 ≈ 1min) and unspecific thereby 
hampering the delivery of controlled amounts of CO to the target cells (Motterlini et al., 2005). To 
improve CO delivery in our system, a novel class of enzyme-triggered CORMs (ET-CORMs) were 
utilised. ET-CORMS exist as stable precursor complexes and, once take up by a cell, are cleaved 
by intracellular esterases releasing CO (Romanski et al., 2011). 
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Figure 6. 2.: CORM-2 alone is not sufficient to reverse the impaired migratory phenotype of 
HO-1-deficient endothelial cells in response to VEGF. HUVEC were transfected with 40 nM 3’-
AlexaFluor488-labelled control siRNA (CTLAF488) or HO-1 specific siRNA (seq2AF488) for 24 h. Cells 
were left untreated or pre-treated wit CORM-2 (50 µM) for 2 h. Confluent monolayers were then 
scratched and treated with 25 ng/ml VEGF for 16 h. Migration was assessed by live cell imaging 
and quantified using ImageJ analysis software (Manual Tracking and Chemotaxis Migration tool). 
(A) represents the Euclidean distance. Plots show the directional migration of HUVEC (B) 
transfected with siCTLAF488 or (C) seq2AF488 and pre-treated with DFO. Data is presented as mean 
± SD (n=3 experiments), ** p<0.01. 
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ET-CORMs, namely Stro074, Stro258 and SROM158, used in this study were kindly provided by 
Prof H. G. Schmalz (Universität zu Köln, Köln, Germany) and initial experiments were conducted 
to validate their toxicity and activity in primary human EC. Cell viability in response to ET-CORMs 
in the absence or presence of VEGF was assessed using the MTS-assay (Fig. 6.3.) Here, dose-
titration experiments demonstrated that all three ET-CORMs used significantly decreased the 
number of viable cells at 100 µM (Fig. 6.3.A) and 50 µM (Fig. 6.3.B) independent of exposure to 
VEGF. Of note, exposure to 50 µM SROM158 had the least toxic effect on HUVEC with or without 
VEGF, resulting in a 20-30% decrease in cell viability compared to ~50% and ~40% for Stro074 
and Stro258, respectively (Fig. 6.3.B). Based on these observations, the dose-dependent effect of 
SROM158 on EC viability was further assessed using concentrations ranging from 12.5 µM to 50 
µM (Fig. 6.4.). Again, pre-treatment and exposure to 50 µM SROM158 for 16 h significantly 
decreased the number of viable cells by 20-25% both in the absence and the presence of VEGF 
compared to DMSO-treated control cells. However, when used at 12.5 µM or 25 µM, SROM158 
had no effect on HUVEC viability (Fig. 6.4.). 
HO-1-derived CO modulates inflammatory responses and CORMs have been shown to inhibit 
TNF-α-induced expression of inflammatory adhesion molecules, including VCAM-1 and E-selectin 
(Sun et al., 2007; Song et al., 2009; Bergstraesser et al., 2012). These anti-inflammatory effects of 
CORMs were used to test for the activity of SROM158 in HUVEC by assessing its effect on TNF-
α-induced VCAM-1 expression (Fig. 6.5.). As assessed by flow cytometry, VCAM-1 upregulation 
in response to 1 ng/ml or 10 ng/ml TNF-α was significantly reduced by the CO donor SROM158. 
Treatment of HUVEC with 12.5 µM SROM158 resulted in a minor but significant reduction in TNF-
α-induced VCAM-1 in the absence and presence of VEGF for 16h, and this effect was more 
pronounced (~25%) when used at a concentration of 25 µM (Fig. 6.5.). Moreover, western blot 
analysis demonstrated treatment with SROM158 up-regulated HO-1 protein in a dose-dependent 
manner in HUVEC in the absence and presence of VEGF, but with no synergistic effect on HO-1 
induction between VEGF and SROM158 (Fig. 6.6.) 
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Figure 6. 3.: Dose-dependent effect of ET-CORMs on EC number. (A) shows the chemical 
formulas of the ET-CORMs Stro074, Stro258 and SROM158. (B, C) HUVEC were sparsely 
seeded onto gelatin-coated culture plates in growth factor-free EBM-2 culture medium 
supplemented with 2% FCS and pre-treated for 30 min with vehicle (DMSO) or ET-CORMs 
(Stro074, Stro258, SROM158) at (B) 100 µM, or (C) 50 µM. Cells were then left untreated (UT) or 
treated with 25 ng/ml VEGF for 16 h. The number of live cells was assessed using the MTS-
assay. Data is presented as mean ± SEM (n=3 experiments), * p<0.05, ** p<0.01 vs untreated 
DMSO control, δ p<0.05, δδδ p<0.001 vs VEGF treated DMSO control.  
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Figure 6. 4.: SROM158 has no effect on EC number at low concentrations. HUVEC were 
sparsely seeded onto gelatin-coated culture plates in growth factor-free EBM-2 culture medium 
supplemented with 2% FCS and pre-treated for 30 min with SROM158 at the indicated 
concentrations. Cells were then left untreated (UT) or treated with 25 ng/ml VEGF for 16 h. The 
number of live cells was assessed using the MTS-assay. Data is presented as mean ± SEM (n=3 
experiments), * p<0.05. 
 
 
 
 
 
 
 
 
Figure 6. 5.: SROM158 suppresses TNF-α-induced VCAM-1 surface expression on EC. 
HUVEC were pre-treated with vehicle (DMSO) or SROM158 at the indicated concentrations. Cells 
were then left untreated or treated with 1 ng/ml TNF-α or 10 ng/ml TNF-α for 16 h prior to analysis 
of VCAM-1 surface expression by flow cytometry using mAb 1.4C3. Data is presented as mean ± 
SEM (n=3 experiments), ** p<0.01 untreated DMSO control vs 1 ng/ml TNF-α, δ p<0.05, δδ 
p<0.01 untreated DMSO control vs 10 ng/ml TNF-α. RFI – relative fluorescence intensity. 
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Taken together, SROM158 used at a concentration of 25 µM has no toxic effect on EC viability 
and partially suppresses expression of VCAM-1 in response to pro-inflammatory stimuli, 
demonstrating its activity. Furthermore, SROM158 markedly induced HO-1 protein. Based on 
these observations, SROM158 at a concentration of 25 µM was used for forthcoming experiments 
investigating the role of CO in HO-1 driven angiogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 6.: SROM158 induces HO-1 protein expression in human EC. HUVEC were pre-
treated with vehicle (DMSO) or SROM158 at the indicated concentrations. Cells were then left 
untreated (UT) or treated with 25 ng/ml VEGF for 16 h prior to assessment of HO-1 protein 
expression by western blotting. GAPDH was used as a loading control. (A) shows a 
representative blot, and (B) shows the corresponding densitometry. Data is presented as mean ± 
SEM (n=3 experiments), * p<0.05, ** p<0.01. 
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To investigate the effect of SROM158 on VEGF-mediated cell proliferation, cells transfected with 
a non-targeting control siRNA (siCTL) or siRNA targeting HO-1 (siHO-1 seq2, siHO-1 pool) were 
stained with the proliferation marker PCNA and PCNA positive cell were identified by flow 
cytometry (Fig. 6.7.). In siCTL-transfected cells exposure to the mitogen VEGF for 24 h resulted in 
a significant increase in EC proliferation compared to vehicle (DMSO)-treated cells. VEGF 
treatment in combination with 25 µM SROM158 enhanced proliferation to a similar extent as seen 
with VEGF alone. In concordance with our previous findings, siRNA-mediated inhibition of HO-1 
attenuated the VEGF-induced proliferation (compare Fig. 6.7. and Fig. 5.8.). Moreover, 30 min 
pre-treatment with SROM158 and subsequent culture for 24 h had no effect on VEGF-induced 
proliferation in siHO-1-transfected cells (Fig. 6.7.). 
Furthermore, as assessed by the migration scratch in vitro assay, SROM158 did not rescue the 
impaired directional migration of HO-1-depleted EC in response to VEGF (Fig. 6.8.). Here, scratch 
closure and the directional migration of HUVEC, quantified by single cell tracking of fluorescently-
labelled cells and expressed as the Euclidean distance, was not affected by SROM158 treatment 
in control siRNA-transfected cultures. As seen before, siRNA-mediated silencing of HO-1 
significantly reduced the Euclidean distance compared to vehicle-treated control siRNA-
transfected cells (compare Fig. 5.15.C and Fig. 6.8.A), and this response was not improved in the 
presence of SROM158 (Fig. 6.8.A). Accordingly, the migration pathway of individual siCTL-
transfected cells treated with SROM158 in combination with VEGF was directed towards the 
scratch and the cells on the opposite site, whereas the migration path of HO-1-depleted cells 
migrated in a non-linear, more circular pattern alongside the edge of the scratch (Fig 6.8.B and C).  
Altogether, these findings suggest that CO, at least own its own, does not mediate the angiogenic 
properties of HO-1, but might act in concert with other HO products or so far unknown 
downstream targets of HO-1. 
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Figure 6. 7.: SROM158 alone is not sufficient to reverse the impaired proliferative 
phenotype of HO-1-deficient endothelial cells in response to VEGF. HUVEC were transfected 
with 40 nM control siRNA (CTL) or HO-1 specific siRNA (seq2, pool) for 24 h. Cells were pre-
treated with vehicle or 25 µM SROM158 for 30 min prior to subsequent culture in growth factor-
free medium in the absence (UT) or presence of 25 ng/ml VEGF for 24 h. Cell proliferation was 
assessed by PCNA staining and FACs analysis. Data is presented as mean ± SEM (n=6 
experiments), * p<0.05. 
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Figure 6. 8.: SROM158 alone is not sufficient to reverse the impaired migratory phenotype 
of HO-1-deficient endothelial cells in response to VEGF. HUVEC were transfected with 40 nM 
3’-AlexaFluor488 control siRNA (CTLAF488) or HO-1 specific siRNA (seq2AF488) for 24 h. Cells were 
pre-treated with vehicle (DMSO) or 25 µM SROM158 for 30 min. Confluent monolayers were then 
scratched and treated with 25 ng/ml VEGF for 16 h. Migration was assessed by live cell imaging 
and quantified using ImageJ analysis software (Manual Tracking and Chemotaxis and Migration 
tool). (A) represents the Euclidean distance. Plots show the directional migration of HUVEC (B) 
transfected with siCTLAF488, or (C) siHO-1 seq2AF488 and pre-treated with SROM158. Data is 
presented as mean ± SD (n=3 experiments), * p<0.05. 
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6.2.3. HO-1 and vasodilator-stimulated phosphoprotein 
Recent work by Deshane and co-workers has demonstrated a link between HO-1 and vasodilator-
stimulated phosphoprotein (VASP), a cytoskeletal-associated protein localised at cell-cell contacts 
and microfilaments (Deshane et al., 2007; Krause et al., 2003). Treatment of MAEC isolated from 
HO-1
+/+
 littermate control mice with SDF-1α resulted in VASP phosphorylation at serine 239 
(Ser239) but not in cells from HO-1 knockout mice. Importantly, treatment with the CO donor 
CORM-2 resulted in phosphorylation of VASP in both HO-1
+/+
 and HO-1
-/-
, suggesting that SDF-1-
α-mediated phosphorylation of VASP is HO-1 dependent. These findings led us to examine the 
effects of VEGF on VASP and to investigate if VASP acts as a downstream effector of HO-1 in 
VEGF-induced angiogenesis. 
Time course experiments were conducted to determine the optimal time point of VEGF-mediated 
phosphorylation of VASP. Here, treatment of HUVEC with 25 ng/ml VEGF had no effect on total 
VASP protein at any time point, but resulted in VASP phosphorylation at Ser239 after 15 min 
exposure, and peaked after 30 min. No increase in phosphorylation compared to untreated control 
cells was observed after 240 min VEGF treatment (Fig. 6.9.). Therefore, 30 min exposure to 
VEGF was adapted for HO-1 inhibition studies. 
To determine if VASP phosphorylation by VEGF is HO-1 dependent, HO-1 expression and activity 
was silenced by siRNA. In HUVEC transfected with siCTL, 30 min VEGF treatment resulted in a 
significant increase in phospho-VASP (Ser239). Even though variable results were obtained, 
inhibition either by siHO-1 seq2 or siHO-1 pool had no significant effect on the phosphorylation 
status of VASP both in the absence and presence of VEGF (Fig. 6.10.). Accordingly, no difference 
in VASP phosphorylation at Ser239 was observed between MAEC isolated from HO-1
-/-
 animals 
and HO-1
+/+
 littermate controls after 30 min VEGF exposure (Fig. 6.11.). In addition, the CO donor 
SROM158 alone or in combination with VEGF had no effect on VEGF-mediated VASP 
phosphorylation either in HO-1
+/+
 or HO-1
-/-
 MAEC (Fig. 6.11.). Altogether, these results suggest 
that VEGF-mediated VASP phosphorylation is HO-1 independent. 
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Figure 6. 9.: VEGF-mediated phosphorylation of vasodilator-stimulated protein is optimal 
after 30 min exposure. HUVEC were cultured in growth factor-free culture medium and left 
untreated (UT) or treated with 25 ng/ml VEGF for the indicated time periods (in min). 
Phosphorylation of VASP at serine 239 (Ser239) was assessed by western blotting and quantified 
by densitometry and is expressed as phospho-VASP (P-VASP) relative to total VASP protein. 
Phospo-VASP (Ser239) antibody only detects endogenous VASP when phosphorylated at serine 
239 as indicated by a double band. GAPDH was used as a loading control. (A) shows a 
representative blot and (B) shows the corresponding densitometry. Data is presented as mean ± 
SEM (n=3 experiments), ** p<0.01. 
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Figure 6. 10.: VEGF-mediated VASP phosphorylation in primary human endothelial cells is 
not HO-1 dependent. HUVEC transfected with 40 nM control siRNA (CTL) or HO-1 specific 
siRNA (seq2, pool) were cultured in growth factor-free medium and left untreated or treated with 
25 ng/ml VEGF for 30 min. Phosphorylation of VASP at serine 239 (Ser239) was assessed by 
western blotting and quantified by densitometry and is expressed as phospho-VASP (P-VASP) 
relative to total VASP protein. GAPDH was used as a loading control. (A) shows a representative 
blot and (B) shows the corresponding densitometry. Data is presented as mean ± SEM (n=3 
experiments), * p<0.05, ns – not significant. 
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Figure 6. 11.: VEGF-mediated phosphorylation of VASP is not altered in murine aortic EC 
isolated from HO-1 knockout mice. MAEC isolated from HO-1
+/+
 littermate controls or HO-1
-/-
 
animals were treated with vehicle control (DMSO), 25 ng/ml VEGF, 25 µM SROM158, or VEGF 
and SROM158 in combination for 30 min. Protein expression and phosphorylation of VASP at 
serine 239 (Ser239) was assessed by western blotting and quantified by densitometry. VASP 
phosphorylation is expressed as phospho-VASP (P-VASP) relative to total VASP protein. GAPDH 
was used as a loading control. (A) shows a representative blot and (B) shows the corresponding 
densitometry. Data is presented as mean ± SEM (n=3 experiments). 
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6.2.4. Identification of novel HO-1 downstream targets – PCR array 
To begin to elucidate downstream effectors of HO-1 in VEGF-driven angiogenesis, the mRNA 
expression profile of HUVEC depleted of HO-1 by siRNA and control cells in response to VEGF 
was compared with the aid of the SABiosciences Human Cytoskeleton Regulators RT
2
 Profiler
TM
 
PCR Array (Qiagen Ltd.). The array profiles the expression of 84 genes controlling the biogenesis, 
organisation and rearrangement, as well as the polymerisation and depolymerisation of the 
cytoskeleton, an important precondition for the process of angiogenesis. 
Umbilical vein EC isolated from three human donors were pooled and either transfected with a 
non-targeting control siRNA (siCTL) or HO-1 specific siRNA (siHO-1 pool) for 24 h prior to 
treatment with 25 ng/ml VEGF and subsequent culture for 16 h. For best results from the PCR 
array, isolated total RNA was quality controlled for concentration and purity by Nanodrop analysis 
and ribosomal RNA band integrity on an Agilent BioAnalyzer using an RNA 6000 Nano LabChip
®
. 
The ratio of absorbance at 260 nm and 280 nm (A260nm:A280nm) is used to assess the purity of RNA 
and a ratio of ~2.0 is generally accepted to describe high-quality ‘pure’ RNA. The A260nm:A230nm
 
ratio is used as a secondary measure of nucleic purity and should be greater than 1.7 (Schroeder 
et al., 2006). Here, total RNA isolation from siCTL-transfected cells yielded a concentration of 
614.5 ng/µl RNA, with an absorbance ratio A260nm:A280nm=2.16 and A260nm:A230nm=1.8 (Tab. 6.1.). 
Similar results were obtained for HO-1-depleted cultures with a total RNA concentration of 626.0 
ng/µl, absorbance ratio A260nm:A280nm=2.12 and A260nm:A230nm=2.07 (Tab. 6.1.). Moreover, analysis 
of ribosomal band integrity demonstrated sharp peaks and bands for the 18S and 28S ribosomal 
RNA (rRNA) on electropherograms and gel-like images, respectively, resulting in an RNA integrity 
number (RIN) of 8.1 for control cells and a RIN of 10.0 for HO-1-depleted cells (Fig. 6.12.). RIN 
values range from 1 (totally degraded) to 10 (intact) (Schroeder et al., 2006). Taken together, 
these results indicate high-quality total RNA isolated from both control and HO-1 siRNA-
transfected cultures, which meets the standards of integrity and purity from protein, organic, or 
genomic DNA contamination required for reliable results from the RT
2
 Profiler PCR array. In 
addition, the siRNA-mediated knockdown of the human HO-1 gene in these samples was 
assessed by qRT-PCR and revealed a sufficient reduction in HO-1 mRNA of 70% in siHO-1 pool-
transfected cells compared to siCTL-transfected cells (Fig. 6.13.). 
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Table 6. 1.: Nanodrop analysis of isolated total RNA. Total RNA from HUVEC pooled from 
three donors either transfected with 40 nM control siRNA (siCTL) or HO-1 specific siRNA (siRNA 
pool) and treated with 25 ng/ml VEGF for 16 h was isolated using the RNeasy Mini Kit and 
quantified by Nanodrop analysis. 
Sample Concentration 
[ng/µl] 
Absorbance ratio 
A260nm:A280nm 
Absorbance ratio 
A260nm:A230nm 
 
siCTL + VEGF 614.5 2.16 1.8 
siHO-1 pool + VEGF 626.0 2.12 2.07 
 
 
Figure 6. 12.: Ribosomal band integrity analysed on the Agilent® 2100 BioAnalyzer. Total 
RNA isolated from HUVEC pooled from three donors either transfected with 40 nM control siRNA 
(siCTL) or HO-1 specific siRNA (siHO-1 pool) and treated with 25 ng/ml VEGF for 16 h was 
analysed using an RNA 6000 Nano LabChip®. The gel-like image and corresponding 
electropherogram show high-quality total RNA as sharp bands and peaks, respectively. RIN – 
RNA integrity number, 28S – 28S ribosomal RNA, 18S – 18S ribosomal RNA. 
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Figure 6. 13.: Validation of siRNA-mediated silencing of HO-1 in human EC. HUVEC either 
transfected with 40 nM control siRNA (CTL) or HO-1 specific siRNA (pool) were treated with 25 
ng/ml VEGF for 16 h. Cells from isolated from three donor were pooled and HO-1 mRNA 
expression was quantified by qRT-PCR. 
 
Gene expression profiling using the Cytoskeleton Regulator PCR array identified numerous genes 
that were differentially expressed between siCTL and siHO-1 pool-transfected cells in response to 
VEGF exposure for 16 h (Tab. 6.2.). In this study, fold changes in mRNA expression were 
considered significantly upregulated when ≥ 2.00 and significantly downregulated when ≤0.50. 
Genes that were significantly upregulated in HO-1-depleted cells compared to control cells include 
ARPC2 (fold change = 2.17), CIT (fold change = 2.03), FSCN2 (fold change = 2.17), and 
PPP1R12B (fold change = 2.03). Among the identified hits, only one gene was significantly 
downregulated by HO-1 inhibition, the positive cell cycle regulator cyclin A1 (CCNA1; fold change 
= 0.44) (Tab. 6.2.). 
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Table 6. 2.: Cytoskeleton Regulator PCR array results. Changes in mRNA expression of 
siCTL- or siHO-1 pool-transfected HUVEC in response to VEGF were assessed using the 
SABiosciences Human Cytoskeleton Regulators RT
2
 Profiler
TM
 PCR Array and quantified using 
the SABiosciences RT
2
 Profiler
TM
 PCR Array Data Analysis version 3.5 online service. Fold up- 
and downregulation ≥ 2.00 and ≤ 0.50 were considered as significant changes in gene expression 
and are highlighted in bold. 
Gene Symbol Gene Name Fold Up- or Down-
Regulation 
ACTR2 ARP2 actin-related protein 2 homolog (yeast) 1.01 
ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0.77 
ARFIP2 ADP-ribosylation factor interacting protein 2 1.34 
ARHGAP6 Rho GTPase activating protein 6 1.16 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 0.82 
ARHGEF11 Rho guanine nucleotide exchange factor (GEF) 11 1.43 
ARPC1B Actin related protein 2/3 complex, subunit 1B, 41kDa 1.34 
ARPC2 Actin related protein 2/3 complex, subunit 2, 34kDa 2.17 
ARPC3 Actin related protein 2/3 complex, subunit 3, 21kDa 0.82 
ARPC4 Actin related protein 2/3 complex, subunit 4, 20kDa 1.54 
ARPC5 Actin related protein 2/3 complex, subunit 5, 16kDa 0.58 
AURKA Aurora kinase A 1.43 
AURKB Aurora kinase B 1.34 
AURKC Aurora kinase C 1.65 
BAIAP2 BAI1-associated protein 2 1.09 
CALD1 Caldesmon 1 0.88 
CALM1 Calmodulin 1 (phosphorylase kinase, delta) 0.95 
CASK Calcium/calmodulin-dependent serine protein kinase 
(MAGUK family) 
1.09 
CCNA1 Cyclin A1 0.44 
CCNB2 Cyclin B2 1.43 
CDC42 Cell division cycle 42 (GTP binding protein, 25kDa) 0.95 
CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) 1.25 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 1.01 
CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 1.16 
CDK5 Cyclin-dependent kinase 5 1.43 
CDK5R1 Cyclin-dependent kinase 5, regulatory subunit 1 (p35) 1.43 
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Table 6.2 continued  
ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH 
domain 1 
1.25 
CFL1 Cofilin 1 (non-muscle) 1.01 
CIT Citron (rho-interacting, serine/threonine kinase 21) 2.03 
CLASP1 Cytoplasmic linker associated protein 1 0.88 
CLASP2 Cytoplasmic linker associated protein 2 0.88 
CLIP1 CAP-GLY domain containing linker protein 1 1.09 
CLIP2 CAP-GLY domain containing linker protein 2 1.25 
CRK V-crk sarcoma virus CT10 oncogene homolog (avian) 0.82 
CTTN Cortactin 1.01 
CYFIP1 Cytoplasmic FMR1 interacting protein 1 0.95 
CYFIP2 Cytoplasmic FMR1 interacting protein 2 1.77 
DIAPH1 Diaphanous homolog 1 (Drosophila) 0.95 
DSTN Destrin (actin depolymerizing factor) 1.01 
EZR Ezrin 1.65 
FNBP1L Formin binding protein 1-like 1.16 
FSCN2 Fascin homolog 2, actin-bundling protein, retinal 
(Strongylocentrotus purpuratus) 
2.17 
GSN Gelsolin (amyloidosis, Finnish type) 1.09 
IQGAP1 IQ motif containing GTPase activating protein 1 0.88 
IQGAP2 IQ motif containing GTPase activating protein 2 1.09 
LIMK1 LIM domain kinase 1 1.09 
LIMK2 LIM domain kinase 2 0.82 
LLGL1 Lethal giant larvae homolog 1 (Drosophila) 1.25 
MACF1 Tubule-actin crosslinking factor 1 0.82 
MAP3K11 Mitogen-activated protein kinase kinase kinase 11 1.54 
MAP4 Tubule-associated protein 4 0.72 
MAPK13 Mitogen-activated protein kinase 13 1.16 
MAPRE1 Tubule-associated protein, RP/EB family, member 1 0.82 
MAPRE2 Tubule-associated protein, RP/EB family, member 2 0.58 
MAPT Tubule-associated protein tau 0.72 
MARK2 MAP/tubule affinity-regulating kinase 2 1.09 
MID1 Midline 1 (Opitz/BBB syndrome) 0.88 
MSN Moesin 0.62 
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Table 6.2. continued  
MYLK Myosin light chain kinase 1.16 
MYLK2 Myosin light chain kinase 2 1.34 
NCK1 NCK adaptor protein 1 1.01 
NCK2 NCK adaptor protein 2 1.01 
PAK1 P21 protein (Cdc42/Rac)-activated kinase 1 1.43 
PAK4 P21 protein (Cdc42/Rac)-activated kinase 4 1.09 
PFN2 Profilin 2 1.09 
PHLDB2 Pleckstrin homology-like domain, family B, member 2 0.95 
PIKFYVE Phosphoinositide kinase, FYVE finger containing 1.16 
PPP1R12A Protein phosphatase 1, regulatory (inhibitor) subunit 12A 1.43 
PPP1R12B Protein phosphatase 1, regulatory (inhibitor) subunit 
12B 
2.03 
PPP3CA Protein phosphatase 3 (formerly 2B), catalytic subunit, 
alpha isoform 
0.82 
PPP3CB Protein phosphatase 3 (formerly 2B), catalytic subunit, beta 
isoform 
0.51 
RAC1 Ras-related C3 botulinum toxin substrate 1 (rho family, 
small GTP binding protein Rac1) 
0.88 
RACGAP1 Rac GTPase activating protein 1 1.25 
RDX Radixin 0.82 
RHOA Ras homolog gene family, member A 0.82 
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 0.95 
SSH1 Slingshot homolog 1 (Drosophila) 1.16 
SSH2 Slingshot homolog 2 (Drosophila) 0.77 
STMN1 Stathmin 1 1.09 
TIAM1 T-cell lymphoma invasion and metastasis 1 1.65 
VASP Vasodilator-stimulated phosphoprotein 1.01 
WAS Wiskott-Aldrich syndrome (eczema-thrombocytopenia) 0.51 
WASF1 WAS protein family, member 1 1.01 
WASL Wiskott-Aldrich syndrome-like 1.16 
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To validate the PCR array result, HUVEC were either treated with the siRNA delivery agent 
geneFECTOR (GF) or transfected with siCTL or siHO-1 (seq2, pool) for 24 h prior to treatment 
with VEGF and subsequent culture for 16 h. VEGF treatment of GF-treated and siCTL-transfected 
cells resulted in a significant increase in cyclin A1 mRNA. Moreover, siRNA-mediated silencing of 
HO-1 not only diminished basal cyclin A1 expression but also inhibited the VEGF response (Fig. 
6.14), thereby confirming the PCR array result. 
 
 
 
 
 
 
 
 
 
Figure 6. 14.: Validation of the PCR array hit cyclin A1 by quantitative real-time PCR. 
HUVEC were either treated with geneFECTOR (GF) or transfected with 40 nM control siRNA 
(CTL) or HO-1 specific siRNA (HO-1; represents pooled data from siHO-1 seq2 and siHO-1 pool) 
for 16 h. Cells were then left untreated or treated with 25 ng/ml VEGF for 24 h prior to mRNA 
quantification by qRT-PCR. Data is presented as mean ± SEM (n=3 experiments), * p<0.05, ** 
p<0.01. δδ p<0.01 vs untreated siCTL-transfected cells. 
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6.2.5. Identification of novel HO-1 downstream targets - Proteomics 
In collaboration with Prof M. Mayr (King’s College London, UK) a proteomic screen of primary 
human EC was performed as a second approach to identify novel HO-1 downstream targets that 
are involved in HO-1-dependent VEGF-mediated angiogenesis. 
Cellular lysates of primary human EC (HUVEC), pooled from three donors either transfected with 
40 nM control siRNA (siCTL) or HO-1 specific siRNA (siHO-1 pool) and treated with VEGF for 16 
h, or alternatively, lysates of HUVEC either infected with a control adenovirus containing an empty 
vector (Ad0) or the recombinant adenovirus expressing the human HO-1 gene (AdHO-1) were 
collected by myself and HO-1 protein expression was assessed by western blotting (Fig. 6.15.). 
Silencing of HO-1 by siRNA in HUVEC resulted in a sufficient decrease in HO-1 expression 
compared to siCTL-transfected cells (Fig. 6.15.A). Likewise, infection of cells with AdHO-1 
markedly upregulated HO-1 protein, an effect not seen with Ad0 (Fig. 6.15.B). 
 
 
 
 
 
 
 
 
 
Figure 6. 15.: Validation of HO-1 protein expression in human primary EC. HUVEC pooled 
from three donors were cultured in gelatin-coated T75 culture flasks and either (A) treated with 
geneFECTOR (GF) or transfected with 40 nM control siRNA (CTL) or HO-1 specific siRNA (pool) 
for 24 h and then left untreated or treated with 25 ng/ml VEGF for 16 h, or (B) left uninfected or 
infected with a control adenovirus containing an empty vector (Ad0) or the recombinant 
adenovirus expressing the HO-1 gene at a MOI of 100 for 2 h in plain M199 medium prior to 
subsequent culture for 16 h. HO-1 protein expression was assessed by western blotting. GAPDH 
was used as a loading control. 
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The validated protein lysates were analysed by difference in-gel electrophoresis (DIGE) coupled 
to mass spectroscopy by our collaborators and a list of differentially expressed proteins was 
returned to our laboratory (Fig. 6.16. and Tab. 6.3.). 
 
Figure 6. 16.: Difference in-gel electrophoresis results. Different samples (GF, GF + VEGF, 
siCRL + VEGF, siHO-1 pool + VEGF, UT, Ad0, AdHO-1; all in triplicates) were labelled with Cy3 
and Cy5 fluorescent dyes and separated by difference in-gel electrophoresis (DIGE). Fluorescent 
images were captured and visualised by silver staining and scanned in transmission scan mode. 
Spots showing a significant difference in intensity, here indicated by red circles and numbers, 
were excised for in-gel tryptic digestion and analysed by mass spectroscopy. 
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Table 6. 3.: Full list of differential expressed proteins.  Each sample was labelled with a 
fluorescent dye (Cy3 or Cy5) and mixed with the internal standard (a mixture of all samples tested 
and labelled wirh Cy2). The table represents the combined hits resulting from each sample 
normalised to the internal standard. 
No. Protein name Accession No. Mw (Da) Protein 
identification 
probability 
No. of 
unique 
peptides 
No. of 
unique 
spectra 
No. of 
total 
spectra 
Coverage 
1 Vimentin VIME_HUMAN 53634,6 100,00% 16 18 30 0,363 
2 Vimentin VIME_HUMAN 53634,6 100,00% 21 25 43 0,483 
3 Vimentin VIME_HUMAN 53634,6 100,00% 35 48 90 0,687 
4 Vimentin VIME_HUMAN 53634,6 100,00% 38 44 81 0,792 
5 Vimentin VIME_HUMAN 53634,6 100,00% 34 40 69 0,71 
6 Vimentin VIME_HUMAN 53634,6 100,00% 34 40 76 0,725 
7 Vimentin VIME_HUMAN 53634,6 100,00% 28 32 52 0,629 
8 Heat shock 70 kDa 
protein 4 
HSP74_HUMAN 94313,9 100,00% 14 17 31 0,202 
9 Periodic tryptophan 
protein 1 homolog 
PWP1_HUMAN 55810,6 100,00% 3 3 5 0,0639 
10 Lamin-B1 LMNB1_HUMAN 66391,6 100,00% 4 4 5 0,0785 
10 Ran GTPase-
activating protein 1 
RAGP1_HUMA
N 
63525,3 100,00% 4 4 6 0,0784 
11 Zyxin ZYX_HUMAN 61258 99,80% 2 2 4 0,0455 
11 Gelsolin GELS_HUMAN 85679,8 100,00% 3 3 4 0,0409 
12 Neutral alpha-
glucosidase AB 
GANAB_HUMA
N 
106857,9 100,00% 4 5 8 0,0424 
13 Procollagen-
lysine,2-
oxoglutarate 5-
dioxygenase 2 
PLOD2_HUMAN 84669,4 100,00% 8 9 17 0,13 
14 Nucleolin NUCL_HUMAN 76597,9 100,00% 3 3 6 0,0437 
14 Procollagen-
lysine,2-
oxoglutarate 5-
dioxygenase 2 
PLOD2_HUMAN 84669,4 100,00% 9 9 14 0,137 
15 Caldesmon CALD1_HUMAN 93232,8 100,00% 10 15 28 0,173 
16 Lamina-associated 
polypeptide 2, 
isoform alpha 
LAP2A_HUMAN 75475,8 100,00% 7 9 13 0,117 
16 Lamin-A/C LMNA_HUMAN 74122,6 100,00% 6 6 11 0,101 
17 Vimentin VIME_HUMAN 53634,6 100,00% 19 22 39 0,438 
18 Vimentin VIME_HUMAN 53634,6 100,00% 10 10 16 0,24 
19 Vimentin VIME_HUMAN 53634,6 100,00% 23 25 47 0,496 
20 Vimentin VIME_HUMAN 53634,6 100,00% 18 20 43 0,397 
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Table 6.3 continued      
21 Heterogeneous 
nuclear 
ribonucleoprotein K 
HNRPK_HUMA
N 
50960,5 100,00% 7 11 19 0,179 
22 Lamin-B2 LMNB2_HUMAN 67671,7 100,00% 6 6 10 0,123 
22 Vimentin VIME_HUMAN 53634,6 100,00% 8 8 16 0,152 
23 Ras GTPase-
activating protein-
binding protein 1 
G3BP1_HUMAN 52144,8 99,90% 3 3 5 0,0622 
24 Annexin A6 ANXA6_HUMAN 75859,5 100,00% 9 10 15 0,146 
25 Heat shock 
cognate 71 kDa 
protein 
HSP7C_HUMAN 70881,8 100,00% 5 5 7 0,0975 
26 Vimentin VIME_HUMAN 53634,6 100,00% 12 13 23 0,311 
26 Protein disulfide-
isomerase 
PDIA1_HUMAN 57100,1 100,00% 6 9 16 0,14 
27 Tubulin beta chain TBB5_HUMAN 49652,6 100,00% 5 5 8 0,133 
27 Vimentin VIME_HUMAN 53634,6 100,00% 9 10 17 0,215 
28 Tubulin alpha-1A 
chain 
TBA1A_HUMAN 50117,7 100,00% 12 16 30 0,335 
28 Vimentin VIME_HUMAN 53634,6 100,00% 20 26 48 0,472 
29 Polymerase I and 
transcript release 
factor 
PTRF_HUMAN 43458,5 100,00% 9 14 26 0,254 
29 Vimentin VIME_HUMAN 53634,6 100,00% 12 15 25 0,322 
30 Heterogeneous 
nuclear 
ribonucleoprotein K 
HNRPK_HUMA
N 
50960,5 100,00% 4 4 7 0,0929 
30 Vimentin VIME_HUMAN 53634,6 100,00% 7 7 11 0,157 
31 Protein disulfide-
isomerase A3 
PDIA3_HUMAN 56766,6 100,00% 11 14 23 0,234 
32 T-complex protein 
1 subunit zeta 
TCPZ_HUMAN 58007,3 100,00% 19 21 36 0,282 
33 Succinyl-CoA:3-
ketoacid-coenzyme 
A transferase 1, 
mitochondrial 
SCOT1_HUMAN 56140,8 100,00% 5 6 9 0,104 
34 Seryl-tRNA 
synthetase, 
mitochondrial 
SYSM_HUMAN 58265,5 95,00% 1 1 2 0,0193 
35 Pyruvate kinase 
isozymes M1/M2 
KPYM_HUMAN 57919,5 100,00% 10 10 19 0,175 
36 Vimentin VIME_HUMAN 53634,6 100,00% 9 9 15 0,155 
37 Thioredoxin 
domain-containing 
protein 5 
TXND5_HUMAN 47611,1 100,00% 16 18 31 0,352 
38 Heterogeneous 
nuclear 
ribonucleoprotein F 
HNRPF_HUMA
N 
45653,8 100,00% 8 11 20 0,234 
39 Endophilin-A2 SH3G1_HUMAN 41473,2 100,00% 11 11 20 0,293 
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Table 6.3. continued 
40 Serpin H1 SERPH_HUMA
N 
46424 100,00% 8 9 16 0,167 
41 Serpin H1 SERPH_HUMA
N 
46424 100,00% 17 22 44 0,409 
42 Eukaryotic 
translation initiation 
factor 3 subunit F 
EIF3F_HUMAN 37545,5 100,00% 6 7 13 0,216 
42 Perilipin-3 PLIN3_HUMAN 47027,6 100,00% 5 5 9 0,184 
43 Protein SET SET_HUMAN 33471,4 100,00% 7 11 18 0,224 
44 Tropomyosin 
alpha-1 chain 
TPM1_HUMAN 32692 100,00% 10 12 19 0,306 
45 Tropomyosin 
alpha-1 chain 
TPM1_HUMAN 32692 100,00% 5 5 7 0,155 
45 Vimentin VIME_HUMAN 53634,6 100,00% 4 4 7 0,0751 
46 Unidentified - - - - - - - 
47 Unidentified - - - - - - - 
48 Actin, cytoplasmic 
1 
ACTB_HUMAN 41719,8 100,00% 8 8 15 0,205 
49 Ubiquitin fusion 
degradation protein 
1 homolog 
UFD1_HUMAN 34483,2 99,80% 3 4 7 0,0782 
50 Heterogeneous 
nuclear 
ribonucleoproteins 
C1/C2 
HNRPC_HUMA
N 
33652,5 100,00% 5 5 7 0,134 
51 Tropomyosin 
alpha-1 chain 
TPM1_HUMAN 32692 100,00% 7 7 13 0,201 
52 Elongation factor 
1-delta 
EF1D_HUMAN 31103,9 96,60% 2 2 3 0,0391 
53 Elongation factor 
1-delta 
EF1D_HUMAN 31103,9 100,00% 13 15 25 0,47 
54 Guanine 
nucleotide-binding 
protein subunit 
beta-4 
GBB4_HUMAN 37549,8 100,00% 4 4 7 0,115 
55 60S acidic 
ribosomal protein 
P0 
RLA0_HUMAN 34256,3 100,00% 10 12 20 0,385 
56 Calponin-2 CNN2_HUMAN 33679,6 100,00% 4 5 9 0,149 
57 Voltage-dependent 
anion-selective 
channel protein 2 
VDAC2_HUMAN 31549,3 100,00% 6 6 10 0,255 
58 Tropomyosin 
alpha-1 chain 
TPM1_HUMAN 32692 100,00% 6 6 12 0,155 
59 Tubule-associated 
protein RP/EB 
family member 1 
MARE1_HUMA
N 
29981,5 100,00% 6 7 13 0,254 
60 Purine nucleoside 
phosphorylase 
PNPH_HUMAN 32100 100,00% 5 5 13 0,218 
61 Voltage-dependent 
anion-selective 
channel protein 2 
VDAC2_HUMAN 31549,3 99,80% 2 2 3 0,068 
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Table 6.3. continued 
62 Unidentified - - - - - - - 
63 Unidentified - - - - - - - 
64 Elongation factor 
1-delta 
EF1D_HUMAN 31103,9 99,20% 3 3 4 0,0712 
64 Elongation factor 
1-beta 
EF1B_HUMAN 24746,2 100,00% 4 5 7 0,231 
65 Elongation factor 
1-delta 
EF1D_HUMAN 31103,9 99,90% 3 3 5 0,0712 
65 Elongation factor 
1-beta 
EF1B_HUMAN 24746,2 100,00% 5 5 7 0,307 
66 Eukaryotic 
translation initiation 
factor 6 
IF6_HUMAN 26580,2 100,00% 6 7 13 0,294 
67 14-3-3 protein 
epsilon 
1433E_HUMAN 29157 100,00% 12 16 30 0,353 
68 Prohibitin PHB_HUMAN 29786,6 100,00% 7 7 13 0,228 
69 Unidentified - - - - - - - 
70 LDLR chaperone 
MESD 
MESD_HUMAN 26059,9 100,00% 7 8 16 0,325 
71 39S ribosomal 
protein L24, 
mitochondrial 
RM24_HUMAN 24897 100,00% 4 4 7 0,208 
71 FK506-binding 
protein 3 
FKBP3_HUMAN 25159,4 100,00% 6 6 10 0,263 
72 Cysteine and 
glycine-rich protein 
1 
CSRP1_HUMAN 20549,1 100,00% 9 10 17 0,508 
73 Transgelin-2 TAGL2_HUMAN 22373,9 100,00% 9 13 23 0,442 
74 Unidentified - - - - - - - 
75 Myosin regulatory 
light chain 12A 
ML12A_HUMAN 19777,2 100,00% 3 3 6 0,175 
76 Myosin regulatory 
light chain 12A 
ML12A_HUMAN 19777,2 100,00% 6 7 16 0,404 
77 Myosin regulatory 
light chain 12A 
ML12A_HUMAN 19777,2 100,00% 7 9 19 0,509 
78 Myosin light 
polypeptide 6 
MYL6_HUMAN 16911,8 100,00% 4 5 9 0,364 
79 Myosin light 
polypeptide 6 
MYL6_HUMAN 16911,8 100,00% 9 12 24 0,636 
80 Myosin light 
polypeptide 6 
MYL6_HUMAN 16911,8 100,00% 4 4 6 0,364 
81 Unidentified - - - - - - - 
82 Actin-related 
protein 2/3 
complex subunit 5 
ARPC5_HUMAN 16302,6 100,00% 5 6 12 0,311 
83 Peptidyl-prolyl cis-
trans isomerase A 
PPIA_HUMAN 17994,9 100,00% 6 8 16 0,394 
84 Peptidyl-prolyl cis-
trans isomerase A 
PPIA_HUMAN 17994,9 100,00% 6 8 20 0,358 
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Table 6.3. continued 
85 Peptidyl-prolyl cis-
trans isomerase A 
PPIA_HUMAN 17994,9 100,00% 7 8 16 0,358 
86 Histone H2B type 
1-B 
H2B1B_HUMAN 13932,8 100,00% 3 3 5 0,167 
86 60S ribosomal 
protein L22 
RL22_HUMAN 14769,3 100,00% 4 4 7 0,242 
86 40S ribosomal 
protein S19 
RS19_HUMAN 16042,5 99,90% 3 3 5 0,172 
87 Unidentified - - - - - - - 
88 Unidentified - - - - - - - 
89 Hemoglobin 
subunit alpha 
HBA_HUMAN 15239,6 100,00% 4 5 9 0,282 
90 Protein S100-A11 S10AB_HUMAN 11723,1 100,00% 3 5 9 0,219 
 
Of the identified hits, 29 proteins were differentially expressed between the proteome of HUVEC 
transfected with a non-targeting control siRNA and HO-1-depleted HUVEC exposed to VEGF for 
16 h. These hits were then analysed using the DAVID Bioinformatics Resources 6.7 online 
software (National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health) 
and grouped according to gene ontology (GO), in terms of cellular component, molecular function, 
and biological process (Tab. 6.4.). The main purpose of the proteomic screen was to identify 
potential downstream targets of HO-1 mediating VEGF-driven angiogenesis.  Here, gene ontology 
identified several proteins that are involved in the regulation of angiogenesis and related GO-
groups including cytoskeletal proteins and intermediate filaments, and proteins that regulate cell 
structure/morphology and motility (Tab. 6.4. highlighted in bolt). Of note, a common hit to all these 
groups was the intermediate filament vimentin, and its role in HO-1-driven angiogenesis will be 
discussed in more detail in Chapter 8. 
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Table 6. 4.: Differentially expressed proteins between HO-1-deficient and control human EC 
in response to VEGF. 29 identified proteins were analysed and grouped according to gene 
ontology (GO) using DAVID Bioinformatics Resources 6.7. Groups of particular importance to this 
study are highlighted in bold. 
Cellular Component   
GO Term Count Gene Name  
intracellular organelle lumen 12 SCOT1 
SET 
IF6 
HNRPF 
HNPRK 
LMNB1 
NUCL 
PHB 
PDIA3 
SERPH 
TXNDC5 
VDAC2 
organelle lumen 12 SCOT1 
SET 
IF6 
HNRPF 
HNPRK 
LMNB1 
NUCL 
PHB 
PDIA3 
SERPH 
TXNDC5 
VDAC2 
membrane-enclosed lumen 12 SCOT1 
SET 
IF6 
HNRPF 
HNPRK 
LMNB1 
NUCL 
PHB 
PDIA3 
SERPH 
TXNDC5 
VDAC2 
nuclear lumen 7 SET 
IF6 
HNRPF 
HNPRK 
LMNB1 
NUCL 
PHB 
spliceosome 3 HNRPC 
HNRPF 
HNPRK 
ribonucleoprotein complex 4 HNRPC 
HNRPF 
HNPRK 
NUCL 
nucleoplasm 5 SET 
HNRPF 
HNPRK 
NUCL 
PHB 
nucleolus 4 IF6 
HNRPF 
HNPRK 
NUCL 
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Table 6.4. continued   
organelle envelope 6 RAGP1 
IF6 
LMNB1 
PHB 
TAGL2 
VDAC2 
envelope 6 RAGP1 
IF6 
LMNB1 
PHB 
TAGL2 
VDAC2 
nuclear envelope 4 RAGP1 
IF6 
LMNB1 
TAGL2 
nuclear membrane 3 IF6 
LMNB1 
TAGL2 
organelle inner membrane 3 IF6 
LMNB1 
PHB 
organelle membrane 5 IF6 
LMNB1 
PHB 
TAGL2 
VDAC2 
endomembrane system 4 RAGP1 
IF6 
LMNB1 
TAGL2 
endoplasmic reticulum lumen 3 PDIA3 
SERPH 
TXNDC5 
endoplasmic reticulum 6 SET 
MESD 
PLOD2 
PDIA3 
SERPH 
TXNDC5 
endoplasmic reticulum part 3 SET 
MESD 
PDIA3 
SERPH 
TXNDC5 
integral to membrane 3 RAGP1 
PHB 
VDAC2 
intrinsic to membrane 3 RAGP1 
PHB 
VDAC2 
intermediate filament 3 Eukaryotic translation initiation factor (IF6) 
Lamin B1(LMNB1) 
Vimentin (VIME) 
intermediate filament 
cytoskeleton 
3 Eukaryotic translation initiation factor (IF6) 
Lamin B1(LMNB1) 
Vimentin (VIME) 
non-membrane-bound organelle 9 RAGP1 
HNRPK 
HNRPF 
IF6 
LMNB1 
NUCL 
TPM1 
VDAC2 
VIME 
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Table 6.4. continued   
intracellular non-membrane bound 
organelle 
9 RAGP1 
HNRPK 
HNRPF 
IF6 
LMNB1 
NUCL 
TPM1 
VDAC2 
VIME 
cytoskeletal part 4 Eukaryotic translation initiation factor (IF6) 
Lamin B1 (LMNB1) 
Tropomyosin alpha-1 chain (TPM1) 
Vimentin (VIME) 
cytoskeleton 4 Eukaryotic translation initiation factor (IF6) 
Lamin B1 (LMNB1) 
Tropomyosin alpha-1 chain (TPM1) 
Vimentin (VIME) 
mitochondrial part 3 SCOT1 
PHB 
VDAC2 
mitochondrion  4 SCOT1 
PHB 
1433E 
VDAC2 
cytosol 9 G3BP1 
SET 
EF1B 
EF1D 
EIF3F 
1433E 
KPYM 
UFD1 
VIME 
plasma membrane 7 G3BP1 
RAGP1 
PLIN3 
PHB 
TAGL2 
TPM1 
VIME 
plasma membrane part  4 RAGP1 
PLIN3 
PHB 
TPM1 
Molecular Function   
GO Term Count  Gene Name 
translation factor activity, nucleic 
acid binding 
  
RNA binding  5 G3BP1 
HNRPC 
HNRPK 
HNRPF 
NUCL 
nucleotide binding 5 G3BP1 
HNRPC 
HNRPF 
NUCL 
VDAC2 
DNA binding 3 G3BP1 
HNRPK 
NUCL 
structural molecule activity 3 Lamin B1 (LMNB1) 
Tropomyosin alpha-1 chain (TPM1) 
Vimentin (VIME) 
metal ion binding 3 CSRP1 
PLOD2 
KPYM 
cation binding 3 CSRP1 
PLOD2 
KPYM 
ion binding  3 CSRP1 
PLOD2 
KPYM 
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Table 6.4. continued   
Biological Process   
GO Term Count Gene Name  
translation 4 EF1B 
EF1D 
EIF3F 
IF6 
RNA splicing, via 
transesterification reactions 
3 HNRPC 
HNRPF 
HNPRK 
nuclear mRNA splicing, via 
spliceosome 
3 HNRPC 
HNRPF 
HNPRK 
RNA splicing 3 HNRPC 
HNRPF 
HNPRK 
mRNA processing 3 HNRPC 
HNRPF 
HNPRK 
mRNA metabolic process 3 HNRPC 
HNRPF 
HNPRK 
RNA processing 3 HNRPC 
HNRPF 
HNPRK 
intracellular transport 5 SET 
PDIA3 
1433E 
TXDN5 
TPM1 
regulation of apoptosis 4 PHB 
PDIA3 
1433E 
TXDN5 
regulation of programmed cell 
death 
4 PHB 
PDIA3 
1433E 
TXDN5 
regulation of cell death 4 PHB 
PDIA3 
1433E 
TXDN5 
cell motion 3 14-3-3 protein epsilon (1433E) 
Tropomyosin alpha-1 chain (TPM1) 
Vimentin (VIME) 
negative regulation of 
macromolecule metabolic process 
3 SET 
PHB 
1433E 
 
  
Chapter 6 
221 
 
6.3. DISCUSSION 
This study and data from previous studies clearly demonstrate a link between the cytoprotective 
enzyme HO-1 and the angiogenic capacity of EC with HO-1 affecting endothelial proliferation, 
migration and vessel assembly (Bussolati and Mason, 2006; Dulak et al., 2008; Kim et al., 2011). 
However, the signalling pathways involved in the regulation of HO-1-driven angiogenesis and 
those used by the HO products CO, biliverdin/bilirubin, and iron remain to be determined.  
Herein, we show that siRNA-mediated inhibition negatively affects chemotactic migration of EC in 
response to the pro-angiogenic mediator VEGF resulting in a significant decrease in the number 
of cell migrating towards the chemotactic stimuli (Fig. 5.15, Fig. 5.16. and Fig. 5.18), whereas 
adenoviral overexpression of HO-1 reverses this response (Fig. 5.17.). To determine whether HO-
1-derived iron and subsequent induction of ferritin subunit ferritin heavy chain (FHC) regulate HO-
1-mediated migration, HUVEC depleted of HO-1 were exposed to the iron chelator deferoxamine 
mesylate (DFO) prior to the assessment of their migratory capacities. DFO chelates intracelluar 
iron, mimicking the activities of ferritin. Ferritin is a ubiquitously existing intracellular multimeric 
protein complex consisting of a heavy chain and a light chain subunit (Harrison and Arosio, 1996). 
Ferritin is able to effectively sequester intracellular iron and, hence, limits the pro-oxidant capacity 
of ferrous iron (Fe
2+
) by catalysing the oxidation to the ferric form (Fe
3+
) (Balla et al., 1992; 
Berberat et al., 2003). It is likely that increased ferritin expression in conjunction with HO-1 
expression may contribute to additional protection afforded by HO-1 (Balla et al., 1992; Ryter et 
al., 2006). In addition, a potential pro-angiogenic function of ferritin has been demonstrated by 
Coffman and colleagues. High molecular weight kininogen (HKa) is a potent inhibitor of 
angiogenesis by inducing the apoptosis of proliferating EC. Supplementation with serum ferritin 
significantly inhibited the anti-angiogenic effects of HKa improving EC proliferation, migration and 
subsequent formation of capillary-like structures (Coffman et al., 2009). Moreover, exposure of 
vascular SMC to DFO increased VEGF synthesis and may influence angiogenesis indirectly 
(Dulak et al., 2002). However, treatment with DFO of HO-1-deficient HUVEC was not able to 
restore their impaired migratory phenotype in response to VEGF (Fig. 6.1.). These data suggest 
that the HO product iron and resulting increased ferritin at least not solely mediate the pro-
migratory properties of HO-1, suggesting a possible role for HO-1-derived CO and/or 
biliverdin/bilirubin in this process.  
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HO-1-derived CO has been recognised as an important intracellular signalling molecule in the 
vascular system inducing numerous beneficial effects including cytoprotection, vasodilation and 
inhibition of inflammation and is likely to be attributable for the angiogenic properties of HO-1. 
Indeed, CO supplementation increased HO-1 expression but also augmented the synthesis of 
VEGF and SDF-1α and potentiated their synergistic effects on EC (Jozkowicz et al., 2003; Lin et 
al., 2009). In an animal model, CO exposure significantly enhanced VEGF synthesis in various 
organs (Marti and Risau, 1998). Moreover, genetic overexpression of HO-1 enhances VEGF 
synthesis in EC, and VEGF was also able to stimulate HO-1 expression. Such a positive feedback 
can be beneficial for angiogenesis (Dulak et al., 2002; Bussolati et al., 2004). HO-1 and CO are 
closely linked to the pro-angiogenic effects of SDF-1α. Treatment with CO enhanced re-
endothelialisation after vascular injury by increasing circulating SDF-1α in a mouse model 
(Deshane et al., 2007). Further, SDF-1α augmented capillary sprouting in EPC and aortic EC 
isolated from HO-1
+/+
 mice. This effect was markedly inhibited in cells from HO-1 knockout mice, 
but restored by CO exposure (Deshane et al., 2007).  
Effective delivery of CO to cells is challenging. The use of gaseous CO is risky and strongly 
limited by the high affinity of CO towards haemoglobin and the resulting systemic effects on 
oxygen transport and low bioavailability. Moreover, gaseous CO is difficult to delivery directly to 
living cells in an accurate, safe and measurable fashion (Johnson et al., 2003; Motterlini et al., 
2005). A promising strategy to circumvent these problems and to deliver controlled amounts of 
CO directly to a tissue is the use of the transition metal carbonyls CO-releasing molecules 
(CORMs). To date, numerous CORMs have been developed and are generally composed of a 
transition metal such as manganese, cobalt, ruthenium or iron, surrounded by a certain number of 
carbonyl (CO) groups as coordinated ligands, thereby storing CO in a stable chemical form. 
Dissociation of CO from the metal centre can be induced by UV activation, ligand substitution, pH, 
or metal oxidation, and is dependent on the relevant CORM (Motterlini et al., 2005). The 
tricarbonlydichlororuthenium II dimer ([Ru(CO)3Cl2]2), generally known as CORM-2, is a water 
soluble transition metal-carbonyl complex that liberates CO upon ligand exchange with DMSO, 
and has been shown to play a critical role in the resolution of inflammatory responses and 
alleviation of cardiovascular diseases (Motterlini et al., 2002; Motterlini et al., 2003). CORM-2 
caused vasodilation of pre-contracted rat aortic rings and attenuated coronary vasoconstriction in 
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hearts ex vivo, significantly reduced acute hypertension and diminished ischaemia/reperfusion 
induced injury in vivo. Moreover, blood platelet aggregation was partially inhibited by CORM-2 and 
macrophages pre-treated with CORM-2 displayed a significant reduction in NO production in 
response to LPS compared to control cells (Motterlini et al., 2002; Johnson et al., 2003). 
Moreover, CORMs have been shown to have anti-inflammatory and anti-apoptotic effects on 
vascular EC. They inhibit EC death via suppression of IL-18-mediated NFκB activation, TNF-α-
induced expression of VCAM-1 and E-selectin in HUVEC and high glucose-induced ICAM-1 
expression on EC (Tranter and Jones, 2008; Sun et al., 2007; Song et al., 2009; Bergstraesser et 
al., 2012; Nizamutdinova et al., 2009). Based on these observations, CORM-2 was used as a CO 
donor to study the role of CO in HO-1-driven angiogenesis. However, pre-treatment and 
subsequent culture of HO-1-deficient HUVEC with CORM-2 did not restore their impaired 
migratory phenotype in response to VEGF when compared to control cells (Fig. 6.2.). This may 
indicate that HO-1-driven migration of EC is not CO-dependent, or that there was insufficient CO 
delivery to the cells in culture over the course of the assay (16 h).  CO release from CORM-2 is 
very fast (t1/2 ≈ 1min) and non-specific (Motterlini et al., 2005), which may hamper the delivery of 
controlled amounts of CO to the target cells. Therefore, to further elucidate the role of CO in HO-
1-driven angiogenesis and to improve CO delivery in our system, a novel class of powerful 
CORMs, so called enzyme-triggered CORMs (ET-CORMs), were adopted. 
ET-CORMs are acylocyclohexadiene-iron tricarbonyl complexes which are stable under 
physiological conditions but are readily converted to the active form by means of enzymatic 
hydrolysis. Once taken up by the cell, ET-CORMs are activated by enzymatic cleavage of the 
ester functionality mediated by intracellular esterases resulting in the dissociative loss of CO. The 
esterase-triggered release of CO was confirmed by means of the carbonmonoxy myoglobin 
(MbCO) content (Romanski et al., 2011; Romanski et al., 2012). Herein, the cytotoxic effect of 
three different ET-CORMs, namely Sto074, Stro258 and SROM158, on primary human EC was 
determined. High doses (50-100 µM) significantly reduced cell viability with all three tested ET-
CORMs. Of note, the cytotoxic effect of SROM158 at high concentration was less pronounced 
than Stro074 and Stro258, and had no effect on cell viability when used at concentrations ranging 
from 12.5 µM to 25 µM (Fig. 6.3. and Fig. 6.4.). Moreover, SROM158 significantly suppressed 
TNF-α-induced surface expression of VCAM-1 on HUVEC (Fig. 6.5.), confirming its activity and 
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reproducing previously published reports demonstrating the inhibitory effect of CORMs on 
expression of inflammatory adhesion molecules in response to TNF-α (Sun et al., 2007; Song et 
al., 2009; Bergstraesser et al., 2012). Further, we can show that exposure to SROM158 
significantly enhanced HO-1 protein in HUVEC both in the absence and presence of VEGF, but 
no synergistic effect was observed (Fig. 6.6.). CO exposure, either administered as a gas or in the 
form of a CORM, induced proliferation of rat aortic EC and enhanced their migratory capacity 
(Wegiel et al., 2010). Moreover, CO has been shown to restore the impaired angiogenic 
responses of EC transduced with antisense HO-1 (Li Volti et al., 2005). However in our study, 
supplementation with the CO donor SROM158 was not sufficient to restore the impaired 
angiogenesis observed in HO-1-deficient cultures, in terms of VEGF-mediated endothelial 
proliferation and migration. In control cells, VEGF alone and in combination with SROM158 
significantly increased EC proliferation, however this effect was diminished by siRNA-mediated 
silencing of HO-1 and not rescued by SROM158 (Fig. 6.7.). Likewise, HO-1-deficient cells 
demonstrated reduced migration in response to VEGF, depicted as the Euclidean distance, and 
this defect in directional migration was not restored by SROM158 (Fig. 6.8.). These findings 
reproduce the observations obtained from CORM-2 studies, showing that even the more powerful 
CORM is not sufficient to reverse the impaired angiogenic phenotype of HO-1-deficient EC. 
Collectively, these data suggest that HO-1 induced angiogenesis and EC migration are dependent 
on HO-1 but are not mediated, at least solely, by the HO products CO or iron. The effect of 
biliverdin/bilirubin on HO-1-driven angiogenesis was not investigated during the course of this 
study, due to technical and time limitations. Of note, a role for the HO products in HO-1 driven 
angiogenesis cannot be completely excluded based on the data from this study, as the products 
may act in concert and may be dependent on each other. Indeed, a cooperative effect of CO and 
biliverdin has been demonstrated in a mouse model of inflammatory liver damage. While single 
administration of a CO donor or biliverdin had some beneficial effects on protection against liver 
damage in response to LPS, only co-administration of both HO products significantly prolonged 
survival of the animals and reduced expression of pro-inflammatory cytokines, including TNF-α 
and IFN-γ (Sass et al., 2004). 
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So far, only one potential downstream effector in HO-1 driven angiogenesis has been described. 
Deshane and colleagues demonstrated that SDF-1α-mediated phosphorylation of vasodilator-
stimulated phosphoprotein (VASP) is HO-1-dependent. Treatment of MAEC with the chemokine 
SDF-1α resulted in VASP phosphorylation at Ser239 in HO-1
+/+
 cells but not in EC from HO-1
-/-
 
mice. Importantly, treatment with CORM-2 was able to phosphorylate VASP in both HO-1
+/+
 and 
HO-1
-/-
 cells (Deshane et al., 2007). VASP, a member of the highly conserved Ena/VASP family of 
actin regulatory proteins, is a cytoskeletal-associated protein localised at cell-cell contacts and 
microfilaments (Krause et al., 2003). VASP has been implicated in actin-based processes such as 
fibroblast and neuronal migration and axon guidance (Bear et al., 2000; Goh et al., 2002; Lanier et 
al., 1999; Krause et al., 2003). In the endothelium, phospho-VASP is localised to cell junctions 
and can be co-immunoprecipated with the tight-junction marker zonula-occludens (ZO)-1 in EC 
(Comerford et al., 2002). Further, VASP has been shown to regulate stress-fibre and membrane 
ruffle formation in EC, thereby influencing endothelial migration and organisation during capillary 
formation (Price and Brindle, 2000). Moreover, the link between VASP and HO-1-driven 
angiogenesis is further strengthened by the finding that CORM-2 supplementation resulted in a 
considerable redistribution of VASP to the filopodia of equine EPCs (Deshane et al., 2007). 
Filopodia are highly dynamic structures generated within minutes after stimulation at the moving 
front of EC (Huber et al., 2003). They probe the environment for the presence of attractive 
guidance cues and initiate migration towards these (Defilippi et al., 1999). Redistribution of VASP 
to filopodia in response to CO suggests a role for VASP in HO-1-driven migration and led us to 
investigate the effect of VEGF on VASP phosphorylation in primary human EC and HO-1-deficient 
cells. In concordance with previous studies, we show VASP phosphorylation at Ser239 in 
response to the mitogen VEGF (Fig. 6.9.) (Fiedler et al., 2009; Chen et al., 2008). However, 
siRNA-mediated inhibition of HO-1 had no effect on VEGF-induced VASP phosphorylation in 
HUVEC (Fig. 6.10.). Further, VASP phosphorylation in response to VEGF was not altered in 
MAEC from HO-1
-/-
 mice when compared to HO-1
+/+
 littermate control cells (Fig. 6.11), suggesting 
that VEGF-mediated VASP phosphorylation is not dependent on HO-1. 
As no link between VEGF-mediated VASP phosphorylation and HO-1-driven angiogenesis could 
be observed, further studies to identify novel downstream effectors of HO-1 regulating this 
pathway are required. We performed a target PCR array and compared the gene expression 
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profiles of HO-1-depleted HUVEC with control cells in response to VEGF. To obtain optimal 
results from the PCR array, isolated total RNA was quality controlled for concentration and purity 
and ribosomal RNA band integrity. The samples showed RNA integrity numbers (RIN) above 7, 
with a RIN of 8.1 for control cells and a RIN of 10.0 for HO-1-depleted cells (Fig. 6.12.). RIN 
values are an algorithm for assessing integrity values to RNA measurements. RIN values range 
from 1 to 10, with 1 describing totally degraded RNA and 10 intact RNA (Schroeder et al., 2006). 
Quantitative RT-PCR revealed a sufficient reduction (~70%) in HO-1 mRNA expression in siHO-1 
pool transfected cells compared to control cells (Fig. 6.13.). Thus, collectively, the prepared 
samples met the standards required to achieve the best results with the PCR array.  
We chose an array which profiles genes involved in the regulation of the cytoskeleton such as 
those controlling the biogenesis, organisation and rearrangement, as well as polymerisation and 
depolymerisation of the cytoskeleton. Cytoskeletal rearrangement is required for endothelial 
migration, an early step in angiogenesis. Genes that were significantly upregulated (fold change ≥ 
2.0) included actin-related protein 2/3 complex, subunit 2 (ARPC2), citron (CIT), fascin homolog 2 
(FSCN2), and protein phosphatase 1, regulatory (inhibitor) subunit 12A (PPP1R12A) (Tab. 6.2.). 
FSCN2 and ARPC2 have been shown to be involved in actin filament assembly, with the latter 
also affecting migratory capacity of epithelial cells (Tubb et al., 2000; Welch et al., 1997; 
Machesky et al., 1997). PPP1R12A has been demonstrated to regulate the formation of cell 
protrusions, including lamellipodia, at the moving front of cells, and CIT regulates cell cycle 
progression during cell mitosis (Kimura et al., 1996; Bavaria et al., 2011; Liu et al., 2003). Among 
the identified hits, the positive cell cycle regulator cyclin A1 (CCNA1) was the only gene to be 
significantly downregulated by HO-1 inhibition (fold change ≤ 0.5) (Tab. 6.2.). Moreover the PCR 
array result was confirmed by qRT-PCR, demonstrating a significant reduction in basal as well as 
VEGF-induced CCNA1 mRNA expression in HO-1-depleted cells compared to the control (Fig. 
6.14.). Cyclin A1 belongs to the highly conserved cyclin family, whose members are characterised 
by a dramatic periodicity in protein abundance through the cell cycle. Cyclin A1 functions as a cell 
cycle regulator though binding to and activation of cyclin-dependent kinases (Cdks) and was 
shown to interact with numerous important cell cycle regulators, including Cdk2, retinoblastoma 
protein (Rb) family members, the transcription factor E2F-1, and the negative cell cycle regulators 
p21 and p27 (Obaya and Sedivy, 2002; Satyanarayana and Kaldis; 2009). HO-1 has been linked 
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to cell cycle progression. Indeed, HO-1 and CO induced cell cycle progression in EC, but not in 
vascular SMC (Li Volti et al., 2002; Liu et al., 2002). Further, HO-1 inhibition resulted in cell cycle 
arrest in EC, an effect associated with increased expression of the cell cycle inhibitors p21 and 
p27 (Li Volti et al., 2005). Moreover, Abraham and colleagues performed a microarray study of the 
genome of human dermal microvascular EC (HMEC-1) transduced with the human HO-1 gene. 
Major findings were upregulation of growth factors VEGF, endothelial growth factor (EGF), and 
hepatic-derived growth factor (HDGF). Importantly, several genes associated with cell cycle 
progression, including cyclin A1 (4-fold increase), cyclin E and D, were significantly upregulated in 
HO-1 overexpressing cells, whereas the expression of the Cdk inhibitors p21 and p27 was 
markedly reduced (Abraham et al., 2003). In addition, the observation that cell cycle regulators 
such as Cdk2, cyclin E and cyclin A are highly expressed in proliferating cells as well as the notion 
that cyclin A1 protein is upregulated after scraping injury to bovine aortic EC monolayers, which 
induces transient EC proliferation and migration (Chen et al., 2000), make cyclin A1 a promising 
candidate as a potential downstream target of HO-1, and may regulate HO-1-dependent 
angiogenesis. A more detailed investigation of a role for cyclin A1 in HO-1-mediated proliferation 
and migration will be discussed in Chapter 7. 
As a second approach to identify HO-1 downstream effectors in the regulation of angiogenesis, a 
proteomic screen was performed in collaboration with Prof M. Mayr (King’s College London). We 
compared the proteome of HO-1-deficient HUVEC with control cells in the presence of VEGF. In 
addition, a comparison of differentially expressed proteins between HO-1 overexpressing cells 
and control cells was performed. Difference in-gel electrophoresis (DIGE) coupled to mass 
spectroscopy revealed 90 differential expressed proteins (Tab. 6.3.), of which 29 were 
differentially expressed between HUVEC transfected with a non-targeting control siRNA (siCTL) 
and HO-1-deficient HUVEC treated with VEGF for 16 h (Tab. 6.4.). Gene ontology analysis further 
revealed the intermediate filament vimentin as an interesting hit with regard to the impaired 
angiogenic capacities of HO-1-deficient EC observed in this study. Vimentin belongs to the protein 
family of intermediate filaments (IFs) and detailed studies of vimentin knockout mice revealed a 
role for vimentin in wound healing, cell migration, vasodilation and homing of leukocytes to lymph 
nodes (Eckes et al., 2000; Eckes et al., 1998; Henrion et al., 1997; Nieminen et al., 2006). 
Further, vimentin
-/-
 animals are characterised by a lack of integrity in vascular endothelium 
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(Nieminen et al., 2006). Interestingly, HO-1-deficient mice also demonstrate impaired 
neovascularisation during wound healing and HO-1-deficient EPC show defective homing and re-
endothelisation of the retinal vasculature compared with wild-type cells following ischaemia 
(Deshane et al., 2007; Grochot-Prezecezek et al., 2009). Vimentin has been also shown to 
participate in a number of important cellular functions such as cell adhesion and migration, as well 
as cell signalling, and more recently angiogenic sprouting (Ivaska et al., 2007; Kwak et al., 2012). 
In Chapter 5, I have demonstrated an impaired angiogenic phenotype of EC depleted of HO-1 in 
terms of their proliferative and migratory capacities as well as in vitro assembly into capillary-like 
structures on 2D Matrigel. The emerging role of vimentin in angiogenesis combined with the 
defective angiogenic responses of HO-1-deficient EC make vimentin a promising candidate as a 
downstream effector of HO-1. This hypothesis is further strengthend by the similiarites between 
vimentin
-/-
 and HO-1
-/-
 animals. Alltoghter, due to its role in cell migration and angiogenesis, as 
well as the similar characteristics between vimentin and HO-1 deficiency, vimentin is of particular 
interest to our study and Chapter 8 will focus on the role of vimentin in HO-1-driven angiogenesis. 
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CHAPTER 7 -  ROLE FOR HO-1 AND CYCLIN A1 IN CELL CYCLE REGULATION AND VEGF-
MEDIATED ANGIOGENESIS 
7.1. INTRODUCTION  
The mammalian cell cycle is a precisely regulated process driven by the coordinated regulation of 
activities of the cyclin-dependent kinases (Cdks), a family of serine/threonine kinases, and 
expression of their binding partners, the cyclins (Morgan, 1997; Satyanarayana and Kaldis, 2009) 
(please see section 1.2.1). The observation that cyclin A1, a positive cell cycle regulator, was 
significantly reduced in proliferating HO-1-deficient EC led us to investigate the potential function 
of HO-1 in cell cycle progression. 
Recent reports postulated a role for the cytoprotective enzyme HO-1 in cell cycle regulation. 
Indeed, EC transfected with the human HO-1 gene demonstrate a significant increase in the 
percentage of cells in G1-phase when compared to control cells (Kushida et al., 2002a). 
Moreover, retroviral overexpression of HO-1 protects human microvessel cells from pyrrolidine 
dithiocarbamate (PDTC)-induced abnormalities in DNA distribution and cell cycle progression, 
whereas inhibition of HO-1 activity results in increased PDTC-mediated abnormalities in cell cycle 
progression (Kushida et al., 2002b). Colombrita and colleagues further demonstrated that HO-1 
expression is cell cycle dependent. Human endothelial cells in G0/G1-phase show a several fold 
higher increase in HO-1 mRNA in response to angiotensin (Ang) II when compared to cycling, 
exponentially grown cells, which might be a protective mechanism against oxidative stress to 
assure normal cell proliferation and decreased DNA damage (Colombrita et al., 2003). Moreover, 
decreased HO-1 activity is associated with endothelial cell cycle arrest, an effect restored by CO 
but not bilirubin (Li Volti et al., 2005). The abnormalities in cell cycle progression in HO-1-deficient 
cells are accompanied by increased expression of the cell cycle inhibitors p21 and p27 (Li Volti et 
al., 2005). Of note, the effect of HO-1 on cell cycle progression appears to be cell type specific. 
While HO-1 deficiency arrests EC in cell cycle progression, the opposite effect is observed in 
SMC (Li Volti et al., 2002). Furthermore, CO negatively regulates the expression of the cell cycle-
specific transcription factor E2F-1 in vascular SMC, thereby suppressing the expression of genes 
required for cell cycle progression (Morita et al., 1997). In an elegant microarray study by 
Abraham and colleagues several cell cycle regulating genes were shown to be differentially 
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expressed between HO-1 overexpressing and control EC. The positive cell cycle regulators cyclin 
D, cyclin E and cyclin A were found to be significantly upregulated in human EC overexpressing 
HO-1, whereas expression of p21 and p27 was downregulated (Abraham et al., 2003). In 
addition, cell cycle regulation is also closely related to cell migration. Indeed, Chen and 
colleagues demonstrated increased Cdk2 activity in proliferating and migrating bovine aortic EC 
(BAEC), an effect accompanied by increased cyclin A but decreased p27 expression (Chen et al., 
2000). 
The aim of this chapter was to further elucidate the role of HO-1 in the regulation of endothelial 
cell cycle progression and to investigate the role for cyclin A1 as a potential downstream target of 
HO-1 in the regulation of angiogenesis.   
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7.2. RESULTS 
7.2.1. HO-1 inhibition arrests EC in cell cycle progression 
The propidium iodide (PI) staining flow cytometric assay, which has been widely used to analyse 
cell cycle parameters of mammalian cells, was here adopted to assess changes in cell cycle 
progression of HO-1-deficient cells in response to VEGF. 
HUVEC, either transfected with a non-targeting control siRNA (siCTL) or siRNA targeting the 
human HO-1 gene (siHO-1 seq2 and siHO-1 pool) were left untreated or treated with VEGF for 48 
h prior to PI staining and subsequent flow cytometric analysis. In response to VEGF, siCTL-
transfected cells progressed from G0/G1-phase to the S-phase of the cell cycle as indicated by an 
increase in DNA content (12.75 ± 0.54% for untreated siCTL vs 15.75 ± 0.81% VEGF-treated 
siCTL). This response was significantly diminished by siRNA-mediated HO-1 inhibition, both in 
the absence and presence of VEGF, resulting in 7.95 ± 0.43% and 11.27 ± 0.62% DNA 
distribution (Fig. 7.1.). 
Figure 7. 1.: HO-1-deficient EC are arrested in cell cycle progression from G1- to S-phase. 
siCTL-transfected or siHO-1-transfected HUVEC were left untreated or treated with 25 ng/ml 
VEGF for 48 h prior to propidium iodide staining and FACs analysis. Data represents pooled data 
from siHO-1 seq2 and siHO-1 pool and is presented as mean ± SEM (n=3 experiments), * p<0.05 
vs siCTL, δ p<0.05 vs siCTL + VEGF. 
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Due to cellular stress and other stimuli, cells can permanently lose their ability to proliferate, a 
process termed cellular senescence (Debacq-Chainiaux et al., 2009). To investigate whether the 
arrest in cell cycle progression of HO-1-depleted cells resulted from premature senescence, 
siCTL-transfected and siHO-1-transfected HUVEC in the absence and presence of VEGF were 
stained for senescence-associated beta-galactosidase (SA-β-gal) activity, which permits the 
identification of senescent cells in culture (Debacq-Chainiaux et al., 2009). 
Prolonged culture of HUVEC, for 12 passages, resulted in a marked increase in the number of 
SA-β-gal positive cells in the absence and presence of VEGF when compared to control cells 
(cultured for 4 passages) and was used as a positive control for senescence (Fig. 7.2.). VEGF 
exposure resulted in a minor but non-significant increase in SA-β-gal activity in both siCTL-
transfected cells and HO-1-deficient EC. Moreover, siRNA-mediated silencing of HO-1 had no 
effect on senescence, either in the absence or presence of VEGF when compared to matched 
control cells (Fig. 7.2.), suggesting that the observed cell cycle arrest of HO-1-depleted cells does 
not result from premature senescence of those cultures.  
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Figure 7. 2.: HO-1 inhibition does not result in premature senescence in HUVEC. HUVEC 
either transfected with 40 nM control siRNA (siCTL) or HO-1 specific siRNA (siHO-1 seq2 or 
siHO-1 pool) were left untreated or treated with 25 ng/ml VEGF for 48 h. Senescent cells were 
identified by SA-β-gal staining and phase-contrast microscopy. HUVEC cultured for 12 passages 
were used as a positive control for senescence. (A) Pictures are representative images from n=3 
experiments, 10X magnification. Bars equal 50 µM. (B) Quantification of SA-β-gal positive cells. 
Data is presented as mean ± SEM (n=3 experiments), ns – not significant. 
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7.2.2. HO-1 inhibition alters the expression profile of cell cycle regulators in proliferating EC 
As basal and VEGF-induced cyclin A1 mRNA expression was significantly decreased in HO-1-
deficient cells, as determined by the target PCR and subsequent validation of the results (Tab. 
6.2. and Fig. 6.14.), and HO-1 depletion arrested EC in cell cycle progression (Fig. 7.1.), we 
investigated the effect of HO-1 inhibition on the expression levels of other cell cycle regulators in 
proliferating EC.  
Initially, knockdown efficiency of HO-1 specific siRNA in proliferating HUVEC was validated and 
revealed a sufficient reduction in HO-1 mRNA of 75%, both in the absence and presence of 
VEGF when compared to control siRNA-transfected cells (Fig. 7.3.). 
 
 
 
 
 
 
 
 
Figure 7. 3.: Knockdown efficiency of HO-1 specific siRNA in proliferating EC. HUVEC were 
either treated with geneFECTOR (GF) alone or transfected with 40 nM control siRNA (CTL) or 
HO-1 specific siRNA (HO-1; data represents pooled data from seq2 and pool) for 16 h. Cells were 
then left untreated or treated with 25 ng/ml VEGF for 24 h prior to mRNA quantification by qRT-
PCR. Data is presented as mean ± SEM (n=3 experiments), ** p<0.01, *** p<0.001. δ p<0.05 vs 
untreated siCTL-transfected cells. 
VEGF exposure significantly increased cyclin mRNA expression of all four tested cyclins, i.e. 
cyclin D1, cyclin E1, cyclin A1, and cyclin B1, in siCTL-transfected cells (Fig. 7.4.). Moreover, 
VEGF treatment markedly upregulated the expression of cyclin B1 and cyclin D1 in HO-1-
deficient cells (Fig. 7.4.A and D). However, basal as well as VEGF-induced mRNA expression of 
cyclin E1 and A1 was significantly reduced by HO-1 inhibition in proliferating HUVEC compared to 
siCTL-transfected cells (Fig. 7.4.B and C).  
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Figure 7. 4.: Effect of HO-1 inhibition on cyclin mRNA expression in proliferating EC. 
HUVEC were either treated with geneFECTOR (GF) alone or transfected with 40 nM control 
siRNA (CTL) or HO-1 specific siRNA (HO-1; data represents pooled data from seq2 and pool) for 
16 h. Cells were then left untreated or treated with 25 ng/ml VEGF for 24 h prior to mRNA 
quantification by qRT-PCR. (A) cyclin D1, (B) cyclin E1, (C) cyclin A1, (D) cyclin B1. Data is 
presented as mean ± SEM (n=3-5 experiments), * p<0.05, *** p<0.001. δ p<0.05, δδ p<0.01 vs 
untreated siCTL-transfected cells. ns – not significant. 
 
Cyclin E1 regulates the transition of cells from G0/G1-phase into the S-phase of the cell cycle, 
while cyclin A1 promotes progression through the S-phase and into G2-phase. Both cyclins form 
complexes with and regulate the activity of Cdk2, while cyclin D1 and B1 regulate Cdk4/6 and 
Cdk1 activity respectively (Obaya and Sedivy, 2002; Satyanarayana and Kaldis, 2009). 
Quantitative RT-PCR demonstrated a 2-fold increase in Cdk2 mRNA in response to VEGF in 
control cells, while the results for Cdk1 were more variable between cords, and no significant 
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difference could be observed (Fig. 7.5.). In addition, basal as well as VEGF-induced Cdk1 mRNA 
was not altered by HO-1 siRNA (Fig. 7.5.A). However, HO-1 inhibition abrogated the VEGF-
induced increase in Cdk2 mRNA, but had no effect on basal Cdk2 (Fig. 7.5.B). 
The CKIs p21 and p27 of the CIP/KIP family inhibit activity of Cdk2 when in complex with either 
cyclin E1 or cyclin A1, but also regulate the activity of other Cdks (Sherr and Roberts, 1995; 
Obaya and Sedivy, 2002). VEGF exposure had no effect on p21 and p27 mRNA expression in 
control cells, and HO-1 inhibition did not affect p21 expression either in untreated or VEGF-
treated HUVEC (Fig. 7.6.A). In contrast, expression of p27 was slightly but significantly 
upregulated by HO-1 inhibition in the absence and the presence of VEGF (Fig. 7.6.B). 
In summary, HO-1 depletion alters the mRNA expression profile of cell cycle regulators resulting 
in a reduced expression of the positive regulators cyclin E1 and cyclin A1, and their binding 
partner Cdk2, but increasing mRNA levels of p27, an inhibitor of cyclin E1/Cdk2 and cyclin 
A1/Cdk2 complexes. 
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Figure 7. 5.: Effect of HO-1 inhibition on Cdk mRNA expression in proliferating EC. HUVEC 
were either treated with geneFECTOR (GF) alone or transfected with 40 nM control siRNA (CTL) 
or HO-1 specific siRNA (HO-1; data represents pooled data from seq2 and pool) for 16 h. Cells 
were then left untreated or treated with 25 ng/ml VEGF for 24 h prior to mRNA quantification by 
qRT-PCR. (A) Cdk1, (B) Cdk2. Data is presented as mean ± SEM (n=3-5 experiments), * p<0.05, 
*** p<0.001. ns – not significant. 
 
 
Figure 7. 6.: Effect of HO-1 inhibition on p21 and p27 mRNA expression in proliferating EC. 
HUVEC were either treated with geneFECTOR (GF) alone or transfected with 40 nM control 
siRNA (CTL) or HO-1 specific siRNA (HO-1; data represents pooled data from seq2 and pool) for 
16 h. Cells were then left untreated or treated with 25 ng/ml VEGF for 24 h prior to mRNA 
quantification by qRT-PCR. (A) p21, (B) p27. Data is presented as mean ± SEM (n=5 
experiments), * p<0.05. ns - not significant. 
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7.2.3. Migrating HO-1
-/-
 EC show decreased cyclin A1 and reduced Cdk2 activity 
Chen and colleagues demonstrated increased Cdk2 activity in proliferating and migrating bovine 
aortic EC in response to scratch-induced injury. Moreover, this effect coincided with a maximal 
increase in cyclin A and a maximal decrease in p27 protein, after 4 to 8 h after scratching (Chen 
et al., 2000). Based on these findings, and my observation that proliferating HO-1-deficient EC 
show an altered cell cycle regulator expression profile, we investigated the effect of HO-1 
inhibition on Cdk2 activity and cyclin A expression in migrating EC. 
HO-1 inhibition significantly inhibited the VEGF-induced increase in Euclidean distance of 
migrating EC when compared to control cells (Fig. 7.7.A and Fig. 5.15.). Western blotting 
revealed a sufficient knockdown of HO-1 protein by siRNA both in the absence and presence of 
VEGF. Interestingly, cyclin A expression was also significantly reduced in HO-1-depleted 
migrating HUVEC (Fig. 7.7.B). 
Cdk2 activity was assessed by phosphorylation of retinoblastoma protein (pRb) at threonine 821 
(Thr821). pRb is a negative regulator of the cell cycle and its active non-phosphorylated form 
binds the transcription factor E2F-1 thereby rendering it inactive and inhibiting the transcription of 
genes necessary for cell cycle progression. Phosphorylation of pRb by active cyclin/Cdk 
complexes results in its inactivation, the release of E2F-1, transcription of cell cycle regulatory 
genes, such as cyclin E and cyclin A, and in turn cell cycle progression (Weinberg, 1995; Dyson, 
1998). Phosphorylation of pRb at Thr821 is mediated by active cyclin E/Cdk2 and cyclin A/Cdk2 
complexes and is thereby a measure of Cdk2 activity (Zarkowska and Mittnacht, 1997). Protein 
analysis of lysates from migrating HUVEC showed an increase in phospho-pRb in response to 16 
h VEGF treatment in siCTL-transfected cells, indicating active Cdk2. However, this effect was 
significantly attenuated by siRNA-mediated silencing of HO-1, demonstrating reduced Cdk2 
activity in migrating HO-1-deficient EC (Fig. 7.8.). Collectively, these findings demonstrate a link 
between cell cycle regulation and HO-1-driven endothelial migration.  
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Figure 7. 7.: Migrating HO-1-deficient EC show reduced cyclin A1 protein. HUVEC were 
either transfected with 40 nM 3’-AlexaFluor488-labelled control siRNA (CTLAF488) or HO-1 specific 
siRNA (seq2AF488) for 24 h. Confluent cell monolayers were scratched and migration was 
assessed by live cell imaging in the absence or presence of VEGF (25 ng/ml) for 16 h and 
quantified using ImageJ analysis software (Manual Tracking and Chemotaxis and Migration tool). 
(A) Represents the Euclidean distance. Data is presented as mean ± SD (n=3 experiments), ** 
p<0.01, p<0.001. (B, C, D) HO-1 and cyclin A1 protein levels were quantified by western blotting 
and quantified by densitometry. GAPDH was used as a loading control. (B) Representative blots 
from n=3 experiments are shown, (C, D) shows the corresponding densitometry for (C) HO-1 and 
(D) cyclin A1. Data is presented as mean ± SEM (n=3 experiments), * p<0.05, ** p<0.01; *** 
p<0.001. 
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Figure 7. 8.: Cdk2 activity is significantly reduced in migrating HO-1-deficient HUVEC. 
HUVEC were either transfected with 40 nM 3’-AlexaFluor488-labelled control siRNA (CTLAF488) or 
HO-1 specific siRNA (seq2AF488) for 24 h. Confluent cell monolayers were scratched and migration 
was assessed by live cell imaging in the absence or presence of VEGF (25 ng/ml) for 16 h. Cdk2 
was assessed by phosphorylation of retinoblastoma protein (pRb) and is expressed as phospho-
pRb (pT821) relative to total pRb. GAPDH was used as a loading control. (A) Representative 
blots from n=3 experiments are shown, (B) shows the corresponding densitometry. Data is 
presented as mean ± SEM (n=3 experiments), * p<0.05, *** p<0.001. 
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7.2.4. HO-1 and cyclin A1 regulate VEGF-driven angiogenesis in vivo 
The in vivo Matrigel plug assay was used to further elucidate the role of HO-1 in angiogenesis 
and to investigate the function of the positive cell cycle regulator cyclin A1, a potential 
downstream target of HO-1, in HO-1-driven angiogenesis.  
In gene-silencing studies, non-targeting control siRNA (siCTL) or murine specific siRNA targeting 
the mouse HO-1 (murine siHO-1 pool) or mouse cyclin A1 (murine siCycA1 pool) gene were co-
injected with Matrigel supplemented with VEGF and heparin near the abdominal midline of female  
C57BL/6 mice. Knockdown efficiency of murine specific siRNA was validated in murine aortic EC 
isolated from HO-1
+/+
 animals by western blotting and/or qRT-PCR prior to the use of siRNA in 
Matrigel plugs in vivo. HO-1 protein and mRNA expression was markedly reduced by siHO-1 pool 
when compared to siCTL-transfected cells, whereas siCycA1 pool had no effect on HO-1 
expression. Moreover, neither of the siRNAs altered the expression of HO-2 (Fig. 7.9.A and B). 
siCycA1 pool decreased cyclin A1 mRNA by 75% in MAEC, but had no effect on the expression 
of cyclin A2 isoform. Interestingly, siHO-1 pool also notably reduced cyclin A1 but not cyclin A2 
mRNA when compared to control cells (Fig. 7.9.C and D), suggesting a potential function for HO-
1 in the regulation of cyclin A1 mRNA expression. 
After 7 days, Matrigel plugs were carefully harvested from CO2-euthanised mice, fixed in 4% 
paraformaldehyde, paraffin embedded, and processed for staining. H&E staining showed that 
VEGF-supplementation of Matrigel plugs containing siCTL resulted in a significant increase in 
their vascularisation in the Matrigel plugs when compared to plugs without VEGF (Fig. 7.10.A and 
B). This was also demonstrated by a significant increase in the percentage area occupied by 
neovessels per field of view (Fig. 7.11.). Although reduced, there was still a significant effect on 
VEGF-induced neovessel formation in plugs containing siHO-1 pool (Fig. 7.11.). Of note, this 
response was quite variable between plugs from different animals with some plugs being highly 
vascularised and others showing a marked inhibition in VEGF-mediated vessel formation (Fig. 
7.10.C and D). Interestingly, siRNA-mediated inhibition of cyclin A1 significantly attenuated vessel 
formation in response to VEGF (Fig. 7.10.E and F), indicative for a role of cyclin A1 in 
angiogenesis in vivo. 
Chapter 7 
242 
 
Figure 7. 9.: Validation of murine siRNA in mouse aortic EC. Mouse aortic EC isolated from 
HO-1
+/+
 littermate control mice were either treated with geneFECTOR (GF) alone or transfected 
with 40 nM control siRNA (CTL), murine cyclin A1 specific siRNA (CycA1), or murine HO-1 
specific siRNA (HO-1) and cultured for 48 h. (A) Protein expression was assessed by western 
blotting, (B, C, D) mRNA expression was assessed by qRT-PCR. (B) HO-1, (C) cyclin A1, (D) 
cyclin A2 (n=1 experiment). 
 
To further elucidate the role of cyclin A1 in angiogenesis and to investigate whether inhibition of 
VEGF-induced vascularisation of Matrigel plugs containing siRNA targeting the cyclin A1 gene is 
reversed by HO-1, we adopted an adenoviral overexpression approach in combination with the 
Matrigel plug assay. H&E staining showed that overexpression of HO-1 significantly increased (> 
2-fold) vascularisation of Matrigel plugs when compared to plugs supplemented with an empty 
control adenovirus (Ad0), an effect also seen in siCTL-containing plugs (Fig. 7.12.A, B, C and E). 
Importantly, a similar response was observed in HO-1 overexpressing plugs in which cyclin A1 
expression was inhibited by siRNA, resulting in a 2-fold increase in vascularisation (Fig. 7.12. D 
and E). Taken together, these results suggest that HO-1 and cyclin A1 regulate VEGF-induced 
angiogenesis in vivo, where cyclin A1 deficiency results in reduced VEGF-mediated vessel 
formation, an effect restored by HO-1.  
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Figure 7. 10.: Silencing of HO-1 and cyclin A1 impairs angiogenesis in vivo. Female 
C57BL/6 mice (10 weeks old) were injected with Matrigel preparations containing (A) a vehicle 
control, (B) 40 ng/ml VEGF in combination with 2 µM control siRNA (CTL), (C, D) VEGF in 
combination with murine siRNA against the HO-1 gene (HO-1), (E, F) VEGF in combination with 
murine siRNA against the CycA1 gene (CycA1). (A, B, C, E) 10X magnification, (D, F) 20X 
magnification, bars equal 50 µm. Representative images are shown (n=3 mice per treatment). 
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Figure 7. 11.: Quantification of vascularised areas relative to the total area. Female C57BL/6 
mice (10 weeks old) were injected with Matrigel preparations containing a vehicle control, 40 
ng/ml VEGF in combination with 2 µM control siRNA (CTL), VEGF in combination with murine 
siRNA against the HO-1 gene (HO-1), or VEGF in combination with murine siRNA against the 
CycA1 gene (CycA1). Vessels were counted in 5 fields of views. Data is presented as mean ± 
SEM (n=3 mice per treatment), * p<0.05, *** p<0.001. 
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Figure 7. 12.: Overexpression of heme oxygenase-1 rescues cyclin A1-impaired 
angiogenesis in vivo. Female C57BL/6 mice (10 weeks old) were injected with Matrigel 
preparations containing (A) an empty control adenovirus (Ad0), (B) the recombinant adenovirus 
expressing the HO-1 gene (AdHO-1), (C) AdHO-1 in combination with 2 µM control siRNA (CTL), 
(D) AdHO-1 in combination with murine siRNA against the CycA1 gene (CycA1). (E) 
Quantification of vascularised areas relative to the total area. Vessels were counted in 5 fields of 
views. Representative images are shown, 20X magnification, bars equal 50 µm. Data is 
presented as mean ± SEM (n=3 mice per treatment), ** p<0.01. ns – not significant. 
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7.2.5. HO-1 and cyclin A1 mRNA stability 
Based on the observation that siRNA-mediated inhibition of HO-1 results in decreased expression 
of cyclin A1 mRNA in proliferating and migrating human primary EC (Tab. 6.2., Fig. 6.14., Fig. 
7.4.C. and Fig. 7.7.B) and also in mouse aortic EC (Fig. 7.9.C), we investigated a potential role for 
HO-1 in the transcriptional regulation of cyclin A1. 
We performed an actinomycin D time course experiment to determine whether HO-1 inhibition 
affects cyclin A1 mRNA stability in migrating EC. HUVEC monolayers treated with either the 
siRNA-delivery agent geneFECTOR (GF) alone or transfected with a non-targeting control siRNA 
(siCTL) or siRNA targeting the human HO-1 gene (siHO-1 pool), were scratched and then left 
untreated or treated with VEGF for 16 h prior to subsequent treatment with actinomycin D. 
Quantitative RT-PCR showed no difference in mRNA stability between GF-treated and siCTL-
transfected EC in response to VEGF when compared to untreated control cells (Fig. 7.13.). 
However, a significant decrease in total mRNA of cyclin A1 in HO-1-depleted cells treated with 
VEGF was observed after 2 h and 4 h exposure to actinomycin D when compared to siCTL-
transfected cells (Fig. 7.13.A). This effect was reflected in a 30% decrease in mRNA half-life as 
determined by curve fitting depicting the one-phase exponential decay (Fig. 7.13.B). These 
preliminary results suggest that the observed downregulation of cyclin A1 mRNA in HO-1-
deficient cells may result from a decrease in mRNA stability and might be indicative for a potential 
function of HO-1 in the transcriptional regulation of gene expression. 
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Figure 7. 13.: HO-1 inhibition decreases cyclin A1 mRNA stability. Confluent HUVEC 
monolayers either treated with geneFECTOR (GF) alone or transfected with 40 nM control siRNA 
(CTL) or HO-1 specific siRNA (pool) were scratched and left untreated or treated with VEGF for 
16 h. (A) mRNA stability was assessed by 5 µg/ml actinomycin D treatment for the indicated time 
points and cyclin A1 mRNA levels were quantified by qRT-PCR. (B) Corresponding one-phase 
exponential decay curves showing cyclin mRNA half-lives were fitted using the TableCurve 2D 
analysis software (Systat Software GmbH, Erkrath, Germany). Data is presented as mean ± SEM 
(n=4 experiments), * p<0.05. 
 
 
  
Chapter 7 
248 
 
7.3. DISCUSSION 
The mammalian cell cycle is a complex, highly regulated process driven by distinct, cell cycle 
phase-specific cyclin-dependent kinases (Cdks) and the sequential expression of their regulatory 
units, the cyclins (Morgan, 1997; Satyanarayana and Kaldis, 2009). Activity of Cdks is further 
controlled by phosphorylation and binding to inhibitory proteins, cyclin-dependent kinase inhibitor 
(CKIs) (Sherr and Robert, 1999). Herein, we show a relationship between the cytoprotective 
enzyme HO-1 and the cell cycle regulator cyclin A1. 
We performed a targeted PCR array comparing the differential expression of genes regulating 
cytoskeletal functions between human primary EC and HO-1-deficient EC in response to the 
mitogen VEGF and demonstrated a significant downregulation in cyclin A1 mRNA following HO-1 
depletion (Tab. 6.2.). We further showed that HO-1 deficiency results in decreased basal as well 
as VEGF-induced expression of cyclin A1 in proliferating HUVEC (Fig. 6.14.). Based on these 
findings we hypothesized a regulatory role for HO-1 in the mammalian cell cycle. Indeed, cell 
cycle analysis by propidium iodide staining revealed that HO-1 deficiency inhibits in EC cell cycle 
progression. The EC demonstrated significant abnormalities in their DNA distribution. HO-1 
depletion resulted in an increased number of cells in the G0/G1-phase, with a subsequent 
significant decrease of cells in S-phase, an effect observed for both untreated and VEGF-treated 
HO-1-depleted EC (Fig. 7.1.). These results suggest that HO-1 deficiency inhibits endothelial cell 
cycle progression from G1- to S-phase and moreover are in agreement with earlier studies by Li 
Volti and colleagues demonstrating impaired cell cycle progression of human microvascular cells 
in response to the HO inhibitor SnPP or transduced with anti-sense HO-1 (Li Volti et al., 2002; Li 
Volti et al., 2005). 
To elucidate the mechanisms underlying the impaired cell cycle progression resulting from HO-1-
deficiency, cells were stained for senescence-associated beta-galactosidase (SA-β-gal) activity, 
permitting the identification of senescent cells in culture (Debacq-Chainiaux et al., 2009). 
Prolonged culture of cells eventually results in their inability to proliferate, a process known as 
cellular senescence (Debacq-Chainiaux et al., 2009). Senescence is a stress and damage 
response phenomenon that locks up mitotically competent diploid cells in a permanent growth 
arrest. Senescence is associated with progressive shortening of telomeres, the physical ends of 
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chromosomes, comprising their functional integrity eventually leading to the induction of a DNA 
damage checkpoint response that halts the cell cycle permanently (Greider, 1998; Shay and 
Wright, 2000; d’Adda di Fagagna et al., 2003). Senescent cells differ in their morphology from 
normal diploid EC, their volume increases and they lose their original shape, acquiring a flattened 
and enlarged appearance (Ben-Porath and Weinberg, 2004). At the molecular level, senescent 
cells undergo distinct changes in gene expression that may cause impairment of cellular function, 
resulting in a pro-inflammatory and pro-thrombotic phenotype in EC (Erusalimsky, 2008). The 
main signalling pathways involved are the p53/p21 and p16/retinoblastoma protein tumour 
suppressor pathway (Campisi and d’Adda di Fagagna, 2007). Herein, we show that HO-1 
deficiency does not result in an increase in SA-β-gal positive cells as seen with EC cultured over 
a prolonged period (Fig. 7.2.), suggesting that the observed cell cycle arrest and proliferative 
defects of HO-1-deficient EC do not result from premature senescence. A small but non-
significant increase in SA-β-gal activity was observed in all tested cultures in response to VEGF 
(Fig. 7.2.). Of note, presence of VEGF resulted in more confluent cell monolayers and this may 
induce senescence in cells in culture (Debacq-Chainiaux et al., 2009).  
To further investigate the underlying mechanisms regulating cell cycle arrest in response to HO-1 
inhibition in EC, we compared the expression profile of numerous cell cycle regulators of HO-1-
depleted cells with control cells. VEGF supplementation increased mRNA levels of all tested 
cyclins, i.e. cyclin D1, cyclin E1, cyclin A1 and cyclin B1, in proliferating control cells (Fig. 7.4.). 
Interestingly, while expression of cyclin D1 and cyclinB1 was not affected by siRNA-mediated 
silencing of HO-1, basal as well as VEGF-induced mRNA levels of cyclin E1 and cyclin A1 were 
significantly downregulated (Fig. 7.4.). Moreover, VEGF-induced Cdk2 was significantly 
diminished in HO-1-depleted EC, whereas expression of the cell cycle inhibitor p27 was 
upregulated both in untreated and VEGF-treated HO-1-deficient EC when compared to control 
cells (Fig. 7.5.B and Fig. 7.6.B). Expression of Cdk1 and p21 was not affected by HO-1 inhibition 
(Fig. 7.5.A and Fig. 7.6.A). This finding further strengthened the results obtained from the SA-β-
gal studies demonstrating that HO-1 inhibition does not induce premature senescence in EC. 
Expression of the cell cycle inhibitor p21 is also linked to senescence. p21 is induced directly by 
p53 in response to DNA damage, and is also upregulated during replicative senescence (El-Deiry 
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et al., 1994; Dulic et al., 1994; Noda et al., 1994; Stein et al., 1999; Campisi and d’Agga di 
Fagagna, 2007). 
Transcription of both cyclin E1 and cyclin A1 is controlled by the cell cycle transcription factor 
E2F-1, which is released from retinoblastoma protein (pRb) upon phosphorylation by active cyclin 
D/Cdk4/6 complexes (Sherr and Roberts, 1999). The E-type cyclins, cyclin E1 and cyclin E2, are 
expressed in mid to late G1-phase and bind to and activate Cdk2. CyclinE/Cdk2 activity is 
required for S-phase entry and the initiation of DNA replication and further phosphorylates pRb 
(Dulic et al., 1992; Koff et al., 1992; Zarkowska and Mittnacht, 1997; Lundberg and Weinberg, 
1998). This hyperphosphorylation of pRb is required for its complete inactivation and in turn leads 
to further E2F-1-mediated transcription (Lundberg and Weinberg, 1998; Stayanarayana and 
Kaldis, 2009). Cyclin A1 together with cyclin A2 belongs to the A-type cyclins and they are 
expressed from late G1- until M-phase of the cell cycle (Lundberg and Weinberg, 1998; Sherr and 
Roberts, 1999). Cyclin A binds to and activates Cdk2 and, to a lesser extent Cdk1. The activity of 
cyclin A/Cdk2 is required for S-phase transition and control of DNA replication (Elledge et al., 
1992; Cardoso et al., 1993), and cyclin A/Cdk1 activity is required for the initiation of prophase 
during mitosis (Furuno et al., 1999). 
Cyclin E/Cdk2 and cyclin A/Cdk2 activities are inhibited by p27. p27 belongs to CIP/KIP family of 
cyclin-dependent kinase inhibitors (CKIs) and negatively regulates progression through the cell 
cycle. p27 levels are generally low in cells transitioning through G1, due to reduced gene 
transcription as well as increased protein turnover (Mateyak et al., 1999; Hengst and Reed, 
1996). However, forced expression of p27 results in a G1 cell cycle arrest of cells through its 
association with cyclin D/Cdk4/6, cyclin E/Cdk2 or cyclin A/Cdk2 complexes (Polyak et al., 1994; 
Toyoshima and Hunter, 1994), suggesting the halt in cell cycle progression observed in HO-1-
deficient cells results from a decrease in Cdk2 activity due to reduced expression of the positive 
regulators cyclin E1 and cyclin A1 and increased levels of p27. The increase in p27 may also 
reflect a decrease in Cdk2 activity, as p27 expression is regulated by Cdk2. In late G1 and early 
S-phase, active cyclin E/Cdk2 and cyclin A/Cdk2 complexes phosphorylate p27 at threonine 187 
(Thr187), which targets p27 for degradation via ubiquitination (Nakayama and Nakayama, 2006). 
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CIP/KIP members were almost solely viewed as nuclear proteins with a principal function as cell 
cycle inhibitors. However, emerging evidence indicates a role for cytoplasmic p27 in the 
regulation of actin dynamics and cell migration. Delivery of p27 into hepatocellular carcinoma cell, 
induced cell migration, whereas p27-deficient fibroblasts were impaired in cell motility, an effect 
rescued by reconstitution of p27. Moreover, p27-mediated cell migration was dependent on 
phosphorylation of cytoplasmic p27 at Ser10 (Nagahara et al., 1998; McAllister et al., 2003). In a 
subsequent study, Besson and colleagues demonstrated that p27-deficient fibroblasts displayed 
an increased amount of stress fibres and focal adhesions, which failed to rearrange into 
membrane ruffles and lamellipodia in response to exposure to PDGF thereby impairing cell 
motility (Besson et al., 2004). Importantly, these properties of cytoplasmic p27 were independent 
on cyclin/Cdk inhibition (Denicourt and Dowdy, 2004). In contrast, another study demonstrated a 
role for p27 in endothelial cell proliferation and migration dependent on cyclin/Cdk activity (Chen 
et al., 2000). They showed that proliferating cells express higher levels of cyclin E and cyclin A 
but reduced p27 associated with increased Cdk2 activity when compared to quiescent control 
cells. Moreover, migrating EC revealed increased Cdk2 activity which was accompanied by a 
maximal increase in cyclin A and a maximal decrease in p27 protein 4 h to 8 h after generation of 
a scratch on a confluent cell monolayer (Chen et al., 2000). Herein, we show that migrating 
HUVEC deficient in HO-1 also show reduced cyclin A1 protein and decreased Cdk2 activity when 
compared to control cells (Fig. 7.7. and Fig. 7.8.), suggesting that the impaired migratory 
phenotype of HO-1-depleted cells results, at least partially, from reduced Cdk2 activity. The low 
level of cyclin A1 is likely to contribute to the reduced Cdk2 activity. In addition high levels of p27 
may be responsible for the low Cdk2 activity in HO-1-deficient cells, and it would be of interest to 
look further at expression levels of p27 and other cell cycle regulators in migrating HO-1-deficient 
EC.  
Altogether, the results obtained during this study link the cytoprotective enzyme HO-1 to cell cycle 
regulation and angiogenesis. We therefore hypothesise that HO-1 plays an important role in the 
regulation of VEGF-mediated angiogenesis and that loss of HO-1 arrests EC early in the cell 
cycle, due to less availability of positive cell cycle regulators cyclin A1 and cyclin E1 and/or 
increased levels of the negative regulator p27, resulting in decreased Cdk2 activity. This not only 
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negatively regulates cell proliferation but also migration of EC towards angiogenic stimuli, 
resulting in impaired vessel formation. 
The role of HO-1 and cyclin A1 in vessel formation was further investigated in an in vivo Matrigel 
plug angiogenesis assay. Here, supplementation of Matrigel plugs with VEGF injected into female 
C57BL/6 mice significantly induced vessel formation when compared to untreated plus (Fig. 7.10. 
and Fig 7.11.). siRNA-mediated inhibition of HO-1 partially inhibited VEGF-induced 
neovascularisation (Fig. 7.10. and Fig. 7.11.). Of note, vessel formation in plugs containing 
murine specific HO-1 siRNA varied between animals, with some animals showing a marked 
response in vessel formation while others showed almost no vessel growth (Fig. 7.10.B and C). 
Previous studies from our laboratory postulated a dual role for HO-1 in VEGF-driven 
angiogenesis, based on earlier findings that pharmacological inhibition of HO-1 by SnPP 
increased VEGF-driven angiogenesis in vivo, with dense leukocytic inflammatory infiltrates seen 
around vessels (Bussolati and Mason, 2006). Here, under physiological conditions, HO-1 
activation by VEGF favours EC proliferation and prevents EC apoptosis, while inhibiting leukocyte 
migration, thus resulting in predominantly non-inflammatory angiogenesis. In contrast, when HO-1 
activation by VEGF is inhibited, increased leukocyte migration occurs with subsequent local 
release of growth factors and induction of inflammatory angiogenesis. This hypothesis is 
confirmed by the observation that supplementation of Matrigel plugs with the HO-1 inducer CoPP 
inhibits LPS-driven leukocyte-dependent angiogenesis in vivo (Bussolati and Mason, 2006). This 
dual effect of HO-1 on angiogenesis might account for the differences in vessel formation in HO-1
-
/-
 plugs observed in this study. Interestingly, siRNA-mediated silencing of cyclin A1 in Matrigel 
plugs supplemented with VEGF resulted in a significant decrease in the vascularised area (Fig. 
7.10.E and F and Fig. 7.11.), indicating a role for the cell cycle regulator cyclin A1 in VEGF-
mediated angiogenesis in vivo. 
To investigate the relationship between HO-1 and cyclin A1 during angiogenesis we adopted an 
adenoviral approach to overexpress HO-1 in cyclin A1 siRNA-treated Matrigel plugs. Addition of 
an adenovirus overexpressing HO-1 (AdHO-1) to Matrigel significantly enhanced vessel formation 
when compared to plugs containing an empty control adenovirus (Ad0) (Fig. 7.12.) A similar 
response was observed in plugs supplemented with AdHO-1 in combination with a non-targeting 
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control siRNA (Fig. 7.12.C and E). Importantly, AdHO-1 also significantly increased vessel growth 
in cyclin A1 depleted plugs (Fig. 7.12.D and E), so restoring the impaired angiogenic response 
seen with cyclin A1 deficiency. Based on this observation we propose that HO-1 regulates 
expression of cyclin A1 which in turn is an essential contributor to the pro-angiogenic capacities of 
HO-1 during VEGF-driven angiogenesis. Of note, knockdown efficiency of siRNA sequences 
targeting murine HO-1 or cyclin A1 was only sufficiently demonstrated in vitro using MAEC 
isolated from HO-1
+/+
 littermate control mice and not tested in vivo due to time constrains. 
However, in future experiments, murine-specific fluorescently-labelled siRNA can be used to 
assess knockdown efficiency directly. Alternatively, immunofluorescent staining of the target gene 
co-stained with an endothelial marker, such as CD31, could be used to monitor transfection 
efficiency. In addition, as shown previously, mRNA expression levels can be assessed by qRT-
PCR from total RNA isolated from harvested plugs, using murine specific primers as against the 
gene of interest (Birdsey et al., 2008).  This does not only allow the determination of knockdown 
efficiency of murine specific siRNAs but simulatenously allows measuring the levels of expression 
in the plug of various angiogenic and/or inflammatory genes.  Taken together, this in turn could 
assist interpretation of the results and changes in transfection and knockdown efficiency may 
explain the variability observed in neovessel formation in HO-1 siRNA-treated Matrigel plugs. 
Interestingly, while siRNA-mediated silencing of cyclin A1 had no effect on HO-1 expression in 
murine aortic EC, depletion of HO-1 significantly decreased cyclin A1 mRNA (Fig. 7.9.), an effect 
also observed in primary human EC (Tab. 6.2., Fig. 6.14., Fig. 7.4.C. and Fig. 7.7.B). These 
findings are supportive for a role of HO-1 upstream of cyclin A1 and may suggest a function for 
HO-1 as a transcriptional regulator. Thus, it would be of a great interest to look at expression 
levels of cyclin A1, and other cell cycle regulators, in neovessels in Matrigel plugs supplemented 
with (i) HO-1 siRNA and (ii) AdHO-1. 
To start to elucidate the function of HO-1 as a potential regulator of gene transcription, we 
performed an actinomycin D chase experiment and compared cyclin A1 mRNA half-lives in HO-1-
deficient EC and control cells in response to VEGF. Inhibition of HO-1 significantly decreased 
total cyclin A1 mRNA, resulting in a 30% decrease in cyclin A1 half-life when compared to siCTL-
transfected HUVEC (Fig. 7.13.). These preliminary results suggest that the observed 
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downregulation of cyclin A1 mRNA in HO-1-deficient cells may result from decreased mRNA 
stability and might be indicative for a potential function of HO-1 in the transcriptional regulation of 
gene expression. Cyclin A expression is controlled by protein degradation through the 
ubiquitination/proteasome pathway involving the anaphase-promoting (APC/C) complex and/or 
acetylation (Mateo et al., 2009). However, it has been long recognised that the expression of cell 
cycle regulators, including cyclin A, is also critically regulated by altering the stability of their 
mRNA (Howe et al., 1995; Maity et al., 1997; Wang et al., 2000). Wang and colleagues 
demonstrated that cyclin A and also cyclin B1 mRNA stability is regulated by the RNA-binding 
protein HuR during cell proliferation (Wang et al., 2000). HuR proteins have been found to bind to 
ARE-containing mRNAs and either stabilise them and/or enhance their translation in turn 
protecting them from degradation (Fan and Steitz, 1998). HO-1 mRNA stability has also been 
shown to be regulated by HuR in human fibroblasts (Kuwano et al., 2009). However, whether HO-
1 itself can function as a transcriptional regulator via a HuR-dependent pathway remains to be 
determined and it would be of interest to investigate the effect of HO-1 on HuR expression and its 
subsequent mRNA-stabilising function. 
In summary, this chapter highlights a role for the cytoprotective enzyme HO-1 in cell cycle 
regulation and strengthens previously published data (Abraham et al., 2003: Li Volit et al., 2002, 
Li Volti et al., 2005). We propose that HO-1 affects the transition of cells through the cell cycle by 
influencing the expression of cell cycle regulators, and in turn by affecting Cdk2 activity. 
Moreover, we have started to elucidate a potential role for cyclin A1 in HO-1-driven angiogenesis. 
However a direct link between HO-1 and cyclin A1 remains to be determined as changes in the 
proliferative capacity of cells and cell cycle progression are ultimately linked to changes in cell 
cycle regulator expression, and reduced cyclin A1 levels might not be specific to HO-1 deficiency.  
Follow-up experiments are required to further explore a potential interaction between HO-1 and 
cyclin A1, i.e. cylin A1 promoter and immunoprecipitation studies. Nontheless, these findings 
might be of importantance in the identification of new therapeutic targets for the manipulation of 
angiogenesis. 
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CHAPTER 8 -  THE INTERMEDIATE FILAMENT VIMENTIN – A NOVEL HO-1 TARGET 
8.1. INTRODUCTION 
A proteomic screen identified vimentin as a potential downstream target of HO-1 in the regulation 
of VEGF-mediated angiogenesis (Tab. 6.3. and Tab. 6.4.). Vimentin belongs to the large protein 
family of intermediate filaments (IFs), which along with actin-containing microfilaments and 
tubules are the three main cyctoskeletal systems of vertebrates and many invertebrate cells. 
Dynamic interactions among the three cytoskeletal systems regulate the structural organisation of 
the cytoplasm of the cell (Chang and Goldman, 2004). 
IF proteins have been classified into five distinct types on the basis of their structure, assembly 
properties and their tissue distribution (Tab. 8.1.).  
Table 8. 1.: Classification of IF proteins. (Modified after Chang and Goldman, 2004). 
Type IF protein Localisation 
 
Type I 
 
acidic keratins 
 
epithelia 
Type II basic keratins epithelia 
Type III vimentin 
desmin 
glial fibrillary acidic protein 
peripherin 
synemin 
mesenchymal cells, endothelial cells 
muscle cells 
glial cells, astrocytes, stellate liver cells 
diverse neuronal cells 
muscle cells 
Type IV neurofilament-L 
neurofilament-M 
neurofilament-H 
nestin 
α-internexin 
syncolin 
neurons 
neurons 
neurons 
neuroepithelial stem cells, muscle cells 
neurons 
muscle cells 
Type V lamins nuclear 
unclassified phakinin 
filensin 
lens 
lens 
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Vimentin belongs to the type-III IF proteins and is expressed in mesenchymal cells and some 
ectodermal cells during early development. Like all cytoplasmic IF proteins, vimentin consists of a 
central α-helical domain, the rod domain, that is flanked by two non-α-helical domains, the head 
and tail domains (Fig. 8.1.). The rod domain is the most conserved region among different IF 
proteins, whereas the amino-terminal head and the carboxy-terminal tail domain share little 
homology among different IFs (Parry and Steinert, 1999). The head domain has been 
demonstrated to regulate filament assembly and the tail domain plays a proposed role in lateral 
interactions and organisation of IF networks (Herrmann et al., 2003). Both non-α-helical domains 
of vimentin have numerous phosphorylation sites that are involved in the regulation of filament 
assembly/disassembly and subcellular organisation (Fig. 8.1.) (Helfand et al., 2003). Type-III IF 
proteins exist in several morphological states, including non-filamentous particles, short filaments 
known as squiggles, and long mature filaments (Prahlad et al., 1998; Yoon et al., 1998). In vitro 
studies show that filament assembly takes place in a three-step process. First vimentin tetramers 
assemble laterally to form unit-length filaments of approximately 16 nm in diameter and 60 nm in 
length. These unit-length filaments associate end-to-end forming loosely packed filaments several 
hundred nm long, reducing their diameter while extending in length. Eventually, loosely packed 
filaments reorganise into compact mature filaments (Strelkov et al., 2003). Filament assembly is 
controlled by rapid phosphorylation and dephosphorylation of vimentin (Eriksson et al., 2004). 
Moreover, many of the novel functions of vimentin are regulated by these post-translational 
modifications, such as cell adhesion and integrin trafficking, cell migration and cell signalling. 
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Figure 8. 1.: Vimentin structure and phosphorylation sites. Vimentin consists of a central α-
helical rod domain, flanked by the amino-terminal head and the carboxy-terminal tail domain. 
Vimentin has a highly complex phosphorylation pattern, with sites specific for different cellular 
states. Many of its functions are regulated by phosphorylation. (Adapted from Ivaska et al., 2007). 
 
Vimentin is a major component of the cytoskeleton and was initially thought to solely function in 
the stabilisation of cells, but subsequent analyses now reveal a more complex role for vimentin. 
Detailed studies of vimentin knockout mice demonstrate that these animals are characterised by 
impaired wound healing due to defects in the capacity of fibroblasts to migrate, decreased flow-
induced dilation of resistance arteries, reflecting a role in the mechanotransduction of shear 
stress, disturbed homing of leukocytes to lymph nodes, and lack of vascular endothelial integrity 
(Eckes et al., 2000; Eckes et al., 1998; Henrion et al., 1997; Nieminen et al., 2006). Moreover, 
vimentin
-/-
 mice show reduced corneal neovascularisation and hypoxia-induced retinal 
neovascularisation (Eckes et al., 2000; Lundkvist et al., 2004). Interestingly, HO-1-deficient mice 
also demonstrate impaired neovascularisation during wound healing and HO-1-deficient EPC 
show defective homing and re-endothelisation of the retinal vasculature compared with wild-type 
cells following ischaemia (Deshane et al., 2007; Grochot-Przeczek et al., 2009). 
Vimentin has been shown to play an essential role in adhesion and cell-cell contacts by regulating 
integrin functions, especially in endothelial cells (Vincent et al., 2004; Green et al., 2005). An 
important adhesion receptor linking EC to the extracellular matrix is αvβ3 integrin. Once bound to 
matrix in EC, αvβ3 can be found linked to vimentin in structures termed vimentin associated matrix 
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adhesions (VAMs). VAMs are sites where vimentin associates with integrins either via actin, or 
indirectly via actin regulatory proteins such as vinculin and plectin (Gonzales et al., 2001). 
Interestingly, VAMs have been shown to be assembled at the moving front of migrating cells and 
in response to shear stress (Geiger et al., 2001; Tsuruta et al., 2003). siRNA-mediated 
knockdown of vimentin results in decreased cell adhesion, strengthening the importance of 
vimentin in the regulation of cell-ECM adhesions (Tsuruta et al., 2003). More recently, vimentin 
was found to associate with α2β1 integrin in EC, mediating cell adhesion to collagen matrices 
(Kreis et al., 2005). 
Moreover, growing evidence points to vimentin as a pro-migratory molecule. In fibroblasts, site-
directed mutagenesis studies revealed that PKCε-dependent phosphorylation of vimentin is 
essential for the haptotactic motility of cells (Ivaska et al., 2002; Ivaska et al., 2005). Furthermore, 
phosphorylation regulated changes in vimentin filament assembly have been implicated in smooth 
muscle cell migration and contraction (Tang et al., 2005). In the endothelium, vimentin has been 
linked to sprouting angiogenesis. In an elegant study, Kwak and colleagues demonstrated that 
growth factor-induced activation of calpains results in vimentin cleavage and increased vimentin 
solubility. Moreover, calpain-dependent cleavage and depolymerisation of vimentin was required 
for the initiation of endothelial sprouting in three-dimensional collagen matrices (Kwak et al., 
2012).  
In a proteomic screen of primary human EC, we found that the intermediate filament vimentin was 
differentially expressed between control and HO-1-deficient cells in the presence of the pro-
angiogenic mediator VEGF. The similarities between vimentin
-/-
 and HO-1
-/-
 mice in regard to their 
neovasularisation responses, as well as vimentin’s role as a regulator of cell adhesion and 
integrin traffic, and its newly reported role in the regulation of cell migration and sprouting 
angiogenesis, make vimentin a promising candidate as a downstream effector of HO-1 in the 
regulation of VEGF-mediated angiogenesis. This chapter aims to validate the result of the 
proteomic study and to further investigate the effect of HO-1 inhibition on vimentin in terms of 
morphology, cellular localisation and phosphorylation state. 
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8.2. RESULTS 
8.2.1. HO-1 inhibition impairs avβ3-dependent adhesion of EC to gelatin matrices 
In proliferation studies using the BrdU ELISA, we observed reduced cell survival in HO-1-deficient 
EC following re-seeding after trypsin digestion when compared to control cells, and hypothesised 
that this defect resulted from impaired cell adhesion of HO-1-deficient EC (Chapter 5).  
To investigate a potential role for HO-1 in cell adhesion, HUVEC were pre-loaded with a 
fluorescent dye 5-chloromethylfluorescein diacetate (Cell Tracker
TM
 dye solution) and re-seeded 
onto either gelatin-coated or collagen type I-coated culture dishes in the presence or absence of 
VEGF for 40 min and cell adhesion was quantified as the cellular fluorescence of bound cells 
relative to the total cellular fluorescence. Cell adhesion onto collagen type I to matrices is mainly 
regulated via the integrin β1, whereas the main integrin regulating cell adhesion to gelatin 
matrices is integrin αvβ3 (Davis, 1992; Kuhn and Eble, 1994).  
VEGF treatment had no significant effect on β1-dependent adhesion of HUVEC to collagen type I. 
Moreover, no difference in the number of adherent cells was observed between control and HO-1-
deficient EC, suggesting that HO-1 depletion has no effect on β1-dependent cell adhesion (Fig. 
8.2.). Similarly, VEGF did not result in a significant change in the adhesion of HUVEC to gelatin 
matrices. However, both in the absence and presence of VEGF, siRNA-mediated inhibition of HO-
1 significantly reduced the number of adherent cells by ~40% for siHO-1 seq2-transfected cells 
and ~15-20% for siHO-1 pool-transfected cells when compared to cells transfected with siCTL 
(Fig. 8.3.), suggesting a function of HO-1 in αvβ3-dependent EC-ECM adhesion.   
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Figure 8. 2.: HO-1 depletion by siRNA has no effect on β1-dependent adhesion of HUVEC to 
collagen type I-matrices. HUVEC either treated with GeneFector (GF) or transfected with control 
siRNA (CTL) or HO-1 specific siRNA (seq2, pool) were labelled with 5-chloromethylfluorescein 
diacetate (Cell TrackerTM Green CMFDA) (6.25 µM) and seeded onto collagen type I-coated 96-
well plates in the absence (UT) or the presence of 25 ng/ml VEGF and allowed to adhere for 40 
min. Total cellular fluorescence was measured prior to washing and subsequent fluorescence 
measurement of bound cells. Adhesion is expressed as the percentage of bound cells relative to 
the total number seeded. Data is presented as mean ± SEM (n=4 experiments), ns – not 
significant. 
 
Flow cyctometric analysis was used to investigate the effect of HO-1 inhibition on αvβ3 surface 
expression. HUVEC expressed αvβ3 constitutively. In geneFECTOR (GF)-treated cells, VEGF 
exposure had no effect on αvβ3 surface levels when compared to untreated HUVEC. In addition, 
αvβ3 protein was not affected by siCTL. Moreover, siRNA-mediated silencing of HO-1, either with 
siHO1 seq2 or siHO-1 pool, had no significant effect on αvβ3 surface expression on EC when 
compared to that on GF-treated cells (Fig. 8.4.), suggesting that the observed impairment in cell 
adhesion of HO-1-deficient EC does not result from changes in αvβ3 expression. 
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Figure 8. 3.: HO-1 depletion reduces αvβ3-dependent adhesion of HUVEC to gelatin-
matrices. HUVEC either treated with geneFECTOR (GF) alone or transfected with 40 nM control 
siRNA (CTL) or HO-1 specific siRNA (seq2, pool) were labelled with 5-chloromethylfluorescein 
diacetate (Cell TrackerTM Green CMFDA) (6.25 µM) and seeded onto gelatin-coated 96-well 
plates in the absence (UT) or the presence of 25 ng/ml VEGF and allowed to adhere for 40 min. 
Total cellular fluorescence was measured prior to washing and subsequent fluorescence 
measurement of bound cells. Adhesion is expressed as the percentage of bound cells relative to 
the total number seeded. Data is presented as mean ± SEM (n=3 experiments), * p<0.05. 
 
 
 
 
 
 
 
Figure 8. 4.: HO-1 depletion by siRNA has no effect on αvβ3-integrin surface expression on 
HUVEC. HUVEC either treated with geneFECTOR (GF) alone or transfected with 40 nM control 
siRNA (CTL) or HO-1 specific siRNA (seq2, pool) were left untreated or treated with 25 ng/ml 
VEGF for 40 min prior to assessing αvβ3-integrin surface expression by flow cytometry. The bar 
chart displays the relative fluorescence intensity (RFI). Data is presented relative to expression in 
cells treated with GF alone and expressed as mean ± SEM (n=4 experiments), ns - not significant 
vs untreated GF. 
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8.2.2. HO-1 inhibition has no effect on vimentin protein expression in EC 
As both HO-1-deficient as well as vimentin-depleted cells show alterations in integrin-mediated 
adhesion to ECM, we further investigated the role of vimentin as a potential downstream effector 
of HO-1. 
The proteomic screen identified vimentin to be differentially expressed between siCTL-transfected 
and HO-1-depleted HUVEC treated with VEGF for 16 h (Tab. 6.3. and Tab.6.4.). To investigate 
this finding, vimentin and HO-1 protein levels were assessed by conventional one-dimensional 
western blotting. HO-1 expression was not significantly altered by VEGF in GF-treated or siCTL-
transfected EC when compared to untreated control cells, while siHO-1 pool decreased HO-1 
protein by 85-90% in HUVEC (Fig. 8.5.A and C). Vimentin was highly expressed constitutively 
and no change in expression in response to VEGF was detected. Furthermore, the vimentin 
protein level was not affected by siRNA-mediated depletion of HO-1 when compared to siCTL-
transfected cells (Fig. 8.5.B and C). These results suggest that the change in intensity on the 2D 
gel may reflect changes in size or phosphorylation. 
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Figure 8. 5.: HO-1 depletion by siRNA has no effect on HUVEC vimentin protein 
expression. HUVEC were either treated with geneFECTOR (GF) alone or transfected with 40 nM 
control siRNA (CTL) or HO-1-specific siRNA (pool) for 24 h prior to treatment with 25 ng/ml VEGF 
or vehicle for additional 16 h. Protein expression was assessed by western blotting and quantified 
by densitometry for (A) HO-1 and (B) vimentin. (C) shows a representative blot. GAPDH was 
used a loading control. Data is presented as mean ± SEM (n=3 experiments), ** p<0.01. 
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8.2.3. Vimentin filament assembly is impaired in HO-1-depleted EC 
To investigate if morphological changes in vimentin account for the differences observed during 
the proteomic study between control and HO-1-deficient EC in response to VEGF, vimentin 
filaments were visualised by immunofluorescent staining. Confocal z-stack analysis revealed that 
siCTL-transfected cells cultured on gelatin-coated coverslips for 16 h demonstrate a punctuate 
vimentin staining pattern, suggesting the presence of vimentin particles and short filaments (Fig. 
8.6.A). Exposure of siCTL-transfected cell to VEGF resulted in the development of widespread 
dense vimentin filament networks (Fig. 8.6.B), and a significant increase in cell area (Fig. 8.6.E). 
HO-1 depletion per se did not markedly change the vimentin staining pattern or cell area when 
compared to untreated siCTL-transfected cells, suggesting the presence of predominately short 
vimentin filaments and particles (Fig. 8.6.C and E). However, the VEGF-induced increase in cell 
area and filament assembly into a mature, well-defined vimentin network was significantly 
attenuated in siHO-1 seq2AF488-transfected cells, as indicated by a disturbed, punctuated vimentin 
staining (Fig. 8.6.D and E).  
Vimentin filament assembly is controlled by rapid phosphorylation and dephosphorylation of the 
protein (Chou et al., 2007), and we therefore hypothesised that impaired or delayed filament 
assembly in HO-1-deficient cells might result from differential phosphorylation. 
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Figure 8. 6.: Vimentin filament assembly is impaired in HO-1-depleted HUVEC. HUVEC 
transfected with 40 nM 3’-AlexaFluor488-labelled control (CTLAF488) (A, B), or HO-1 specific 
siRNA (seq2AF488) (C, D) were seeded onto gelatin-coated coverslips in the absence (UT) or the 
presence of 25 ng/ml VEGF for 16 h prior to methanol fixation and vimentin staining with mAb 
RV202. Nuclei were stained with Draq5. Immunofluorescent staining was analysed by z-stack 
confocal microscopy and representative images are shown, 63X magnification. Bar equals 50 µm. 
(E) The cell area in 15 cells was quantified using ImageJ and is expressed in pixels. Data is 
presented as mean ± SEM (n=5 experiments), * p<0.05, *** p<0.001.  
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8.2.4. Phos-tag
TM
 SDS-PAGE reveals multiple bands for vimentin 
Vimentin is an abundant protein and present in multiple isoforms and post-translational 
modifications (Chang and Goldman, 2004; Chou et al., 2007). To identify if the changes in 
vimentin observed during the proteomic study are due to changes in vimentin phosphorylation 
rather than expression, we used a novel technique called Phos-tag
TM
 SDS-PAGE gel 
electrophoresis. Phos-tag
TM
 is a functional molecule that binds specifically to phosphorylated 
forms of serine, threonine and tyrosine residues thereby separating phosphorylated from non-
phosphorylated proteins in the same sample. Binding of Phos-tag
TM
 to phosphorylated proteins 
alters their MW thereby decreasing their migration speed and resulting in multiple bands on SDS-
PAGE gels after visualisation by antibody staining. 
Phos-tag
TM
 SDS-PAGE resulted in one band for vimentin in HUVEC treated with the siRNA 
delivery agent (GF) alone. However, exposure to VEGF for 16 h resulted in multiple bands in GF-
treated and also siCTL-transfected cells, suggesting that VEGF alters the phosphorylation status 
of vimentin (Fig. 8.7). Interestingly, the appearance of multiple bands for vimentin was markedly 
reduced in siHO-1 pool-transfected cells (Fig. 8.7.), which might indicate differential 
phosphorylation of vimentin resulting from the different treatments and in turn suggesting a 
function for HO-1 in VEGF-mediated phosphorylation of vimentin. 
To confirm that the multiple bands appearing in response to VEGF represent phosphorylated 
forms of vimentin, protein lysates were treated with lambda phosphatase (λ PP) prior to analysis 
on Phos-tag
TM
 SDS-PAGE. However, λ PP treatment had no marked effect on the appearance on 
band number and intensity appearing in response to VEGF when compared to untreated GF-
treated cells (Fig. 8.8.). Moreover, band number and intensity was not affected by λ PP in HO-1-
deficient cells (compare Fig. 8.7. and Fig. 8.8.), suggesting that the multiple bands observed by 
Phos-tag
TM
 SDS-PAGE do not represent de novo phosphorylation. 
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Figure 8. 7.: Phos-tag
TM
 SDS-PAGE electrophoresis reveals multiple bands for vimentin. 
HUVEC were either treated with geneFECTOR alone (GF) or transfected with 40 nM control 
siRNA (siCTL) or HO-1-specific siRNA (pool) for 24 h prior to treatment with 25 ng/ml VEGF or 
vehicle for additional 16 h. Vimentin protein expression was assessed by Phos-tag
TM
 SDS-PAGE 
and a representative blot is shown. GAPDH was used as a loading control (n=3 experiments). 
 
 
 
 
 
 
 
 
 
Figure 8. 8.: Lambda phosphatase treatment has no effect on vimentin protein band 
intensity observed on Phos-tag
TM
 SDS-PAGE blots. HUVEC were either treated with 
geneFECTOR (GF) or transfected with 40 nM control siRNA (siCTL) or HO-1-specific siRNA 
(pool) for 24 h prior to treatment with 25 ng/ml VEGF or vehicle for additional 16 h. Protein lysates 
were treated with 200 units lambda phosphatase (λ PP) and vimentin protein expression was 
assessed by Phos-tag
TM
 SDS-PAGE and a representative blot is shown. GAPDH was used as a 
loading control (n=2 experiments). 
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8.2.5. HO-1 inhibition results in reduced vimentin cleavage in EC 
Growth factors, including VEGF and bFGF, have been shown to result in vimentin cleavage via 
the activation of calpains (Kwak et al., 2012). Cleaved vimentin appears on 1D SDS-PAGE as 
multiple bands due to differences in their molecular weight compared to full-length vimentin. As 
the number and intensity of vimentin bands observed on Phos-tag
TM
 SDS-PAGE gels in response 
to VEGF was not affected by λ PP, we hypothesised that the multiple bands represent cleaved 
fragments rather than new phosphorylated forms of vimentin.  
Conventional 1D western blotting revealed a sufficient knockdown of HO-1 protein in siHO-1 pool 
transfected HUVEC, whereas siCTL had no effect on HO-1 expression (Fig. 8.9.A). Over-
exposure of membranes probed with a total vimentin antibody, showed one major band at 
approximately 51 kDa for all tested conditions, with no obvious difference in band intensity (Fig. 
8.9.A). This band appeared at the same molecular weight as previously (Fig. 8.5.). VEGF 
exposure for 16 h resulted in multiple new bands appearing in GF-treated and siCTL-transfected 
cells (Fig. 8.9.A), suggesting the presence of cleaved vimentin fragments of different sizes as 
indicated by the reduced molecular weights (~40-50 kDa). Interestingly, this effect was notably 
diminished by HO-1 inhibition, with a reduction in band number and intensity (Fig. 8.9.A). To 
quantify these observations, for each condition band intensity was determined by densitometry for 
full-length vimentin and all cleaved fragments. The accumulated band intensity was then 
normalised to GAPDH and is expressed as the total vimentin fragment intensity. Here, VEGF 
significantly increased the fragment intensity by ~50% in GF-treated and siCTL-transfected 
HUVEC, an effect attenuated by HO-1 depletion (Fig. 8.9.B). 
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Figure 8. 9.: HO-1 depletion by siRNA results in reduced vimentin cleavage in human 
umbilical vein endothelial cells. HUVEC were either treated with geneFECTOR (GF) alone or 
transfected with 40 nM control siRNA (CTL) or HO-1-specific siRNA (pool) for 24 h prior to 
treatment with 25 ng/ml VEGF or vehicle for additional 16 h. Vimentin and HO-1 protein 
expression was assessed by western blotting and GAPDH was used as a loading control. A 
representative blot is shown. (B) Intensity of vimentin cleavage products was quantified by 
densitometry and normalised to GAPDH. Data is presented as mean ± SEM (n=5 experiments), ** 
p<0.01. 
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VEGF-dependent cleavage of vimentin requires calpain activity (Kwak et al., 2012). To investigate 
whether HO-1 depletion has an effect on calpain activation, HUVEC were loaded with the calpain 
substrate tBoc-LM-CMAC prior to VEGF exposure and subsequent validation of calpain activity by 
flow cytometry. Calpain activity was significantly increased after 60 min and 90 min VEGF 
treatment in GF-treated and siCTL-transfected HUVEC compared to the control (Fig. 8.10.). 
Interestingly, the VEGF-induced increase in calpain activity was partially but significantly reduced 
by HO-1 inhibition (Fig. 8.10.), suggesting that the impaired vimentin cleavage observed in HO-1-
deficient cells might result from decreased calpain activity.  
 
 
 
 
 
 
 
 
 
 
Figure 8. 10.: Calpain activation by VEGF is inhibited in HO-1-depleted HUVEC. HUVEC 
were either treated with geneFECTOR (GF) alone or transfected with 40 nM control siRNA (CTL) 
or HO-1-specific siRNA (seq2, pool) for 24 h. Cells were pre-loaded with the calpain substrate 
tBoc-LM-CMAC prior to treatment with 25 ng/ml VEGF or vehicle for the indicated time points. 
Calpain activity was assessed by flow cytometry and is expressed as the mean fluorescence 
intensity (MFI). Data is presented as mean ± SEM (n=2 experiments for 30 min, n=4 experiments 
for 60 min, and n=3 experiments for 90 min VEGF treatment), * p<0.05, *** p<0.001.  
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8.3. DISCUSSION 
The comparison of the proteome of HO-1-depleted primary EC exposed to the pro-angiogenic 
factor VEGF and HO-1
+/+
 control cells, identified the intermediate filament vimentin as a potential 
downstream target of HO-1 in VEGF-mediated angiogenesis. Vimentin is the major IF protein of 
mesenchymal cells and is highly conserved throughout all vertebrates, indicating an important 
role for the protein in cell physiology (Chang and Goldman, 2004; Ivaska et al., 2007). Vimentin 
was long thought to function solely in the stabilisation of cells through dynamic interactions with 
the other two major components of the cytoskeleton, actin-containing microfilaments and tubules. 
However, detailed studies of vimentin knockout mice recently revealed a more complex function 
for vimentin in the regulation of cell adhesion, integrin trafficking, and cell migration, as well as a 
regulator of signal transduction (Ivaska et al., 2007). 
Vimentin regulates cell adhesion and cell-cell contacts through association with 
hemidesmosomes, and has also been shown to regulate integrin function. Integrins are 
heterodimeric transmembrane receptors comprised of a non-covalently associated α- and a β-
subunit. They mediate cell-cell and cell-matrix adhesions by binding extracellular ligands with their 
long N-terminal extracellular domain. The transmembrane segments and the short intracellular 
domain connect the extracellular ligand to the cytoskeleton and signal transduction machinery 
translating matrix-derived signals into cellular responses, including changes in cell morphology, 
cell migration, and proliferation (Brakebusch and Fassler, 2003; Calderwood, 2004; Liu et al., 
2000). Vimentin has been found to associate with integrin receptors either via actin, or via actin 
regulatory proteins in complexes known as vimentin associated matrix adhesion (VAMs) 
(Gonzales et al., 2001). In endothelial cells, the integrin αvβ3 is an important regulator of cell-
matrix adhesions and was found in VAMs (Geiger et al., 2001). Moreover, VAMs are actively 
assembled at the forefront of migrating cells and vimentin appears to be an important regulator of 
VAM size and stability, as flow-induced VAM assembly is inhibited by siRNA-mediated depletion 
of vimentin, resulting in decreased cell adhesion (Tsuruta et al., 2003). Furthermore, vimentin has 
been shown to regulate cell adhesion to collagen matrices via association with the α2β1 integrin 
receptor (Kreis et al., 2005). 
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Herein, we show that HO-1 inhibition results in reduced αvβ3-dependent adhesion of cells to 
gelatin-matrices, whereas β1-dependent adhesion is not affected (Fig. 8.2. and Fig. 8.3.). 
Vimentin has been shown to regulate endo- and exocytic traffic of integrins through PKCε-
dependent phosphorylation of the protein, in turn facilitating directional cell motility (Parsons et al., 
2002; Woods et al., 2004; Ivaska et al., 2002; Ivaska et al., 2005). Based on this observation, we 
hypothesised that the reduced adherence of HO-1-deficient EC might result from impaired 
vimentin regulation and/or expression and subsequent decreased integrin surface expression. 
However, flow cytometric analysis showed no differences in αvβ3 surface levels in HO-1-deficient 
EC when compared to control cells (Fig. 8.4.). These data suggest that the impaired attachment 
of HO-1-deficient EC is not resulting from decreased availability of binding receptors but rather 
due to a functional defect possibly affecting the capacity of integrins to recognise and bind to 
ECM ligands, and/or to signal to the cytoskeleton. 
The finding that siRNA-mediated knockdown of either vimentin or HO-1 decreased endothelial 
adhesive properties suggested vimentin was a promising candidate as a potential HO-1 target.  
The idea of an interplay between the cytoprotective enzyme HO-1 and the IF protein might be 
supported by the phenotypic similarities between vimentin
-/-
 and HO-1
-/- 
mice. Vimentin knockout 
animals demonstrate vascular endothelial dysfunction characterised by defects in barrier function 
(Nieminen et al., 2006), as well as dysregulated formation of granulation tissue, a process that 
involves extensive angiogenic sprouting (Eckes et al., 2000). A pro-angiogenic function for 
vimentin is strengthened by the finding that growth-factor induced activation of calpains is 
required for vimentin cleavage and subsequent endothelial sprouting (Kwak et al., 2012), and by 
their proposed role in cell migration (Ivaska et al., 2007). Furthermore, vimentin deficient mice 
show reduced flow-induced dilation of resistance arteries, and disturbed homing of leukocytes to 
lymph nodes (Eckes et al., 2000; Eckes et al., 1998; Henrion et al., 1997). HO-1 knockout mice 
also demonstrate reduced neovascularisation during wound healing and defective EPC homing 
and re-endothelisation of the retinal vasculature in response to ischaemia-induced injury 
(Deshane et al., 2007; Grochot-Przeczek et al., 2009). Of note, vimentin
-/-
 mice also show 
reduced corneal neovascularisation and hypoxia-induced retinal neovascularisation (Eckes et al., 
2000; Lundkvist et al., 2004).  
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In order to further investigate a potential function for vimentin in HO-1-driven angiogenesis, the 
initial step was to validate the results obtained from the proteomic study. Conventional one-
dimensional western blotting suggested that HO-1 inhibition had no effect on vimentin protein 
expression (Fig. 8.5.). 1D electrophoresis separates proteins only according to their molecular 
weight not taking into account any post-translational modifications. In contrast, two-dimensional 
SDS-PAGE, as used in the proteomic study, separates proteins according to their molecular 
weight in the first dimension and according to their isoelectric point (pI) in the second dimension. 
The pI is the pH at which a protein carries no net electrical charge and a shift in pI is indicative of 
post-translational modifications of a protein, such as a change in the phosphorylation state 
(Halligan, 2009). The technical limitations in terms of sensitivity of 1D western blotting might 
explain why no differences in total vimentin were observed, whereas the proteomic screen 
identified vimentin as a protein to be differentially expressed between HO-1-deficient and HO-1
+/+
 
control cells.   
As vimentin is abundantly expressed and exists in many different morphological states, isoforms, 
and with various post-translational modifications (Chang and Goldman, 2004), we hypothesised 
that differences in vimentin morphology, localisation and/or phosphorylation account for the 
differential expression of vimentin as observed by 2D SDS-PAGE. 
Depending on the functional state of a cell, vimentin exists as non-filamentous particles, short 
filaments, or long mature filaments (Prahlad et al., 1998; Chou et al., 2007). Immunofluorescent 
staining of vimentin with confocal z-stack analysis revealed a punctuate staining pattern for 
vimentin in HUVEC transfected with a non-targeting control siRNA, suggesting vimentin exists in 
the form of non-filamentous particles or short filaments (Fig. 8.6.A). VEGF exposure of siCTL-
transfected cells resulted in a significant increase in cell area and development of a dense 
vimentin network consisting of long mature filaments covering the complete cell area (Fig. 8.6.B 
and E). Similar responses in vimentin reorganisation have been reported in the spreading 
fibroblast, where during early spreading vimentin was found in the form of non-filamentous 
particles or short filaments predominately near the edges of the cell. In contrast, in fully spread 
cells an extensive and complex vimentin network was formed from the assembly of these short 
filaments and particles into long mature filaments covering the complete area of the cell (Prahlad 
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et al., 1998; Chou et al., 2007). This suggests that VEGF initiates cell spreading, and 
reorganisation of vimentin in EC, resulting in increased cell area and a complex vimentin filament 
network, which in turn might regulate, at least to some extent, the angiogenic properties of EC in 
response to VEGF. Interestingly, while HO-1 depletion alone had no significant effect on vimentin 
morphology and cell size when compared to siCTL-transfected EC, the VEGF-induced increase in 
cell area was significantly inhibited (Fig. 8.6.A, C and E). Moreover, cells showed a disturbed, 
punctuate staining pattern and failed to form an intact filamentous vimentin network in response to 
VEGF (Fig. 8.6.D). These data suggest a role for HO-1 in vimentin filament assembly, where HO-
1 inhibition impairs and/or delays filament assembly in response to VEGF which might in turn 
result in defective angiogenic capacities of EC. 
Vimentin filament assembly is a three step process involving the primary association of vimentin 
tetramers, which then bind each other end-to-end forming unit-length filaments. These unit-length 
filaments further expand into loosely packed filaments which simultaneously compact in diameter 
and reorganise into long mature vimentin filaments (Strelkov et al., 2003). Vimentin filament 
assembly is controlled by rapid phosphorylation and dephosphorylation of the protein (Eriksson et 
al., 2004; Chou et al., 2007) and we therefore hypothesised that the impaired or maybe delayed 
filament assembly in HO-1-deficient cells might result from differential phosphorylation. 
In this study, we adopted a novel western blotting technique which allows the identification of 
phosphorylated and non-phosphorylated forms of a protein in the same sample. Phos-tag
TM 
SDS-
PAGE utilises just a total antibody targeting the protein of interest rather than numerous phospho-
specific antibodies. Phos-tag
TM
 is a functional molecule that is directly added to the 
electrophoresis gel and binds specifically to phosphorylated serine, threonine and tyrosine 
residues, thereby affecting the molecular weight and migration speed of proteins, and resulting in 
multiple separate bands after antibody staining and chemiluminescent visualisation.  
Phos-tag
TM
 SDS-PAGE revealed one band, with a similar expression intensity at the same 
molecular weight for all four tested conditions (Fig. 8.7.). VEGF exposure resulted in the 
appearance of multiple lower molecular weight bands underneath in cells treated with the siRNA 
delivery agent alone of cell transfected with a control siRNA (Fig 8.7.), suggesting that VEGF 
phosphorylates vimentin at multiple phosphorylation sites. Of note, the appearance of multiple 
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bands in response to VEGF was diminished in HO-1-depleted EC (Fig. 8.7.). These data suggest 
that VEGF-induced phosphorylation of vimentin is at least in part dependent on HO-1 and that 
HO-1 deficiency impairs VEGF-induced vimentin phosphorylation which might affect vimentin 
filament assembly and in turn the angiogenic properties of EC.  
To confirm the hypothesis that HO-1 is required for VEGF-mediated phosphorylation, the same 
protein lysates as used for Phos-tag
TM
 SDS-PAGE were treated with a lambda phosphatase (λ 
PP) prior to electrophoresis. λ PP is a protein phosphatase with activity towards phosphorylated 
serine, threonine and tyrosine residues, mediating the release of phosphate groups (Cohen and 
Cohen, 1989). Thus, λ PP treatment should reduce the appearance and/or intensity of multiple 
bands on Phos-tag
TM
 gels. However, band number and intensity was not affected by λ PP 
treatment in either control cells or in HO-1-deficient EC (Fig. 8.8.), indicating that the observed 
bands do not represent new phosphorylated forms of vimentin and hence that HO-1 inhibition has 
no effect on vimentin phosphorylation. More likely, these lower molecular weight bands are 
vimentin cleavage products. To strengthen this hypothesis and further exclude de novo 
phosphorylation as an explanation for the presence of multiple bands, a positive control for λ PP 
activity should be used in future experiments. A variety of protein kinases, including PKA, PKC, 
and Cdc2 kinase have been shown to phosphorylate vimentin (Tzivion et al., 2000). In addition, 
Kinoshita and colleagues recently reported rapid hyperphosphorylation of vimentin in the 
presence of the protein phosphatase inhibitor calyculin A as shown by Phos-tag
TM
 western 
blotting (Kinoshita et al., 2012). Thus in future experiments, vimentin phosphorylation in human 
EC could be induced by either protein kinases or calyculin A and serve as a positive control for 
phosphorylation. Moreover, λ PP treatment should markedly inhibit vimentin phosphorylation in 
these samples in turn serving as a positive control for λ PP activity. 
Recently, Kwak and colleagues demonstrated that growth factor-induced activation of calpains 
results in vimentin cleavage which in turn is required for angiogenic sprouting of EC (Kwak et al., 
2012). Calpains are intracellular calcium-activated cysteine proteases and have been shown to 
regulate cell migration through cleavage of numerous actin regulatory proteins, including talin, 
vinculin and paxillin. Calpains are required for the formation of membrane protrusions and cell 
membrane release during cell spreading (Franco et al., 2004; Wells et al., 2005). Moreover, 
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calpains can cleave the amino-terminus of vimentin (Fischer et al., 1986; Tompa et al., 2004). The 
amino-terminal head domain of vimentin has been shown to regulate filament assembly, thus 
calpain-induced cleavage renders vimentin incapable of forming insoluble, polymerised filaments 
(Herrmann et al., 2003). 
In the study by Kwak and colleagues vimentin cleavage was demonstrated by western blotting 
analysis of total cell lysates (Kwak et al., 2012). Here full-length vimentin resulted in a band at 
approximately 60 kDa, which is in agreement with the molecular weight of vimentin, which is 57 
kDa (Dahl et al., 1981). Cleaved vimentin fragments were identified as multiple bands below the 
full-length vimentin with reduced molecular weights (Kwak et al., 2012). We hypothesised that full-
length vimentin is the most abundant form of vimentin expressed in human EC and therefore easy 
to identify by conventional 1D SDS-PAGE, whereas cleaved vimentin fragments are less 
abundantly expressed and might be more difficult to identify on electrophoresis. This might also 
explain the fact, that no differences in vimentin expression could be observed in our initial 
validation studies (Fig. 8.5.). To further investigate this hypothesis, 1D western blot analyses 
comparing the expression of vimentin in HO-1-deficient EC with control cells were repeated, but 
the blots were exposed for longer durations. Indeed, in all tested conditions one highly expressed 
band was apparent at approximately 51 kDa with no significant differences in expression between 
treatments (Fig. 8.9.A). We identified this band as full-length vimentin. Interestingly, VEGF 
treatment resulted in multiple bands with a lower molecular weight appearing underneath the 
band for full-length vimentin in geneFECTOR-treated and siCTL-transfected cells, but not in HO-
1-deficient HUVEC (Fig. 8.9.A). We identified those bands as truncated forms of vimentin, with 
molecular weights ranging from approximately 40-50 kDa. Accordingly, quantification revealed a 
significant decrease in vimentin fragment intensity in HO-1-depleted cells in response to VEGF 
when compared to HO-1
+/+
 control cells (Fig. 8.9.B). Moreover, we can show that VEGF-mediated 
calpain activation is significantly inhibited by siRNA-mediated silencing of HO-1 (Fig. 8.10.), which 
might account for the defect in vimentin fragmentation in response to VEGF observed in HO-1-
deficient EC. In their study, Kwak and colleagues demonstrated the re-localisation of vimentin to 
cell edges in response to growth factor treatment, an effect attenuated in the presence of calpain 
inhibitors (Kwak et al., 2012). Thus, impaired vimentin filament assembly, as observed in HO-1-
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deficient cells (Fig. 8.6.), might also result from decreased calpain activation and subsequent 
inhibition of vimentin re-localisation to cell edges. 
Altogether, these results are indicative of a role of vimentin as a downstream target of HO-1 in 
VEGF-mediated angiogenesis, where VEGF induces HO-1 expression and/or activity which is 
required for activation of the calcium-dependent protease calpain. Calpain activation in turn leads 
to cleaved, soluble, depolymerised vimentin localising to cell edges thereby driving the angiogenic 
responses of EC.  
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CHAPTER 9 - CONCLUDING REMARKS 
9.2. DISCUSSION 
Over the past decades, tremendous technological and methodological advances in cell and 
molecular biology have greatly improved our understanding of the vascular endothelium and its 
role in health and disease. The endothelium constitutes the cellular lining of all vessels in the 
cardiovascular system, and forms a physiological and structural barrier between the intravascular 
space and extravascular tissue. The endothelium is no longer viewed as an inert structure, but 
rather has been recognised to be a highly complex, dynamic and heterogeneous organ important 
in several house-keeping functions. It actively regulates the passage of solutes, macromolecules 
and blood cells across the wall, generates and integrates biological signals and plays an essential 
role in haemostasis, leukocyte traffic and vascular tone, maintaining an anti-thrombotic, fibrinolytic 
and anti-inflammatory surface (Cines et al., 1998). Endothelial cells are also involved in the 
control of growth, development and differentiation of the vessel wall in the processes of 
vasculogenesis and angiogenesis (Risau, 1997). Impairment of these endothelial cell-mediated 
processes leads to a dysfunctional endothelium and has been implicated in the pathogenesis of 
atherosclerosis and other pathological conditions affecting the cardiovascular system, including 
hypertension, coronary and peripheral artery disease, chronic heart failure, as well as 
autoimmune diseases such as diabetes mellitus and systemic lupus erythematosus (Ross, 1999; 
Schachinger et al., 2000; Heitzer et al., 2001; Bijl, 2003; Endemann and Schiffrin, 2004, Higashi 
et al., 2009). To counteract harmful stimuli and limit local and systemic pathogenic responses 
following vascular injury, the vascular endothelium has developed intrinsic cytoprotective 
signalling pathways and expresses several anti-inflammatory and cytoprotective proteins, 
including soluble anti-inflammatory molecules, cell surface proteins and receptors, as well as 
intercellular adhesion molecules. The principal aim of our research group is to identify these 
intrinsic mediators and the signalling pathways regulating them. By establishing a more detailed 
understanding of the underlying cytoprotective mechanisms of the endothelium, we hope that they 
might represent future therapeutic targets for the restoration of endothelial homeostasis, the 
prevention of endothelial dysfunction and subsequent atherogenesis in patients with systemic 
inflammatory diseases. 
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Of particular interest to our group is the role of the enzyme heme oxygenase-1 and its products in 
vascular cytoprotection and angiogenesis. HO-1 catalyses the degradation of free heme into 
equal molar amounts of carbon monoxide, ferrous iron with subsequent induction of ferritin, and 
biliverdin, which is rapidly converted into bilirubin. Biologic activities of the end-products alone or 
in combination with HO-1 protein itself exhibit multiple cytoprotective effects in the cardiovascular 
system (Ali et al., 2007; Kinderlerer et al., 2008; Grochot-Przeczek et al., 2012). Moreover, 
induction of HO-1 is an important cellular adaptive response, minimising tissue injury and 
facilitating repair, as revealed in multiple models of disease and the severe endothelial damage in 
human HO-1 deficiency (Yachie et al., 1999). But the recognised roles for HO-1 are far beyond 
cytoprotection, and HO-1 and its products have been implicated in cell proliferation, differentiation 
and apoptosis (Dulak et al., 2008). Recently, it has been shown that the pro-angiogenic factors 
VEGF and SDF-1α induce HO-1 expression and enhance its enzymatic activity, in turn 
modulating the angiogenic capacities of endothelial cells (Bussolati et al., 2004; Deshane et al., 
2007). Accordingly, VEGF treatment results in HO-1 induction in the chick embryo chorioallantoic 
membrane (Fernandez and Bonkovsky, 2003). However, the precise transcriptional and signalling 
pathways underlying growth factor-induced HO-1 activation remain elusive. Therefore, in Chapter 
4, I determined the optimal time point of HO-1 induction in response to VEGF and SDF-1α in 
primary human umbilical vein EC in the hope of identifying transcriptional regulators and 
signalling pathways mediating this effect.  
In accordance with previously published studies, exposure to VEGF or SDF-1α significantly up-
regulated HO-1 message and protein levels in EC. Of note, high variability in basal HO-1 
expression was observed between all experiments, and induction of HO-1 by both VEGF and 
SDF-1α varied notably between cell isolates from different donors. Moreover, high basal HMOX1 
promoter activity was observed in HO-1 promoter studies, while no difference in promoter activity 
was observed in cells exposed to VEGF or SDF-1α. We hypothesise that the variability in basal 
and induced HO-1 may results from microsatellite polymorphisms within the gene promoter. 
These variable GT-rich regions have been shown to affect transcription, modulate basal and 
induced HO-1 expression and are of clinical relevance (Chen et al., 2002; Song et al., 2009). 
Moreover, longer (GT)n repeats have been shown to diminish the responsiveness of EC to the 
pro-angiogenic factor VEGF, as indicated by reduced VEGF-mediated proliferation (Taha et al., 
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2010). The basal promoter activity observed may be caused by a stress-response of cells in 
culture. Indeed, HO-1 is a stress-inducible enzyme and numerous stress responsive elements 
have been identified within the HMOX1 promoter sequence. These in turn meditate transcriptional 
activation in response to a large variety of HO-1 inducers (Ryter et al., 2006). The high basal 
HMOX1 promoter activity may mask any effects afforded by VEGF and SDF-1α. Therefore, to 
date it has not been proven possible to identify potential transcriptional pathways involved in the 
regulation of HO-1-driven angiogenesis utilising primary human EC. Genotyping of the HO-1 
promoter of human cell isolates for (GT)n repeats, as well as the use of cell lines or primary cell 
isolates from species not possessing these polymorphisms, may assist in follow-up studies to 
identify transcriptional and signalling mechanisms involved in the regulation of HO-1 by pro-
angiogenic mediators.   
VEGF is the most important molecule in the regulation of blood vessel morphogenesis, controlling 
cell permeability, endothelial proliferation, migration and survival (Ferrara et al., 2003). The notion 
that VEGF induces expression of the cytoprotective enzyme HO-1, which itself has been shown to 
induce the synthesis of VEGF, implicates a potential role for HO-1 in VEGF-mediated 
angiogenesis (Dulak et al., 2008). Indeed, HO-1 overexpression enhanced proliferation and in 
vitro tube formation or capillary sprouting in response to VEGF, while inhibition of HO-1 activity 
attenuated cell proliferation and migration of cultured EC (Deramaudt et al., 1998; Jozkowicz et 
al., 2003; Bussolati and Mason, 2006). Despite the considerable progress made in defining the 
role for HO-1 in the vasculature, further studies are required to identify the specific role of HO-1 
during the individual steps of the angiogenic process. Moreover, the functions of the end-products 
of HO-1-mediated degradation of heme, carbon monoxide, biliverdin/bilirubin, and ferritin, in the 
regulation of angiogenesis remain poorly understood. We tried to further shed light onto this field 
of research by specific silencing of HO-1 using targeted siRNAs, or conversely by the use of an 
adenoviral vector expressing the human HO-1 gene. Herein, we show that specific inhibition of 
human HO-1 significantly decreased the proliferative capacity of primary EC in response to the 
potent pro-angiogenic mitogen VEGF, whereas adenoviral-induced overexpression of HO-1 
significantly enhanced EC proliferation and exhibited a synergistic effect on VEGF-driven 
proliferation. These observations confirm previous findings from our laboratory utilising the less 
specific pharmacological agonist CoPP or the synthetic HO-1 antagonists SnPP and ZnPP 
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(Bussolati et al., 2004; Bussolati and Mason, 2006). Of note, the metalloprotoporphyrins SnPP 
and ZnPP not only inhibit the activity of HO-1 but also interfere with the constitutive HO-2, and 
therefore lack specificity (Ryter et al., 2006). The use of specific siRNA targeting the human HO-1 
gene in this study now demonstrated that loss of only the inducible isoform HO-1 is sufficient to 
impair the proliferative capacity of EC in culture, and that HO-2 does not compensate for the loss 
of HO-1 in our system.  
Both VEGF and HO-1 have been shown to play important anti-apoptotic functions in the 
vasculature. VEGF protected EC from serum starvation through the induction of the anti-apoptotic 
genes A1 and Bcl-2, while murine aortic EC from HO-1 null mice are more susceptible to 
apoptotic stimuli and have increased caspase-3 activity compared with EC from HO-1
+/+
 littermate 
controls (Gerber et al., 1998; Berberat et al., 2000; Chen et al., 2004). Thus, an increased rate of 
apoptosis may contribute to the apparent proliferative defects of HO-1-depleted EC. In line with 
this, we show increased apoptosis in EC cultures depleted of HO-1, however this effect is rescued 
by VEGF and associated with an upregulation in A1 message and Bcl-2 protein. Moreover, VEGF 
protected HO-1-deficient HUVEC from serum starvation-induced cell death. These findings 
suggest that the reduced proliferation properties observed in HO-1-deficient EC in response to 
VEGF do not reflect increased apoptosis. Moreover, cytoprotective mechanisms of VEGF 
mediated through increased induction of A1 and Bcl-2 are HO-1-independent.  
Endothelial motility is essential to the angiogenic growth. Deshane and colleagues recently 
demonstrated a link between HO-1 and both EC and EPC migration in response to the chemokine 
SDF-1α. Furthermore, pharmacological inhibition of HO-1 was shown to reduce the migratory 
capacity of EC, whilst HO-1 overexpression enhanced endothelial migration as demonstrated by 
increased propensity to form capillary-like structures in Matrigel (Jozkowicz et al., 2003; 
Deramaudt et al., 1998). Herein, we demonstrate that HO-1 is an important regulator of 
endothelial migration in response to VEGF. Closure of artificial wounds generated on HUVEC 
monolayers was impaired by HO-1 inhibition, and HO-1-deficient cells demonstrated a significant 
reduction in their linear migration, expressed as the Euclidean distance, in response to VEGF 
when compared to control cells. These findings are confirmed by analysis of the directional 
movement of individual cells, revealing that HO-1-deficient cells migrated in a rather random, 
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circular pattern alongside the scratch edge, whereas control cells showed a more linear, 
directional movement across the scratch and towards cells on the opposite site. Conversely, the 
migratory capacity of EC was notably enhanced in cells overexpressing the human HO-1 gene. 
Moreover, we report, to our knowledge for the first time, impaired chemotactic migration of HO-1-
deficient EC towards a pro-angiogenic stimuli. HO-1 deficiency significantly reduced the number 
of EC migrating towards a VEGF gradient as assessed by the Ibidi µ-slide chemotaxis assay. 
However, further studies are required to establish the specific role of HO-1 and its products in the 
process. The directed forward movement of EC requires the rearrangement of the cytoskeleton 
and subsequent morphological changes resulting in the expansion of cell protrusion at the moving 
front. Lamellipodia and filopodia are both capable of probing the environment for attractive 
guidance cues and initiate migration towards these (Defilippi et al., 1999). Their formation is 
regulated by activation of the small GTPases Rac1 and Cdc42, respectively (Lamalice et al., 
2007). It would be of great interest to investigate whether (i) changes in the morphological 
appearance, i.e. changes in lamellipodia and filopodia protrusions, or (ii) changes in small 
GTPase-mediated signalling contribute to the impaired migratory capacity of HO-1-deficient cells 
in response to VEGF. In the final step of the angiogenic process, migrating EC rearrange into 
lumenised capillary structures that undergo maturation and remodelling. Herein, we show that 
formation of capillary-like structures on Matrigel in response to VEGF is significantly impaired by 
HO-1 depletion. Altogether our data demonstrate a role for HO-1 in the regulation of VEGF-
induced angiogenesis, and demonstrate that the cytoprotective enzyme HO-1 affects the 
angiogenic capacity of EC in culture at various levels.  
The products of HO-1-dependent heme degradation carbon monoxide, biliverdin/bilirubin and 
ferritin are well recognised for their cytoprotective effects in the vascular system and have also 
been linked to angiogenesis. Moreover, HO-1 products are likely to be responsible for its 
biological activity and anti-inflammatory, anti-oxidant and anti-apoptotic actions. In this study we 
investigated whether the end-products of heme metabolism also contribute to the pro-angiogenic 
effects of HO-1. Deferoxamine mesylate chelates intracellular iron and mimics the activity of 
ferritin, which has been shown to inhibit the anti-apoptotic effects of high molecular weight 
kininogen, improving the proliferation, migration and subsequent formation of capillary-like 
structures of EC (Coffman et al., 2009). Moreover, exposure of vascular SMC to DFO increased 
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VEGF synthesis and may influence angiogenesis indirectly (Dulak et al., 2002). However, in my 
experiments, treatment of HO-1-deficient HUVEC with DFO did not restore their impaired 
migratory phenotype in response to VEGF.  
HO-1-derived CO is likely to be predominantly responsible for the angiogenic properties of HO-1. 
CO supplementation increased HO-1 expression and augmented the synthesis of VEGF in EC in 
culture (Jozkowicz et al., 2003; Lin et al., 2009). This effect has also been described in an animal 
model, resulting in increased VEGF biosynthesis in various tissues and organs following CO 
exposure (Marti and Risau, 1998). Herein, we used CO-releasing molecules to delivery CO in a 
safe, accurate and measurable fashion to cells in culture. CORM-2 is a water soluble transition 
metal-carbonyl complex that liberates CO upon ligand exchange with DMSO, and has been 
shown to play a critical role in the resolution of inflammatory responses and alleviation of 
cardiovascular diseases (Motterlini et al., 2002; Motterlini et al., 2003). However, pre-treatment 
and subsequent culture of HO-1-deficient HUVEC with CORM-2 did not restore their impaired 
migratory phenotype in response to VEGF. CO release from CORM-2 is very fast (t1/2 ≈ 1min) and 
non-specific, which may hamper the delivery of controlled amounts of CO to the target cells 
(Motterlini et al., 2005). Thus inadequate CO2 may have been responsible for the lack of effect. 
Enzyme-triggered CORMs represent a novel class of powerful CORMs, which are stable under 
physiological conditions, but are rapidly converted to the active form by means of enzymatic 
hydrolysis when taken up by cells. Enzymatic cleavage of the ester functionality by intracellular 
esterases results in the dissociative loss of CO (Romanski et al., 2011; Romanski et al., 2012). 
The biological activity of the ET-CORM SROM158 was confirmed by its inhibitory effect on TNF-
α-induced surface expression of VCAM-1, and SROM158 either on its own or in combination with 
VEGF significantly induced HO-1 in HUVEC. However, as seen with CORM-2, the more powerful 
SROM158 was not sufficient to reverse the dysfunctional angiogenic capacities of HUVEC 
deficient in HO-1, in terms of VEGF-mediated proliferation and migration. Collectively, these data 
suggest that HO-1-induced angiogenesis and EC migration are dependent on HO-1 but are not 
mediated, at least solely, by the HO products CO or iron. The role of the bile pigments biliverdin 
and bilirubin in angiogenesis is poorly understood, but biliverdin may have an indirect effect on 
angiogenesis by stimulating the production of pro-angiogenic factors, such as VEGF and IL-8 in 
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human keratinocytes (Jawza et al., 2006; Lobada et al., 2008). Thus, HO-1-derived 
biliverdin/bilirubin might contribute to the pro-angiogenic effects of HO-1 and human EC. 
Moreover, a role for CO and iron in HO-1-driven angiogenesis cannot be completely excluded 
solely based on the data from this study, as the products may act in concert and may be 
dependent on each other. Indeed, co-administration of CO and biliverdin greatly enhanced their 
anti-inflammatory and anti-apoptotic effects in a mouse model of liver damage when compared to 
single administration of either CO or biliverdin (Sass et al., 2004). 
Angiogenesis is involved in the progression of numerous diseases. Excessive angiogenesis, due 
to the overproduction of normal or aberrant forms of angiogenic mediators, or a relative deficiency 
in angiogenic inhibitors, is associated with chronic inflammatory diseases, such as 
atherosclerosis, diabetes mellitus and rheumatoid arthritis, as well as tumour growth and 
metastasis. In other diseases, such as ischaemic heart disease or preeclampsia, the angiogenic 
switch is insufficient, causing EC dysfunction, vessel malformation or regression, or preventing 
revascularisation, healing and regeneration (Carmeliet, 2005). Study of anti-angiogenic agents for 
the treatment of various malignant diseases is of special interest, and a variety of angiogenic 
inhibitors, targeting VEGF or VEGF-R2, such as bevacizumab, are available for clinical use, with 
others in clinical trials (Buysschaert et al., 2007; Carmeliet et al., 2009). Conversely, the use of 
angiogenic stimulators, although initially promising in animal models and small uncontrolled pilot 
studies in patients with ischaemic heart disease or peripheral arterial occlusive disease, so far do 
not show any convincing therapeutic benefit, demonstrating the need for further studies to identify 
novel therapeutic targets for the manipulation of angiogenesis.  HO-1 and its associated pathways 
may represent a new target. However, a better understanding of the signalling pathways and 
downstream effectors of HO-1 in the regulation of angiogenesis is required and one of the main 
aspects of my project. 
Vasodilator-stimulated phosphoprotein has been proposed as a potential downstream target of 
HO-1 in SDF-1α-mediated angiogenesis. SDF-1α-induced VASP phosphorylation was attenuated 
in HO-1-deficient murine aortic EC, an effect restored by a CO donor (Deshane et al., 2007). 
However herein we show that VEGF-mediated VASP phosphorylation is not altered by HO-1 
depletion, suggesting that VASP is not a downstream effector of HO-1 in VEGF-induced 
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angiogenesis. Therefore, to identify potential novel targets of HO-1 in angiogenesis, we 
performed (i) a targeted PCR array and (ii) a proteomic screen comparing the differential 
expression of genes and proteins, respectively, in HO-1-deficient human primary EC and control 
cells in response to the mitogen VEGF. 
Cyclin A1 mRNA levels were significantly reduced by HO-1 depletion as identified by the PCR 
array. In addition, further analyses revealed a significant reduction in basal and VEGF-induced 
expression of the positive cell cycle regulators cyclin E1 and the cyclin-dependent kinase Cdk2, 
but increased expression of the Cdk2 inhibitor p27 in proliferating HUVEC. These findings are in 
line with previously a published microarray study, demonstrating increased cyclin E and cyclin A 
expression in EC transduced with the human HO-1 gene (Abraham et al., 2003). Moreover, we 
show that migrating EC deficient in HO-1 exhibit reduced cyclin A1 protein and this is 
accompanied by a decrease in Cdk2 activity. The altered expression profile of cell cycle 
regulators might in turn be responsible for the halt in transition from G1- to S-phase observed in 
HO-1-deficient HUVEC in the absence and also the presence of VEGF. Both E-type cyclins as 
well as A-type cyclins bind to and activate Cdk2. The active cyclin E/Cdk2 complex is required for 
S-phase entry, while active cyclin A/Cdk triggers the progression through S-phase (Dulic et al., 
1992; Koff et al., 1992; Elledge et al., 1992; Cardoso et al., 1993). In addition, the activity of both 
complexes is inhibited by p27 (Mateyak et al., 1999; Hengst and Reed, 1996). Thus, reduced 
Cdk2 activity, resulting from reduced availability of the positive cell cycle regulators cyclin A1 and 
cyclin E1 and/or increased levels of the negative regulator p27, may contribute to the impaired 
angiogenic capacities of HO-1-deficient EC, not only inhibiting their proliferation but also 
chemotactic migration, and subsequently resulting in vascular malformations. 
In this study, human EC isolated from the umbilical vein were used as an in vitro model for studies 
on angiogenesis. The use of primary cells has the advantage that the characteristics of early 
passage cells in culture are closer to their parent EC when compared to cell lines, in terms of their 
gene expression profile and reponses to stimuli. They often more closely resemble the tissue they 
are taken from and they are more representative of the human population, due to the high degree 
of heterogeneity between preparations form different individuals. However, when studying 
angiogenesis, it this fundamental to consider the in vivo angiogenic characteristics of the cells 
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used, as some EC, including cells lining the human umblical vein, do not undergo extensive 
angiogenic sprouting in vivo. Moreover, it has to be considered that EC from different tissues are 
locally specialised in their functional characteristics. Cells express specific subsets of genes 
according to tissue origin as well as source, i.e. arterial versus venous EC and/or EC of the 
microvasculature versus cell of the macrovasculature. Thus, the use of HUVEC alone is not 
sufficient to model endothelial function in multiple vascular beds, and caution is needed when 
interpretating the results of in vitro studies, stressing the need for more sophisticated in vivo 
angiogenesis models. 
We further started to elucidate a potential role for HO-1 and cyclin A1 in in vivo angiogenesis. 
siRNA-mediated inhibition of HO-1 partially inhibited VEGF-induced neovascularisation, and 
cyclin A1 silencing in Matrigel plugs resulted in a significant decrease in the vascularised area in 
response to VEGF. Conversely, adenoviral overexpression of HO-1 in Matrigel plugs significantly 
enhanced vessel formation when compared to plugs containing an empty control adenovirus. 
Interestingly, AdHO-1 also significantly increased vessel growth in cyclin A1 depleted plugs, so 
restoring the impaired angiogenic response seen with cyclin A1 deficiency. We therefore propose 
that HO-1 regulates expression of cyclin A1, which in turn is an essential contributor to the pro-
angiogenic capacities of HO-1 during VEGF-driven angiogenesis. The role for HO-1 as an 
upstream effector of cyclin A1 is further supported by the finding that depletion of HO-1 
significantly decreased cyclin A1 mRNA levels in murine aortic EC and human primary EC. 
Moreover, actinomycin D chase experiments demonstrated a significant reduction in cyclin A1 
mRNA stability and subsequent a decrease in cyclin A1 half-lives in HO-1-deficient HUVEC, 
suggesting a potential function for HO-1 as a transcriptional regulator of gene expression.  
The proteomic screen identified the intermediate filament vimentin as a potential downstream 
target of HO-1 in the regulation of angiogenesis. Vimentin is the major IF protein expressed in 
mesenchymal cells and is involved in integrin trafficking, cell adhesion and migration, and has 
been proposed to be an important mediator of signal transduction (Ivaska et al., 2007). 
Interestingly, HO-1 and vimentin deficiency share similar characteristics. siRNA-mediated 
silencing of vimentin has been shown to reduce integrin-mediated endothelial cell adhesion 
(Tsuruta et al., 2003). We show that HO-1 depletion significantly reduces αvβ3-dependent 
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adhesion of HUVEC when compared to control cells, an effect not resulting from altered αvβ3 
surface expression levels. Thus, the impaired adherence of HO-1-deficient EC is not due to 
decreased availability of binding receptors but rather due to a functional defect, possibly affecting 
the capacity of integrins to recognise and bind to ECM ligands, and/or to signal to the 
cytoskeleton. Moreover, vimentin null mice are characterised by impaired wound healing due to 
defects in the capacity of fibroblast to migrate, and they show reduced corneal neovascularisation 
and hypoxia-induced retinal neovascularisation (Eckes et al.,1998; Eckes et al., 2000; Lundkvist 
et al., 2004). HO-1-deficient mice also demonstrate impaired neovascularisation during wound 
healing and HO-1-deficient EPC show defective homing and re-endothelisation of the retinal 
vasculature compared with wild-type cells following ischaemia (Deshane et al., 2007; Grochot-
Przeczek et al., 2009).  
These similarities between vimentin
-/-
 and HO-1
-/-
 animals make vimentin a promising candidate 
as a downstream effector of HO-1. To further investigate a potential function for vimentin in HO-1-
driven angiogenesis, we initially validated the results obtained from the proteomic screen, but 
were not able to show an effect of HO-1 depletion on vimentin protein expression by conventional 
one-dimensional electrophoresis. This may be explained by technical limitations and reduced 
sensitivity of 1D electrophoresis when compared to 2D SDS-PAGE. 2D electrophoresis not only 
separates proteins according to their molecular weight, but also according to their isoelectric point 
in the second dimension, allowing the identification of post-translational modifications (Halligan, 
2009). Vimentin is abundantly expressed and exists in many morphological states, isoforms and 
has numerous phosphorylation sites (Chang and Goldman 2004). Thus, changes in vimentin 
observed by 2D SDS-PAGE may represent differences in vimentin morphology, localisation, 
and/or phosphorylation. Indeed, using immunofluorescent staining we demonstrate differences in 
vimentin organisation and filament assembly between control cells and HO-1-depleted HUVEC. In 
control cells vimentin predominantly exists as non-filamentous particles or short vimentin 
filaments that reorganise into long mature vimentin filaments and form a dense, widespread 
filamentous network in response to VEGF, while HO-1 depletion inhibits or and/or delays VEGF-
induced filament assembly.  
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Vimentin filament assembly is controlled by rapid phosphorylation and dephosphorylation of the 
protein (Eriksson et al., 2004; Chou et al., 2007), and thus defective filament assembly of HO-1-
deficient cells might result from differential phosphorylation. In fact, Phos-tag
TM
 SDS-PAGE 
revealed multiple lower molecular weight bands in response to VEGF in control cells, suggesting 
that VEGF phosphorylates vimentin at multiple sites. Interestingly, the appearance of multiple 
bands in response to VEGF was diminished by HO-1 depletion, suggesting that VEGF-induced 
vimentin phosphorylation is at least in part dependent on HO-1. However, the appearance and 
intensity of low molecular weight bands either in control or HO-1-deficient cells was not affected 
by treatment with a lambda phosphatase. This indicates that the observed bands do not represent 
new phosphorylated forms of vimentin and hence that HO-1 inhibition has no effect on vimentin 
phosphorylation. More likely, these lower molecular weight bands represent cleaved vimentin 
fragments. Kwak and colleagues recently demonstrated that growth factor-induced activation of 
calpains results in vimentin cleavage which in turn is required for angiogenic sprouting of EC 
(Kwak et al., 2012). In line with these observations, we demonstrate calpain activation and 
vimentin cleavage in response to VEGF in control cells, as indicated by the presence of low 
molecular weight vimentin, ranging from 40-50 kDa, in addition to full-length vimentin (51 kDa). 
Interestingly, VEGF-induced calpain activation was significantly reduced by HO-1 depletion and 
vimentin fragmentation was inhibited in HO-1-deficient EC. Re-localisation of vimentin to cell 
edges in response to growth factors has also been shown to be dependent on calpain activity 
(Kwak et al., 2012). Thus, impaired vimentin filament assembly, as observed in HO-1-deficient 
HUVEC, might also result from decreased calpain activation and subsequent inhibition of vimentin 
re-localisation to cell edges. This in turn may impair the angiogenic properties of endothelial cells 
in response to growth factor stimulation. 
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9.3. CONCLUSION 
Herein we show an important role for the cytoprotective enzyme HO-1 in the regulation of in vitro 
and in vivo angiogenesis. HO-1 deficiency alters the angiogenic phenotype of endothelial cells at 
various levels; HO-1 inhibition attenuates endothelial proliferation in response to the mitogen 
VEGF and significantly impairs EC directional migration towards a pro-angiogenic stimulus. 
Furthermore, HO-1-deficient EC fail to form an intact tubular network in a 2D Matrigel assay and 
VEGF-driven neovascularisation of Matrigel plugs is partially reduced by siRNA-mediated HO-1 
knockdown. 
HO-1 deficiency prevents cell cycle progression. Moreover, HO-1-deficient proliferating and 
migrating EC exhibit altered cell cycle regulator expression, with reduced positive cell cycle 
regulators cyclin A1 and cyclin E1, but increased levels of the cell cycle inhibitor p27, resulting in 
reduced Cdk2 activity. We propose that the aberrant expression of cell cycle regulators and 
subsequent impaired Cdk2 activation of HO-1-deficient EC not only affects their proliferative 
capacity but also their migration, which in turn accounts for the impaired organisation into blood 
vessels. 
We further propose a role for the intermediate filament vimentin as a downstream effector of HO-1 
in the regulation of VEGF-mediated angiogenesis, where VEGF induced HO-1 is required 
expression for activation of the calcium-dependent protease calpain. Calpain activation in turn 
leads to cleaved, soluble, depolymerised vimentin localising to cell edges, thereby driving the 
angiogenic responses of EC. 
The identification of cyclin A1, and other cell cycle regulators, as well as vimentin as HO-1 
downstream effectors in the regulation of VEGF-mediated angiogenesis may assist studies in the 
development of new therapeutic agents for the manipulation of angiogenesis. 
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9.4. FUTURE WORK 
The role of HO-1 during angiogenesis is complex and remains to be fully understood. The data 
obtained during the course of this thesis provide a better understanding of the functional 
importance of HO-1 in the regulation of VEGF-mediated angiogenesis but in turn raises several 
new questions: 
1. How does HO-1 deficiency impair the chemotactic migration of endothelial cells? Has 
HO-1 inhibition an effect on small GTPase activation and signalling? Do changes in 
protrusion formation account for the impaired migratory phenotype of HO-1-deficient EC? 
2. Does the halt in cell cycle progression account for the impaired migratory capacities of 
HO-1-deficient EC. Are expression levels of cell cycle regulators other than cyclin A1 
affected by HO-1 depletion in migrating EC? What is the role for p27 in HO-1-driven 
migration? 
3. Do the end-products of HO-1-mediated heme metabolism have an effect on cell cycle 
regulator expression and cell cycle progression? 
4. How does cell cycle progression affect angiogenesis in vivo? Are cell cycle regulator 
expression levels altered in (i) HO-1 siRNA treated, or (ii) AdHO-1 treated Matrigel plugs? 
5. Does HO-1 act as a transcriptional regulator of gene expression? If so, what are the 
mechanisms? 
6. Is there a role for the intermediate filament vimentin in HO-1-driven angiogenesis in vivo? 
Is vimentin expression altered in HO-1 siRNA treated Matrigel plugs? 
7. Do CO, biliverdin/bilirubin, and or ferritin have an effect on vimentin expression, 
morphology and localisation, and/or phosphorylation? 
8. Is there a link between vimentin, cyclin A1 and HO-1? 
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APPENDIX 
Table A. 1.: Monoclonal and polyclonal primary antibodies for western blotting. Target 
antigens are listed in an alphabetical order and working dilutions were prepared in 1X TBS-T. 
Target Antigen Source Species Supplier Dilution 
α-tubulin mouse, ascites fluid Sigma-Aldrich Ltd. 1:30,000 
Bcl-2 (C-2) mouse monoclonal Santa Cruz Biotechnology, Inc. 1:1,000 
Bcl-xl (H-62) rabbit polyclonal Santa Cruz Biotechnology, Inc. 1:1,000 
cyclin A (B-8) mouse monoclonal Santa Cruz Biotechnology, Inc. 1:1,000 
GAPDH mouse monoclonal Millipore 1:30,000 
HO-1 mouse monoclonal Stressgen 1:1,000 
HO-2 rabbit polyclonal Stressgen 1:1,000 
PKCε rabbit polyclonal Santa Cruz Biotechnology, Inc. 1:1,000 
Phospho-PKCε (Ser729) rabbit polyclonal Millipore 1:1,000 
Rb (C-2) mouse monoclonal Santa Cruz Biotechnology, Inc. 1:1,000 
Phospho-Rb (pT821) rabbit polyclonal Invitrogen 1:1,000 
VASP (9A2) rabbit monoclonal Cell Signaling 1:1,000 
Phospho-VASP (Ser239) rabbit polyclonal Cell Signaling 1:1,000 
Vimentin mouse monoclonal Abcam 1:10,000 
 
Table A. 2.: Secondary antibodies for western blotting. Working dilutions were prepared in 1X 
TBS-T. 
Target Antigen Source Species Supplier Dilution 
HRP-conjugated anti-mouse goat Dako 1:1,500 – 1:30,000 
HRP-conjugated anti-rabbit swine Dako 1:3,000 
 
Table A. 3.: Primary antibodies for immunofluorescence staining. Target antigens are listed 
in an alphabetical order and working dilutions were prepared in 3% BSA in PBS with Ca
2+
 and 
Mg
2+
. 
Target Antigen Source Species Supplier Dilution 
HO-1 rabbit polyclonal Santa Cruz Biotechnology, Inc. 1:200 
Vimentin mouse 
monoclonal 
Abcam 1:200 
Negative control mouse 
IgG1 
mouse Dako 1:20 
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Table A. 4.: Secondary antibodies for immunofluorescence staining. Working dilutions were 
prepared in 3% BSA in PBS with Ca
2+
 and Mg
2+
. 
Target Antigen Source Species Supplier Dilution 
anti-mouse IgG1 Alexa Fluor 
488 
goat Invitrogen 1:1,000 
anti-mouse IgG1 Alexa Fluor 
568 
goat Invitrogen 1:1,000 
anti-rabbit IgG1 Alexa Fluor 568 goat Invitrogen 1:1,000 
 
Table A. 5.: Primary antibodies for flow cytometry. Target antigens are listed in an 
alphabetical order and working dilutions were prepared in HBSS with Ca
2+
 and Mg
2+
 
supplemented with 1% FCS. 
Target 
Antigen 
Source Species Supplier Dilution 
CD31 mouse monoclonal Developmental Studies Hybridoma 
Bank 
neat supernatant 
Endoglin mouse monoclonal Dr A. d’Apice 1:50 
ICAM-2 mouse monoclonal D. T. Springer 1:50 
Integrin αvβ3 mouse monoclonal Millipore 1:50 
PCNA mouse monoclonal Santa Cruz Biotechnology, Inc. 1:50 
VCAM-1 mouse monoclonal generated in house neat supernatant 
 
Table A. 6.: Secondary antibodies for flow cytometry. Working dilutions were prepared in 
HBSS with Ca
2+
 and Mg
2+
 supplemented with 1% FCS. 
Target Antigen Source Species Supplier Dilution 
FITC-labelled anti-mouse rabbit polyclonal Dako 1: 50 
 
 
 
 
